fluorouracil has been researched along with Carcinoma in 1064 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5-Fluorouracil plus cisplatin is the most commonly used chemotherapy regimen for nasopharyngeal carcinoma (NPC)." | 9.22 | Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma. ( Fang, W; Hu, Z; Huang, Y; Li, Y; Lin, Y; Liu, W; Ma, Y; Qin, T; Salamone, SJ; Sheng, J; Yang, Y; Zhang, L; Zhang, Y; Zhao, H; Zhao, L; Zhao, Y; Zou, B, 2016) |
| "To investigate the efficacy and safety of selective radiotherapy after distant metastasis of nasopharyngeal carcinoma (NPC) treated with dose-dense cisplatin plus fluorouracil." | 9.20 | Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil. ( Bu, JG; Chen, BY; Chen, KQ; Cheng, JL; Feng, J; Gao, WW; Liang, WC; Liang, Y; Xu, YC, 2015) |
| "The present study aimed to evaluate efficacy and adverse effects of Nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in the treatment of advanced oral carcinoma." | 9.19 | Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma. ( Gu, QP; Guo, W; Li, ZP; Meng, J; Meng, QF; Si, YM; Zhang, J; Zhuang, QW, 2014) |
| "Although cisplatin combined with 5-fluorouracil is a common first-line regimen for advanced nasopharyngeal carcinoma (NPC), there are no standard regimens for refractory or relapsed patients." | 9.19 | Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy. ( Bai, B; Cai, QC; Cai, QQ; Gao, Y; Huang, HQ; Wang, XX, 2014) |
| "Palliative chemotherapy with cisplatin/5-fluorouracil (5FU) is the commonest regimen employed for metastatic and recurrent head and neck squamous cell carcinoma (SCCHN) and nasopharyngeal carcinoma (NPC)." | 9.17 | Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma. ( Aslan, NM; Chee Ee Phua, V; Ismail, F; Kua, VF, 2013) |
| "To investigate the association of colonic methane, formed by methanogenic achaea, and pH with gastrointestinal symptoms during colorectal cancer chemotherapy." | 9.17 | Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer. ( Blom, M; Holma, R; Korpela, R; Osterlund, P; Poussa, T; Rautio, M; Sairanen, U; Saxelin, M, 2013) |
| "We aimed to investigate the efficacy and tolerability of sorafenib combined with cisplatin and 5-fluorouracil (5-FU) in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)." | 9.17 | Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. ( Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY, 2013) |
| "Registered dose capecitabine monotherapy is active against metastatic breast cancer (MBC), but retrospective analyses indicate that lower doses may be as effective and better tolerated." | 9.16 | Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. ( Calvani, N; Cinefra, M; Cinieri, S; Fedele, P; Marino, A; Mazzoni, E; Nacci, A; Orlando, L; Rizzo, P; Schiavone, P; Sponziello, F, 2012) |
| "The Breast Cancer Study Group of the Hellenic Oncology Research Group conducted a phase III trial of single-agent capecitabine versus the vinorelbine/gemcitabine doublet in patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes." | 9.16 | A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. ( Ardavanis, A; Boukovinas, I; Georgoulias, V; Malamos, N; Mavroudis, D; Pallis, AG; Varthalitis, I, 2012) |
| "To evaluate the efficacy of concurrent oral capecitabine with accelerated hypofractionated radical radiotherapy in locally advanced squamous cell carcinoma of the head and neck (SCCHN)." | 9.15 | Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study. ( Birzgalis, A; Homer, J; Jegannathen, A; Lee, L; Mais, K; Ryder, WD; Slevin, N; Sykes, A; Yap, B, 2011) |
| "This study aimed to evaluate acute major toxicities, the response rate, 3-year overall survival and progression-free survival rate of locally advanced nasopharyngeal carcinoma patients on concurrent carboplatin chemoradiotherapy followed by carboplatin and 5-fluorouracil." | 9.15 | Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouracil in locally advanced nasopharyngeal carcinoma. ( Dechaphunkul, T; Pruegsanusak, K; Sangthawan, D; Sunpaweravong, P, 2011) |
| "The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and combination of capecitabine with oxaliplatin (CAPOX) plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC)." | 9.15 | Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K, 2011) |
| "This phase II study was conducted to determine the efficacy and safety of capecitabine and bevacizumab in untreated elderly metastatic colorectal cancer patients." | 9.14 | A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. ( Fakih, MG; Khushalani, N; Mashtare, T; Puthillath, A; Romano, K; Ross, ME; Steinbrenner, L; Wilding, G; Wisniewski, M, 2009) |
| "The addition of capecitabine to docetaxel significantly improves overall survival in anthracycline-pretreated metastatic breast cancer." | 9.14 | Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results. ( Gennatas, K; Gennatas, S; Michalaki, V, 2009) |
| "The present study aimed at investigating whether the simultaneous evaluation of pharmacokinetic, pharmacogenetic and demographic factors could improve prediction on toxicity and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil (5FU)/leucovorin therapy." | 9.14 | Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. ( Barile, C; Bolzonella, C; Bononi, A; Crepaldi, G; Ferrazzi, E; Frigo, AC; Gusella, M; Marinelli, R; Menon, D; Padrini, R; Pasini, F; Stievano, L; Toso, S, 2009) |
| "To determine the efficacy and tolerability of capecitabine combined with oxaliplatin (CAPOX) or irinotecan (CAPIRI) as first-line treatment in patients with advanced/metastatic colorectal cancer aged > or =70 years." | 9.14 | Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. ( Bordonaro, R; Caputo, G; Cordio, S; Manzione, L; Novello, G; Reggiardo, G; Rosati, G, 2010) |
| "This phase II study was designed in order to evaluate efficacy and safety of the combination of vinorelbine (VNB), fluorouracil (FU) and leucovorin (LV) in patients with metastatic breast carcinoma (MBC) previously treated with anthracyclines and taxanes." | 9.14 | Vinorelbine and fluorouracil plus leucovorin combination (ViFL) in patients with anthracycline and taxane-pretreated metastatic breast cancer: a phase II study. ( Bergnolo, P; Bianco, L; Boglione, A; Comandone, A; Cutin, SC; Dal Canton, O; Garetto, F; Inguì, M; Oliva, C; Pochettino, P, 2010) |
| "A dose-finding study was performed to evaluate the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD) and the recommended dose (RD) of escalating the doses of capecitabine and fixed doses of irinotecan and oxaliplatin on a biweekly schedule for metastatic colorectal cancer patients (mCRC)." | 9.14 | Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. ( Bandres, E; Bitarte, N; Chopitea, A; Gacía-Foncillas, J; Patiño-Garcia, A; Ponz-Sarvise, M; Ramirez, N; Rodríguez, J; Viudez, A; Zarate, R, 2010) |
| "0 Gy/5 weeks can be safely administered to the tumor bed, concurrently with capecitabine (1600 mg/m (2)) in patients with resected pancreatic carcinoma." | 9.14 | Capecitabine based postoperative accelerated chemoradiation of pancreatic carcinoma. A dose-escalation study. ( Caprino, P; Caravatta, L; Cellini, N; Deodato, F; Di Lullo, L; Giglio, G; Ingrosso, M; Ippolito, E; Macchia, G; Massaccesi, M; Mattiucci, GC; Mignogna, S; Morganti, AG; Picardi, V; Sofo, L; Tambaro, R; Valentini, V, 2010) |
| " This phase I/II trial was carried out to evaluate the combination of capecitabine and the proteasome inhibitor bortezomib in anthracycline and/or taxane-pretreated patients with metastatic breast cancer." | 9.13 | A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H, 2008) |
| "This study was conducted to determine, in patients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administered orally for 7 days followed by a 7-day rest (7/7), a schedule based on a mathematical method for the optimization of anticancer drug scheduling." | 9.13 | Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. ( Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA, 2008) |
| " Capecitabine plus irinotecan appears to be a feasible first-line treatment for patients with advanced colorectal carcinoma." | 9.12 | Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study. ( Akkermans-Vogelaar, JM; Antonini, NF; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Punt, CJ; Rodenburg, CJ; Vreugdenhil, G; Wals, J, 2006) |
| "Capecitabine is a fluoropyrimidine carbamate that acts as a prodrug, mimics continuous infusion of 5-fluorouracil (5-FU), and has encouraging antitumor activity in women with metastatic breast cancer." | 9.12 | Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study. ( Fasolo, A; Gianni, L; Marchiano, A; Mariani, G; Moliterni, A; Petrelli, F; Valagussa, P; Zambetti, M, 2006) |
| "The purpose of this study was to compare the activity and toxicity of an irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) combination with a standard regimen of 5FU and LV, in patients with advanced colorectal carcinoma." | 9.12 | A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma. ( Andreadis, C; Gennatas, C; Michalaki, V; Mouratidou, D; Pafiti, A; Papaxoinis, G; Tsavaris, N, 2006) |
| "The aim of the study was to compare our reference adjuvant chemotherapy, FEC100 (fluorouracil 500 mg m(-2), epirubicin 100 mg m(-2) and cyclophosphamide 500 mg m(-2), six cycles every 21 days), to an epirubicin-vinorelbine (Epi-Vnr) combination for early, poor-prognosis breast cancer patients." | 9.12 | Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial. ( Audhuy, B; Bonneterre, J; Chollet, P; Clavère, P; Eymard, JC; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Lortholary, A; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Simon, H; Veyret, C; Walter, S, 2007) |
| "The aim of this study was to investigate the efficacy and safety of combination chemotherapy with weekly paclitaxel and 5-fluorouracil (5-FU) as first-line treatment in patients with advanced or recurrent gastric carcinoma." | 9.12 | Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma. ( Ando, T; Hirabayashi, N; Kawamura, S; Kobayashi, M; Kojima, H; Kondo, K; Konno, H; Matsuo, K; Miyashita, Y; Morita, S; Musha, N; Nagata, N; Ninomiya, M; Oba, K; Sakamoto, J; Usuki, H, 2007) |
| "Forty-two rectal carcinoma (T(3-4)N(0-2)M(0)) patients with grade 2 or 3 diarrhea refractory to loperamide were enrolled to receive octreotide." | 9.12 | Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma. ( Karaoglu, A; Topkan, E, 2006) |
| "To assess the efficacy and tolerability of combination therapy with capecitabine and cisplatin in patients with recurrent carcinoma of the uterine cervix." | 9.12 | A pilot phase II study of capecitabine plus cisplatin in the treatment of recurrent carcinoma of the uterine cervix. ( Benjapibal, M; Inthasorn, P; Leelaphatanadit, C; Therasakvichya, S; Thirapakawong, C, 2007) |
| "Gastric cancer patients with cytologically confirmed malignant ascites were treated with cycles of oxaliplatin at 85 mg/m(2) plus leucovorin 20 mg/m(2) on the first day of treatment, followed by 5-fluorouracil (5-FU) via a 400 mg/m(2) bolus and a 22 h continuous infusion of 600 mg/m(2) 5-FU on Days 1-2 at 2-week intervals." | 9.12 | A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. ( Jang, JS; Jeong, JS; Kim, HJ; Kim, MC; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY; Yoo, HS, 2007) |
| "The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as first-line treatment in metastatic colorectal carcinoma (CRC)." | 9.11 | Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. ( Artale, S; Bajetta, E; Beretta, E; Biasco, G; Bonaglia, L; Bonetti, A; Buzzoni, R; Carreca, I; Cassata, A; Cortinovis, D; Di Bartolomeo, M; Ferrario, E; Frustaci, S; Iannelli, A; Lambiase, A; Mariani, L; Marini, G; Pinotti, G, 2004) |
| "The current study was designed to evaluate the antitumor activity and toxicity of capecitabine and oxaliplatin in previously untreated patients with advanced colorectal carcinoma." | 9.11 | Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. ( Marshall, JL; Meropol, NJ; Shields, AF; Zalupski, MM, 2004) |
| "To evaluate the toxicity and efficacy of concurrent chemoirradiation with cisplatin followed by adjuvant ifosfamide, 5-fluorouracil and leucovorin in patients with stage IVb nasopharyngeal carcinoma (NPC) PATIENTS AND METHODS: Between October 1998 and August 2001, 35 Chinese patients with stage IVb NPC (N3a:12, N3b:23) were treated with by concurrent chemoirradiation using cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with 1." | 9.11 | A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma. ( Au, GK; Chua, DT; Sham, JS, 2004) |
| "The objective of the trial is to evaluate the efficacy of capecitabine in patients with metastatic hormone-resistant prostate carcinoma (HRPC), in terms of prostate-specific antigen (PSA) response and clinical benefit (decrease of pain or analgesic score) and its safety profile." | 9.11 | Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. ( Bauer, J; Bernhard, J; Bonomo, M; Borner, M; Cerny, T; Dietrich, D; Gillessen, S; Gschwend, A; Hanselmann, S; Hering, F; Morant, R; Rochlitz, C; Schmid, HP; Wernli, M, 2004) |
| " In an effort to improve the therapeutic effect of a MAb-based regimen in colorectal carcinoma (CRC) patients, the effects of a combination of alpha-interferon (alpha-IFN), 5-fluorouracil (5-FU), granulocyte-macrophage colony-stimulating factor (GM-CSF) and mouse MAb17-1A was evaluated in 27 patients with metastatic disease." | 9.11 | Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. ( Frödin, JE; Liljefors, M; Mellstedt, H; Nilsson, B; Ragnhammar, P; Ullenhag, G, 2004) |
| "A single-arm phase II multicenter trial of the combination of cyclophosphamide (C), epirubicin (E), and 5-fluorouracil (F) followed by docetaxel as neoadjuvant chemotherapy is being conducted by the Japan Breast Cancer Research Group." | 9.11 | Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma. ( Akiyama, F; Hisamatsu, K; Iwata, H; Kaise, H; Kuroi, K; Kurosumi, M; Kusama, M; Masuda, N; Nakamura, S; Ohno, S; Sato, Y; Shin, E; Takatsuka, Y; Toi, M; Tsuda, H; Yamazaki, K, 2005) |
| "Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma." | 9.11 | Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study. ( Casaretti, R; Cataldis, GD; Comella, P; Farris, A; Lucia, LD; Maiorino, L; Massidda, B; Natale, D; Palmeri, S; Tafuto, S, 2005) |
| "The purpose of this multicenter phase III trial was to assess the impact of a time-intensification of FEC (fluorouracil, epirubicin, cyclophosphamide) and MMM (mitoxantrone, methotrexate, mitomycin C) regimens, supported by lenograstim (G-CSF) on the objective response rate, time to progression and survival of patients with chemotherapy-naive metastatic breast cancer (mbc)." | 9.10 | Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma. ( Capotorto, AM; Da Prada, GA; Farris, A; Lelli, G; Martoni, A; Massidda, B; Pavesi, L; Pedrazzoli, P; Robustelli della Cuna, G; Zamagni, C, 2003) |
| "Twenty-three patients with advanced or recurrent endometrial carcinoma entered a prospective study of chemotherapy which consisted of carboplatin (300 mg/m2), methotrexate (30 mg/m2), and 5-fluoruracil (500 mg/m2) given on day 1, in a 3-weekly schedule, in combination with medroxyprogesterone acetate (MPA): 300 mg daily, p." | 9.09 | Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic cooperative oncology group study. ( Aravantinos, G; Bafaloukos, D; Bakoyiannis, C; Katsifis, G; Kosmidis, P; Samonis, G; Skarlos, D, 1999) |
| "This phase-II study was conducted to investigate the potential benefit from the addition of mitomycin to a conventional anthracycline-cisplatin- and 5-fluorouracil-based chemotherapy for recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type (UCNT)." | 9.09 | Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. ( Alonso, S; Armand, JP; Chouaki, N; Cortès-Funes, H; Cvitkovic, E; Fandi, A; Hasbini, A; Lianes, P; Mahjoubi, R; Raymond, E; Taamma, A, 1999) |
| "The combination of 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (I-OHP) was shown to be both more active against metastatic colorectal carcinoma and better tolerated if the drug delivery rate was chronomodulated according to circadian rhythms rather than constant." | 9.09 | A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. ( Brienza, S; Chollet, P; Dogliotti, L; Focan, C; Le Rol, A; Letourneau, Y; Lévi, F; Llory, JF; Perpoint, B; Rotarski, M; Zidani, R, 1999) |
| "The aim of this study was to evaluate the toxicity and efficacy of the combination of 5-fluorouracil, bleomycin, epirubicin, and cisplatin (FBEC) in the treatment of patients with undifferentiated carcinoma of nasopharyngeal type (UCNT)." | 9.09 | Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. ( Armand, JP; Azli, N; Chouaki, N; Couteau, C; Cvitkovic, E; Fandi, A; Hasbini, A; Taamma, A; Wibault, P, 1999) |
| "To evaluate the outcome in patients with stage II hormone receptor-positive breast cancer treated or not treated with low-dose, short-term chemotherapy in addition to tamoxifen in terms of disease-free and overall survival." | 9.09 | Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer. ( Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kolb, R; Kubista, E; Manfreda, D; Mittlböck, M; Mlineritsch, B; Samonigg, H; Steger, G; Steindorfer, P; Stierer, M; Tschurtschenthaler, G, 1999) |
| "Thymidylate synthase (TS) is regarded as a parameter of 5-fluorouracil (5-FU) chemosensitivity for colorectal carcinoma." | 9.09 | Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. ( Fujii, S; Hatano, K; Kitayama, J; Matsuda, K; Muto, T; Nagawa, H; Nita, ME; Takenoue, T; Tsuruo, T, 2000) |
| "Sixty eligible patients who had previously untreated, measurable, metastatic colorectal carcinoma were treated with oral eniluracil 50 mg on Days 1-7, 5-FU 20 mg/m(2) on Days 2-6, and LV 50 mg on Days 2-6." | 9.09 | Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. ( Hollis, D; Mayer, RJ; Meropol, NJ; Niedzwiecki, D; Schilsky, RL, 2001) |
| "The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer." | 9.09 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001) |
| "Infusional 5-fluorouracil (F) with cisplatin (C) and epirubicin (E), so-called infusional ECF, is a highly active new schedule against locally advanced or metastatic breast cancer." | 9.08 | Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen. ( Allum, WH; Baum, M; Bonnefoi, H; Ebbs, S; O'Brien, ME; Powles, TJ; Seymour, MT; Smith, IE, 1996) |
| "Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma." | 9.08 | Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996) |
| "A carboplatin and 5-fluorouracil (CF) chemotherapy protocol was designed to evaluate tumor response and toxicity in patients with metastatic nasopharyngeal carcinoma (NPC)." | 9.08 | Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. ( Chan, AT; Johnson, PJ; Lee, WY; Leung, SF; Leung, TW; Teo, PM; Yeo, W, 1996) |
| " levofolinic acid and oral hydroxyurea on a weekly schedule is well tolerated by the vast majority of patients with locally advanced and/or metastatic carcinoma of the pancreas or the gallbladder." | 9.08 | Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). ( Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giotta, F; Giuseppe, S; Majello, E; Pezzella, G; Riccardi, F; Testa, A, 1996) |
| "A phase I trial of 5-fluorouracil (5-FU), leucovorin (LV) and interferon (IFN) was conducted in 15 advanced colorectal cancer patients refractory to a bolus regimen of 5-FU/LV." | 9.08 | A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. ( Cascinu, S; Catalano, G; Del Ferro, E; Ligi, M, 1996) |
| " The authors examined whether the administration of 5-fluorouracil (5-FU) enhanced apoptosis of gastric carcinoma cells, and investigated the relationship between apoptosis and the expression of Ki-67 and the Bax gene." | 9.08 | Enhanced induction of apoptosis of human gastric carcinoma cells after preoperative treatment with 5-fluorouracil. ( Itoh, H; Kaibara, N; Kimura, O; Maeta, M; Makino, M; Shirai, H; Sugamura, K, 1997) |
| "Previous Phase II studies using the combination of mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) in the treatment of metastatic breast carcinoma have shown this regimen to be active and well tolerated." | 9.08 | Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial. ( Birch, R; Greco, FA; Hainsworth, JD; Hopkins, LG; Jolivet, J, 1997) |
| "The purpose of this study was to compare the objective response rate, duration of remission, and survival of 5-fluorouracil (5-FU) versus those of 5-FU plus levamisole in metastatic colorectal cancer using the same dose and schedule of these agents as in the North Central Cancer Treatment Group and intergroup studies of adjuvant therapy." | 9.08 | Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. ( Bandealy, MT; Einhorn, LH; Gonin, R; Loehrer, PJ; Monaco, F, 1998) |
| "Infusional 5-fluorouracil in advanced breast cancer has been associated with improved clinical response rates when compared with conventional bolus therapy." | 9.08 | Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90). ( Asselain, B; Beuzeboc, P; Diéras, V; Dorval, T; Garcia-Giralt, E; Jouve, M; Livartowski, A; Palangié, T; Pierga, JY; Pouillart, P; Scholl, S, 1998) |
| "A wide variety of fluorouracil (FU)-plus-leucovorin (LV) dose schedules are in clinical use for the treatment of advanced colorectal cancer." | 9.08 | The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK). ( Bacchi, M; Borner, MM; Castiglione, M; Fey, MF; Goldhirsch, A; Hanselmann, S; Herrmann, R; Leyvraz, S; Morant, R; Pagani, O; Pestalozzi, B; Weber, W, 1998) |
| "We evaluated the pharmacokinetics of 5-fluorouracil (5-FU) combined with recombinant human interferon (IFN)-alpha 2a in 10 previously untreated patients with advanced colorectal carcinoma." | 9.08 | Pharmacokinetics of recombinant human interferon-alpha 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma. ( Kim, J; Koss-Twardy, SG; Passe, SM; Patel, IH; Pazdur, R; Satoh, H; Zhi, J, 1998) |
| "Thirty patients with measurable metastatic breast carcinoma were treated with a combination of cyclophosphamide 600 mg/m2 on day 1, levofolinic acid 100 mg/m2 plus 5-fluorouracil 375 mg/m2 on days 1-3, and epidoxorubicin (EDXR) in three refracted doses on days 1-3 with G-CSF rescue for 10 days." | 9.07 | A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma. ( Amato, C; Callari, A; Cannata, G; Cipolla, C; Cusimano, MP; Garascia, C; Gebbia, N; Gebbia, V; Latteri, MA; Testa, A, 1994) |
| "Twenty-two patients with metastatic colorectal cancer entered a Phase I-II trial to assess the maximum tolerable dose of alpha-2B-interferon administered intramuscularly three times per week in combination with fixed doses of 5-fluorouracil (450 mg/m2 IV for 5 days, and, from day 28, weekly) and folinic acid (200 mg/m2 IV before 5-fluorouracil) and the efficacy of this combination." | 9.07 | Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients. ( Bertuccelli, M; Brunetti, I; Cianci, C; Conte, PF; Falcone, A; Ricci, S, 1994) |
| "Thirty-one patients with hepatic metastases from colorectal carcinoma were treated with carboplatin (CBDCA), 55 mg/m2, given in a 4-hour intra-arterial infusion daily for 5 days, and 5-fluorouracil, 900 mg/m2, given in a 20-hour intra-arterial infusion daily for 5 days." | 9.07 | Intra-arterial hepatic treatment with carboplatin (CBDCA) and 5-fluorouracil (5-FU) in metastases from colorectal carcinoma. ( Abuchaibe, O; Bilbao, I; Hidalgo, OF; Pardo, F; Rebollo, J; Tangco, E; Vieitez, JM, 1993) |
| "One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5-FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i." | 9.07 | Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. ( Hahn, RG; Krook, JE; Laurie, JA; Mailliard, JA; Morton, RF; Patel, SR; Therneau, TM; Twito, DI; Windschitl, HE, 1992) |
| "Twenty-two patients with previously untreated metastatic breast cancer and nineteen patients with refractory metastatic breast cancer were treated with trimetrexate (TMTX)." | 9.07 | Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. ( Carey, RW; Clamon, GH; Costanza, ME; Dawson, NA; Korzun, AH; Norton, L; Pollak, M; Vogelzang, NJ, 1991) |
| "We conducted a phase II clinical trial of 5-fluorouracil (5 day continuous infusion), cis-diamminedichloroplatinum and etoposide in previously untreated patients with metastatic carcinoma of unknown primary origin." | 9.07 | Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. ( Abbruzzese, JL; Faintuch, J; Frost, P; Raber, MN; Sumrall, C, 1991) |
| "A phase I study of 5-fluorouracil 600 mg/m2/week and folinic acid 500 mg/m2/week on day 1 and cisplatin administered weekly on day 2 was carried out on 30 patients with metastatic colorectal carcinoma of which 20 patients were pretreated with 5-fluorouracil." | 9.07 | A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinoma. ( Creaven, P; Gebbia, N; Gebbia, V; Palmeri, S; Petrelli, N; Rausa, L; Russo, A; Rustum, Y, 1991) |
| "A total of 21 untreated patients (5 males, 16 females; median age, 55 years; range, 28-72) with advanced measurable colorectal carcinoma were treated with an association of 5-fluorouracil (1000 mg/weekly) and alpha-2 interferon (three times a week s." | 9.06 | Alpha-2 interferon and 5-fluorouracil in advanced colorectal cancer. ( Aversa, SM; Daniele, O; Fiorentino, MV; Fornasiero, A; Ghiotto, C; Morandi, P, 1990) |
| "On the strength of recent evidence of the activity of the combination of cisplatin and 5-fluorouracil against squamous malignancies of the esophagus and head and neck, this regimen was evaluated in a phase II trial against metastatic or recurrent squamous carcinoma of the uterine cervix." | 9.06 | A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. ( Alberts, DS; Boutselis, JG; Green, S; Hannigan, EV; Surwit, EA; Wallace, DL; Weiss, GR, 1990) |
| "Three hundred thirty-one women with metastatic breast cancer were randomized to receive combination chemotherapy with either cyclophosphamide, Novantrone (mitoxantrone; Lederle Laboratories, Wayne, NJ), and fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and fluorouracil (CAF)." | 9.06 | A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. ( Bennett, JM; Cartwright, K; Doroshow, JH; Dukart, G; Krementz, ET; Muss, HB; Reisman, A; Schoch, I; Wolff, S, 1988) |
| "Fifty consecutive patients with recurrent and metastatic endometrial carcinoma were treated with melphalan, 5-fluorouracil, and medroxyprogesterone acetate with or without tamoxifen as first-line chemotherapy." | 9.06 | Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma. ( Emrich, LJ; Lele, SB; Patsner, B; Piver, MS, 1986) |
| "We performed the present systematic review and meta-analysis to evaluate the efficacy and safety for S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma (mCRC)." | 9.01 | Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis. ( Chen, J; Wang, J, 2019) |
| "Both capecitabine and bevacizumab are established agents in the treatment of metastatic breast cancer, but until recently clinical data supporting their use in combination were limited." | 8.88 | Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review. ( Martin, M; Miles, D; Robert, N; Vrdoljak, E; Zielinski, C, 2012) |
| " In this review, we summarized the current status of our knowledge about the effectiveness of curcumin when given in combination with current chemotherapeutics such as 5-fluorouracil, oxaliplatin, and gemcitabine in treatment of gastrointestinal cancers with particular reference to colorectal cancer." | 8.85 | Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview. ( Majumdar, AP; Patel, BB, 2009) |
| "Three clinical trials have been conducted with fluorouracil (5-FU) and recombinant interferon alfa-2a (rIFN-alpha 2a) in the treatment of advanced colorectal carcinoma." | 8.78 | Clinical trials of fluorouracil with alpha-interferon in advanced colorectal carcinomas. ( Bready, B; Moore, DF; Pazdur, R, 1991) |
| "Seventy-five previously untreated patients with measurable advanced colorectal cancer were treated with 5 fluorouracil 1,000 mg/m2 as a 24-hour intravenous (i." | 8.78 | 120-hour 5-fluorouracil (5-FU) continuous infusion (CI) plus BCNU in advanced colorectal cancer. ( Aguilo, J; Asencio, F; Candel, MT; Delgado, F; García-Reinoso, J; Martínez-Abad, M; Sánchez, JJ; Sanchis, C; Viciano, V; Villar-Grimalt, A, 1991) |
| "We retrospectively evaluated the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin, and 5-fluorouracil (TPF) for T3 N0 glottic carcinoma without vocal cord fixation." | 8.12 | Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil for T3 N0 Glottic Carcinoma Without Vocal Cord Fixation. ( Fukugawa, Y; Matsuyama, T; Murakami, D; Nishimoto, K; Orita, Y; Oya, N; Saito, T; Toya, R; Watakabe, T, 2022) |
| "To investigate the effects of mitomycin-C (MMC) and 5-fluorouracil (5-FU) on the viability, proliferation, and migratory capacity of cultured ocular adnexal sebaceous carcinoma (SC) cells." | 8.12 | Effects of Mitomycin-C and 5-Fluorouracil on Ocular Adnexal Sebaceous Carcinoma Cells. ( Gallo, RA; Gomez, A; Lang, SH; Pelaez, D; Rong, AJ; Sabater, AL; Tse, DT, 2022) |
| "5-Fluorouracil-based therapy remains the main approach in colorectal cancer, even though there are still some drawbacks, such as chemoresistance." | 7.96 | Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5-fluorouracil in vivo. ( Achim, M; Banciu, M; Casian, T; Dragos, N; Drotar, DM; Licarete, E; Luput, L; Muntean, D; Patras, L; Porfire, A; Rauca, VF; Sesarman, A; Stejerean, I; Toma, VA; Tomuta, I; Vlase, L, 2020) |
| " The present study aimed to investigate the effect of Rosmarinic acid (RA) on chemoresistance to 5-Fu and its molecular mechanism in gastric carcinoma." | 7.91 | Rosmarinic acid reduces the resistance of gastric carcinoma cells to 5-fluorouracil by downregulating FOXO4-targeting miR-6785-5p. ( Chen, DQ; Feng, JF; Li, WB; Liu, HX; Lu, JW; Yu, C, 2019) |
| " In this study, we investigated the effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma (CRC) cells and its mechanism." | 7.88 | The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism. ( Jiang, GS; Liu, GW; Liu, YH; Ren, WD, 2018) |
| "This study analyzes the anti-tumor effects of evodiamine on cellular growth, tumorigenesis, cell cycle and apoptosis induction of human urothelial cell carcinoma (UCC) cells." | 7.85 | Evodiamine Induces Cell Growth Arrest, Apoptosis and Suppresses Tumorigenesis in Human Urothelial Cell Carcinoma Cells. ( Chin, CC; Huang, YC; Kuo, YH; Lee, YR; Li, JM; Shi, CS, 2017) |
| "To evaluate the efficacy of induction chemotherapy with docetaxel, cisplatin and fluorouracil (TPF) followed by concurrent chemoradiotherapy (IC+CCRT) or CCRT alone in non-endemic locally advanced nasopharyngeal carcinoma (NPC) patients." | 7.83 | Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. ( Blanchard, P; De Felice, F; Deutsch, E; El Khoury, C; Even, C; Gorphe, P; Janot, F; Levy, A; Nguyen, F; Ou, D; Tao, Y; Temam, S, 2016) |
| "We surmise that 5-fluorouracil, levofolinate, and oxaliplatin have the potential to provide a good response for tumors that are sensitive to fluorinated pyrimidine and platinum-containing anticancer drugs such as breast cancer." | 7.80 | An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report. ( Goto, M; Ishiyama, S; Kojima, Y; Komiyama, H; Niwa, K; Okuzawa, A; Sakamoto, K; Sugimoto, K; Takahashi, M; Tomiki, Y; Yaginuma, Y, 2014) |
| "Our aim was to evaluate the efficacy and toxicity of cisplatin, fluorouracil, and docetaxel chemotherapy plus intensity-modulated radiotherapy (IMRT) for locoregionally advanced nasopharyngeal carcinoma (NPC)." | 7.79 | Experience with combination of docetaxel, cisplatin plus 5-fluorouracil chemotherapy, and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma. ( Du, C; Hu, C; Ying, H; Zhang, Y; Zhou, J, 2013) |
| "We previously demonstrated that 14-3-3σ was downregulated in 5-fluorouracil (5-Fu)-resistant MCF-7 breast cancer cells (MCF-7/5-Fu)." | 7.78 | 14-3-3σ regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation. ( He, Z; Peng, B; Xiong, Y; Yi, S; Zhang, Q; Zhang, W; Zheng, G, 2012) |
| "On the basis of this small retrospective survey, we conclude that CMFVP combination chemotherapy is both effective and safe in patients with metastatic breast cancer previously treated with both taxanes and anthracyclines." | 7.78 | Efficacy of the CMFVP regimen in patients with metastatic breast cancer previously treated with anthracycline and taxane. ( Grenader, T, 2012) |
| " In this study, patient-derived tumor tissue (PDTT) xenograft models of primary colon carcinoma and lymphatic and hepatic metastases were established for assessment of the antitumor activity of FP3 in combination with capecitabine." | 7.78 | Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. ( Cao, F; Han, N; He, K; Jin, K; Lan, H; Li, G; Teng, L; Xie, B; Xu, Z, 2012) |
| "The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using cytoreductive surgery prior to treatment with hyperthermic intraperitoneal chemotherapy with mitomycin C as part of a multidrug regimen." | 7.77 | Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. ( Chang, D; Mahteme, H; Stuart, OA; Sugarbaker, PH; Van der Speeten, K, 2011) |
| "5-fluorouracil chemotherapy in patients with dihydropyrimidine dehydrogenase deficiency, can give rise to ocular and cutaneous toxicity." | 7.77 | A bilateral cicatricial ectropion and bilateral upper lid shortening caused by 5-fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. ( Kemp, E; McDonald, A; Obi, EE, 2011) |
| " In the present study, we evaluated the characteristics of paclitaxel (PTX) and 5-fluorouracil (5-FU) penetration and their effects on tissue penetration using MCLs of human colorectal cancer cells (DLD-1 and HT-29) grown in Transwell inserts." | 7.77 | Penetration of paclitaxel and 5-fluorouracil in multicellular layers of human colorectal cancer cells. ( Choi, MS; Kim, SH; Kuh, HJ, 2011) |
| " We aimed to evaluate the effect of pretreatment serum metabolic profiles generated by (1)H NMR spectroscopy on toxicity in patients with inoperable colorectal cancer receiving single agent capecitabine." | 7.77 | Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. ( Backshall, A; Clarke, SJ; Keun, HC; Sharma, R, 2011) |
| "In patients with advanced hepatocellular carcinoma (HCC), combination chemotherapy using 5- fluorouracil, cisplatin, and mitoxantrone (FMP) could achieve a response rate > 20%, but the beneficial effect was compromised by formidable adverse events." | 7.77 | Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. ( Chen, HC; Hsu, CL; Hung, CF; Lin, CC; Pan, KT; Sung, CM; Tseng, JH; Yeh, CT, 2011) |
| "Germline DNA was available from 568 previously untreated patients with advanced colorectal cancer participating in the CAIRO2 trial, assigned to capecitabine, oxaliplatin, and bevacizumab ± cetuximab." | 7.77 | Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. ( Beijnen, JH; Burylo, AM; Cats, A; de Boer, A; Deenen, MJ; Doodeman, VD; Guchelaar, HJ; Punt, CJ; Schellens, JH; Smits, PH; Tol, J; Vincent, A, 2011) |
| " Toxicity (primarily gastrointestinal) necessitated dosage modification in 10 patients (29%)." | 7.77 | Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review. ( Balaban, EP; Bull, J; Frenkel, EP; Graham, M; Periman, P; Perkins, S; Pruitt, B; Ross, M; Ruud, C; Sheehan, RG, 1994) |
| "The global lapatinib expanded access programme provided access to lapatinib combined with capecitabine for women with HER2-positive metastatic breast cancer (MBC) who previously received anthracycline, taxane and trastuzumab." | 7.76 | Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. ( Ashley, S; Bhatti, R; Camburn, T; Chan, S; Davidson, N; Johnston, SR; Miles, D; Nouras, H; Shehata, M; Sutherland, S; Wardley, A, 2010) |
| " To investigate the molecular basis for the effect of TP on the metabolic process and the anticancer effect of 5-fluorouracil (5-FU), human gastric carcinoma AZ521 cells and epidermoid carcinoma KB cells were transfected with TP cDNA, and AZ521/TP and KB/TP were cloned." | 7.76 | The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells. ( Akiyama, S; Che, XF; Furukawa, T; Ikeda, R; Kanekura, T; Kanzaki, T; Mataki, H; Matsushita, S; Minami, K; Miyadera, K; Nishizawa, Y; Tabata, S; Tajitsu, Y; Takeda, Y; Ushiyama, M; Yamada, K; Yamamoto, M, 2010) |
| "After cisplatin / 5-fluorouracil chemotherapy for nasopharyngeal carcinoma, an 18-year female patient developed aortobifemoral embolism." | 7.76 | Aortobifemoral embolism in an 18-year old patient following cisplatin and 5-fluorouracil chemotherapy for nasopharyngeal carcinoma. ( Bode, U; Born, M; Fleischhack, G; Heinrich, N; Hoebert, E; Simon, A; Verrel, F, 2010) |
| "To evaluate the efficacy and the safety of combined 5-Fluorouracil, irinotecan, bevacizumab and sirolimus in refractory advanced colorectal carcinoma." | 7.75 | Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study. ( Chauffert, B; Ghiringhelli, F; Guiu, B; Ladoire, S, 2009) |
| "To investigate the inhibitive effects of triptolide (TPL) combined with 5-fluorouracil (5-FU) on colon carcinoma HT-29 cells in vitro and in vivo and their side effects." | 7.74 | Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. ( Lin, XL; Tang, XY; Tao, WH; Wei, B; Zhu, YQ, 2007) |
| "The levels of both VEGF and PDGF-BB were measured in three time points, in the serum of 32 rectal carcinoma patients receiving daily reduced-dose/continuous capecitabine in combination with preoperative pelvic irradiation." | 7.74 | Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients. ( Be'ery, E; Fenig, E; Koren, C; Lavi, I; Loven, D; Shaked, Y; Sulkes, A; Yerushalmi, R, 2008) |
| "5-Fluorouracil (5-FU) is a key drug in the treatment of esophageal squamous cell carcinoma (ESCC)." | 7.74 | Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines. ( Ando, T; Fujii, Y; Ishiguro, H; Katada, T; Kimura, M; Kuwabara, Y; Mitsui, A; Mori, R; Ogawa, R; Sugito, N, 2008) |
| "5-Fluorouracil (5-FU) is an important chemotherapeutic agent for nasopharyngeal carcinoma (NPC)." | 7.74 | Downregulation of BMI-1 enhances 5-fluorouracil-induced apoptosis in nasopharyngeal carcinoma cells. ( Feng, Y; Kong, QL; Li, MZ; Liao, DF; Qian, CN; Qin, L; Song, LB; Weng, GX; Zeng, MS; Zeng, YX; Zhang, L; Zhang, X, 2008) |
| "The objective of this study was to determine whether HER-2 overexpression is associated with improved response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) in patients with breast carcinoma." | 7.72 | Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. ( Buzdar, AU; Esteva, FJ; Hortobagyi, GN; Kau, SW; Kuerer, HM; McConathy, JM; Pusztai, L; Smith, T; Symmans, WF; Yang, Y; Zhang, F, 2003) |
| " We report two cases of NM from breast carcinoma and a third with esophageal carcinoma, which responded to treatment with capecitabine, an oral prodrug for 5-flurouracil." | 7.72 | Response of neoplastic meningitis from solid tumors to oral capecitabine. ( Giglio, P; Groves, MD; Tremont-Lukats, IW, 2003) |
| "Prior to the administration of 5-fluorouracil chemotherapy, the authors examined 14 colorectal carcinoma patients with unresectable liver metastases using a single PET scan and 18F-labeled fluorouracil (18F-FU)." | 7.70 | 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. ( Dimitrakopoulou-Strauss, A; Gutzler, F; Moehler, M; Raeth, U; Strauss, LG; Stremmel, W, 1998) |
| "A left radical mastectomy was performed on a 53-year-old woman, diagnosed with left inflammatory breast cancer, after local arterial chemotherapy with cyclophosphamide (CPA), doxorubicin and 5-fluorouracil (5-FU)." | 7.70 | [A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)]. ( Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E, 2000) |
| "We report the results of a chemotherapy regimen combining oxaliplatin, 5-fluorouracil, and folinic acid in patients with metastatic renal cell carcinoma." | 7.70 | Oxaliplatin, 5-fluorouracil, and folinic acid (Folfox) in patients with metastatic renal cell carcinoma: results of a pilot study. ( Chaouche, M; Franiatte, J; Grandjean, M; Kamioner, D; Pasturaud, AL; Tourani, JM, 2000) |
| "We studied the effect of combined chemo-immunotherapy, 5-FU followed by thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2) at low doses, on liver metastases from colorectal cancer, induced by splenic injection of DHD/K12 cells (1,2-dimethylhydrazine-induced colon adenocarcinoma) in syngeneic BDIX rats." | 7.69 | Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. ( Garaci, E; Pierimarchi, P; Rasi, G; Silecchia, G; Sinibaldi-Vallebona, P; Sivilia, M; Spaziani, E; Tremiterra, S, 1994) |
| "The metabolism of 5-fluorouracil (5-FU) was monitored non-invasively in two xenografts, a hypopharynx carcinoma and a colon carcinoma (CSM) by 19F-magnetic resonance spectroscopy following an i." | 7.69 | 5-Fluorouracil metabolism and cytotoxicity after pre-treatment with methotrexate or thymidine in human hypopharynx and colon carcinoma xenografts: a 19F-nuclear magnetic resonance spectroscopy study in vivo. ( Baumgart, F; Köpf-Maier, P; Tausch-Treml, R; Ziessow, D, 1996) |
| "A new delivery formulation (5FU-MS) of 5-fluorouracil (5FU), 5FU incorporated in microspheres composed of poly(glycolide-co-lactide) matrix, has been developed for the treatment of peritoneal carcinomatosis, and is designed to slowly release the incorporated 5FU for 3 weeks." | 7.69 | Pharmacological effects of 5-fluorouracil microspheres on peritoneal carcinomatosis in animals. ( Fujita, T; Hagiwara, A; Imanishi, T; Muranishi, S; Ohgaki, M; Sakakura, C; Sawai, K; Takahashi, T; Tsujimoto, H; Yamamoto, A; Yamazaki, J, 1996) |
| "A 40-year-old male patient with carcinoma of the tonsil was put on a 5-fluorouracil and cisplatinum regimen." | 7.68 | Myocardial ischemia after 5-fluorouracil chemotherapy. ( Ayyagari, S; Chag, M; Rastogi, N, 1993) |
| "To perform an economic evaluation of the joint use of 5-fluorouracil and levamisole as adjuvant chemotherapy in patients with fully resected Dukes' Stage C carcinoma of the colon, compared with resection and no chemotherapy." | 7.68 | A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. ( Gurney, H; Hall, J; Harnett, PR; Smith, RD, 1993) |
| "Fourteen patients with progressive metastatic adrenal cortical carcinoma were treated with a combination of 5-fluorouracil (5-FU), doxorubicin, and cisplatin (FAP)." | 7.68 | 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. ( Brugieres, L; Droz, JP; Gicquel, C; Parmentier, C; Schlumberger, M; Travagli, JP, 1991) |
| "Forty-three patients with nonmetastatic inflammatory breast carcinoma have been treated by initial doxorubicin, 5-fluorouracil, and cyclophosphamide (FAC) combination chemotherapy." | 7.68 | Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. ( Bergerat, JP; Boilletot, A; Duclos, B; Dufour, P; Giron, C; Haennel, P; Herbrecht, R; Jaeck, D; Jung, G; Maloisel, F, 1990) |
| "Nine patients (5 males, 4 females; median age, 62 years) with recurrent high-grade malignancies of major (7 cases) and minor (2 cases) salivary gland origin (4 adenoid cystic carcinomas, 2 adenocarcinomas, 2 poorly differentiated carcinomas, 1 mixed malignant tumor) were treated with cisplatin (60 mg/m2), epirubicin (50 mg/m2) and 5-fluorouracil (600 mg/m2) (CEF) by intravenous injections on the first day of a 21-day regimen." | 7.67 | Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. ( Airoldi, M; Brando, V; Gabriele, P; Giordano, C; Pedani, F, 1989) |
| "Based on the in vitro and in vivo data suggesting synergistic cytolysis by the combination of 5-fluorouracil and interferon-gamma against a variety of malignant cell lines including a human colon carcinoma cell line (HT-29), we initiated studies in patients with advanced colon or rectal carcinoma." | 7.67 | Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. ( Abbruzzese, JL; Ajani, JA; Edwards, C; Ende, K; Faintuch, JS; Gutterman, JU; Levin, B; Rios, AA; Saks, S, 1989) |
| "Effects of N-(6-aminohexyl)-1-naphthalenesulfonamide (W-5) and N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7) on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur, FT) and a mixture of FT and uracil (UFT) were determined in nude mice bearing human ovarian carcinoma (KF cells)." | 7.67 | Adjuvant effects of calmodulin antagonists on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur) and a mixture of ftorafur and uracil (UFT) in nude mice bearing human ovarian carcinomas. ( Iwano, I; Kikuchi, Y; Kita, T; Kizawa, I; Kuki, E; Miyauchi, M; Oomori, K, 1989) |
| "Based on in vitro studies that have demonstrated synergy between recombinant alfa-2a-interferon (rIFN alpha-2a) and the fluoropyrimidine, fluorouracil (5FU), against two human colon cancer cell lines, a pilot clinical trial was initiated to determine the effects of the combination of 5FU and rIFN alpha-2a in patients with advanced, unresectable colorectal carcinoma." | 7.67 | Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. ( Goldman, M; Itri, L; Lyver, A; Rader, M; Schwartz, EL; Wadler, S; Weinberg, V; Wiernik, PH; Zimmerman, M, 1989) |
| "Following the observation of antitumor activity for the combination of 5-fluorouracil (5-FU) and cisplatin in metastatic colorectal carcinoma, the combination of 5-FU and iproplatin was tested, also in colorectal carcinoma, in the hope of attaining equivalent activity without the nephrotoxicity observed with 5-FU/cisplatin." | 7.67 | Phase II trial of continuous-infusion iproplatin (CHIP) and 5-fluorouracil (5-FU) in advanced colorectal carcinoma. ( Creaven, PJ; Herrera, L; Mittelman, A; Petrelli, NJ, 1989) |
| "Parameters for inhibition of thymidylate synthase (TS) in a DMH-induced transplantable rat colon carcinoma were studied after intraperitoneal administration of bolus doxifluridine (5'-dFUR) 200 mg/kg." | 7.67 | Inhibition of thymidylate synthase after administration of doxifluridine in a transplantable colon carcinoma in the rat. ( Almersjö, O; Berne, M; Gustavsson, B; Spears, P; Sundström, E, 1988) |
| "Five patients with metastatic adrenal cortical carcinoma were treated with a combination of 5-fluorouracil (5-FU), doxorubicin, and cisplatin." | 7.67 | 5-Fluorouracil, doxorubicin, and cisplatin regimen in adrenal cortical carcinoma. ( Bellaiche, M; Droz, JP; Ostronoff, M; Parmentier, C; Rougier, P; Schlumberger, M, 1988) |
| "Twenty-five consecutive cases of inflammatory breast carcinoma were treated with high-dose cyclophosphamide and 5-fluorouracil in 5-day courses every 3 weeks for 2 years, with total mastectomy performed after the third course." | 7.67 | Two years of high-dose cyclophosphamide and 5-fluorouracil followed by surgery after 3 months for acute inflammatory breast carcinomas. A phase II study of 25 cases with a median follow-up of 35 months. ( Breau, JL; Israël, L; Morere, JF, 1986) |
| "Combination three-drug chemotherapy with adriamycin (ADM), cyclophosphamide (CPM), and 5-fluorouracil (5-FU) was performed in 24 cases of advanced bladder cancer who underwent surgical treatment, and three cases with recurrent or metastatic bladder cancer." | 7.66 | Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil. ( Machida, T; Masuda, F; Ohishi, Y; Tashiro, K, 1983) |
| "Advanced gastric cancer is associated with poor survival despite chemotherapy." | 7.30 | Study of Efficacy and Toxicity of Capecitabine Maintenance After Response to Docetaxel, Cisplatin, and 5-Fluracil-Based Chemotherapy in Advanced Carcinoma Stomach. ( Chaudhari, K; Doval, DC; Goel, V; Goyal, P; Koyyala, VPB; Maheshwari, U; Patnaik, N; Talwar, V, 2023) |
| "Patients with stage III-IVa-b NPC received lobaplatin at a dose of 30 mg/m2 on days 1 and 22 combined with a continuous 120-h intravenous injection of 5-fluorouracil at a dose of 4 g/m2 followed by lobaplatin at a dose of 50 mg/m2 on days 43 and 64 concomitant with intensity-modulated radiation therapy." | 6.84 | Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial. ( Guo, X; Huang, XJ; Ke, LR; Liang, H; Liu, GY; Lv, X; Qiu, WZ; Xia, WX; Xiang, YQ; Yang, J; Ye, YF; Yu, YH, 2017) |
| " Treatment consisted of paclitaxel at a dose of 135 mg/m(2) on day 1, cisplatin 25 mg/m(2)/day from day 1 to day 3 and 5-FU-continuous infusion for 120 h at a variable dosage from 600 to 1,000 mg/m(2)/day according to prior radiation." | 6.78 | Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma. ( An, X; Chen, C; Li, YH; Liang, Y; Luo, HY; Wang, FH; Wang, ZQ; Zhang, L, 2013) |
| "Cediranib is an oral highly potent VEGF signalling inhibitor that inhibits all three VEGF receptors." | 6.77 | Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study. ( Amagai, K; Baba, H; Bando, H; Denda, T; Fukase, K; Hazama, S; Kato, T; Mishima, H; Muro, K; Shi, X; Skamoto, J; Yamaguchi, K, 2012) |
| "Although anaplastic thyroid carcinoma has a dismal prognosis, some patients show favorable survival following multimodal treatment with surgery, external irradiation and chemotherapy." | 6.76 | A novel chemo-radiotherapy with low-dose daily cisplatin, 5-fluorouracil and doxorubicin for anaplastic thyroid carcinoma: a preliminary report. ( Fujimoto, Y; Sugitani, I; Tanaka, K, 2011) |
| "To evaluate the efficacy and the toxicity of front line FOLFOX4 combined with bevacizumab in patients with metastatsic CRC (mCRC)." | 6.73 | Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. ( Agelaki, S; Androulakis, N; Chatzidakis, A; Christophylakis, C; Diamandidou, E; Emmanouilides, C; Georgoulias, V; Kalbakis, K; Kalykaki, A; Kotsakis, A; Mavroudis, D; Sfakiotaki, G; Souglakos, J; Touroutoglou, N; Vamvakas, L, 2007) |
| "Median time from breast cancer diagnosis to the development of CNS metastasis was 48 (18-165) months." | 6.73 | Capecitabine therapy of central nervous system metastases from breast cancer. ( Abrey, LE; Deangelis, LM; Ekenel, M; Hormigo, AM; Peak, S, 2007) |
| " Severe taxane-related toxic effects were more frequent in group A, while severe thrombocytopenia was low and present only in group A." | 6.73 | Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. ( Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N, 2008) |
| "The addition of cetuximab to capecitabine, oxaliplatin and bevacizumab in the first-line treatment of ACC appears to be safe and feasible." | 6.73 | A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. ( Antonini, NF; Cats, A; Creemers, GJ; Erdkamp, FL; Koopman, M; Mol, L; Punt, CJ; Rodenburg, CJ; Schrama, JG; Tol, J; Vos, AH, 2008) |
| "Patients with untreated advanced colorectal cancer were enrolled to this single arm phase II multi-center cooperative group trial of bevacizumab combined with IFL." | 6.72 | A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. ( Benson, AB; Catalano, PJ; Giantonio, BJ; Levy, DE; Meropol, NJ; O'dwyer, PJ, 2006) |
| "There are 106 women treated for breast cancer T1c-3a, N0-1, M0 in the study." | 6.69 | [Comparison of adjuvant chemotherapy in breast carcinoma with a combination of cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and AC (doxorubicin, cyclophosphamide). Initial results of a national cooperative study]. ( Bauer, J; Bustová, I; Dorazilová, V; Fischer, J; Hacklová, M; Honová, H; Kohoutek, M; Kůta, M; Kyselá, T; Machácek, J; Miller, V; Petruzelka, L; Pribylová, O; Siffnerová, H; Suk, J; Tajblová, J; Vodvárka, P, 1998) |
| " A single dose of IFNalpha as low as 3 MIU m(-2) can cause sustained elevation of PBL TP activity in vivo indicating that biochemical markers are important pharmacodynamic endpoints for developing optimal schedules of IFNalpha for biomodulation of 5-FU." | 6.69 | Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha. ( Braybrooke, JP; Ganesan, TS; Harris, AL; Houlbrook, S; Koukourakis, MI; Love, SD; O'Byrne, KJ; Patterson, AV; Propper, DJ; Talbot, DC; Taylor, M; Varcoe, S, 2000) |
| " These results show that there is no pharmacokinetic advantage to the use of 6S-LV rather than 6R,S-LV as a modulator of 5-FU." | 6.68 | A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma. ( Berghorn, E; Blumenson, LE; Creaven, PJ; Frank, C; Meropol, NJ; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, YM, 1995) |
| "Thirty-two patients (76%) had no oral mucositis." | 6.68 | Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. ( Chan, WK; Chen, KY; Chen, SY; Chi, KH; Law, CK; Shu, CH; Yen, SH, 1995) |
| "Grade 4 leukopenia was observed in 1 case and grade 3 to 4 thrombocytopenia was observed in two cases, respectively." | 6.68 | The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD). ( Antón-Torres, A; Aranda, E; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Massutí, T, 1996) |
| "Treatment with levamisole alone had no detectable effect." | 6.67 | Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. ( Emerson, WA; Fleming, TR; Glick, JH; Goodman, PJ; Haller, DG; Laurie, JA; Macdonald, JS; Moertel, CG; Tormey, DC; Ungerleider, JS, 1990) |
| "More than 80% of undifferentiated carcinoma nasopharyngeal type patients with N3 disease (AJC-UICC 1987) will die with or from distant metastases within 3 years after the first symptom." | 6.38 | Alternating chemo-radiotherapy with cisplatin and 5-fluorouracil plus bleomycin by continuous infusion for locally advanced undifferentiated carcinoma nasopharyngeal type. ( Armand, JP; Azli, N; Bachouchi, M; Boussen, H; Cvitkovic, E; Eschwege, F; Gasmi, J; Rahal, M; Schwaab, G; Wibault, P, 1992) |
| "Forty patients with locally advanced cervical carcinoma were entered into a protocol utilizing the bolus administration of both mitomycin C (10 or 15 mg) on Day 1 and 5-fluorouracil (400 mg) on Day 1-5 followed by sequential pelvic irradiation on Day 6 between September 1980 and October 1985." | 6.18 | Bolus mitomycin C and 5-FU with sequential radiation for poor-prognosis locally advanced cervical cancer. ( Breen, JL; Denehy, TR; Eastman, R; Gregori, CA; SanFilippo, L, 1996) |
| "The efficacy of mitotane in providing objective tumour responses in patients with adrenocortical carcinoma (ACC), has been recently questioned." | 6.17 | Cytotoxic chemotherapy for adrenocortical carcinoma. ( Alì, A; Angeli, A; Berruti, A; Dogliotti, L; Paccotti, P; Pia, A, 1995) |
| "Chloroquine (CQ) is an effective and safe antimalarial drug that is also used as a disease-modifying antirheumatic drug." | 5.91 | Chloroquine prevents hypoxic accumulation of HIF-1α by inhibiting ATR kinase: implication in chloroquine-mediated chemosensitization of colon carcinoma cells under hypoxia. ( Ju, S; Jung, Y; Kang, C; Kim, J, 2023) |
| "Nitazoxanide (NTZ) is an emerging cancer therapy and its targeted GSTP1 evidence remains a knowledge need." | 5.91 | The GSTP1/MAPKs/BIM/SMAC modulatory actions of nitazoxanide: Bioinformatics and experimental evidence in subcutaneous solid Ehrlich carcinoma-inoculated mice. ( Abd El-Moneam, SM; Abdelmaogood, AKK; Elaidy, SM; Elkholy, SE; Faisal, S; Imbaby, S; Mansour, BSA; Mehana, AE, 2023) |
| "5-Fluorouracil has been considered as a cornerstone therapy for colorectal cancer; however, it suffers from low therapeutic response rate and severe side effects." | 5.46 | Apoptosis mediated chemosensitization of tumor cells to 5-fluorouracil on supplementation of fish oil in experimental colon carcinoma. ( Agnihotri, N; Kaur, S; Kumar, S; Rani, I; Sharma, B, 2017) |
| "Distant metastases was the predominant site of failure, seen in 5 patients (20%)." | 5.46 | Induction Methotrexate, Cisplatin, and 5-Fluorouracil Versus Cisplatin and 5-Fluorouracil Followed by Radiotherapy in Pediatric Nasopharyngeal Carcinoma: A Retrospective Analysis in a Tertiary Cancer Center. ( Abu-Hijlih, R; Al Mousa, A; Ismael, T; Mohamad, I; Mula-Hussain, L; Salem, A; Sultan, I, 2017) |
| "Peritoneal metastasis is common in gastric cancer." | 5.46 | Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready? ( Chan, DY; Chee, CE; Nga, ME; Phua, JN; Shabbir, A; So, JB; Soh, TI; Syn, NL; Yap, R; Yong, WP, 2017) |
| " The chemotherapy drugs were administered as follows: 135 mg/m(2) paclitaxel on day 1, 25 mg/m(2)/day cisplatin on days 1-3, followed by continuously infused intravenous fluorouracil for 120 h at a variable dosage from 600 to 800 mg/m(2)/day, depending on prior radiation." | 5.43 | A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery. ( Jiang, YX; Li, YH; Liang, Y; Luo, HY; Wang, DS; Wang, FH; Wang, Y; Wang, ZQ, 2016) |
| "In 5-fluorouracil (5-FU)-treated patients, the tumour overexpression of SOX9 correlated with markedly poorer survival (HR=8." | 5.39 | Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients. ( Candy, PA; Colley, SM; Davidson, JA; Leedman, PJ; Phillips, MR; Redfern, AD; Stuart, LM; Wood, BA; Zeps, N, 2013) |
| "5-Fluorouracil (5-FU) is an anti-metabolite that is in clinical use for treatment of several cancers." | 5.39 | 5-Fluorouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells. ( Akpinar, B; Baran, Y; Can, G; Olsson, M; Zhivotovsky, B, 2013) |
| "The primary treatment for nasopharyngeal carcinoma (NPC) is external beam radiotherapy." | 5.38 | Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response. ( Jiang, X; Wang, YX; Yan, D; Yan, S; Yang, J, 2012) |
| "We report on a 45-year-old breast cancer patient with disseminated hepatic metastases." | 5.36 | Successful remission of extensive liver metastases in a breast cancer patient with acute liver failure using a combined chemotherapy regimen with mitomycin, folinate, and 5-fluorouracil (Mi/Fo/FU). ( Eichbaum, MH; Hauser, N; Hohl, MK; Sohn, C; Stoiber, B; Stoiber, N, 2010) |
| "Capecitabine is an antineoplastic agent used for the treatment of patients with metastatic solid tumors (breast and colon)." | 5.34 | [Capecitabine-induced hyperpigmentation]. ( Galán-Gutiérrez, M; Jiménez-Puya, R; Moreno-Giménez, JC; Rodríguez-Bujaldón, AL; Vázquez-Bayo, C, 2007) |
| "Resistant HCT-8 colon cancer cell lines (HCT-8/FUI/15R and HCT-8/FUB/2R) were selected from parental sensitive HCT-8 cells by long-term and short-term exposure schedules, respectively." | 5.33 | Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules. ( Caciagli, B; Capaccioli, S; Donnini, M; Landini, I; Lapucci, A; Lulli, M; Mazzei, T; Mini, E; Morganti, M; Nobili, S; Papucci, L; Perna, F; Schiavone, N; Sobrero, A; Tempestini, A; Witort, E, 2005) |
| "Type 1 undifferentiated carcinoma (non-small cell type) was detected in the middle of the thoracic esophagus in August 1999." | 5.32 | [Complete remission of esophageal undifferentiated carcinoma with nedaplatin and 5-FU chemotherapy and endoesophageal brachytherapy]. ( Iwashige, M; Kikuchi, H; Kumada, K; Midorikawa, T; Nagasaki, H; Nemoto, H; Sanada, Y; Takeuchi, S; Takizawa, K; Tate, G; Yagi, H; Yoshizawa, Y, 2003) |
| "Colorectal carcinomas are well known to highly express COX-2 and their growth is markedly inhibited by COX-2 inhibitors, but little is known about head and neck carcinomas." | 5.32 | Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. ( Hashitani, S; Maeda, T; Nishimura, N; Noguchi, K; Sakurai, K; Takaoka, K; Urade, M, 2003) |
| "Irofulven has demonstrated potent activity against a broad range of solid tumors in both cellular and xenograft models and has shown promising activity in clinical trials." | 5.32 | Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells. ( Cvitkovic, E; Koeppel, F; Larsen, AK; Poindessous, V; Raymond, E; Waters, SJ, 2003) |
| "A prospective analysis was performed using data from the Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial, a randomized, double-blinded, placebo-controlled trial of topical 5-fluorouracil for chemoprevention of KC." | 5.30 | Effects of increased actinic keratosis count on skin-related quality of life: results from the Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) Trial. ( Beatson, M; Chren, MM; Siegel, JA; Weinstock, MA, 2019) |
| "Mitomycin C (10 mg/m2) was administered as a bolus injection on day 2." | 5.28 | Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. ( Coia, LR; Engstrom, PF; Hanks, GE; Paul, AR; Stafford, PM, 1991) |
| " The dosage of raIFN-2a could not be further escalated above 12 x 10(6) IU." | 5.28 | 5-Fluorouracil and recombinant alpha interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study. ( Gebbia, V; Palmeri, S; Rausa, L, 1990) |
| "Tumor response to neoadjuvant chemotherapy using the regimen of cisplatin and 5-fluorouracil could define high-risk patients with locoregionally advanced nasopharyngeal carcinoma (NPC)." | 5.24 | Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial. ( Chen, L; Guo, R; Guo, Y; Li, WF; Ma, J; Mao, YP; Peng, H; Sun, Y; Zhang, Y, 2017) |
| "5-Fluorouracil plus cisplatin is the most commonly used chemotherapy regimen for nasopharyngeal carcinoma (NPC)." | 5.22 | Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma. ( Fang, W; Hu, Z; Huang, Y; Li, Y; Lin, Y; Liu, W; Ma, Y; Qin, T; Salamone, SJ; Sheng, J; Yang, Y; Zhang, L; Zhang, Y; Zhao, H; Zhao, L; Zhao, Y; Zou, B, 2016) |
| " Ocular discomfort occurred in 43 of 49 patients in the fluorouracil group versus 36 of 49 in the placebo group, epiphora occurred in 24 versus five, and eyelid skin inflammation occurred in seven versus none." | 5.22 | Topical fluorouracil after surgery for ocular surface squamous neoplasia in Kenya: a randomised, double-blind, placebo-controlled trial. ( Burton, MJ; Gichuhi, S; Kabiru, J; Macharia, E; Maina, J; Munene, R; Ollando, E; Onyuma, T; Rono, H; Sagoo, MS; Wachira, J; Weiss, HA; Zindamoyen, AM, 2016) |
| "A multicenter randomized trial was performed comparing oral tegafur/gimeracil/oteracil (S-1) and uracil-tegafur/ leucovorin (UFT/LV) as adjuvant therapy for stage III colorectal cancer." | 5.22 | Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer. ( Kaiho, T; Kobayashi, S; Koda, K; Kosugi, C; Maruyama, T; Matsubara, H; Miyauchi, H; Takiguchi, N, 2016) |
| "A current recommendation for locoregionally advanced nasopharyngeal carcinoma (NPC) is conventional fractionated radiotherapy with concurrent cisplatin plus adjuvant cisplatin and fluorouracil (PF)." | 5.20 | Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr ( Chan, AT; Chan, LL; Chan, OS; Chappell, R; Cheng, A; Cheung, FY; Choi, H; Kwong, DL; Lee, AW; Lu, TX; Ng, WT; Ngan, RK; Tung, SY; Wong, F; Yau, S; Yiu, H; Yuen, KT, 2015) |
| "To investigate the efficacy and safety of selective radiotherapy after distant metastasis of nasopharyngeal carcinoma (NPC) treated with dose-dense cisplatin plus fluorouracil." | 5.20 | Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil. ( Bu, JG; Chen, BY; Chen, KQ; Cheng, JL; Feng, J; Gao, WW; Liang, WC; Liang, Y; Xu, YC, 2015) |
| "The present study aimed to evaluate efficacy and adverse effects of Nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in the treatment of advanced oral carcinoma." | 5.19 | Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma. ( Gu, QP; Guo, W; Li, ZP; Meng, J; Meng, QF; Si, YM; Zhang, J; Zhuang, QW, 2014) |
| "Although cisplatin combined with 5-fluorouracil is a common first-line regimen for advanced nasopharyngeal carcinoma (NPC), there are no standard regimens for refractory or relapsed patients." | 5.19 | Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy. ( Bai, B; Cai, QC; Cai, QQ; Gao, Y; Huang, HQ; Wang, XX, 2014) |
| "Palliative chemotherapy with cisplatin/5-fluorouracil (5FU) is the commonest regimen employed for metastatic and recurrent head and neck squamous cell carcinoma (SCCHN) and nasopharyngeal carcinoma (NPC)." | 5.17 | Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma. ( Aslan, NM; Chee Ee Phua, V; Ismail, F; Kua, VF, 2013) |
| "A single-arm, multicentre, phase II, open-label study evaluated four 3-weekly cycles of FEC (5-fluorouracil 600 mg/m(2), epirubicin 90 mg/m(2) and cyclophosphamide 600 mg/m(2)) followed by 12 cycles of weekly paclitaxel (80 mg/m(2)) in combination with bevacizumab 10 mg/kg every 2 weeks as neoadjuvant therapy for HER2-negative stage III locally advanced or inflammatory breast carcinoma." | 5.17 | Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. ( Aitini, E; Bighin, C; Bisagni, G; Clavarezza, M; De Placido, S; Del Mastro, L; Durando, A; Galli, A; Garrone, O; Levaggi, A; Restuccia, E; Saracchini, S; Scalamogna, R; Turazza, M, 2013) |
| "To investigate the association of colonic methane, formed by methanogenic achaea, and pH with gastrointestinal symptoms during colorectal cancer chemotherapy." | 5.17 | Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer. ( Blom, M; Holma, R; Korpela, R; Osterlund, P; Poussa, T; Rautio, M; Sairanen, U; Saxelin, M, 2013) |
| "We aimed to investigate the efficacy and tolerability of sorafenib combined with cisplatin and 5-fluorouracil (5-FU) in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)." | 5.17 | Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. ( Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY, 2013) |
| "In this study we evaluated the clinical efficacy and tolerability of low dose, capecitabine (500mg twice daily) together with oral cyclophosphamide (CTX) (a dose of 50mg once daily) in patients with metastatic breast cancer." | 5.16 | Metronomic chemotherapy in metastatic breast cancer: impact on VEGF. ( El Mahdy, MM; El-Arab, LR; Swellam, M, 2012) |
| "Registered dose capecitabine monotherapy is active against metastatic breast cancer (MBC), but retrospective analyses indicate that lower doses may be as effective and better tolerated." | 5.16 | Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. ( Calvani, N; Cinefra, M; Cinieri, S; Fedele, P; Marino, A; Mazzoni, E; Nacci, A; Orlando, L; Rizzo, P; Schiavone, P; Sponziello, F, 2012) |
| "The Breast Cancer Study Group of the Hellenic Oncology Research Group conducted a phase III trial of single-agent capecitabine versus the vinorelbine/gemcitabine doublet in patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes." | 5.16 | A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. ( Ardavanis, A; Boukovinas, I; Georgoulias, V; Malamos, N; Mavroudis, D; Pallis, AG; Varthalitis, I, 2012) |
| "Adjuvant cisplatin and fluorouracil chemotherapy did not significantly improve failure-free survival after concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma." | 5.16 | Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. ( Chen, L; Chen, XZ; Chen, Y; Chen, YM; Chen, YY; Cheng, ZB; Guo, Y; Hu, CS; Hu, GQ; Li, B; Li, WX; Liang, SB; Liu, MZ; Long, GX; Ma, J; Mao, YP; Sun, Y; Tang, LL; Wang, SY; Xie, FY; Xu, TT; Zheng, BM, 2012) |
| "To evaluate the efficacy of concurrent oral capecitabine with accelerated hypofractionated radical radiotherapy in locally advanced squamous cell carcinoma of the head and neck (SCCHN)." | 5.15 | Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study. ( Birzgalis, A; Homer, J; Jegannathen, A; Lee, L; Mais, K; Ryder, WD; Slevin, N; Sykes, A; Yap, B, 2011) |
| "After a first standard dosed FEC course (5-fluorouracil 600 mg/m(2), epirubicin 60 mg/mg(2) and cyclophosphamide 600 mg/m(2)), patients who did not reach leukopenia grade III or IV were randomised to standard doses (group standard) or doses tailored to achieve grade III leukopenia (group tailored) at courses 2-7." | 5.15 | Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1. ( Ahlgren, J; Andersson, M; Bengtsson, NO; Bergh, J; Bjerre, K; Blomqvist, C; Edlund, P; Holmberg, SB; Jakobsen, E; Lindman, H; Mouridsen, H; Møller, S, 2011) |
| "From March 1994 to March 1998, breast cancer patients (an estimated relapse risk with 70% or more within five years with standard therapy) were randomised to treatment with tailored fluorouracil, epirubicin, and cyclophosphamide (FEC) therapy or FEC followed by marrow-supported high dose therapy in the Scandinavian Breast Group 9401 study." | 5.15 | Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levels. ( Bergh, J; Brandberg, Y; Iiristo, M; Wiklund, T; Wilking, N, 2011) |
| "This study aimed to evaluate acute major toxicities, the response rate, 3-year overall survival and progression-free survival rate of locally advanced nasopharyngeal carcinoma patients on concurrent carboplatin chemoradiotherapy followed by carboplatin and 5-fluorouracil." | 5.15 | Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouracil in locally advanced nasopharyngeal carcinoma. ( Dechaphunkul, T; Pruegsanusak, K; Sangthawan, D; Sunpaweravong, P, 2011) |
| "The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and combination of capecitabine with oxaliplatin (CAPOX) plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC)." | 5.15 | Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K, 2011) |
| "This phase II study was conducted to determine the efficacy and safety of capecitabine and bevacizumab in untreated elderly metastatic colorectal cancer patients." | 5.14 | A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. ( Fakih, MG; Khushalani, N; Mashtare, T; Puthillath, A; Romano, K; Ross, ME; Steinbrenner, L; Wilding, G; Wisniewski, M, 2009) |
| "The addition of capecitabine to docetaxel significantly improves overall survival in anthracycline-pretreated metastatic breast cancer." | 5.14 | Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results. ( Gennatas, K; Gennatas, S; Michalaki, V, 2009) |
| "The present study aimed at investigating whether the simultaneous evaluation of pharmacokinetic, pharmacogenetic and demographic factors could improve prediction on toxicity and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil (5FU)/leucovorin therapy." | 5.14 | Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. ( Barile, C; Bolzonella, C; Bononi, A; Crepaldi, G; Ferrazzi, E; Frigo, AC; Gusella, M; Marinelli, R; Menon, D; Padrini, R; Pasini, F; Stievano, L; Toso, S, 2009) |
| "To determine the efficacy and tolerability of capecitabine combined with oxaliplatin (CAPOX) or irinotecan (CAPIRI) as first-line treatment in patients with advanced/metastatic colorectal cancer aged > or =70 years." | 5.14 | Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. ( Bordonaro, R; Caputo, G; Cordio, S; Manzione, L; Novello, G; Reggiardo, G; Rosati, G, 2010) |
| "This phase II study was designed in order to evaluate efficacy and safety of the combination of vinorelbine (VNB), fluorouracil (FU) and leucovorin (LV) in patients with metastatic breast carcinoma (MBC) previously treated with anthracyclines and taxanes." | 5.14 | Vinorelbine and fluorouracil plus leucovorin combination (ViFL) in patients with anthracycline and taxane-pretreated metastatic breast cancer: a phase II study. ( Bergnolo, P; Bianco, L; Boglione, A; Comandone, A; Cutin, SC; Dal Canton, O; Garetto, F; Inguì, M; Oliva, C; Pochettino, P, 2010) |
| "This phase II study in breast cancer patients assessed the utility of a single 6 mg subcutaneous dose of pegfilgrastim administered on day 9 of an intravenous (IV) "split" CMF (cyclophosphamide 600 mg/m(2), methotrexate 40 mg/m(2) and 5-fluorouracil 600 mg/m(2)) chemotherapy regimen administered on days 1 and 8 and repeated every 28 days for 6 cycles." | 5.14 | Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen. ( Bacon, P; Casas, A; Castellanos, J; Duque, A; Falcone, A; Gridelli, C; Lawrinson, S; Mansutti, M; Mattioli, R; Skacel, T, 2009) |
| "Patients suffering from locally-advanced (T3-4 any N M0 or any T N1-3 M0) gastric carcinoma, staged with endoscopic ultrasound, bone scan, computed tomography, and laparoscopy, were assigned to receive four 21 d/cycles of TCF (docetaxel 75 mg/m(2) day 1, cisplatin 75 mg/m(2) day 1, and fluorouracil 300 mg/m(2) per day for days 1-14), either before (Arm A) or after (Arm B) gastrectomy." | 5.14 | Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. ( Andreoni, B; Biffi, R; Bonomo, G; Chiappa, A; Crosta, C; Fazio, N; Fiori, G; Huber, O; Luca, F; Orsi, F; Roth, A; Schuller, JC; Zampino, MG, 2010) |
| "A dose-finding study was performed to evaluate the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD) and the recommended dose (RD) of escalating the doses of capecitabine and fixed doses of irinotecan and oxaliplatin on a biweekly schedule for metastatic colorectal cancer patients (mCRC)." | 5.14 | Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. ( Bandres, E; Bitarte, N; Chopitea, A; Gacía-Foncillas, J; Patiño-Garcia, A; Ponz-Sarvise, M; Ramirez, N; Rodríguez, J; Viudez, A; Zarate, R, 2010) |
| "0 Gy/5 weeks can be safely administered to the tumor bed, concurrently with capecitabine (1600 mg/m (2)) in patients with resected pancreatic carcinoma." | 5.14 | Capecitabine based postoperative accelerated chemoradiation of pancreatic carcinoma. A dose-escalation study. ( Caprino, P; Caravatta, L; Cellini, N; Deodato, F; Di Lullo, L; Giglio, G; Ingrosso, M; Ippolito, E; Macchia, G; Massaccesi, M; Mattiucci, GC; Mignogna, S; Morganti, AG; Picardi, V; Sofo, L; Tambaro, R; Valentini, V, 2010) |
| "Patients with nonkeratinizing nasopharyngeal carcinoma staged T1-4N2-3M0 were randomly assigned to RT (176 patients) or to CRT (172 patients) using cisplatin (100 mg/m(2)) every 3 weeks for three cycles in concurrence with radiotherapy, followed by cisplatin (80 mg/m(2)) plus fluorouracil (1000 mg per m(2) per day for 4 days) every 4 weeks for three cycles." | 5.14 | Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. ( Au, GK; Au, JS; Chappell, R; Choi, CW; Chua, DT; Fung, KK; Lau, JT; Lau, WH; Law, SC; Lee, AW; Leung, TW; Ng, WT; Ngan, RK; O'Sullivan, B; Siu, L; Sze, WK; Sze, WM; Tung, R; Tung, SY; Yau, TK, 2010) |
| " This phase I/II trial was carried out to evaluate the combination of capecitabine and the proteasome inhibitor bortezomib in anthracycline and/or taxane-pretreated patients with metastatic breast cancer." | 5.13 | A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H, 2008) |
| "This study was conducted to determine, in patients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administered orally for 7 days followed by a 7-day rest (7/7), a schedule based on a mathematical method for the optimization of anticancer drug scheduling." | 5.13 | Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. ( Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA, 2008) |
| " Capecitabine plus irinotecan appears to be a feasible first-line treatment for patients with advanced colorectal carcinoma." | 5.12 | Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study. ( Akkermans-Vogelaar, JM; Antonini, NF; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Punt, CJ; Rodenburg, CJ; Vreugdenhil, G; Wals, J, 2006) |
| "Capecitabine is a fluoropyrimidine carbamate that acts as a prodrug, mimics continuous infusion of 5-fluorouracil (5-FU), and has encouraging antitumor activity in women with metastatic breast cancer." | 5.12 | Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study. ( Fasolo, A; Gianni, L; Marchiano, A; Mariani, G; Moliterni, A; Petrelli, F; Valagussa, P; Zambetti, M, 2006) |
| "The purpose of this study was to compare the activity and toxicity of an irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) combination with a standard regimen of 5FU and LV, in patients with advanced colorectal carcinoma." | 5.12 | A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma. ( Andreadis, C; Gennatas, C; Michalaki, V; Mouratidou, D; Pafiti, A; Papaxoinis, G; Tsavaris, N, 2006) |
| "The aim of the study was to compare our reference adjuvant chemotherapy, FEC100 (fluorouracil 500 mg m(-2), epirubicin 100 mg m(-2) and cyclophosphamide 500 mg m(-2), six cycles every 21 days), to an epirubicin-vinorelbine (Epi-Vnr) combination for early, poor-prognosis breast cancer patients." | 5.12 | Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial. ( Audhuy, B; Bonneterre, J; Chollet, P; Clavère, P; Eymard, JC; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Lortholary, A; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Simon, H; Veyret, C; Walter, S, 2007) |
| "The aim of this study was to investigate the efficacy and safety of combination chemotherapy with weekly paclitaxel and 5-fluorouracil (5-FU) as first-line treatment in patients with advanced or recurrent gastric carcinoma." | 5.12 | Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma. ( Ando, T; Hirabayashi, N; Kawamura, S; Kobayashi, M; Kojima, H; Kondo, K; Konno, H; Matsuo, K; Miyashita, Y; Morita, S; Musha, N; Nagata, N; Ninomiya, M; Oba, K; Sakamoto, J; Usuki, H, 2007) |
| "Forty-two rectal carcinoma (T(3-4)N(0-2)M(0)) patients with grade 2 or 3 diarrhea refractory to loperamide were enrolled to receive octreotide." | 5.12 | Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma. ( Karaoglu, A; Topkan, E, 2006) |
| "To assess the efficacy and tolerability of combination therapy with capecitabine and cisplatin in patients with recurrent carcinoma of the uterine cervix." | 5.12 | A pilot phase II study of capecitabine plus cisplatin in the treatment of recurrent carcinoma of the uterine cervix. ( Benjapibal, M; Inthasorn, P; Leelaphatanadit, C; Therasakvichya, S; Thirapakawong, C, 2007) |
| "Gastric cancer patients with cytologically confirmed malignant ascites were treated with cycles of oxaliplatin at 85 mg/m(2) plus leucovorin 20 mg/m(2) on the first day of treatment, followed by 5-fluorouracil (5-FU) via a 400 mg/m(2) bolus and a 22 h continuous infusion of 600 mg/m(2) 5-FU on Days 1-2 at 2-week intervals." | 5.12 | A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. ( Jang, JS; Jeong, JS; Kim, HJ; Kim, MC; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY; Yoo, HS, 2007) |
| "The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as first-line treatment in metastatic colorectal carcinoma (CRC)." | 5.11 | Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. ( Artale, S; Bajetta, E; Beretta, E; Biasco, G; Bonaglia, L; Bonetti, A; Buzzoni, R; Carreca, I; Cassata, A; Cortinovis, D; Di Bartolomeo, M; Ferrario, E; Frustaci, S; Iannelli, A; Lambiase, A; Mariani, L; Marini, G; Pinotti, G, 2004) |
| "The current study was designed to evaluate the antitumor activity and toxicity of capecitabine and oxaliplatin in previously untreated patients with advanced colorectal carcinoma." | 5.11 | Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. ( Marshall, JL; Meropol, NJ; Shields, AF; Zalupski, MM, 2004) |
| "To evaluate the toxicity and efficacy of concurrent chemoirradiation with cisplatin followed by adjuvant ifosfamide, 5-fluorouracil and leucovorin in patients with stage IVb nasopharyngeal carcinoma (NPC) PATIENTS AND METHODS: Between October 1998 and August 2001, 35 Chinese patients with stage IVb NPC (N3a:12, N3b:23) were treated with by concurrent chemoirradiation using cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with 1." | 5.11 | A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma. ( Au, GK; Chua, DT; Sham, JS, 2004) |
| "5-Fluorouracil (5-FU), an antitumor agent, is used clinically against a variety of malignancies, including bladder carcinoma." | 5.11 | Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma. ( Fukushima, M; Li, YN; Miki, T; Mizutani, Y; Nakanishi, H; Wada, H; Yoshida, O, 2004) |
| "The objective of the trial is to evaluate the efficacy of capecitabine in patients with metastatic hormone-resistant prostate carcinoma (HRPC), in terms of prostate-specific antigen (PSA) response and clinical benefit (decrease of pain or analgesic score) and its safety profile." | 5.11 | Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. ( Bauer, J; Bernhard, J; Bonomo, M; Borner, M; Cerny, T; Dietrich, D; Gillessen, S; Gschwend, A; Hanselmann, S; Hering, F; Morant, R; Rochlitz, C; Schmid, HP; Wernli, M, 2004) |
| " In an effort to improve the therapeutic effect of a MAb-based regimen in colorectal carcinoma (CRC) patients, the effects of a combination of alpha-interferon (alpha-IFN), 5-fluorouracil (5-FU), granulocyte-macrophage colony-stimulating factor (GM-CSF) and mouse MAb17-1A was evaluated in 27 patients with metastatic disease." | 5.11 | Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. ( Frödin, JE; Liljefors, M; Mellstedt, H; Nilsson, B; Ragnhammar, P; Ullenhag, G, 2004) |
| "The combination of irinotecan and a fluoropyrimidine has been widely accepted as a treatment for advanced colorectal carcinoma." | 5.11 | Gene expression profiles of colorectal carcinoma in response to neo-adjuvant chemotherapy. ( Hiro, J; Inoue, Y; Kobayashi, M; Kusunoki, M; Miki, C; Mori, K; Shirane, M; Tanaka, K; Yanagi, H, 2004) |
| "A single-arm phase II multicenter trial of the combination of cyclophosphamide (C), epirubicin (E), and 5-fluorouracil (F) followed by docetaxel as neoadjuvant chemotherapy is being conducted by the Japan Breast Cancer Research Group." | 5.11 | Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma. ( Akiyama, F; Hisamatsu, K; Iwata, H; Kaise, H; Kuroi, K; Kurosumi, M; Kusama, M; Masuda, N; Nakamura, S; Ohno, S; Sato, Y; Shin, E; Takatsuka, Y; Toi, M; Tsuda, H; Yamazaki, K, 2005) |
| "Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma." | 5.11 | Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study. ( Casaretti, R; Cataldis, GD; Comella, P; Farris, A; Lucia, LD; Maiorino, L; Massidda, B; Natale, D; Palmeri, S; Tafuto, S, 2005) |
| "The purpose of this multicenter phase III trial was to assess the impact of a time-intensification of FEC (fluorouracil, epirubicin, cyclophosphamide) and MMM (mitoxantrone, methotrexate, mitomycin C) regimens, supported by lenograstim (G-CSF) on the objective response rate, time to progression and survival of patients with chemotherapy-naive metastatic breast cancer (mbc)." | 5.10 | Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma. ( Capotorto, AM; Da Prada, GA; Farris, A; Lelli, G; Martoni, A; Massidda, B; Pavesi, L; Pedrazzoli, P; Robustelli della Cuna, G; Zamagni, C, 2003) |
| " Patients with locoregional carcinoma of the nasopharynx were randomized to receive two courses of chemotherapy, consisting of cisplatin and 5-fluorouracil (CDDP-5FU), that were administered before radiation therapy (CT arm) or radiotherapy alone." | 5.10 | A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. ( Fukuda, S; Hareyama, M; Himi, T; Nishio, M; Nishioka, T; Oouchi, A; Saitoh, A; Sakata, K; Shirato, H; Suzuki, K, 2002) |
| "Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration of cisplatin 40 mg m(-2), 5-fluorouracil 500 mg m(-2), epidoxorubicin 35 mg m(-2), 6S stereoisomer of leucovorin 250 mg m(-2) and glutathione 1." | 5.09 | Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). ( Barni, S; Battelli, N; Casaretti, R; Cascinu, S; Catalano, G; Cellerino, R; Comella, G; Frontini, L; Labianca, R; Pirovano, M; Zonato, S, 1999) |
| "Twenty-three patients with advanced or recurrent endometrial carcinoma entered a prospective study of chemotherapy which consisted of carboplatin (300 mg/m2), methotrexate (30 mg/m2), and 5-fluoruracil (500 mg/m2) given on day 1, in a 3-weekly schedule, in combination with medroxyprogesterone acetate (MPA): 300 mg daily, p." | 5.09 | Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic cooperative oncology group study. ( Aravantinos, G; Bafaloukos, D; Bakoyiannis, C; Katsifis, G; Kosmidis, P; Samonis, G; Skarlos, D, 1999) |
| "This phase-II study was conducted to investigate the potential benefit from the addition of mitomycin to a conventional anthracycline-cisplatin- and 5-fluorouracil-based chemotherapy for recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type (UCNT)." | 5.09 | Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. ( Alonso, S; Armand, JP; Chouaki, N; Cortès-Funes, H; Cvitkovic, E; Fandi, A; Hasbini, A; Lianes, P; Mahjoubi, R; Raymond, E; Taamma, A, 1999) |
| "The combination of 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (I-OHP) was shown to be both more active against metastatic colorectal carcinoma and better tolerated if the drug delivery rate was chronomodulated according to circadian rhythms rather than constant." | 5.09 | A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. ( Brienza, S; Chollet, P; Dogliotti, L; Focan, C; Le Rol, A; Letourneau, Y; Lévi, F; Llory, JF; Perpoint, B; Rotarski, M; Zidani, R, 1999) |
| "The aim of this study was to evaluate the toxicity and efficacy of the combination of 5-fluorouracil, bleomycin, epirubicin, and cisplatin (FBEC) in the treatment of patients with undifferentiated carcinoma of nasopharyngeal type (UCNT)." | 5.09 | Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. ( Armand, JP; Azli, N; Chouaki, N; Couteau, C; Cvitkovic, E; Fandi, A; Hasbini, A; Taamma, A; Wibault, P, 1999) |
| "To evaluate the outcome in patients with stage II hormone receptor-positive breast cancer treated or not treated with low-dose, short-term chemotherapy in addition to tamoxifen in terms of disease-free and overall survival." | 5.09 | Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer. ( Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kolb, R; Kubista, E; Manfreda, D; Mittlböck, M; Mlineritsch, B; Samonigg, H; Steger, G; Steindorfer, P; Stierer, M; Tschurtschenthaler, G, 1999) |
| "The efficacy of a new chemotherapeutic combination consisting of Cis-diammineglycolatoplatinum (Nedaplatin), a derivative of cisplatin (CDDP), and 5-fluorouracil (5FU) was evaluated in patients with advanced esophageal carcinomas." | 5.09 | A new combination chemotherapy with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers. ( Gamoh, M; Ishibashi, S; Ishioka, C; Kanamaru, R; Kato, S; Murakawa, Y; Shibata, H; Shimodaira, H; Shineha, R; Suzuki, T; Yoshioka, T, 1999) |
| " Diarrhea was the principal dose-limiting toxicity of oral 5-FU and eniluracil given on this chronic schedule." | 5.09 | Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. ( Baker, SD; Diasio, RB; Donehower, RC; Grochow, LB; Hohneker, JA; Khor, SP; Lucas, VS; O'Reilly, S; Rowinsky, EK; Sartorius, SE; Spector, T, 2000) |
| "Thymidylate synthase (TS) is regarded as a parameter of 5-fluorouracil (5-FU) chemosensitivity for colorectal carcinoma." | 5.09 | Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. ( Fujii, S; Hatano, K; Kitayama, J; Matsuda, K; Muto, T; Nagawa, H; Nita, ME; Takenoue, T; Tsuruo, T, 2000) |
| "Sixty eligible patients who had previously untreated, measurable, metastatic colorectal carcinoma were treated with oral eniluracil 50 mg on Days 1-7, 5-FU 20 mg/m(2) on Days 2-6, and LV 50 mg on Days 2-6." | 5.09 | Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. ( Hollis, D; Mayer, RJ; Meropol, NJ; Niedzwiecki, D; Schilsky, RL, 2001) |
| "Forty-four patients with carcinoma of the esophagus or gastroesophageal junction were prospectively entered into a phase II trial of preoperative 5-fluorouracil, cisplatin, and interferon alfa with concurrent external beam radiotherapy before esophagectomy." | 5.09 | Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma. ( Gooding, WE; Lew, JI; Posner, MC; Ribeiro, U; Safatle-Ribeiro, AV, 2001) |
| "Between August 1990 and December 1997, 25 patients with stage III and IV nasopharyngeal carcinoma received an accelerated and hyperfractionated radiotherapy with concurrent chemotherapy (5-FU and mitomycin C)." | 5.09 | Accelerated hyperfractionated radiotherapy with concurrent chemotherapy in locally advanced nasopharyngeal carcinoma: a phase II study. ( Budach, V; Fischer, M; Jahnke, K; Klahold, M; Sack, H; Stüben, G; Stuschke, M, 2001) |
| "The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer." | 5.09 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001) |
| "Infusional 5-fluorouracil (F) with cisplatin (C) and epirubicin (E), so-called infusional ECF, is a highly active new schedule against locally advanced or metastatic breast cancer." | 5.08 | Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen. ( Allum, WH; Baum, M; Bonnefoi, H; Ebbs, S; O'Brien, ME; Powles, TJ; Seymour, MT; Smith, IE, 1996) |
| "In a randomized Phase II study, the authors evaluated the activity and toxicity of the new cisplatin, doxorubicin, and mitomycin C (PAM) combination, that includes cisplatin (P) instead of 5-fluorouracil as in the 5-fluorouracil, doxorubicin, and mitomycin C (FAM) combination, in patients with advanced gastric carcinoma." | 5.08 | The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research. ( Angelini, F; Cavicchi, F; Cocconi, G; De Lisi, V; Di Costanzo, F; Finardi, C; Gilli, G; Rodinò, C; Soldani, M; Tonato, M, 1996) |
| "Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma." | 5.08 | Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996) |
| "A carboplatin and 5-fluorouracil (CF) chemotherapy protocol was designed to evaluate tumor response and toxicity in patients with metastatic nasopharyngeal carcinoma (NPC)." | 5.08 | Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. ( Chan, AT; Johnson, PJ; Lee, WY; Leung, SF; Leung, TW; Teo, PM; Yeo, W, 1996) |
| " levofolinic acid and oral hydroxyurea on a weekly schedule is well tolerated by the vast majority of patients with locally advanced and/or metastatic carcinoma of the pancreas or the gallbladder." | 5.08 | Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). ( Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giotta, F; Giuseppe, S; Majello, E; Pezzella, G; Riccardi, F; Testa, A, 1996) |
| "A phase I trial of 5-fluorouracil (5-FU), leucovorin (LV) and interferon (IFN) was conducted in 15 advanced colorectal cancer patients refractory to a bolus regimen of 5-FU/LV." | 5.08 | A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. ( Cascinu, S; Catalano, G; Del Ferro, E; Ligi, M, 1996) |
| " The authors examined whether the administration of 5-fluorouracil (5-FU) enhanced apoptosis of gastric carcinoma cells, and investigated the relationship between apoptosis and the expression of Ki-67 and the Bax gene." | 5.08 | Enhanced induction of apoptosis of human gastric carcinoma cells after preoperative treatment with 5-fluorouracil. ( Itoh, H; Kaibara, N; Kimura, O; Maeta, M; Makino, M; Shirai, H; Sugamura, K, 1997) |
| "Previous Phase II studies using the combination of mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) in the treatment of metastatic breast carcinoma have shown this regimen to be active and well tolerated." | 5.08 | Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial. ( Birch, R; Greco, FA; Hainsworth, JD; Hopkins, LG; Jolivet, J, 1997) |
| "The purpose of this study was to compare the objective response rate, duration of remission, and survival of 5-fluorouracil (5-FU) versus those of 5-FU plus levamisole in metastatic colorectal cancer using the same dose and schedule of these agents as in the North Central Cancer Treatment Group and intergroup studies of adjuvant therapy." | 5.08 | Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. ( Bandealy, MT; Einhorn, LH; Gonin, R; Loehrer, PJ; Monaco, F, 1998) |
| "Infusional 5-fluorouracil in advanced breast cancer has been associated with improved clinical response rates when compared with conventional bolus therapy." | 5.08 | Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90). ( Asselain, B; Beuzeboc, P; Diéras, V; Dorval, T; Garcia-Giralt, E; Jouve, M; Livartowski, A; Palangié, T; Pierga, JY; Pouillart, P; Scholl, S, 1998) |
| "We have used a relatively new trial methodology, the group sequential design, to prospectively evaluate two dose levels of bolus/infusional 5-fluorouracil (5-FU) and folinic acid in 192 consecutive-patients with advanced colorectal carcinoma." | 5.08 | Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation. ( Canney, PA; Cassidy, J; Habeshaw, T; Jodrell, DI; Mackean, MJ; McInnes, A; Paul, J; Reed, NS; Robertson, AG; Twelves, CJ; Yosef, H, 1998) |
| "A wide variety of fluorouracil (FU)-plus-leucovorin (LV) dose schedules are in clinical use for the treatment of advanced colorectal cancer." | 5.08 | The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK). ( Bacchi, M; Borner, MM; Castiglione, M; Fey, MF; Goldhirsch, A; Hanselmann, S; Herrmann, R; Leyvraz, S; Morant, R; Pagani, O; Pestalozzi, B; Weber, W, 1998) |
| "We evaluated the pharmacokinetics of 5-fluorouracil (5-FU) combined with recombinant human interferon (IFN)-alpha 2a in 10 previously untreated patients with advanced colorectal carcinoma." | 5.08 | Pharmacokinetics of recombinant human interferon-alpha 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma. ( Kim, J; Koss-Twardy, SG; Passe, SM; Patel, IH; Pazdur, R; Satoh, H; Zhi, J, 1998) |
| "Thirty patients with measurable metastatic breast carcinoma were treated with a combination of cyclophosphamide 600 mg/m2 on day 1, levofolinic acid 100 mg/m2 plus 5-fluorouracil 375 mg/m2 on days 1-3, and epidoxorubicin (EDXR) in three refracted doses on days 1-3 with G-CSF rescue for 10 days." | 5.07 | A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma. ( Amato, C; Callari, A; Cannata, G; Cipolla, C; Cusimano, MP; Garascia, C; Gebbia, N; Gebbia, V; Latteri, MA; Testa, A, 1994) |
| "5-Fluorouracil (5-FU) activity for various carcinomas of adults has been enhanced through the synergistic effect of leucovorin." | 5.07 | Phase II study of 5-fluorouracil/leucovorin for pediatric patients with malignant solid tumors. ( Bowman, LC; Douglass, EC; Houghton, JA; Howlett, N; Kun, LE; Meyer, WH; Mounce, K; Poe, D; Pratt, CB, 1994) |
| "The combination of cisplatin, epirubicin, and leucovorin preceding fluorouracil (PELF) includes three novel agents compared with the standard combination of fluorouracil, doxorubicin, and mitomycin (FAM) in the treatment of advanced gastric carcinoma." | 5.07 | Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. ( Algeri, R; Bella, M; Cocconi, G; De Lisi, V; Di Costanzo, F; Luppi, G; Mazzocchi, B; Rodinò, C; Soldani, M; Zironi, S, 1994) |
| "Twenty-two patients with metastatic colorectal cancer entered a Phase I-II trial to assess the maximum tolerable dose of alpha-2B-interferon administered intramuscularly three times per week in combination with fixed doses of 5-fluorouracil (450 mg/m2 IV for 5 days, and, from day 28, weekly) and folinic acid (200 mg/m2 IV before 5-fluorouracil) and the efficacy of this combination." | 5.07 | Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients. ( Bertuccelli, M; Brunetti, I; Cianci, C; Conte, PF; Falcone, A; Ricci, S, 1994) |
| "From April 1990 to April 1992, a comparative study was carried out in 46 patients with advanced breast cancer treated by CMxMF (Cyclophosphamide, mitoxantrone, methotrexate, 5-fluorouracil) and CAMF regimens (Cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil)." | 5.07 | [Comparison of the therapeutic effect of CMxMF and CAMF regimens in the management of advanced breast cancer patients]. ( Chen, JA, 1993) |
| "Thirty-one patients with hepatic metastases from colorectal carcinoma were treated with carboplatin (CBDCA), 55 mg/m2, given in a 4-hour intra-arterial infusion daily for 5 days, and 5-fluorouracil, 900 mg/m2, given in a 20-hour intra-arterial infusion daily for 5 days." | 5.07 | Intra-arterial hepatic treatment with carboplatin (CBDCA) and 5-fluorouracil (5-FU) in metastases from colorectal carcinoma. ( Abuchaibe, O; Bilbao, I; Hidalgo, OF; Pardo, F; Rebollo, J; Tangco, E; Vieitez, JM, 1993) |
| "One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5-FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i." | 5.07 | Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. ( Hahn, RG; Krook, JE; Laurie, JA; Mailliard, JA; Morton, RF; Patel, SR; Therneau, TM; Twito, DI; Windschitl, HE, 1992) |
| "Twenty-two patients with previously untreated metastatic breast cancer and nineteen patients with refractory metastatic breast cancer were treated with trimetrexate (TMTX)." | 5.07 | Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. ( Carey, RW; Clamon, GH; Costanza, ME; Dawson, NA; Korzun, AH; Norton, L; Pollak, M; Vogelzang, NJ, 1991) |
| "We conducted a phase II clinical trial of 5-fluorouracil (5 day continuous infusion), cis-diamminedichloroplatinum and etoposide in previously untreated patients with metastatic carcinoma of unknown primary origin." | 5.07 | Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. ( Abbruzzese, JL; Faintuch, J; Frost, P; Raber, MN; Sumrall, C, 1991) |
| "A phase I study of 5-fluorouracil 600 mg/m2/week and folinic acid 500 mg/m2/week on day 1 and cisplatin administered weekly on day 2 was carried out on 30 patients with metastatic colorectal carcinoma of which 20 patients were pretreated with 5-fluorouracil." | 5.07 | A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinoma. ( Creaven, P; Gebbia, N; Gebbia, V; Palmeri, S; Petrelli, N; Rausa, L; Russo, A; Rustum, Y, 1991) |
| "A total of 21 untreated patients (5 males, 16 females; median age, 55 years; range, 28-72) with advanced measurable colorectal carcinoma were treated with an association of 5-fluorouracil (1000 mg/weekly) and alpha-2 interferon (three times a week s." | 5.06 | Alpha-2 interferon and 5-fluorouracil in advanced colorectal cancer. ( Aversa, SM; Daniele, O; Fiorentino, MV; Fornasiero, A; Ghiotto, C; Morandi, P, 1990) |
| "On the strength of recent evidence of the activity of the combination of cisplatin and 5-fluorouracil against squamous malignancies of the esophagus and head and neck, this regimen was evaluated in a phase II trial against metastatic or recurrent squamous carcinoma of the uterine cervix." | 5.06 | A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. ( Alberts, DS; Boutselis, JG; Green, S; Hannigan, EV; Surwit, EA; Wallace, DL; Weiss, GR, 1990) |
| "One hundred twenty-two chemotherapy-naive patients with histologically confirmed colorectal adenocarcinoma were entered into a randomized trial comparing infusional fluorouracil (FU) versus cisplatin (CDDP) and FU." | 5.06 | Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. ( Bosselli, B; Botet, J; Chapman, D; Cochran, C; Israel, K; Kemeny, N; Minsky, B; Niedzwiecki, D; Rosenbluth, R; Vinciguerra, V, 1990) |
| "Fifty patients with locally far progressed or metastasizing gastric carcinoma were treated with 5-fluorouracil, adriamycin and methotrexate using a slight modification of the FAMeth schema." | 5.06 | [The results of a modified FAMeth chemotherapy protocol in metastatic stomach carcinoma]. ( Crone-Münzebrock, W; Garbrecht, M; Henne-Bruns, D; Hossfeld, DK; Kremer, B; Platz, D; Weh, HJ, 1989) |
| "Three hundred thirty-one women with metastatic breast cancer were randomized to receive combination chemotherapy with either cyclophosphamide, Novantrone (mitoxantrone; Lederle Laboratories, Wayne, NJ), and fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and fluorouracil (CAF)." | 5.06 | A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. ( Bennett, JM; Cartwright, K; Doroshow, JH; Dukart, G; Krementz, ET; Muss, HB; Reisman, A; Schoch, I; Wolff, S, 1988) |
| "Fifty consecutive patients with recurrent and metastatic endometrial carcinoma were treated with melphalan, 5-fluorouracil, and medroxyprogesterone acetate with or without tamoxifen as first-line chemotherapy." | 5.06 | Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma. ( Emrich, LJ; Lele, SB; Patsner, B; Piver, MS, 1986) |
| "Fifty-seven evaluable patients with advanced ovarian carcinoma were randomized to receive either a combination of hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil (Hexa-CAF) or high-dose cyclophosphamide alone given intravenously intermittently." | 5.05 | Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF). ( Carmo-Pereira, J; Costa, FO; Henriques, E; Ricardo, JA, 1981) |
| "Two consecutive studies were undertaken in patients with advanced adenocarcinoma of the ovary to compare melphalan, adriamycin and 5-fluorouracil (MAF) with cyclophosphamide, adriamycin and 5-fluorouracil (CAF)." | 5.05 | Triple drug chemotherapy for advanced ovarian carcinoma: comparative study of two regimens. ( Aroney, RS; Dalley, DN; Levi, JA, 1981) |
| "In a prospective, randomized study the effect of cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy was compared to the single agent, chloroethyl-cyclohexy-nitrosourea, in the treatment of hormonally refractive metastatic prostatic carcinoma." | 5.05 | Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexy-nitrosourea in the treatment of metastatic prostatic cancer. ( Herr, HW, 1982) |
| "A prospective controlled study of combined chemotherapy with 5-fluorouracil, vinblastine and cyclophosphamide was conducted in 53 patients with radical resection for gastric carcinoma." | 5.05 | Gastric carcinoma treated by chemotherapy after resection: a controlled study. ( Baschet, C; Bernard, PF; Destroyes, JP; Huguier, M; Le Henand, F, 1980) |
| "This National Cooperative Study has randomly compared the usefulness of 5-fluorouracil (5-FU), cyclophosphamide (Cytoxan) and standard therapy in patients with advanced carcinoma of the prostate (Stage D)." | 5.04 | Prostatic carcinoma. relationship between primary tumor, histologic grade, and response to chemotherapy. ( Gibbons, RP; Johnson, DE; Murphy, GP; Prout, GR; Schmidt, JD; Scott, WW, 1976) |
| "We performed the present systematic review and meta-analysis to evaluate the efficacy and safety for S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma (mCRC)." | 5.01 | Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis. ( Chen, J; Wang, J, 2019) |
| "Both capecitabine and bevacizumab are established agents in the treatment of metastatic breast cancer, but until recently clinical data supporting their use in combination were limited." | 4.88 | Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review. ( Martin, M; Miles, D; Robert, N; Vrdoljak, E; Zielinski, C, 2012) |
| " In this review, we summarized the current status of our knowledge about the effectiveness of curcumin when given in combination with current chemotherapeutics such as 5-fluorouracil, oxaliplatin, and gemcitabine in treatment of gastrointestinal cancers with particular reference to colorectal cancer." | 4.85 | Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview. ( Majumdar, AP; Patel, BB, 2009) |
| "The case history is presented of a 46-year-old lady who was treated postoperatively for breast cancer with combination chemotherapy containing the antitumour agent epirubicin." | 4.80 | Recall phenomenon following epirubicin. ( Carder, P; Gooi, J; Nishikawa, H; Wilson, J, 1999) |
| "Three clinical trials have been conducted with fluorouracil (5-FU) and recombinant interferon alfa-2a (rIFN-alpha 2a) in the treatment of advanced colorectal carcinoma." | 4.78 | Clinical trials of fluorouracil with alpha-interferon in advanced colorectal carcinomas. ( Bready, B; Moore, DF; Pazdur, R, 1991) |
| "Seventy-five previously untreated patients with measurable advanced colorectal cancer were treated with 5 fluorouracil 1,000 mg/m2 as a 24-hour intravenous (i." | 4.78 | 120-hour 5-fluorouracil (5-FU) continuous infusion (CI) plus BCNU in advanced colorectal cancer. ( Aguilo, J; Asencio, F; Candel, MT; Delgado, F; García-Reinoso, J; Martínez-Abad, M; Sánchez, JJ; Sanchis, C; Viciano, V; Villar-Grimalt, A, 1991) |
| "We retrospectively evaluated the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin, and 5-fluorouracil (TPF) for T3 N0 glottic carcinoma without vocal cord fixation." | 4.12 | Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil for T3 N0 Glottic Carcinoma Without Vocal Cord Fixation. ( Fukugawa, Y; Matsuyama, T; Murakami, D; Nishimoto, K; Orita, Y; Oya, N; Saito, T; Toya, R; Watakabe, T, 2022) |
| "To investigate the effects of mitomycin-C (MMC) and 5-fluorouracil (5-FU) on the viability, proliferation, and migratory capacity of cultured ocular adnexal sebaceous carcinoma (SC) cells." | 4.12 | Effects of Mitomycin-C and 5-Fluorouracil on Ocular Adnexal Sebaceous Carcinoma Cells. ( Gallo, RA; Gomez, A; Lang, SH; Pelaez, D; Rong, AJ; Sabater, AL; Tse, DT, 2022) |
| "5-Fluorouracil-based therapy remains the main approach in colorectal cancer, even though there are still some drawbacks, such as chemoresistance." | 3.96 | Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5-fluorouracil in vivo. ( Achim, M; Banciu, M; Casian, T; Dragos, N; Drotar, DM; Licarete, E; Luput, L; Muntean, D; Patras, L; Porfire, A; Rauca, VF; Sesarman, A; Stejerean, I; Toma, VA; Tomuta, I; Vlase, L, 2020) |
| " The present study aimed to investigate the effect of Rosmarinic acid (RA) on chemoresistance to 5-Fu and its molecular mechanism in gastric carcinoma." | 3.91 | Rosmarinic acid reduces the resistance of gastric carcinoma cells to 5-fluorouracil by downregulating FOXO4-targeting miR-6785-5p. ( Chen, DQ; Feng, JF; Li, WB; Liu, HX; Lu, JW; Yu, C, 2019) |
| "During a regular MR control, the patient developed anaphylactic reaction to Gadolinium, and after that a rectosigmoid ischemia with total necrosis of the posterior rectal wall was diagnosed and surgically treated with Hartmann procedure." | 3.91 | Hypovolemic shock after pelvic radiotherapy. A rare combination leading to a devastating complication. ( Calvisi, G; Carlei, F; Di Sibio, A; Di Staso, M; Giuliani, A; Lombardi, L; Marchese, M; Romano, L; Romanzi, F; Schietroma, M, 2019) |
| " In this study, we investigated the effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma (CRC) cells and its mechanism." | 3.88 | The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism. ( Jiang, GS; Liu, GW; Liu, YH; Ren, WD, 2018) |
| "We represent in this study the long term results of docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by concurrent chemoradiotherapy in Tunisian patients with locally advanced nasopharyngeal carcinoma." | 3.88 | TPF induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: Long term results of a Tunisian series. ( Ben Kridis, W; Bouzguenda, R; Daoud, J; Frikha, M; Ghorbel, A; Khanfir, A; Mnejja, W; Toumi, N, 2018) |
| "Sinonasal undifferentiated carcinoma (SNUC) is a rare and aggressive malignancy with optimal management remains unclear." | 3.87 | Trimodality management of sinonasal undifferentiated carcinoma and review of the literature. ( Culliney, B; Harrison, LB; Hauerstock, D; Hu, KS; Jacobson, A; Li, Z; Manolidis, S; Mourad, WF; Persky, M; Schantz, S; Shourbaji, RA; Tran, T; Urken, M, 2013) |
| "This study analyzes the anti-tumor effects of evodiamine on cellular growth, tumorigenesis, cell cycle and apoptosis induction of human urothelial cell carcinoma (UCC) cells." | 3.85 | Evodiamine Induces Cell Growth Arrest, Apoptosis and Suppresses Tumorigenesis in Human Urothelial Cell Carcinoma Cells. ( Chin, CC; Huang, YC; Kuo, YH; Lee, YR; Li, JM; Shi, CS, 2017) |
| "To evaluate the efficacy of induction chemotherapy with docetaxel, cisplatin and fluorouracil (TPF) followed by concurrent chemoradiotherapy (IC+CCRT) or CCRT alone in non-endemic locally advanced nasopharyngeal carcinoma (NPC) patients." | 3.83 | Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. ( Blanchard, P; De Felice, F; Deutsch, E; El Khoury, C; Even, C; Gorphe, P; Janot, F; Levy, A; Nguyen, F; Ou, D; Tao, Y; Temam, S, 2016) |
| "Betulinic acid selectively inhibits the growth of ovarian carcinoma cell lines without affecting the normal cells." | 3.81 | Sequential treatment with betulinic acid followed by 5-fluorouracil shows synergistic cytotoxic activity in ovarian cancer cells. ( Dou, YC; Liu, JB; Wang, YJ, 2015) |
| "A9 years boy diagnosed with nasopharyngeal carcinoma was started on chemotherapy protocol including 5-fluorouracil." | 3.81 | Chemotherapy Induced Acute Pericarditis in a Child. ( Almoukirish, S; Jadoon, S; Khan, MA; Momenah, TS; Rahman, A, 2015) |
| "We surmise that 5-fluorouracil, levofolinate, and oxaliplatin have the potential to provide a good response for tumors that are sensitive to fluorinated pyrimidine and platinum-containing anticancer drugs such as breast cancer." | 3.80 | An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report. ( Goto, M; Ishiyama, S; Kojima, Y; Komiyama, H; Niwa, K; Okuzawa, A; Sakamoto, K; Sugimoto, K; Takahashi, M; Tomiki, Y; Yaginuma, Y, 2014) |
| "We describe a case of multifocal anaplastic pancreatic carcinoma treated with neoadjuvant FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil and leucovorin) and total pancreatectomy with subsequent patient disease-free survival currently at 12 months." | 3.79 | Multifocal anaplastic pancreatic carcinoma requiring neoadjuvant chemotherapy and total pancreatectomy: report of a case. ( Gajdos, C; Jones, EL; Jones, TS; McManus, M; Shah, R, 2013) |
| " We report the detailed assessment of few cardiac parameter of toxicity in patients of advanced colorectal carcinoma subjected to two Schedules of high and low dose Folinic Acid, 5-Fluorouracil, bolus and continuous infusion." | 3.79 | Comparative cardiac toxicity in two treatment schedules of 5-FU/LV for colorectal carcinoma. ( Bano, N; Mateen, A; Najam, R, 2013) |
| "Uracil mustard and 5-fluorouracil (UM-FU) combination chemotherapy was used as one of the earliest combination chemotherapies in ovarian carcinoma from 1964 to 1971 at Yale New Haven Medical Center." | 3.79 | Uracil mustard and 5-fluorouracil combination chemotherapy: a historic record. ( Kohorn, EI, 2013) |
| "Our aim was to evaluate the efficacy and toxicity of cisplatin, fluorouracil, and docetaxel chemotherapy plus intensity-modulated radiotherapy (IMRT) for locoregionally advanced nasopharyngeal carcinoma (NPC)." | 3.79 | Experience with combination of docetaxel, cisplatin plus 5-fluorouracil chemotherapy, and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma. ( Du, C; Hu, C; Ying, H; Zhang, Y; Zhou, J, 2013) |
| "We previously demonstrated that 14-3-3σ was downregulated in 5-fluorouracil (5-Fu)-resistant MCF-7 breast cancer cells (MCF-7/5-Fu)." | 3.78 | 14-3-3σ regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation. ( He, Z; Peng, B; Xiong, Y; Yi, S; Zhang, Q; Zhang, W; Zheng, G, 2012) |
| "On the basis of this small retrospective survey, we conclude that CMFVP combination chemotherapy is both effective and safe in patients with metastatic breast cancer previously treated with both taxanes and anthracyclines." | 3.78 | Efficacy of the CMFVP regimen in patients with metastatic breast cancer previously treated with anthracycline and taxane. ( Grenader, T, 2012) |
| " We aimed to assess the prognostic role of VEGF, bFGF, PDGF-AA, EGF, HGF, and E-selectin in patients with metastatic colorectal cancer treated with capecitabine and oxaliplatin (XELOX) chemotherapy protocol." | 3.78 | Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer. ( Berk, V; Elmalı, F; Er, O; Inanç, M; Karaca, H; Ozkan, M; Saraymen, R, 2012) |
| "A total of 595 patients with high risk, [corrected] early breast cancer were treated in a 2-arm trial (HE10/97) with dose-dense sequential epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with or without paclitaxel." | 3.78 | Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. ( Aravantinos, G; Bafaloukos, D; Christodoulou, C; Eleftheraki, AG; Fountzilas, G; Gogas, H; Kalogeras, KT; Kotoula, V; Kronenwett, R; Makatsoris, T; Nikitas, N; Pavlidis, N; Pectasides, D; Razis, E; Televantou, D; Timotheadou, E; Wirtz, RM, 2012) |
| " In this study, patient-derived tumor tissue (PDTT) xenograft models of primary colon carcinoma and lymphatic and hepatic metastases were established for assessment of the antitumor activity of FP3 in combination with capecitabine." | 3.78 | Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. ( Cao, F; Han, N; He, K; Jin, K; Lan, H; Li, G; Teng, L; Xie, B; Xu, Z, 2012) |
| " Two of the patients could not be treated with 5-FU any more because they had developed a myocardial ischemia, which was most likely caused by fluorouracil." | 3.78 | 5-FU-induced cardiac toxicity--an underestimated problem in radiooncology? ( Hautmann, MG; Kölbl, O; Steger, F, 2012) |
| "The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using cytoreductive surgery prior to treatment with hyperthermic intraperitoneal chemotherapy with mitomycin C as part of a multidrug regimen." | 3.77 | Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. ( Chang, D; Mahteme, H; Stuart, OA; Sugarbaker, PH; Van der Speeten, K, 2011) |
| "5-fluorouracil chemotherapy in patients with dihydropyrimidine dehydrogenase deficiency, can give rise to ocular and cutaneous toxicity." | 3.77 | A bilateral cicatricial ectropion and bilateral upper lid shortening caused by 5-fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. ( Kemp, E; McDonald, A; Obi, EE, 2011) |
| "Several long-standing chemotherapy regimens are available to treat metastatic colorectal cancer (mCRC) including: oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin (FOLFOX); and irinotecan plus 5-FU and leucovorin (FOLFIRI)." | 3.77 | Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics. ( Barber, B; Gregory, C; Long, SR; Song, X; Wang, PF; Zhao, Z, 2011) |
| " In the present study, we evaluated the characteristics of paclitaxel (PTX) and 5-fluorouracil (5-FU) penetration and their effects on tissue penetration using MCLs of human colorectal cancer cells (DLD-1 and HT-29) grown in Transwell inserts." | 3.77 | Penetration of paclitaxel and 5-fluorouracil in multicellular layers of human colorectal cancer cells. ( Choi, MS; Kim, SH; Kuh, HJ, 2011) |
| " We aimed to evaluate the effect of pretreatment serum metabolic profiles generated by (1)H NMR spectroscopy on toxicity in patients with inoperable colorectal cancer receiving single agent capecitabine." | 3.77 | Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. ( Backshall, A; Clarke, SJ; Keun, HC; Sharma, R, 2011) |
| "When applying the topoisomerase inhibitor irinotecan (CPT) with the infusional fluorouracil/levofolinate (FOLFIRI) ± bevacizumab chemotherapy regimen in cases of advanced colorectal carcinoma, the international standard dose for CPT is 180 mg/m(2)." | 3.77 | Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma. ( Akutsu, N; Fujii, H; Hamamoto, Y; Miyamoto, J; Nagase, M; Nishi, T; Warita, E; Yamanaka, Y, 2011) |
| "In patients with advanced hepatocellular carcinoma (HCC), combination chemotherapy using 5- fluorouracil, cisplatin, and mitoxantrone (FMP) could achieve a response rate > 20%, but the beneficial effect was compromised by formidable adverse events." | 3.77 | Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. ( Chen, HC; Hsu, CL; Hung, CF; Lin, CC; Pan, KT; Sung, CM; Tseng, JH; Yeh, CT, 2011) |
| "Germline DNA was available from 568 previously untreated patients with advanced colorectal cancer participating in the CAIRO2 trial, assigned to capecitabine, oxaliplatin, and bevacizumab ± cetuximab." | 3.77 | Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. ( Beijnen, JH; Burylo, AM; Cats, A; de Boer, A; Deenen, MJ; Doodeman, VD; Guchelaar, HJ; Punt, CJ; Schellens, JH; Smits, PH; Tol, J; Vincent, A, 2011) |
| "The clinical course of 122 patients with Barrett's carcinoma, who all underwent a neoadjuvant chemotherapy with cisplatin, five fluorouracil and leucovorin and following oesophagectomy, was reviewed." | 3.77 | The amount of neoadjuvant chemotherapy for Barrett's carcinoma does not correlate with long-term survival. ( Friess, H; Knoefel, WT; Schauer, M; Theisen, J, 2011) |
| "We retrospectively analyzed all metastatic breast cancer patients treated with 5-fluorouracil as continuous infusion (CI-5FU) with daily doses of 150-300 mg/m(2)." | 3.77 | 5FU continuous infusion in heavily pretreated advanced breast cancer patients. ( Dieing, A; Eucker, J; Lehenbauer-Dehm, S; Possinger, K; Regierer, AC; Reinecke, F; Schwarzlose-Schwarck, S; Weigel, A, 2011) |
| " Toxicity (primarily gastrointestinal) necessitated dosage modification in 10 patients (29%)." | 3.77 | Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review. ( Balaban, EP; Bull, J; Frenkel, EP; Graham, M; Periman, P; Perkins, S; Pruitt, B; Ross, M; Ruud, C; Sheehan, RG, 1994) |
| "Gene expression profiling was done on fine-needle aspirations of 100 stage I to III breast cancers before preoperative paclitaxel, 5-fluorouracil, doxorubicin, and cyclophosphamide combination chemotherapy." | 3.76 | Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. ( Baggerly, K; Coutant, C; Kim, YC; Lee, JK; Pusztai, L; Qi, Y; Rouzier, R; Symmans, WF; Theodorescu, D, 2010) |
| "The global lapatinib expanded access programme provided access to lapatinib combined with capecitabine for women with HER2-positive metastatic breast cancer (MBC) who previously received anthracycline, taxane and trastuzumab." | 3.76 | Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. ( Ashley, S; Bhatti, R; Camburn, T; Chan, S; Davidson, N; Johnston, SR; Miles, D; Nouras, H; Shehata, M; Sutherland, S; Wardley, A, 2010) |
| " To investigate the molecular basis for the effect of TP on the metabolic process and the anticancer effect of 5-fluorouracil (5-FU), human gastric carcinoma AZ521 cells and epidermoid carcinoma KB cells were transfected with TP cDNA, and AZ521/TP and KB/TP were cloned." | 3.76 | The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells. ( Akiyama, S; Che, XF; Furukawa, T; Ikeda, R; Kanekura, T; Kanzaki, T; Mataki, H; Matsushita, S; Minami, K; Miyadera, K; Nishizawa, Y; Tabata, S; Tajitsu, Y; Takeda, Y; Ushiyama, M; Yamada, K; Yamamoto, M, 2010) |
| "After cisplatin / 5-fluorouracil chemotherapy for nasopharyngeal carcinoma, an 18-year female patient developed aortobifemoral embolism." | 3.76 | Aortobifemoral embolism in an 18-year old patient following cisplatin and 5-fluorouracil chemotherapy for nasopharyngeal carcinoma. ( Bode, U; Born, M; Fleischhack, G; Heinrich, N; Hoebert, E; Simon, A; Verrel, F, 2010) |
| "Cyclophosphamide, methotrexate and 5-fluorouracile (CMF)-based chemotherapy for adjuvant treatment of breast cancer reduces the risk of relapse." | 3.75 | Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy. ( Annecke, K; Busch, R; Harbeck, N; Hoefler, H; Kiechle, M; Klein-Hitpass, L; Kruse, E; Langer, R; Mages, J; Naehrig, J; Reich, U; Schmitt, M; Smida, J; Specht, K, 2009) |
| "This monoinstitutional retrospective study compares the results of both treatment schedules: 315 patients with locally advanced carcinoma (UICC stage III and IV) of the oral cavity and the orohypopharynx were treated from January 1990 to March 2006 with a radiochemotherapy combination based on mitomycin C and fluorouracil (HART-CC: 203 patients, CFRT-CC: 112 patients, total dose: 70-72 Gy) with curative intent." | 3.75 | Hyperfractionated accelerated radiotherapy versus conventional fractionation both combined with chemotherapy in patients with locally advanced head and neck carcinomas: a retrospective analysis of a monoinstitutional series. ( Abu Jawad, J; Budach, V; Jahnke, K; Lehnerdt, G; Pöttgen, C; Sack, H; Stüben, G; Stuschke, M; Welz, H; Wierlemann, A; Wittig, A, 2009) |
| " We analyzed the influence of codon 751 Lys-->Gln polymorphism of XPD on its protein expression levels, clinico-pathological features, and outcome of 188 Chinese patients with metastatic colorectal carcinoma (CRC) that had been treated with first-line Oxaliplatin + Leucovorin + 5-Fluorouracil (FOLFOX-4) chemotherapy." | 3.75 | Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. ( Chen, PM; Chen, WS; Jiang, JK; Lai, JI; Lin, JK; Lin, TC; Tzeng, CH; Wang, HS; Wang, WS, 2009) |
| "To evaluate the efficacy and the safety of combined 5-Fluorouracil, irinotecan, bevacizumab and sirolimus in refractory advanced colorectal carcinoma." | 3.75 | Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study. ( Chauffert, B; Ghiringhelli, F; Guiu, B; Ladoire, S, 2009) |
| "The national Prostatic Cancer Project has evaluated single and combination chemotherapeutic agents for the treatment of patients with advanced prostatic cancer that has been unresponsive to hormonal therapy." | 3.75 | Chemotherapy of hormonally unresponsive prostatic carcinoma. ( deKernion, JB; Lindner, A, 1984) |
| " A major obstacle in the treatment of colorectal cancer is relative insensitivity to the chemotherapeutic agent 5-Fluorouracil (5-FU)." | 3.74 | Single-cell transcription site activation predicts chemotherapy response in human colorectal tumors. ( Augenlicht, LH; Gandhi, SJ; Pestell, RG; Pezo, RC; Shirley, LA; Singer, RH, 2008) |
| ") on sensitivity to chemotherapeutic agents, paclitaxel and doxorubicin as MDR1/P-glycoprotein substrates, and cisplatin and 5-fluorouracil as non-substrates, in human cervical carcinoma HeLa cells, and paclitaxel-resistant and cisplatin-resistant derivatives (HeLa/TXL and HeLa/CDDP, respectively)." | 3.74 | Effects of Agaricus blazei Murill extract on sensitivity to chemotherapeutic agents in HeLa cells and its resistant sublines. ( Kitada, N; Obata, Y; Ohnishi, N; Shin, Y; Takara, K; Yokoyama, T, 2008) |
| "The aim of this study is to evaluate the safety and efficacy of hepatic artery infusion (HAI) of 5-fluorouracil (5FU) for patients with liver metastases from colorectal carcinoma after radiological placement of infusion catheters." | 3.74 | Outcomes of hepatic artery infusion therapy for hepatic metastases from colorectal carcinoma after radiological placement of infusion catheters. ( Hirayama, I; Horikoshi, H; Motegi, K; Saito, T; Sameshima, S; Sawada, T; Tomozawa, S, 2007) |
| "To investigate the inhibitive effects of triptolide (TPL) combined with 5-fluorouracil (5-FU) on colon carcinoma HT-29 cells in vitro and in vivo and their side effects." | 3.74 | Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. ( Lin, XL; Tang, XY; Tao, WH; Wei, B; Zhu, YQ, 2007) |
| "The levels of both VEGF and PDGF-BB were measured in three time points, in the serum of 32 rectal carcinoma patients receiving daily reduced-dose/continuous capecitabine in combination with preoperative pelvic irradiation." | 3.74 | Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients. ( Be'ery, E; Fenig, E; Koren, C; Lavi, I; Loven, D; Shaked, Y; Sulkes, A; Yerushalmi, R, 2008) |
| "From January 1991 to December 2006, 18 patients with invasive carcinoma of the male urethra referred to our institution were treated with a chemoradiation therapy protocol, consisting of 2 cycles of 5-fluorouracil (1,000 mg/m(2)) on days 1 to 4 and days 29 to 32, and mitomycin-C (10 mg/m(2)) on days 1 and 29 with concurrent external beam radiation therapy (45 to 55 Gy in 25 fractions during 5 weeks) to the genitalia, perineum, and inguinal and external iliac lymph nodes." | 3.74 | Coordinated chemoradiation therapy with genital preservation for the treatment of primary invasive carcinoma of the male urethra. ( Billmeyer, B; Cohen, MS; Girshovich, L; Hanley, RS; Oberfield, RA; Shuster, T; Triaca, V; Zinman, L, 2008) |
| "5-Fluorouracil (5-FU) is a key drug in the treatment of esophageal squamous cell carcinoma (ESCC)." | 3.74 | Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines. ( Ando, T; Fujii, Y; Ishiguro, H; Katada, T; Kimura, M; Kuwabara, Y; Mitsui, A; Mori, R; Ogawa, R; Sugito, N, 2008) |
| "5-Fluorouracil (5-FU) is an important chemotherapeutic agent for nasopharyngeal carcinoma (NPC)." | 3.74 | Downregulation of BMI-1 enhances 5-fluorouracil-induced apoptosis in nasopharyngeal carcinoma cells. ( Feng, Y; Kong, QL; Li, MZ; Liao, DF; Qian, CN; Qin, L; Song, LB; Weng, GX; Zeng, MS; Zeng, YX; Zhang, L; Zhang, X, 2008) |
| " Similarly, constitutive hTERT expression inhibited wild-type p53-dependent apoptosis in response to mitomycin C or 5-fluorouracil in HCT116 colon carcinoma cells carrying endogenous p53." | 3.73 | hTERT antagonizes p53-induced apoptosis independently of telomerase activity. ( Latonen, L; Rahman, R; Wiman, KG, 2005) |
| "Patients undergoing cytoreductive surgery and perioperative hyperthermic chemotherapy (mitomycin C, intraoperatively; 5-fluorouracil early post-operatively) for peritoneal carcinomatosis from colorectal cancer from 1996 to 2003 were evaluated retrospectively." | 3.73 | Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy. ( Ceranic, MS; Kecmanovic, DM; Kovacevic, PA; Pavlov, MJ; Sepetkovski, AV; Stamenkovic, AB, 2005) |
| "to evaluate the feasibility, tolerance/toxicity and therapeutic efficacy of 5-fluorouracil (5-FU) by topical application and systemic use, in facial carcinoma associated with XP." | 3.73 | [Topical and systemic chemotherapy with 5-fluouracil in facial carcinoma secondary to xeroderma pigmentosum]. ( Boussen, H; Boussen, I; Ferjaoui, M; Gritli, S; Khader, A; Ladgham, A; Nouira, R; Oueslati, Z, 2005) |
| "We report the case of a 35-year-old pregnant woman with inflammatory breast carcinoma initially treated with 5-fluorouracil/doxorubicin/cyclophosphamide beginning her 13th week of pregnancy." | 3.73 | Docetaxel administered during pregnancy for inflammatory breast carcinoma. ( Aramendía, JM; Fernández-Hidalgo, O; García-Manero, M; López, G; Nieto, Y; Santisteban, M, 2006) |
| " In our report, a middle age patient suffering from locally advanced gastric cancer with peritonitis carcinomatosa and ascites was treated with neoadjuvant chemotherapy (DCF: docetaxel, cisplatin, fluorouracil protocol) successfully, as at the restaging examination total tumor regression was found." | 3.73 | [Complete regression after neoadjuvant chemotherapy in locally advanced gastric cancer causing peritonitis carcinomatosa--a case report]. ( Ember, A; Esik, O; Horváth, OP; Kalmár, K; Papp, A; Yousuf, AF, 2006) |
| "The objective of this study was to determine whether HER-2 overexpression is associated with improved response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) in patients with breast carcinoma." | 3.72 | Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. ( Buzdar, AU; Esteva, FJ; Hortobagyi, GN; Kau, SW; Kuerer, HM; McConathy, JM; Pusztai, L; Smith, T; Symmans, WF; Yang, Y; Zhang, F, 2003) |
| " We investigated the combination effect of 5-fluorouracil (5-FU), a first-choice drug for the treatment of colorectal cancer and adenovirus-mediated transfer of caspase-8 in DLD-1 colon cancer cells." | 3.72 | 5-Fluorouracil efficiently enhanced apoptosis induced by adenovirus-mediated transfer of caspase-8 in DLD-1 colon cancer cells. ( Hamada, H; Kitayama, J; Nagawa, H; Shinoura, N; Uchida, H; Watanabe, T, 2003) |
| " We report two cases of NM from breast carcinoma and a third with esophageal carcinoma, which responded to treatment with capecitabine, an oral prodrug for 5-flurouracil." | 3.72 | Response of neoplastic meningitis from solid tumors to oral capecitabine. ( Giglio, P; Groves, MD; Tremont-Lukats, IW, 2003) |
| "We examined the mechanisms underlying the enhancement of radiosensitivity and chemosensitivity to gamma-irradiation (IR) and 5-Fluorouracil (5-FU) in human oral carcinoma cells (B88) in which NF-kappaB activity was constitutively suppressed." | 3.72 | Enhanced radiosensitization and chemosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8. ( Ashida, Y; Azuma, M; Harada, K; Kawaguchi, S; Motegi, K; Sato, M; Takashima, R; Tamatani, T, 2004) |
| "To assess the mechanism of action of 5-fluorouracil (5-FU) apoptosis (AI) and proliferation (PI) indices were determined histochemically in colon carcinoma and normal colon tissue of 7 patients treated preoperatively with 5-FU (300 mg/m2/day for 5 days) and 11 controls." | 3.71 | Selective induction of colon cancer cell apoptosis by 5-fluorouracil in humans. ( Dervenis, C; Giannakou, N; Kozoni, V; Rigas, A; Rigas, B; Shiff, SJ, 2002) |
| "5-Fluorouracil (5-FU) is a pyrimidine antimetabolite active against colorectal carcinoma and other malignancies of the digestive tract." | 3.71 | In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase. ( Aquino, A; Correale, P; Cusi, MG; De Vecchis, L; Francini, G; Giorgi, G; Micheli, L; Nencini, C; Petrioli, R; Pozzessere, D; Prete, SP; Rausa, L; Sabatino, M; Sanguedolce, R; Turriziani, M, 2001) |
| " We examined TP expression using immunohistochemistry (654-1 Mab) in 182 invasive breast carcinomas (67 N0 and 115 N1/2; median follow-up 78 months [range, 3-177]; 51 patients treated with adjuvant systemic cyclophosphamide, methotrexate and 5-fluorouracil [CMF] chemotherapy and 82 with tamoxifen)." | 3.71 | Prognostic value of thymidine phosphorylase expression in breast carcinoma. ( Barbareschi, M; Caffo, O; Dalla Palma, P; Galligioni, E; Kakudo, K; Mauri, F; Mori, I; Muscarà, M; Nakamura, M; Nakamura, Y; Sakurai, T; Yang, Q; Yoshimura, G, 2002) |
| " Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma." | 3.71 | gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001) |
| "The objective of this study was to investigate the possible prognostic factors in patients with metastatic colorectal cancer (CRC) treated with protracted venous infusion (PVI) of 5-fluorouracil (5-FU)." | 3.71 | Prognostic factors for patients with metastatic colorectal cancer receiving protracted venous infusion of 5-FU. ( Gotoh, M; Hamaguchi, T; Matsumura, Y; Mizuno, T; Muro, K; Namiki, Y; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2002) |
| "Prior to the administration of 5-fluorouracil chemotherapy, the authors examined 14 colorectal carcinoma patients with unresectable liver metastases using a single PET scan and 18F-labeled fluorouracil (18F-FU)." | 3.70 | 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. ( Dimitrakopoulou-Strauss, A; Gutzler, F; Moehler, M; Raeth, U; Strauss, LG; Stremmel, W, 1998) |
| "We retrospectively reviewed 47 patients with locally advanced or bulky cervical carcinoma treated with two courses of intraarterial infusion of cisplatin, doxorubicin, mitomycin C, and 5-fluorouracil (5-FU), followed by radical hysterectomy at our hospital between 1988 and 1995." | 3.70 | Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma. ( Kataoka, N; Konishi, I; Mandai, M; Mori, T; Nagata, Y; Nanbu, K; Tsuruta, Y, 1998) |
| "For almost 40 years, 5-fluorouracil (5-FU) has been the only useful drug with clinically meaningful activity in metastatic colorectal carcinoma." | 3.70 | Continuous infusion 5-fluorouracil as salvage chemotherapy in patients with advanced colorectal cancer. ( Au, E; Khoo, KS; Koo, WH; Lim, WT, 1999) |
| "This study involved a subset of 129 patients from a series of 174 with T2-3, N0-1, M0 or T1, N1, M0 breast carcinoma (Stage IIA, IIB, or IIIA ) who were registered in a prospective IC trial using paclitaxel or a combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC)." | 3.70 | The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy. ( Ames, FC; Buzdar, AU; Feig, BW; Hunt, KK; Lenert, JT; Mirza, NQ; Ross, MI; Singletary, SE; Vlastos, G, 2000) |
| "A left radical mastectomy was performed on a 53-year-old woman, diagnosed with left inflammatory breast cancer, after local arterial chemotherapy with cyclophosphamide (CPA), doxorubicin and 5-fluorouracil (5-FU)." | 3.70 | [A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)]. ( Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E, 2000) |
| "We report the results of a chemotherapy regimen combining oxaliplatin, 5-fluorouracil, and folinic acid in patients with metastatic renal cell carcinoma." | 3.70 | Oxaliplatin, 5-fluorouracil, and folinic acid (Folfox) in patients with metastatic renal cell carcinoma: results of a pilot study. ( Chaouche, M; Franiatte, J; Grandjean, M; Kamioner, D; Pasturaud, AL; Tourani, JM, 2000) |
| " In order to test a combination therapy of UCN-01 and 5-fluorouracil (5-FU), growth inhibition of CRL 1420 (MIA PaCa-2; undifferentiated pancreatic carcinoma) by four different treatments was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay." | 3.70 | UCN-01 (7-hydroxystaurosporine) enhances 5-fluorouracil cytotoxicity through down-regulation of thymidylate synthetase messenger RNA. ( Abe, S; Furukawa, T; Kitajima, M; Kubota, T; Kumai, K; Otani, Y; Watanabe, M, 2000) |
| "Between 1982 and 1992, 139 patients with epidermoid carcinoma of the anal canal were treated by radiation and chemotherapy with 5-fluorouracil (5-Fu) and mitomycin C (MMC)." | 3.69 | [The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients]. ( Budach, V; Döker, R; Grabenbauer, GG; Huber, K; Hültenschmidt, B; Hutter, M; Kuhne-Velte, HJ; Panzer, M; Rühl, U; Wendt, T, 1994) |
| "In 62 human gastric carcinomas, the expression of GST pi was immunohistochemically evaluated, and sensitivity to the anticancer drugs, cisplatin (CDDP), doxorubicin (DXR) aclacinomycin A (aclarubicin), (ACR), 5-fluorouracil (5-FU), mitomycin C (MMC) and carboquone (carbazilquinon) (CQ) was examined using the in vitro succinate dehydrogenase inhibition test." | 3.69 | Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin. ( Adachi, Y; Baba, H; Endo, K; Kuwano, M; Maehara, Y; Okuyama, T; Sugimachi, K, 1994) |
| "We studied the effect of combined chemo-immunotherapy, 5-FU followed by thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2) at low doses, on liver metastases from colorectal cancer, induced by splenic injection of DHD/K12 cells (1,2-dimethylhydrazine-induced colon adenocarcinoma) in syngeneic BDIX rats." | 3.69 | Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. ( Garaci, E; Pierimarchi, P; Rasi, G; Silecchia, G; Sinibaldi-Vallebona, P; Sivilia, M; Spaziani, E; Tremiterra, S, 1994) |
| " Adenocarcinoma patients receive mitomycin C and 5-fluorouracil; sarcoma patients receive cisplatin and doxorubicin." | 3.69 | Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis. ( Sugarbaker, PH, 1994) |
| "The metabolism of 5-fluorouracil (5-FU) was monitored non-invasively in two xenografts, a hypopharynx carcinoma and a colon carcinoma (CSM) by 19F-magnetic resonance spectroscopy following an i." | 3.69 | 5-Fluorouracil metabolism and cytotoxicity after pre-treatment with methotrexate or thymidine in human hypopharynx and colon carcinoma xenografts: a 19F-nuclear magnetic resonance spectroscopy study in vivo. ( Baumgart, F; Köpf-Maier, P; Tausch-Treml, R; Ziessow, D, 1996) |
| "The optimal schedule for the administration of 5-fluorouracil (5-FU) in the management of advanced colorectal cancer remains to be determined." | 3.69 | Bioavailability of subcutaneous 5-fluorouracil: a case report. ( Carlin, W; Dunlop, DJ; Eatock, MM; Soukop, M; Watson, DG, 1996) |
| "A new delivery formulation (5FU-MS) of 5-fluorouracil (5FU), 5FU incorporated in microspheres composed of poly(glycolide-co-lactide) matrix, has been developed for the treatment of peritoneal carcinomatosis, and is designed to slowly release the incorporated 5FU for 3 weeks." | 3.69 | Pharmacological effects of 5-fluorouracil microspheres on peritoneal carcinomatosis in animals. ( Fujita, T; Hagiwara, A; Imanishi, T; Muranishi, S; Ohgaki, M; Sakakura, C; Sawai, K; Takahashi, T; Tsujimoto, H; Yamamoto, A; Yamazaki, J, 1996) |
| "A 40-year-old male patient with carcinoma of the tonsil was put on a 5-fluorouracil and cisplatinum regimen." | 3.68 | Myocardial ischemia after 5-fluorouracil chemotherapy. ( Ayyagari, S; Chag, M; Rastogi, N, 1993) |
| "To perform an economic evaluation of the joint use of 5-fluorouracil and levamisole as adjuvant chemotherapy in patients with fully resected Dukes' Stage C carcinoma of the colon, compared with resection and no chemotherapy." | 3.68 | A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. ( Gurney, H; Hall, J; Harnett, PR; Smith, RD, 1993) |
| " One patient had severe ileitis caused by intravenous administration of 5-fluorouracil; the other had severe duodenitis caused by infusion of 5-floxuridine into the hepatic artery by an implanted pump." | 3.68 | Gastrointestinal toxicity of 5-FU and 5-FUDR: radiographic findings. ( Hiehle, JF; Levine, MS, 1991) |
| "Experimental chemotherapy with 5-fluorouracil (5-FU; 60 mg/kg), 1-hexylcarbamoyl-5-fluorouracil (HCFU; 70 mg/kg), 3-(3-(6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl)-1-ethoxym ethyl-5- fluorouracil (BOF-A2; 30 mg/kg) and UFT (20 mg/kg as tegafur with uracil at a molar ratio of 1:4) was performed using human gastric (H-111) and colon (Co-4) carcinoma strains in nude mice." | 3.68 | Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition. ( Abe, O; Arisawa, Y; Fujita, S; Ishibiki, K; Josui, K; Kodaira, S; Kubota, T; Mabuchi, K; Suto, A; Yamamoto, T, 1991) |
| "Fourteen patients with progressive metastatic adrenal cortical carcinoma were treated with a combination of 5-fluorouracil (5-FU), doxorubicin, and cisplatin (FAP)." | 3.68 | 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. ( Brugieres, L; Droz, JP; Gicquel, C; Parmentier, C; Schlumberger, M; Travagli, JP, 1991) |
| "Forty-three patients with nonmetastatic inflammatory breast carcinoma have been treated by initial doxorubicin, 5-fluorouracil, and cyclophosphamide (FAC) combination chemotherapy." | 3.68 | Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. ( Bergerat, JP; Boilletot, A; Duclos, B; Dufour, P; Giron, C; Haennel, P; Herbrecht, R; Jaeck, D; Jung, G; Maloisel, F, 1990) |
| "Prognostic factors were identified in a group of 210 patients with inflammatory breast carcinoma (IBC) treated at Institut Gustave Roussy from 1976-1985 with three successive induction protocols: Group A (n = 91), 1976-1980, doxorubicin, vincristine, methotrexate (AVM); Group B (n = 79), 1980-1982, doxorubicin, vincristine, cyclophosphamide, methotrexate, 5-fluorouracil (AVCMF); Group C (n = 40), 1983-1985, AVCMF." | 3.68 | Therapeutic strategies in inflammatory breast carcinoma based on prognostic factors. ( Friedman, S; Mouriesse, H; Rouëssé, J; Sarrazin, D; Spielmann, M, 1990) |
| "50 patients with recurrent cervical carcinoma were included in a phase II study of cisplatinum and 5-fluorouracil." | 3.68 | [A phase II study of 5-fluorouracil/cisplatin in recurrent cervical cancer]. ( Abeler, V; Kaern, J; Kjørstad, KE; Nordal, R; Sandvei, R; Sundfør, K; Tropé, C; Vergote, I; Vossli, S, 1990) |
| "Bilateral total corneal epithelial erosion and descement folds are reported as toxic side effects of 5-fluorouracil in a patient with end stage carcinoma of the stomach." | 3.68 | Bilateral total corneal epithelial erosion as a side effect of cytotoxic therapy. ( Alhalel, A; Avni, I; Brener, H; Hirsh, A; Weiss, A, 1990) |
| "Three patients with metastatic carcinoma of the ampulla of Vater received celiac artery infusion of 5-fluorouracil, adriamycin, mitomycin-C, and streptozotocin followed by intravenous administration of the same combination." | 3.67 | Combination chemotherapy for metastatic carcinoma of the ampulla of Vater--report of three cases. ( Bukowski, RM; Hermann, RE; Theodors, A, 1984) |
| "Eighty-nine patients with advanced gastric carcinoma were treated with a combination chemo-immunotherapy regimen that consisted of active immunotherapy with Vibrio cholerae neuraminidase (VCN) treated autologous tumor cells admixed with BCG and drugs including cyclophosphamide, mitomycin C (MMC) and 5-fluorouracil, followed by long term tegafur (FT) and immunomodulators." | 3.67 | Combination chemoimmunotherapy for advanced gastric carcinoma. ( Akiyoshi, T; Arinaga, S; Kawaguchi, M; Koba, F; Miyazaki, S; Tsuji, H; Wada, T, 1984) |
| "Nine patients (5 males, 4 females; median age, 62 years) with recurrent high-grade malignancies of major (7 cases) and minor (2 cases) salivary gland origin (4 adenoid cystic carcinomas, 2 adenocarcinomas, 2 poorly differentiated carcinomas, 1 mixed malignant tumor) were treated with cisplatin (60 mg/m2), epirubicin (50 mg/m2) and 5-fluorouracil (600 mg/m2) (CEF) by intravenous injections on the first day of a 21-day regimen." | 3.67 | Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. ( Airoldi, M; Brando, V; Gabriele, P; Giordano, C; Pedani, F, 1989) |
| "Based on the in vitro and in vivo data suggesting synergistic cytolysis by the combination of 5-fluorouracil and interferon-gamma against a variety of malignant cell lines including a human colon carcinoma cell line (HT-29), we initiated studies in patients with advanced colon or rectal carcinoma." | 3.67 | Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. ( Abbruzzese, JL; Ajani, JA; Edwards, C; Ende, K; Faintuch, JS; Gutterman, JU; Levin, B; Rios, AA; Saks, S, 1989) |
| "Effects of N-(6-aminohexyl)-1-naphthalenesulfonamide (W-5) and N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7) on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur, FT) and a mixture of FT and uracil (UFT) were determined in nude mice bearing human ovarian carcinoma (KF cells)." | 3.67 | Adjuvant effects of calmodulin antagonists on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur) and a mixture of ftorafur and uracil (UFT) in nude mice bearing human ovarian carcinomas. ( Iwano, I; Kikuchi, Y; Kita, T; Kizawa, I; Kuki, E; Miyauchi, M; Oomori, K, 1989) |
| "Hexamethylmelamine, mitomycin C and 5-fluorouracil infusion (HexMF) achieved a median survival of 9 months for the 45 patients with either metastatic stage III or unresectable stage II carcinoma of the pancreas." | 3.67 | Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion. ( Bruckner, HW; Butwell, N; Gorbaty, MI; Kalman, J; McKenna, A; Spigelman, M; Storch, J, 1989) |
| "Twenty-four patients with carcinoma of the anus were treated with a combined regimen of external irradiation (50 Gy) and mitomycin C and 5-fluorouracil." | 3.67 | Primary treatment of carcinoma of the anus by combined radiotherapy and chemotherapy. ( Flokkmann, A; Fosså, SD; Guldvog, I; Haffner, J; Karlsen, KO; Tveit, KM, 1989) |
| "Four human head and neck xenograft (HNX) tumour lines grown in nude mice and two murine colon carcinomas (Colon 26 and 38) were tested for their sensitivity to 5-fluorouracil (5-FU) and its prodrug 5'deoxy-5-fluorouridine (Doxifluridine, 5'd-FUR)." | 3.67 | Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes. ( Braakhuis, BJ; de Bruijn, EA; Laurensse, EJ; Peters, GJ; Pinedo, HM; van Walsum, M, 1989) |
| "Based on in vitro studies that have demonstrated synergy between recombinant alfa-2a-interferon (rIFN alpha-2a) and the fluoropyrimidine, fluorouracil (5FU), against two human colon cancer cell lines, a pilot clinical trial was initiated to determine the effects of the combination of 5FU and rIFN alpha-2a in patients with advanced, unresectable colorectal carcinoma." | 3.67 | Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. ( Goldman, M; Itri, L; Lyver, A; Rader, M; Schwartz, EL; Wadler, S; Weinberg, V; Wiernik, PH; Zimmerman, M, 1989) |
| "Three hundred thirty-six patients with stage II or stage III breast cancer were treated on an adjuvant protocol containing fluorouracil, doxorubicin, cyclophosphamide, vincristine, and prednisone (FACVP)." | 3.67 | Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma. ( Ang, PT; Buzdar, AU; Hortobagyi, GN; Kau, S; Smith, TL, 1989) |
| "Following the observation of antitumor activity for the combination of 5-fluorouracil (5-FU) and cisplatin in metastatic colorectal carcinoma, the combination of 5-FU and iproplatin was tested, also in colorectal carcinoma, in the hope of attaining equivalent activity without the nephrotoxicity observed with 5-FU/cisplatin." | 3.67 | Phase II trial of continuous-infusion iproplatin (CHIP) and 5-fluorouracil (5-FU) in advanced colorectal carcinoma. ( Creaven, PJ; Herrera, L; Mittelman, A; Petrelli, NJ, 1989) |
| "Parameters for inhibition of thymidylate synthase (TS) in a DMH-induced transplantable rat colon carcinoma were studied after intraperitoneal administration of bolus doxifluridine (5'-dFUR) 200 mg/kg." | 3.67 | Inhibition of thymidylate synthase after administration of doxifluridine in a transplantable colon carcinoma in the rat. ( Almersjö, O; Berne, M; Gustavsson, B; Spears, P; Sundström, E, 1988) |
| "Five patients with metastatic adrenal cortical carcinoma were treated with a combination of 5-fluorouracil (5-FU), doxorubicin, and cisplatin." | 3.67 | 5-Fluorouracil, doxorubicin, and cisplatin regimen in adrenal cortical carcinoma. ( Bellaiche, M; Droz, JP; Ostronoff, M; Parmentier, C; Rougier, P; Schlumberger, M, 1988) |
| "Twenty-five consecutive cases of inflammatory breast carcinoma were treated with high-dose cyclophosphamide and 5-fluorouracil in 5-day courses every 3 weeks for 2 years, with total mastectomy performed after the third course." | 3.67 | Two years of high-dose cyclophosphamide and 5-fluorouracil followed by surgery after 3 months for acute inflammatory breast carcinomas. A phase II study of 25 cases with a median follow-up of 35 months. ( Breau, JL; Israël, L; Morere, JF, 1986) |
| "Combination three-drug chemotherapy with adriamycin (ADM), cyclophosphamide (CPM), and 5-fluorouracil (5-FU) was performed in 24 cases of advanced bladder cancer who underwent surgical treatment, and three cases with recurrent or metastatic bladder cancer." | 3.66 | Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil. ( Machida, T; Masuda, F; Ohishi, Y; Tashiro, K, 1983) |
| "Thirty-two patients with inflammatory breast cancer were treated with a combined modality approach consisting of combination chemotherapy with fluorouracil, doxorubicin hydrochloride, and cyclophosphamide, followed by radiation therapy." | 3.66 | Management of inflammatory carcinoma of breast with combined modality approach - an update. ( Barker, JL; Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Montague, ED, 1981) |
| " The antitumor activity of this compound was superior to those of 5-FU and 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur, Ftorafur) in the treatment of transplantable tumors, not only 5-FU-sensitive tumors such as adenocarcinoma 755, lymphosarcoma LS-1, and plasmacytoma X5563, but also 5-FU-resistant tumors such as Lewis lung carcinoma and Walker carcinosarcoma 256." | 3.66 | Antitumor activity of methyl (5-fluoro-1H-2-oxo-4-pyrimidinyl beta-D-glucopyranosid)uronate against various experimental tumors. ( Arakawa, M; Inomata, T; Sasagawa, K; Shimizu, F; Shinkai, K, 1981) |
| "Twenty-four patients with confirmed Stage D carcinoma of the prostate were treated with a combination of bilateral orchiectomy, estrogens (diethylstilbestrol) and chemotherapy (5-fluorouracil), and cyclophosphamide soon after diagnosis was established." | 3.66 | Early combined hormonal and chemotherapy for metastatic prostatic carcinoma. ( Lurie, H; Mukamel, E; Nissenkorn, I; Servadio, C, 1983) |
| "Following surgery for epithelial carcinoma of the ovary, FIGO stages IIc, III and IV, 110 patients received chemotherapy in one of four treatment regimens (Melphalan; Cyclophosphamide-Methotrexate-Fluoro uracil; Cyclophosphamide-Cisplatinum; Cyclophosphamide-Cisplatinum-Fluoro-uracil)." | 3.66 | [Advanced epithelial cancers of the ovary: results of 4 chemotherapy protocols (110 cases)]. ( Aguilera, J; Breau, JL; Israël, L; Lepage, E, 1982) |
| "Lambdamycin, a chromoglycoside antibiotic like chartreusin was found to be very active against leukemias L 1210 and P 388 and moderate effective against melanoma B 16 and Lewis lung carcinoma of mice." | 3.66 | [Antineoplastic activity of lambdamycin in different murine test models compared with cyclophosphamide, 6-mercaptopurine and 5-fluorouracil (author's transl)]. ( Fleck, WF; Gutsche, W; Jungstand, W; Wohlrabe, K, 1981) |
| "The effect of sequential methotrexate and 5-fluorouracil on the clonal growth of the human colon adenocarcinoma cell, HCT-8, and the hormone-dependent human breast carcinoma cell, 47-DN, was examined." | 3.66 | Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines. ( Benz, C; Cadman, E; Choti, M; Schoenberg, M, 1980) |
| "A carcinostatic substance (5-fluorouracil) was instilled into the mediastinal lymph nodes, the pleural cavity or the internal thoracic artery by continuous perfusion before operation on patients with bronchial carcinoma." | 3.65 | [Continuous local application of cytostatics for bronchial carcinoma and mediastinal lymph node metastasisization (author's transl)]. ( Inoguchi, T; Kita, T; Kuwano, K; Yamasaki, I; Yazuka, K, 1976) |
| " In squamous cell cancer of the lung 48 patients were administered methotrexate (90 mg per course), 18 patients with adenocarcinoma--5-fluoruracil, 29 patients with undifferentiated cancer-cyclophosphane (3 g of each substance)." | 3.65 | [Late results of lung cancer therapy (according to material from the Kazakh Scientific Research Institute of Oncology and Radiology)]. ( Abisatov, KhA; Khan, SV, 1976) |
| "In 1966, we published the case report of a patient with adrenal carcinoma and wide spread metatasis who, after treatment with mitotane (o,p-DDD) and fluorouracil, developed Addison disease accompanied by a clinical remission." | 3.65 | Metastatic adrenal cortical carcinoma. Documented cure with combined chemotherapy. ( Ostuni, JA; Roginsky, MS, 1975) |
| "Advanced gastric cancer is associated with poor survival despite chemotherapy." | 3.30 | Study of Efficacy and Toxicity of Capecitabine Maintenance After Response to Docetaxel, Cisplatin, and 5-Fluracil-Based Chemotherapy in Advanced Carcinoma Stomach. ( Chaudhari, K; Doval, DC; Goel, V; Goyal, P; Koyyala, VPB; Maheshwari, U; Patnaik, N; Talwar, V, 2023) |
| "Patients with stage III-IVa-b NPC received lobaplatin at a dose of 30 mg/m2 on days 1 and 22 combined with a continuous 120-h intravenous injection of 5-fluorouracil at a dose of 4 g/m2 followed by lobaplatin at a dose of 50 mg/m2 on days 43 and 64 concomitant with intensity-modulated radiation therapy." | 2.84 | Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial. ( Guo, X; Huang, XJ; Ke, LR; Liang, H; Liu, GY; Lv, X; Qiu, WZ; Xia, WX; Xiang, YQ; Yang, J; Ye, YF; Yu, YH, 2017) |
| " Treatment consisted of paclitaxel at a dose of 135 mg/m(2) on day 1, cisplatin 25 mg/m(2)/day from day 1 to day 3 and 5-FU-continuous infusion for 120 h at a variable dosage from 600 to 1,000 mg/m(2)/day according to prior radiation." | 2.78 | Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma. ( An, X; Chen, C; Li, YH; Liang, Y; Luo, HY; Wang, FH; Wang, ZQ; Zhang, L, 2013) |
| " In the high RKIP expression subgroup, chemotherapy combined with radiotherapy improved the DMFS when compared with the RT group, but this effect was not observed in the low RKIP expression subgroup." | 2.78 | Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a prospective study. ( Guo, X; Hong, MH; Li, SW; Liu, ML; Lv, X; Mai, HQ; Wang, H; Xia, WX; Xiang, YQ; Zeng, MS; Zhang, HB, 2013) |
| "Patients with untreated metastatic pancreatic cancer received oral capecitabine at 1,000 mg/m(2) twice daily on days 1-14, of a 21-day treatment cycle; and oral erlotinib at 150 mg daily." | 2.78 | Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study). ( Aldana, GQ; DE LA Cámara Gómez, J; Fernández, MJ; Fernández, MS; Folgar, SC; López, MR; López, R; Méndez, CM; Reinoso, CR; Vázquez, MR, 2013) |
| "Cediranib is an oral highly potent VEGF signalling inhibitor that inhibits all three VEGF receptors." | 2.77 | Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study. ( Amagai, K; Baba, H; Bando, H; Denda, T; Fukase, K; Hazama, S; Kato, T; Mishima, H; Muro, K; Shi, X; Skamoto, J; Yamaguchi, K, 2012) |
| "The aim of this study was to determine the safety and efficacy of metronomic chemotherapy combined with targeted drugs in patients with metastatic breast cancer (MBC)." | 2.77 | Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. ( Bagnardi, V; Bertolini, F; Calleri, A; Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Intra, M; Luini, A; Montagna, E; Pastrello, D; Perri, G; Rampinelli, C; Veronesi, P; Viale, G, 2012) |
| "Additional treatment with aVQ is safe and was associated with improved QoL of gastric cancer patients." | 2.77 | Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study. ( Eisenbraun, J; Huber, R; Kim, BS; Kim, KC; Yook, JH, 2012) |
| "In this multicenter phase Ib study, drozitumab was given in combination with the mFOLFOX6 regimen and bevacizumab in patients with previously untreated, locally advanced recurrent or metastatic colorectal cancer on day 1 of every 14-day cycle." | 2.77 | Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. ( Amler, LC; Baranda, JC; Bayraktar, S; Flores, AM; MacIntyre, J; Montero, A; Portera, C; Raja, R; Rocha Lima, CM; Royer-Joo, S; Stern, H; Wallmark, J, 2012) |
| "Although anaplastic thyroid carcinoma has a dismal prognosis, some patients show favorable survival following multimodal treatment with surgery, external irradiation and chemotherapy." | 2.76 | A novel chemo-radiotherapy with low-dose daily cisplatin, 5-fluorouracil and doxorubicin for anaplastic thyroid carcinoma: a preliminary report. ( Fujimoto, Y; Sugitani, I; Tanaka, K, 2011) |
| "Patients suffering from advanced colorectal cancer can experience unintended weight loss and/or treatment-induced gastrointestinal toxicity." | 2.75 | Early supplementation of parenteral nutrition is capable of improving quality of life, chemotherapy-related toxicity and body composition in patients with advanced colorectal carcinoma undergoing palliative treatment: results from a prospective, randomize ( Essenbreis, M; Hasenberg, T; Herold, A; Post, S; Shang, E, 2010) |
| "The first UKCCCR Anal Cancer Trial (1996) demonstrated the benefit of chemoradiation over radiotherapy (RT) alone for treating epidermoid anal cancer, and it became the standard treatment." | 2.75 | Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). ( Glynne-Jones, R; James, R; Jitlal, M; Ledermann, J; Meadows, H; Northover, J; Sebag-Montefiore, D; Wan, S, 2010) |
| "Peritoneal carcinomatosis (PC), which has hitherto been regarded as a lethal entity, can now be cured with surgery (treating macroscopic tumor seeding) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) (treating residual microscopic disease)." | 2.73 | Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. ( Billard, V; Blot, F; Elias, D; Goere, D; Kohneh-Shahri, N; Pocard, M; Raynard, B, 2007) |
| "To evaluate the efficacy and the toxicity of front line FOLFOX4 combined with bevacizumab in patients with metastatsic CRC (mCRC)." | 2.73 | Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. ( Agelaki, S; Androulakis, N; Chatzidakis, A; Christophylakis, C; Diamandidou, E; Emmanouilides, C; Georgoulias, V; Kalbakis, K; Kalykaki, A; Kotsakis, A; Mavroudis, D; Sfakiotaki, G; Souglakos, J; Touroutoglou, N; Vamvakas, L, 2007) |
| "Median time from breast cancer diagnosis to the development of CNS metastasis was 48 (18-165) months." | 2.73 | Capecitabine therapy of central nervous system metastases from breast cancer. ( Abrey, LE; Deangelis, LM; Ekenel, M; Hormigo, AM; Peak, S, 2007) |
| " Severe taxane-related toxic effects were more frequent in group A, while severe thrombocytopenia was low and present only in group A." | 2.73 | Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. ( Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N, 2008) |
| "on day 1 every 3 weeks until disease progression or unacceptable toxicities." | 2.73 | A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer. ( Chang, HM; Kang, HJ; Kang, YK; Kim, BS; Kim, TW; Lee, JS; Oh, ST; Ryu, MH; Sohn, HJ; Yook, JH, 2008) |
| "The addition of cetuximab to capecitabine, oxaliplatin and bevacizumab in the first-line treatment of ACC appears to be safe and feasible." | 2.73 | A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. ( Antonini, NF; Cats, A; Creemers, GJ; Erdkamp, FL; Koopman, M; Mol, L; Punt, CJ; Rodenburg, CJ; Schrama, JG; Tol, J; Vos, AH, 2008) |
| "There were 64 women with Stage II breast carcinoma and 36 women with UICC Stage III breast carcinoma." | 2.72 | Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. ( Amiconi, G; Candeloro, G; Cesta, A; Di Blasio, A; Rea, S; Recchia, F; Saggio, G, 2006) |
| "Our data suggest that esophageal cancers with activated NF-kappaB have aggressive clinical biology and poor treatment outcome." | 2.72 | Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. ( Aggarwal, BB; Ajani, JA; Chao, KS; Ensor, J; Hittelman, WN; Izzo, JG; Lee, JH; Liao, Z; Luthra, R; Malhotra, U; Swisher, SG; Wu, TT, 2006) |
| "Patients with untreated advanced colorectal cancer were enrolled to this single arm phase II multi-center cooperative group trial of bevacizumab combined with IFL." | 2.72 | A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. ( Benson, AB; Catalano, PJ; Giantonio, BJ; Levy, DE; Meropol, NJ; O'dwyer, PJ, 2006) |
| "Tissue samples from 44 patients with breast cancer were used to assess telomerase activity using the TRAP method and the expression of ERalpha, ERbeta and bcl-2 by means of immunocytochemical techniques." | 2.72 | Telomerase activity, estrogen receptors (alpha, beta), Bcl-2 expression in human breast cancer and treatment response. ( Astudillo-De la Vega, H; Benitez-Bribiesca, L; Castillo-Medina, S; Malacara, JM; Murillo-Ortiz, B, 2006) |
| "Capecitabine/docetaxel dosing flexibility allows management of side-effects without compromising efficacy." | 2.72 | Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? ( Barak-Wigler, N; Bexon, AS; Chan-Navarro, CA; Gorbounova, V; Harker, WG; Leonard, R; Maraninchi, D; McKendrick, JJ; O'Shaughnessy, J; Twelves, C; Vukelja, S, 2006) |
| "Treatment of locoregionally advanced nasopharyngeal cancer with induction chemotherapy followed by concomitant chemoradiotherapy resulted in excellent overall survival with acceptable toxicity." | 2.71 | Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. ( Haraf, DJ; Kies, MS; Mittal, BB; Oh, JL; Vokes, EE; Weichselbaum, RR; Witt, ME, 2003) |
| "The median dysphagia free time was 9." | 2.71 | A phase I/II study of CHARTWEL with concurrent chemotherapy in locally advanced, inoperable carcinoma of the oesophagus. ( Glynne-Jones, R; Goodchild, K; Harney, J; Hoskin, PJ; Phillips, H; Saunders, MI, 2003) |
| "Colorectal peritoneal carcinomatosis (PC) is a frequent and very lethal event." | 2.71 | Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. ( Baton, O; Benhamou, E; Delperro, JR; Elias, D; Giovannini, M; Lasser, P; Pocard, M; Sideris, L, 2004) |
| "Peritoneal carcinomatosis in the absence of distant metastasis occurs in approximately 8 per cent of patients with colorectal cancer." | 2.71 | Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. ( van Ruth, S; van Tinteren, H; Verwaal, VJ; Zoetmulder, FA, 2004) |
| "Distant metastases rate (DMR) was significantly reduced with CRT (14." | 2.71 | Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. ( Au, GK; Chan, RT; Cheng, AC; Choy, DD; Chua, DT; Kwok, CC; Kwong, DL; Kwong, PW; Law, MW; Sham, JS; Wan, KY; Wu, PM; Yau, CC, 2004) |
| "Forty patients with locally advanced breast carcinoma underwent neoadjuvant chemotherapy." | 2.71 | Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. ( Arbion, F; Body, G; Brunereau, L; Chapiron, C; Denis, F; Desbiez-Bourcier, AV, 2004) |
| "Despite curative resection, 50%-90% of gastric cancer patients die of disease relapse." | 2.71 | Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. ( Czupryna, A; Kulig, J; Popiela, T; Szczepanik, AM; Zembala, M, 2004) |
| "Progression-free and freedom from metastases rates were 29." | 2.71 | Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy coo ( Bamberg, M; Baumann, M; Budach, V; Budach, W; Geismar, D; Grabenbauer, G; Herrmann, T; Hinkelbein, W; Jahnke, K; Lammert, I; Stueben, G; Stuschke, M; Wernecke, KD; Wust, P, 2005) |
| "Published data suggests that docetaxel combined with 5-fluorouracil (5-FU) may have synergistic activity in treating advanced gastric cancer." | 2.71 | Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer. ( Bang, SM; Cho, EK; Chung, M; Lee, JH; Lee, WK; Park, SH; Shin, DB, 2005) |
| "For patients with rectal cancer treated with full thickness local excision the risk of mesorectal nodal metastases has to be very low." | 2.71 | Prediction of mesorectal nodal metastases after chemoradiation for rectal cancer: results of a randomised trial: implication for subsequent local excision. ( Bujko, K; Kepka, L; Nasierowska-Guttmejer, A; Nowacki, MP; Oledzki, J; Rogowska, D; Serkies, K; Stryczyńska, G; Suwiński, R; Tokar, P; Wieczorek, A; Winkler-Spytkowska, B, 2005) |
| "Patients with peritoneal carcinomatosis (PC) underwent complete cytoreductive surgery followed by intraoperative i." | 2.70 | Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. ( Antoun, S; Bonnay, M; Bourget, P; Ducreux, M; El Otmany, A; Elias, D; Lasser, P; Laurent, S; Paci, A, 2002) |
| "Distant metastases remain the main cause of treatment failure in NPC." | 2.70 | Neoadjuvant chemotherapy plus conventional radiotherapy or accelerated hyperfractionation in stage III and IV nasopharyngeal carcinoma--a phase II study. ( Allam, A; El-Badawi, S; El-Serafi, M; El-Weshi, A; Ibrahim, E; Khafaga, Y; Mosseri, V, 2001) |
| "There are 106 women treated for breast cancer T1c-3a, N0-1, M0 in the study." | 2.69 | [Comparison of adjuvant chemotherapy in breast carcinoma with a combination of cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and AC (doxorubicin, cyclophosphamide). Initial results of a national cooperative study]. ( Bauer, J; Bustová, I; Dorazilová, V; Fischer, J; Hacklová, M; Honová, H; Kohoutek, M; Kůta, M; Kyselá, T; Machácek, J; Miller, V; Petruzelka, L; Pribylová, O; Siffnerová, H; Suk, J; Tajblová, J; Vodvárka, P, 1998) |
| " The levels of free platin decreased triphasically, with a mean terminal half-life of 27." | 2.69 | Oxaliplatin pharmacokinetics during a four-hour infusion. ( Böttger, B; Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Schleyer, E, 1999) |
| " Pharmacodynamic studies were performed to assess drug effects on levels of deoxyuridine triphosphate (dUTP) and thymidine triphosphate (TTP) pools in peripheral-blood mononuclear cells (PBMCs) before and 6 hours after treatment using a highly sensitive DNA polymerase assay." | 2.69 | Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract. ( Berkenblit, R; Damle, S; Haynes, H; Kaleya, R; Ladner, RD; Murgo, A; Schechner, R; Wadler, S, 1999) |
| " Only one patient required a dosage adjustment of cisplatin for a serum creatinine elevation >2." | 2.69 | Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up. ( Braly, P; Doroshow, JH; Johnson, D; Kogut, N; Leong, L; Longmate, J; Margolin, K; McNamara, M; Morgan, RJ; Nagasawa, S; Najera, L; Raschko, J; Schinke, S; Shibata, S; Somlo, G, 2000) |
| "Patients with inflammatory breast cancer or more than nine ipsilateral lymph node involvement without evidence of distant metastasis were randomized to receive either standard dose 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) every 3 weeks for nine courses (control) or six courses of FAC followed by two courses of cyclophosphamide (5." | 2.69 | A phase III study of high-dose intensification without hematopoietic progenitor cells support for patients with high-risk primary breast carcinoma. ( Aref, IM; Cross, PW; Gertler, SZ; Grimard, LJ; Hanson, J; Huan, SD; Malik, ST; St Cyr, DA; Stewart, DJ; Tomiak, EM; Verma, S; Yau, JC, 2000) |
| " A single dose of IFNalpha as low as 3 MIU m(-2) can cause sustained elevation of PBL TP activity in vivo indicating that biochemical markers are important pharmacodynamic endpoints for developing optimal schedules of IFNalpha for biomodulation of 5-FU." | 2.69 | Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha. ( Braybrooke, JP; Ganesan, TS; Harris, AL; Houlbrook, S; Koukourakis, MI; Love, SD; O'Byrne, KJ; Patterson, AV; Propper, DJ; Talbot, DC; Taylor, M; Varcoe, S, 2000) |
| "Of 104 patients with peritoneal carcinomatosis from colon or rectal adenocarcinoma, five patients (4." | 2.69 | Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. ( Pestieau, SR; Sugarbaker, PH, 2000) |
| " These results show that there is no pharmacokinetic advantage to the use of 6S-LV rather than 6R,S-LV as a modulator of 5-FU." | 2.68 | A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma. ( Berghorn, E; Blumenson, LE; Creaven, PJ; Frank, C; Meropol, NJ; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, YM, 1995) |
| "Thirty-two patients (76%) had no oral mucositis." | 2.68 | Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. ( Chan, WK; Chen, KY; Chen, SY; Chi, KH; Law, CK; Shu, CH; Yen, SH, 1995) |
| "From January 1990 to April 1993, 60 oesophageal cancer patients were enrolled in a protocol of non-surgical treatment that consisted of induction chemotherapy followed by concurrent chemoradiotherapy." | 2.68 | Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer. ( Aman, E; Barugel, M; Blajman, C; Carraro, S; Fiorini, A; Giglio, R; Gonzalez, G; Jarentchuk, A; Kneitschel, R; Milano, C; Nadal, J; Navigante, A; Pennella, E; Roca, E; Santarelli, MT; Sardi, M, 1996) |
| "Human colonic cancer is associated with multiple genetic deletions, mutations, and alterations in gene expression; in contrast, gene amplification has not been recognized as a prominent characteristic of human colonic tumors." | 2.68 | Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. ( Augenlicht, LH; Benson, A; Corner, G; Haller, D; Heerdt, BG; Multani, AS; Pathak, S; Richards, C; Ryan, L; Wadler, S, 1997) |
| "Grade 4 leukopenia was observed in 1 case and grade 3 to 4 thrombocytopenia was observed in two cases, respectively." | 2.68 | The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD). ( Antón-Torres, A; Aranda, E; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Massutí, T, 1996) |
| "The majority of patients with head and neck cancer die of locoregional recurrence of disease following surgery and/or radiotherapy." | 2.67 | Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. ( Haraf, DJ; McEvilly, JM; Mick, R; Panje, WR; Vokes, EE; Weichselbaum, RR, 1992) |
| "Thirty-nine patients with head and neck cancer were entered into Phase I-II study of simultaneous radiation therapy with continuous infusion fluorouracil at 800 mg/m2/day and escalating doses of hydroxyurea." | 2.67 | Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. ( Haraf, DJ; Panje, WR; Vokes, EE; Weichselbaum, RR, 1991) |
| "Treatment with levamisole alone had no detectable effect." | 2.67 | Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. ( Emerson, WA; Fleming, TR; Glick, JH; Goodman, PJ; Haller, DG; Laurie, JA; Macdonald, JS; Moertel, CG; Tormey, DC; Ungerleider, JS, 1990) |
| "In well differentiated squamous cell carcinoma, a marked positive effect was obtained in 48." | 2.65 | [Cooperative trials of the Council of Mutual Economic Aid countries on chemoradiotherapy of lung cancer]. ( Bidiak, IP; Kiseleva, ES; Pitskhelauri, VG; Trakhtenberg, AKh; Zholkiver, KI, 1984) |
| " There were no differences in response to therapy or in survival between the patients treated with melphalan followed by 5-fluorouracil and then by methotrexate in high dosage and the patients treated with the same agents in combination." | 2.65 | Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer. ( Boyes, DA; Dodds, DJ; Gerulath, A; Kirk, ME; Klaassen, DJ; Levitt, M; Miller, AB; Pearson, JG; Wall, C, 1980) |
| "Antibody against a breast carcinoma antigen was present in patients with breast carcinoma and other cancer more often (P less than ." | 2.64 | Immunology and adjuvant chemoimmunotherapy of breast cancer. ( Morton, DL; Ramming, KP; Silver, HK; Sparks, FC; Wile, AG; Wolk, RW, 1976) |
| "Sinonasal undifferentiated carcinoma (SNUC) represents less than 1% of all malignancies." | 2.53 | Management of sinonasal undifferentiated carcinoma with intracerebral invasion: Clinical experience at a single institution and review of the literature. ( Clauditz, T; Knecht, R; Laban, S; Muenscher, A; Schafhausen, P; Tribius, S; Veldhoen, S; Zielinski, V, 2016) |
| "Colorectal cancer is the third most common cancer, with recent advances in the management of unresectable metastatic lesions." | 2.50 | Options for metastatic colorectal cancer beyond the second line of treatment. ( Foubert, F; Matysiak-Budnik, T; Touchefeu, Y, 2014) |
| "The majority of the head and neck cancers are squamous cell carcinomas, which commonly overexpress the EGF receptor (EGFR)." | 2.47 | Cetuximab in the treatment of squamous cell carcinoma of the head and neck. ( Specenier, P; Vermorken, JB, 2011) |
| "Colorectal carcinoma is one of the most common cancers in Hungary, responsible for about 5000 deaths each year." | 2.43 | [Chemotherapy agents, response rates and mechanisms of resistance in the therapy of the colorectal carcinoma]. ( Gyôrffy, B; Tegze, B; Tulassay, Z, 2006) |
| "Paclitaxel was well tolerated." | 2.40 | Treatment of patients with upper gastrointestinal carcinomas. ( Ajani, JA, 1997) |
| "The management of distal rectal cancer is in evolution." | 2.40 | Sphincter preservation in rectal cancer. Local excision followed by postoperative radiation therapy. ( Willett, CG, 1998) |
| "In general, patients with pancreatic cancer who are irradiated appear to do better than those who are not." | 2.39 | Radiotherapy for carcinoma of the pancreas. ( Thomas, PR, 1996) |
| "Survival from colorectal cancer has not improved over the last four decades despite advances in surgery and anaesthesia." | 2.39 | Adjuvant therapy for colorectal cancer--is there a place for a Northern Ireland study? ( Houston, RF; Moorehead, RJ; Wilson, RH, 1994) |
| "More than 80% of undifferentiated carcinoma nasopharyngeal type patients with N3 disease (AJC-UICC 1987) will die with or from distant metastases within 3 years after the first symptom." | 2.38 | Alternating chemo-radiotherapy with cisplatin and 5-fluorouracil plus bleomycin by continuous infusion for locally advanced undifferentiated carcinoma nasopharyngeal type. ( Armand, JP; Azli, N; Bachouchi, M; Boussen, H; Cvitkovic, E; Eschwege, F; Gasmi, J; Rahal, M; Schwaab, G; Wibault, P, 1992) |
| "Chloroquine (CQ) is an effective and safe antimalarial drug that is also used as a disease-modifying antirheumatic drug." | 1.91 | Chloroquine prevents hypoxic accumulation of HIF-1α by inhibiting ATR kinase: implication in chloroquine-mediated chemosensitization of colon carcinoma cells under hypoxia. ( Ju, S; Jung, Y; Kang, C; Kim, J, 2023) |
| "Nitazoxanide (NTZ) is an emerging cancer therapy and its targeted GSTP1 evidence remains a knowledge need." | 1.91 | The GSTP1/MAPKs/BIM/SMAC modulatory actions of nitazoxanide: Bioinformatics and experimental evidence in subcutaneous solid Ehrlich carcinoma-inoculated mice. ( Abd El-Moneam, SM; Abdelmaogood, AKK; Elaidy, SM; Elkholy, SE; Faisal, S; Imbaby, S; Mansour, BSA; Mehana, AE, 2023) |
| "Gastric carcinoma is a frequently detected malignancy worldwide, while its mainstream drugs usually result in some adverse reactions, including immunosuppression." | 1.91 | The Antitumor Potential of λ-Carrageenan Oligosaccharides on Gastric Carcinoma by Immunomodulation. ( Chen, H; Chen, J; Tang, M; Wang, F; Wu, W; Zhai, L, 2023) |
| " Using cell models of colorectal and pancreatic cancers, we show that cotreatment with Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone, AcB), a natural flavone from Achyrocline bogotensis, allows for four-fold reduction in 5-Fu dosage without loss of efficacy." | 1.91 | Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone) synergizes with 5-fluorouracil allowing for dose reduction and reduced off-target toxicity in the treatment of colonic and pancreatic cancers. ( Cartwright, BM; Corso, JN; Krishnan, K; Lightner, J; Palau, VE; Torrenegra, RD; Whitted, C, 2023) |
| "Metastatic colorectal cancer patients treated with aflibercept beyond second-line therapy were included." | 1.56 | Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study. ( Artru, P; Auclin, E; Auvray, M; Coriat, R; Hammel, P; Hautefeuille, V; Lecaille, C; Lecomte, T; Locher, C; Moulin, V; Pernot, S; Sickersen, G; Taieb, J; Tougeron, D; Vernerey, D, 2020) |
| " No statistical differences were observed in treatment-related adverse events, hospital admissions, or further treatment lines between age groups." | 1.51 | Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. ( Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E, 2019) |
| "Peritoneal carcinomatosis (PC) from colorectal cancer is associated with poor prognosis." | 1.51 | Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study. ( Burnett, A; Cloutier, AS; Dubé, P; Gervais, MK; Lecompte, MA; Sideris, L; Trabulsi, N; Trilling, B, 2019) |
| "Capecitabine (Xeloda) is an oral 5-FU prodrug of comparable pharmacodynamic activity, currently preferred in place of 5-FU infusion, its established counterpart in neoadjuvant CRT for rectal cancer." | 1.48 | Comparing pathological complete response rate using oral capecitabine versus infusional 5-fluorouracil with preoperative radiotherapy in rectal cancer treatment. ( Evans, T; Jootun, N; Mak, J; Makin, G; Platell, C, 2018) |
| "Undifferentiated carcinoma of pancreas (pancreatic cancer - PC) is a rare subtype of malignant PC." | 1.48 | Undifferentiated Carcinoma of the Pancreas - a Case Report. ( Bumberová, M; Dolinský, J; Janega, P; Jurišová, S; Kašperová, B; Macúch, J; Mego, M, 2018) |
| "5-Fluorouracil has been considered as a cornerstone therapy for colorectal cancer; however, it suffers from low therapeutic response rate and severe side effects." | 1.46 | Apoptosis mediated chemosensitization of tumor cells to 5-fluorouracil on supplementation of fish oil in experimental colon carcinoma. ( Agnihotri, N; Kaur, S; Kumar, S; Rani, I; Sharma, B, 2017) |
| " TW-37 does not have significant impact on the chemotherapeutics-treated NPE cell viability at a dosage that efficiently reduces chemotherapeutics-treated NPC cell viability." | 1.46 | Small molecule inhibitor TW-37 is tolerable and synergistic with chemotherapy in nasopharyngeal carcinoma. ( Chen, D; Huang, H; Jiang, Z; Lu, Y; Wang, R; Wu, S; Yang, H, 2017) |
| "Distant metastases was the predominant site of failure, seen in 5 patients (20%)." | 1.46 | Induction Methotrexate, Cisplatin, and 5-Fluorouracil Versus Cisplatin and 5-Fluorouracil Followed by Radiotherapy in Pediatric Nasopharyngeal Carcinoma: A Retrospective Analysis in a Tertiary Cancer Center. ( Abu-Hijlih, R; Al Mousa, A; Ismael, T; Mohamad, I; Mula-Hussain, L; Salem, A; Sultan, I, 2017) |
| "Metastatic colorectal cancer (mCRC) patients with mutant KRAS or NRAS are ineligible for anti-epidermal growth factor receptor (anti-EGFR) therapy, as RAS mutations activate downstream pathways independently of EGFR and induce primary resistance." | 1.46 | Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma. ( Amar, Y; Berger, F; Bieche, I; Cacheux, W; Canet, J; Cartier, A; de Koning, L; Guimbaud, R; Guyetant, S; Lecomte, T; Lièvre, A; Mariani, O; Ouine, B; Selves, J, 2017) |
| "CTCs in 2 (10%) of 20 breast carcinomas, more than 1 CTC was detected before adjuvant therapy, and both cases showed a decrease to 0 after chemotherapy." | 1.46 | Usefulness of CTC and DTC-BM Detection for Adjuvant Therapy Effects and Prognosis Prediction in Early Breast Carcinoma: Results of 8-11 Years of Follow-up Evaluation. ( Kinoshita, S; Shimada, T; Takeyama, H; Uchida, K, 2017) |
| "Peritoneal metastasis is common in gastric cancer." | 1.46 | Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready? ( Chan, DY; Chee, CE; Nga, ME; Phua, JN; Shabbir, A; So, JB; Soh, TI; Syn, NL; Yap, R; Yong, WP, 2017) |
| "Histology revealed an undifferentiated anaplastic carcinoma, on the basis of a poorly differentiated ductal adenocarcinoma." | 1.46 | Granulocyte Colony-stimulating Factor Producing Anaplastic Carcinoma of the Pancreas: Case Report and Review of the Literature. ( Gloor, B; Rau, T; Vinzens, S; Wochner, A; Zindel, J; Zweifel, M, 2017) |
| " However, patients in the CCRT group exhibited more severe acute adverse events than did patients in the NACT + RT group during radiotherapy, including leukopenia (30." | 1.46 | Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis. ( Chen, L; Ma, J; Mao, YP; Sun, Y; Tang, LL; Yao, JJ; Yu, XL; Zhang, F; Zhang, WJ; Zhou, GQ, 2017) |
| "The aim of this study is to discuss the curative effect of introperitoneal hyperthermic perfusion chemotherapy(IHPC) combined with systemic neoadjuvant chemotherapy on the gastric cancer patients with peritoneal carcinomatosis." | 1.43 | [Study of introperitoneal hyperthermic perfusion chemotherapy combined with systemic neoadjuvent chemotherapy in treatment of gastric cancer patients with peritoneal carcinomatosis]. ( Chen, Y; Guo, Y; Suo, J; Wang, D; Xing, Y; Zhang, Y, 2016) |
| " The chemotherapy drugs were administered as follows: 135 mg/m(2) paclitaxel on day 1, 25 mg/m(2)/day cisplatin on days 1-3, followed by continuously infused intravenous fluorouracil for 120 h at a variable dosage from 600 to 800 mg/m(2)/day, depending on prior radiation." | 1.43 | A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery. ( Jiang, YX; Li, YH; Liang, Y; Luo, HY; Wang, DS; Wang, FH; Wang, Y; Wang, ZQ, 2016) |
| "45 patients with anal cancer who underwent pre-treatment FDG-PET/CT were included." | 1.43 | Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival. ( Behrendt, FF; Eble, MJ; Heinzel, A; Mohammadkhani Shali, S; Mottaghy, FM; Schmitt, V; Verburg, FA; Winz, OH, 2016) |
| "Treatment of T3 laryngeal cancer in the Netherlands is generally comparable, with CT-RT for voluminous T3N0 and most T3N+ tumors, but there are some differences between the centers in the use of chemotherapy and the dose-fractionation schemes." | 1.42 | Treatment of T3 laryngeal cancer in the Netherlands: a national survey. ( Doornaert, P; Kaanders, JH; Terhaard, CH, 2015) |
| "Nasopharyngeal carcinoma is an extremely rare pediatric malignancy predominantly occurring in adolescent males." | 1.42 | Pediatric advanced stage nasopharyngeal carcinoma - case report. ( Mascarin, M; Matijašić, N; Roganović, J, 2015) |
| "Patients with stage IV colorectal cancer and peritoneal carcinomatosis are increasingly treated with curative intent and perioperative systemic chemotherapy combined with targeted therapy." | 1.40 | Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. ( Elias, D; Eveno, C; Gayat, E; Glehen, O; Goéré, D; Passot, G; Pocard, M; Soyer, P, 2014) |
| "Twelve to 13% of patients with colorectal cancer (CRC) develop peritoneal carcinomatosis (PC), the majority of whom present with unresectable disease." | 1.40 | A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer. ( Aalbers, A; Boot, H; Hompes, D; Prevoo, W; van Tinteren, H; van Velthuysen, ML; Verwaal, V; Vogel, W, 2014) |
| "To investigate the efficacy and safety of PCF chemotherapy combined with surgery in the treatment of late-stage gastric cancer." | 1.40 | PCF Chemotherapy Combined with Surgical Treatment of Late Gastric Cancer. ( Cheng, X; Dong, R; Du, Y; Huang, L; Wang, B; Xu, Z; Yang, L; Yu, P; Zhou, Y, 2014) |
| "Stage III rectal cancer was found in 64." | 1.39 | Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy. ( Arbea, L; Arredondo, J; Baixauli, J; Beorlegui, C; Chopitea, A; Hernández-Lizoáin, JL; Rodríguez, J; Sola, JJ, 2013) |
| "Head and neck carcinomas are among the most frequent tumor diseases and, because of different multimodal therapy options, cause enormous costs." | 1.39 | Cost effectiveness of neoadjuvant chemotherapy in locally advanced operable head and neck cancer followed by surgery and postoperative radiotherapy: a Markov model-based decision analysis. ( Guntinas-Lichius, O; Hartmann, M; Himmel, M, 2013) |
| "In 5-fluorouracil (5-FU)-treated patients, the tumour overexpression of SOX9 correlated with markedly poorer survival (HR=8." | 1.39 | Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients. ( Candy, PA; Colley, SM; Davidson, JA; Leedman, PJ; Phillips, MR; Redfern, AD; Stuart, LM; Wood, BA; Zeps, N, 2013) |
| "5-Fluorouracil (5-FU) is an anti-metabolite that is in clinical use for treatment of several cancers." | 1.39 | 5-Fluorouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells. ( Akpinar, B; Baran, Y; Can, G; Olsson, M; Zhivotovsky, B, 2013) |
| "Median age at gastric cancer diagnosis was 48." | 1.39 | Chemosensitivity in ovarian metastases from gastric cancer: a case series. ( Berger, A; Brieau, B; Dubreuil, O; Landi, B; Lepère, C; Markoutsaki, T; Rougier, P; Roussel, H; Taieb, J; Trouilloud, I; Vaillant, JN; Zaanan, A, 2013) |
| "Peritoneal carcinomatosis (PC), considered to have a dismal prognosis, is exclusively sub-classified into stage IVB, even though other metastases to a sole organ are sub-classified into stage IVA, which is considered to be associated with better survival." | 1.39 | Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy? ( Baba, H; Haga, N; Hatano, S; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Matsuzawa, T; Okada, N, 2013) |
| "Carcinomas were categorized by MRI as mucinous (mucin proportion >50% within the tumor volume), and as nonmucinous." | 1.38 | Rectal cancer: mucinous carcinoma on magnetic resonance imaging indicates poor response to neoadjuvant chemoradiation. ( Düber, C; Hansen, T; Heintz, A; Hötker, AM; Junginger, T; Kreft, A; Kreitner, KF; Menig, M; Oberholzer, K; Schmidberger, H; Schneider, A, 2012) |
| "RFA combined with chemotherapy is a promising treatment for NPC metastatic liver disease with improved local response, PFS, and OS compared to current chemotherapy protocols." | 1.38 | Radiofrequency ablation combined with systemic chemotherapy in nasopharyngeal carcinoma liver metastases improves response to treatment and survival outcomes. ( Cai, XY; Cai, YC; Cao, Y; Jiang, WQ; Jin, Y; Shi, YX; Tan, YT, 2012) |
| "Human colorectal cancer cell lines HCT116 and DLD-1 were treated with a panel of small interfering RNAs directed against the PI3K/AKT/mTOR and Ras pathways; proliferation, apoptosis, and protein expression were assessed." | 1.38 | Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer. ( Elliott, VA; Evers, BM; Gao, T; Mustain, WC; Rychahou, PG; Valentino, JD; Wang, C; Zaytseva, YY, 2012) |
| "The primary treatment for nasopharyngeal carcinoma (NPC) is external beam radiotherapy." | 1.38 | Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response. ( Jiang, X; Wang, YX; Yan, D; Yan, S; Yang, J, 2012) |
| "Unresectable pancreatic cancer (UPC) has low survival." | 1.38 | Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation. ( Golden, DW; Liauw, SL; Minsky, BD; Novak, CJ, 2012) |
| "Furthermore, HNSCC-driven squamospheres appeared to be chemoresistant to cisplatin, 5-fluorouracil (FU), paclitaxel and doxetaxel, and showed increased levels of ABCG2, one of the ATP-binding cassette (ABC) transporters." | 1.37 | Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas. ( Cha, YY; Jin, X; Kim, H; Kim, SH; Lim, YC; Oh, SY, 2011) |
| "It is said that disseminated carcinomatosis of the bone marrow has a poor prognosis, but we were able to obtain a good response in this case by chemotherapy." | 1.37 | [Successful chemotherapy of carcinomatosis of the bone marrow with disseminated intravascular coagulation from a rectal carcinoma found by eosinophilia]. ( Abiko, S; Gotoh, J; Higashiyama, A; Kawamura, A; Kawamura, N; Kudo, M; Meguro, J; Nagasako, T; Takano, M; Tamaki, T; Tanino, M; Yamamoto, Y; Yonekawa, M, 2011) |
| "One hundred and fourteen cases of breast cancer with NA therapy were analyzed and clinical data were collected from March 2007 to December 2010." | 1.37 | [Primary systemic therapy in breast cancer patients (2007-2010)]. ( Farkas, R; Horváth, OP; Kálmán, E; Kovács, G; Kövér, E; Pavlovics, G; Szalai, G; Tizedes, G; Zapf, I, 2011) |
| "Pemphigus is an autoimmune intraepidermal blistering disease mediated by autoantibodies targeting desmosomes." | 1.37 | Radiotherapy-induced pemphigus vulgaris with autoantibodies targeting a 110 kDa epidermal antigen. ( Badri, T; Benmously-Mlika, R; Fenniche, S; Hammami, H; Lachkham, A; Mokhtar, I, 2011) |
| "However, the role of CSCs in colorectal cancer metastasis is unclear." | 1.36 | A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. ( Cheung, LW; Chow, AK; Chu, AC; Lam, CS; Lan, HY; Lan, XR; Law, WL; Ng, L; Pang, R; Poon, JT; Poon, RT; Tan, VP; Wong, BC; Yau, TC, 2010) |
| "We report on a 45-year-old breast cancer patient with disseminated hepatic metastases." | 1.36 | Successful remission of extensive liver metastases in a breast cancer patient with acute liver failure using a combined chemotherapy regimen with mitomycin, folinate, and 5-fluorouracil (Mi/Fo/FU). ( Eichbaum, MH; Hauser, N; Hohl, MK; Sohn, C; Stoiber, B; Stoiber, N, 2010) |
| " We investigated the anti-tumor effects of CG2 (an HDACI) in combination with irinotecan, 5-FU, or oxaliplatin." | 1.36 | Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts. ( Cho, DH; Hong, YS; Jin, DH; Jung, KA; Kim, JC; Kim, SM; Kim, TW; Lee, JS; Na, YS; Ro, S; Ryu, MH; Yang, SJ, 2010) |
| "Blood test showed severe disseminated intravascular coagulation (DIC)." | 1.36 | [mFOLFOX6 for treatment of anal canal cancer with disseminated carcinomatosis of bone marrow--a case report]. ( Doi, M; Okamoto, Y; Shinozaki, K; Yamauchi, M, 2010) |
| "The growing number of patients with head and neck cancer is a reason to search for new effective treatment strategies." | 1.36 | [Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results]. ( Chilimoniuk, M; Maksimowicz, T; Olszewska, E, 2010) |
| "However, G-CSF-producing colorectal cancer (CRC) has never been reported in the English literature." | 1.35 | Granulocyte-colony stimulating factor producing rectal cancer. ( Akamo, Y; Funahashi, H; Ochi, N; Sakamoto, M; Satoh, M; Sawai, H; Takahashi, H; Takayama, S; Takeyama, H; Wakasugi, T; Yasuda, A, 2008) |
| "Endoscopy revealed gastric cancer with pyloric stenosis and MRI showed multiple metastasis of thoracic vertebral body." | 1.35 | [A case of gastric cancer accompanied by disseminated carcinomatosis of bone marrow with DIC recovered by sequential therapy consisting of MTX and 5-FU]. ( Akazai, Y; Kimura, T; Seita, M; Takahata, T; Yasuda, K, 2008) |
| " Since all these measures are accompanied by relatively low risks of chronic bleeding a choice of palliative or radical dosage of radiation is possible." | 1.35 | [Intra-arterial chemotherapy and chemoembolization in the combined treatment for locally advanced carcinoma of the head and neck]. ( Korytova, LI; Sokurenko, VP; Suvorova, IuV; Tarazov, PG, 2008) |
| "Seventy-six metastatic colorectal cancer patients receiving cetuximab plus FOLFIRI or FOLFOX-4 chemotherapy were enrolled." | 1.35 | Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. ( Chang, YT; Chen, CW; Chu, KS; Lin, SR; Lu, CY; Tsai, HL; Wang, HM; Wang, JY; Yeh, YS; Yen, LC, 2009) |
| "SS in cervical cancer is a feasible and safe pretreatment procedure, and when associated with CT, it improves OS and DFS." | 1.35 | Impact of surgical staging in locally advanced cervical cancer and subsequent chemotherapy. ( Clagnan, WS; de Andrade, JM; Dos Reis, FJ; Garieri, AP; Marana, HR; Tiezzi, DG; Zola, FE, 2009) |
| "Capecitabine is an antineoplastic agent used for the treatment of patients with metastatic solid tumors (breast and colon)." | 1.34 | [Capecitabine-induced hyperpigmentation]. ( Galán-Gutiérrez, M; Jiménez-Puya, R; Moreno-Giménez, JC; Rodríguez-Bujaldón, AL; Vázquez-Bayo, C, 2007) |
| "Advanced colorectal cancer specimens (n=97) were prepared for immunohistochemical staining using monoclonal antibodies against TP, p53, vascular endothelial growth factor (VEGF), factor VIII, CD68 and thymidylate synthase (TS)." | 1.33 | Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma. ( Koike, M; Matsumoto, H; Mori, T; Shimizu, S; Takahashi, K; Takizawa, T; Toi, M; Yamaguchi, T; Yasuno, M, 2005) |
| "Ten patients (77%) had undifferentiated carcinoma (WHO type III) and three patients (23%) had nonkeratinizing carcinoma (WHO type II)." | 1.33 | Nasopharyngeal carcinoma in the pediatric age group: the northern Israel (Rambam) medical center experience, 1989-2004. ( Arush, MW; Bar-Sela, G; Barak, AB; Bernstein, Z; Gez, E; Haimi, M; Kuten, A; Postovsky, S, 2005) |
| "Drug-induced immune thrombocytopenia (DITP) should be considered in patients who experience a sudden, isolated drop in platelet levels while being treated with chemotherapeutic agents, especially when adequate numbers of megakaryocytes are present in the bone marrow." | 1.33 | Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. ( Aster, RH; Blank, J; Curtis, BR; Kaliszewski, J; Marques, MB; McFarland, JG; Nabelle, L; Saif, MW, 2006) |
| "Resistant HCT-8 colon cancer cell lines (HCT-8/FUI/15R and HCT-8/FUB/2R) were selected from parental sensitive HCT-8 cells by long-term and short-term exposure schedules, respectively." | 1.33 | Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules. ( Caciagli, B; Capaccioli, S; Donnini, M; Landini, I; Lapucci, A; Lulli, M; Mazzei, T; Mini, E; Morganti, M; Nobili, S; Papucci, L; Perna, F; Schiavone, N; Sobrero, A; Tempestini, A; Witort, E, 2005) |
| "The histological diagnosis was undifferentiated carcinoma of sigmoid colon." | 1.33 | [A case of successfully treated unresectable multiple liver metastases from colon cancer by hepatic arterial infusion chemotherapy and systemic chemotherapy]. ( Iwazawa, T; Kanoh, T; Kimura, Y; Monden, T; Nakano, Y; Ohnishi, T; Shiozaki, K; Takemoto, H; Tono, T; Yano, H, 2006) |
| "Type 1 undifferentiated carcinoma (non-small cell type) was detected in the middle of the thoracic esophagus in August 1999." | 1.32 | [Complete remission of esophageal undifferentiated carcinoma with nedaplatin and 5-FU chemotherapy and endoesophageal brachytherapy]. ( Iwashige, M; Kikuchi, H; Kumada, K; Midorikawa, T; Nagasaki, H; Nemoto, H; Sanada, Y; Takeuchi, S; Takizawa, K; Tate, G; Yagi, H; Yoshizawa, Y, 2003) |
| "Colorectal carcinomas are well known to highly express COX-2 and their growth is markedly inhibited by COX-2 inhibitors, but little is known about head and neck carcinomas." | 1.32 | Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. ( Hashitani, S; Maeda, T; Nishimura, N; Noguchi, K; Sakurai, K; Takaoka, K; Urade, M, 2003) |
| "Chemotherapy of solid tumors is presently largely ineffective at dosage levels that are compatible with survival of the patient." | 1.32 | Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. ( Ahlström, H; Iversen, VV; Johansson, L; Koisti, M; Reed, RK; Rubin, K; Salnikov, AV; Sjöquist, M; Stuhr, LB; Sundberg, C, 2003) |
| "Irofulven has demonstrated potent activity against a broad range of solid tumors in both cellular and xenograft models and has shown promising activity in clinical trials." | 1.32 | Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells. ( Cvitkovic, E; Koeppel, F; Larsen, AK; Poindessous, V; Raymond, E; Waters, SJ, 2003) |
| " Pharmacokinetic modulating chemotherapy (PMC), a combination of infused 5-fluorouracil and oral uracil-tegafur, has been proven to be highly effective for the treatment of colorectal carcinoma." | 1.32 | Modified pharmacokinetic modulating chemotherapy using 5-fluorouracil, UFT, and taxotere (docetaxel) for advanced gastric cancer. ( Kobayashi, M; Konishi, N; Kusunoki, M; Mohri, Y; Ohmori, Y; Tanaka, K; Tonouchi, H, 2003) |
| "The deleted in colorectal cancer (DCC) gene predicts a poor outcome for patients with colorectal carcinoma." | 1.32 | Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients. ( Gal, R; Klein, B; Koren, R; Sadikov, E; Sulkes, J, 2004) |
| " This could account for both the toxic effects and the response." | 1.32 | Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?--a prospective clinical study. ( Bansal, A; Lyall, A; Saxena, S; Singh, JP; Singhal, V, 2004) |
| "Secretory breast carcinoma (SBC) is a rare type of invasive breast cancer." | 1.32 | Secretory breast carcinoma--case report and review of the medical literature. ( Costa, NM; Matos, E; Pardal, F; Pereira, H; Rodrigues, H, 2004) |
| "Lymphoepithelioma-like carcinoma (LELC) of the lung, an Epstein-Barr virus-associated undifferentiated carcinoma, is a rare entity of pulmonary malignancy." | 1.31 | Chemoradiotherapy for advanced lymphoepithelioma-like carcinoma of the lung. ( Ho, JC; Lam, B; Lam, WK; Ooi, GC; Tsang, KW, 2000) |
| " In addition to evaluation of GL331's single agent activity, the use of GL331 in combination with other established therapeutic agents was also evaluated." | 1.31 | In vitro evaluation of GL331's cancer cell killing and apoptosis-inducing activity in combination with other chemotherapeutic agents. ( Chen, LT; Huang, TS; Lee, CC; Shu, CH; Whang-Peng, J, 2000) |
| " Thirty-one patients with superficial oesophageal or gastric cardiac carcinomas, who refused or were unsuitable for surgery, received endoscopic Nd:YAG laser therapy combined with local injection of chemotherapeutic drugs 5-fluorouracil and mitomycin." | 1.31 | Endoscopic Nd:YAG laser therapy combined with local chemotherapy of superficial carcinomas of the oesophagus and gastric cardia. ( Huang, T; Jia, J; Wang, Y; Zhou, C, 2001) |
| "The 3-year metastasis-free survival rates were 49." | 1.31 | Evaluation of cytokeratin-19 mRNA as a tumor marker in the peripheral blood of nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. ( Chen, KY; Jan, JS; Liang, WM; Lin, JC; Wang, WY; Wei, YH, 2002) |
| "Some degree of aneuploidy was detected in all primary carcinomas." | 1.31 | Markers of drug resistance in relapsing colon cancer. ( Davaris, PS; Kavantzas, NG; Lazaris, AC; Tsavaris, NV; Zorzos, HS, 2002) |
| "We retrospectively examined the acute toxicity of (neo-)adjuvant combined treatment for rectal cancer in an attempt to evaluate potential factors that influence the severity of toxic side effects." | 1.30 | [The acute toxicity of the simultaneous radiochemotherapy of rectal carcinoma]. ( Fietkau, R; Grabenbauer, GG; Keilholz, L; Kessler, H; Martus, P; Rödel, C; Sauer, R, 1997) |
| "Thymic carcinomas are rare tumors for which the main treatments have been surgery, radiotherapy, or both." | 1.30 | [Thymic anaplastic carcinoma successfully controlled by combination chemotherapy]. ( Honma, S; Nakanishi, F; Sakamoto, K; Shijubo, N; Shiratori, M, 1998) |
| "Metaplastic breast cancer is a rare disease with little information available to guide therapy." | 1.30 | Metaplastic breast cancer: prognosis and response to systemic therapy. ( Adjei, AA; Ingle, JN; Rayson, D; Suman, VJ; Wold, LE, 1999) |
| "Acanthosis nigricans is an uncommon skin condition characterized by hyperkeratosis and skin hyperpigmentation." | 1.30 | Malignant acanthosis nigricans: potential role of chemotherapy. ( Anderson, SH; Hudson-Peacock, M; Muller, AF, 1999) |
| "All 1992 phase II colorectal cancer abstracts from the 1992 Proceedings of the American Society of Clinical Oncology were reviewed and analyzed for descriptive and quantitative data and conclusions." | 1.29 | The style of early clinical research reporting: what are we saying and how do we say it? ( Gedney, C; Weissman, DE, 1993) |
| "Chemotherapy for cervical cancer patients with recurrent and/or advanced disease has been complicated by excessive toxicity and short duration of responses, leading to little or no improvement in survival." | 1.29 | Chemotherapy of recurrent/advanced cervical cancer: results of the Yale University PBM-PFU protocol. ( Chambers, JT; Chambers, SK; Kohorn, EI; Lamb, L; Schwartz, PE, 1994) |
| "A group of 298 patients with epithelial ovarian cancer were treated with combination chemotherapy between July 1979 and January 1986 at the Tokai Ovarian Tumor Study Group." | 1.29 | Long-term follow-up of patients with epithelial carcinoma of the ovary. ( Arii, Y; Hattori, S; Kawai, M; Kikkawa, F; Ohta, M; Tomoda, Y, 1994) |
| "In patients with locally advanced cervical cancer, most of the treatment failures occur within the pelvis." | 1.29 | Concomitant chemoradiation prior to surgery in the treatment of advanced cervical carcinoma. ( Boubli, L; Cowen, D; Delpero, JR; Gamerre, M; Gouvernet, J; Houvenaeghel, G; Noirclerc, M; Perez, T; Resbeut, M; Viens, P, 1994) |
| "Cavitation has been shown to hinder colon cancer cell proliferation in vitro." | 1.29 | Increased chemocytotoxicity to colon cancer cells by shock wave-induced cavitation. ( Beaumatin, J; Cathignol, D; Chapelon, JY; Luccioni, C; Pansu, D; Ponchon, T; Prat, F; Sibille, A, 1994) |
| " The optimal scheduling and dosage of concomitant chemoradiotherapy should be further researched." | 1.29 | Concomitant chemoradiotherapy for advanced head and neck cancer. ( Hsu, CY; Jan, JS; Lin, JC, 1994) |
| " Rats were dosed p." | 1.29 | 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. ( Baccanari, DP; Cao, S; Davis, ST; Joyner, SS; Rustum, YM; Spector, T, 1995) |
| "These two cases suggest that dehydration and electrolyte disturbance from high stomal output could be a serious problem following chemoradiation therapy in patients with an ileostomy." | 1.29 | Ileostomy dysfunction with adjuvant chemoradiation for rectal carcinoma requiring in-hospital management: a cause for concern. ( Chen, FC; Mackay, JR; Woods, RJ, 1996) |
| " Our preliminary data indicate that postradiation adjuvant chemotherapy with a weekly FP regimen at our dosage is not recommended for high-risk NPC." | 1.29 | Preliminary report of outpatient weekly adjuvant chemotherapy for high-risk nasopharyngeal carcinoma. ( Hsu, CY; Jan, JS; Lin, JC, 1996) |
| "Intra-abdominal panniculitis can result in mass lesions in the mesentery and omentum." | 1.28 | Intra-abdominal panniculitis can mimic recurrent stomach carcinoma. ( Cunningham, D; Husband, JE; MacVicar, D; Menzies-Gow, N; Taylor, R, 1992) |
| "Mitomycin C (10 mg/m2) was administered as a bolus injection on day 2." | 1.28 | Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. ( Coia, LR; Engstrom, PF; Hanks, GE; Paul, AR; Stafford, PM, 1991) |
| "Twenty-two advanced consecutive thyroid cancer patients with varying histologies were treated with the so called BAP regime which consisted of bleomycin (B) 30 mg a day for three days, adriamycin (A) 60 mg/m2 iv in day 5, and cisplatinum (P) 60 to mg/m2 iv in day 5." | 1.28 | Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. ( Busnardo, B; Casara, D; De Besi, P; Fiorentino, MV; Girelli, ME; Nacamulli, D; Simioni, N; Toso, S; Zorat, P, 1991) |
| " The dosage of raIFN-2a could not be further escalated above 12 x 10(6) IU." | 1.28 | 5-Fluorouracil and recombinant alpha interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study. ( Gebbia, V; Palmeri, S; Rausa, L, 1990) |
| " Mice bearing murine renal cancer (Renca) were also protected from the acute toxic effects of Cy (450 mg/kg) by pretreatment with rhIL-1 alpha." | 1.28 | Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy. ( Futami, H; Jansen, R; Keller, J; Longo, DL; MacPhee, MJ; McCormick, K; Oppenheim, JJ; Ruscetti, FW; Wiltrout, RH, 1990) |
| "We report preliminary results on treatment of anal carcinoma by radiotherapy and chemotherapy." | 1.28 | [Anal neoplasms. Treatment with radiotherapy and exclusive chemotherapy]. ( Armando, S; Arraztoa, J; Morales, Y; San Martín, S, 1989) |
| "Eighty-one patients with operable breast cancers received the short-term and intensive preoperative chemotherapy, followed by radical mastectomy are presented." | 1.28 | [Preoperative intensive chemotherapy of operable breast cancer]. ( Zhang, B, 1989) |
| "Thirty-two patients with infiltrating bladder cancer were treated with transurethral resection followed by one course of alternating chemoradiotherapy before radical cystectomy (group A, 20 patients) or two courses as definitive procedure (group B, 12 patients)." | 1.28 | Neoadjuvant or definitive alternating chemotherapy and radiotherapy for infiltrating bladder cancer. ( Curotto, A; Giuliani, L; Martorana, G; Merlano, M; Michelotti, A; Orsatti, M; Rosso, R; Scarpati, D; Venturini, M, 1989) |
| "5-Fluorouracil (FUra) is a clinically useful antineoplastic agent." | 1.27 | Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid. ( Casper, ES; Martin, DS; Vale, K; Williams, LJ; Young, CW, 1983) |
| "Ninety-one patients with malignant epithelial tumors of the nasopharynx seen in our department from 1970 to 1982 were evaluated." | 1.27 | Carcinoma of the nasopharynx. An analysis of 91 cases and a comparison of differing treatment approaches. ( Barzilay, J; Rahima, M; Rakowsky, E; Sidi, J, 1986) |
| "Twenty-eight patients with inflammatory breast cancer were treated with combined modality therapy consisting of (1) intraarterial infusion chemotherapy (IA chemotherapy) through the internal thoracic artery and subclavian artery, (2) surgical ablation, (3) extended radical mastectomy, and (4) adjuvant chemotherapy in that order." | 1.27 | Management of inflammatory carcinoma of the breast with combined modality therapy including intraarterial infusion chemotherapy as an induction therapy. Long-term follow-up results of 28 patients. ( Koyama, H; Miyauchi, K; Nishizawa, Y; Noguchi, S; Terasawa, T, 1988) |
| "32 cases of colon cancer were given I/V 5-fluorouracil for at least one year." | 1.27 | Advanced colorectal carcinoma--5 year survival of 76 cases treated at the Department of Therapeutic Radiology, Singapore General Hospital. ( Chia, KB; Chua, EJ; Khor, TH; Sethi, VK; Tan, BC; Tan, TM, 1987) |
| " This allows an examination of dose-response relationships and comparisons of therapeutic index." | 1.27 | Comparison of unique leucovorin and 5-fluorouracil "escalating" and "maximum" dosage strategies. ( Bruckner, HW; Mayer, R; Novak, J; Petrelli, NJ; Stablein, D, 1987) |
| " The mean phenazone half-life time (t0." | 1.27 | Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ( Cieślińska, A; Orzechowska-Juzwenko, K; Roszkowska, E; Wiela, A, 1987) |
| "Sixteen patients with dermal lymphatic carcinomatosis and 10 patients with negative skin biopsies had median RFS of 31 and 46 months, respectively (p = 0." | 1.27 | Management of inflammatory carcinoma of the breast. A combined modality approach. ( Blumenschein, GR; Buzdar, AU; Fastenberg, NA; Hortobagyi, GN; Jessup, JM; Martin, RG; Montague, ED, 1985) |
| "Patients with squamous cell carcinoma or good performance status were somewhat more likely to respond." | 1.27 | Cisplatin bolus and 5-FU infusion chemotherapy for non-small cell lung cancer. ( Einstein, AB; Rudolph, RH; Weiden, PL, 1985) |
| "In the total 70 cases including those of undifferentiated carcinoma and adenocarcinoma, the 3-year and 5-year actual survival rates were 75." | 1.26 | Analysis of the results of our combined therapy for maxillary cancer. ( Inoue, S; Konno, A; Togawa, K, 1980) |
| "One of the responding patients with colon cancer and two with breast cancer had failed to respond to prior therapy with 5-FU; one of the responding patients with breast cancer had previously received an inadequate trial of a similar regimen." | 1.26 | Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU. ( Ervin, TJ; Kufe, DW; Meshad, MW; Weiss, GR, 1982) |
| "A group of patients with metastatic breast cancer treated by a distinct drug regimen is analyzed with special respect to clinical and psychological problems." | 1.26 | [Experiences with drug therapy of advanced metastatic carcinoma of the breast (author's transl)]. ( Fernholz, HJ; Frik, W; Nüvemann, M, 1976) |
| "In additional 13 cases with gastric cancer, the active 5-FU concentrations in the regional lymph nodes were determined." | 1.26 | Histological evaluation of the effect of 5-FU emulsion on lymph node metastasis of stomach cancer. ( Cho, K; Fujita, Y; Majima, S; Morisawa, K; Nakao, E; Nishioka, B; Takahashi, T; Ueda, T; Watanabe, S, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 277 (26.03) | 18.7374 |
| 1990's | 208 (19.55) | 18.2507 |
| 2000's | 268 (25.19) | 29.6817 |
| 2010's | 288 (27.07) | 24.3611 |
| 2020's | 23 (2.16) | 2.80 |
| Authors | Studies |
|---|---|
| Li, S | 2 |
| Xu, Z | 3 |
| Alrobaian, M | 1 |
| Afzal, O | 1 |
| Kazmi, I | 1 |
| Almalki, WH | 1 |
| Altamimi, ASA | 1 |
| Al-Abbasi, FA | 1 |
| Alharbi, KS | 1 |
| Altowayan, WM | 1 |
| Singh, T | 1 |
| Akhter, MH | 1 |
| Gupta, M | 1 |
| Rahman, M | 1 |
| Beg, S | 1 |
| Toya, R | 1 |
| Watakabe, T | 1 |
| Murakami, D | 1 |
| Matsuyama, T | 1 |
| Saito, T | 2 |
| Fukugawa, Y | 1 |
| Nishimoto, K | 1 |
| Orita, Y | 1 |
| Oya, N | 1 |
| Gallo, RA | 1 |
| Lang, SH | 1 |
| Gomez, A | 1 |
| Sabater, AL | 1 |
| Tse, DT | 1 |
| Pelaez, D | 1 |
| Rong, AJ | 1 |
| Mahmoud, M | 1 |
| Abdollah, MRA | 1 |
| Elsesy, ME | 1 |
| Abou El Ella, DA | 1 |
| Zada, SK | 1 |
| Tolba, MF | 1 |
| Bess, SN | 1 |
| Greening, GJ | 1 |
| Rajaram, N | 1 |
| Muldoon, TJ | 1 |
| Okebalama, VC | 1 |
| Nwadiokwu, JI | 1 |
| Osaze, E | 1 |
| Ayodeji, AA | 1 |
| Chinatu-Nwankwo, OM | 1 |
| Čižauskaitė, A | 1 |
| Šimčikas, D | 1 |
| Schultze, D | 1 |
| Kallifatidis, G | 1 |
| Bruns, H | 1 |
| Čekauskas, A | 1 |
| Herr, I | 1 |
| Baušys, A | 1 |
| Strupas, K | 1 |
| Schemmer, P | 1 |
| Kang, C | 2 |
| Ju, S | 2 |
| Kim, J | 3 |
| Jung, Y | 2 |
| Imbaby, S | 1 |
| Elkholy, SE | 1 |
| Faisal, S | 1 |
| Abdelmaogood, AKK | 1 |
| Mehana, AE | 1 |
| Mansour, BSA | 1 |
| Abd El-Moneam, SM | 1 |
| Elaidy, SM | 1 |
| Hołota, M | 1 |
| Michlewska, S | 1 |
| Garcia-Gallego, S | 1 |
| Del Olmo, NS | 1 |
| Ortega, P | 1 |
| Bryszewska, M | 1 |
| de la Mata, FJ | 1 |
| Ionov, M | 1 |
| Icsel, C | 1 |
| Yilmaz, VT | 1 |
| Aygun, M | 1 |
| Erkisa, M | 1 |
| Ulukaya, E | 1 |
| Mao, J | 1 |
| Yang, W | 1 |
| Guo, H | 2 |
| Dong, R | 2 |
| Ren, L | 1 |
| Maheshwari, U | 1 |
| Goyal, P | 1 |
| Goel, V | 1 |
| Patnaik, N | 1 |
| Koyyala, VPB | 1 |
| Chaudhari, K | 1 |
| Doval, DC | 1 |
| Talwar, V | 1 |
| Tang, M | 1 |
| Zhai, L | 1 |
| Chen, J | 4 |
| Wang, F | 2 |
| Chen, H | 1 |
| Wu, W | 2 |
| Shaker, SA | 1 |
| Alshufta, SM | 1 |
| Gowayed, MA | 1 |
| El-Salamouni, NS | 1 |
| Bassam, SM | 1 |
| Megahed, MA | 1 |
| El-Tahan, RA | 1 |
| Cartwright, BM | 1 |
| Corso, JN | 1 |
| Lightner, J | 1 |
| Whitted, C | 1 |
| Torrenegra, RD | 1 |
| Krishnan, K | 1 |
| Palau, VE | 1 |
| Beatson, M | 1 |
| Siegel, JA | 1 |
| Chren, MM | 1 |
| Weinstock, MA | 1 |
| Auvray, M | 1 |
| Tougeron, D | 1 |
| Auclin, E | 1 |
| Moulin, V | 1 |
| Artru, P | 1 |
| Hautefeuille, V | 1 |
| Hammel, P | 2 |
| Lecomte, T | 2 |
| Locher, C | 2 |
| Sickersen, G | 1 |
| Coriat, R | 2 |
| Lecaille, C | 1 |
| Vernerey, D | 1 |
| Taieb, J | 3 |
| Pernot, S | 1 |
| Abdel Raouf, SM | 1 |
| Ibrahim, TR | 1 |
| Abdelaziz, LA | 1 |
| Farid, MI | 1 |
| Mohamed, SY | 1 |
| Luput, L | 1 |
| Sesarman, A | 1 |
| Porfire, A | 1 |
| Achim, M | 1 |
| Muntean, D | 1 |
| Casian, T | 1 |
| Patras, L | 1 |
| Rauca, VF | 1 |
| Drotar, DM | 1 |
| Stejerean, I | 1 |
| Tomuta, I | 1 |
| Vlase, L | 1 |
| Dragos, N | 1 |
| Toma, VA | 1 |
| Licarete, E | 1 |
| Banciu, M | 1 |
| Villard, C | 1 |
| Habib, M | 1 |
| Nordenvall, C | 1 |
| Nilsson, PJ | 1 |
| Jorns, C | 1 |
| Sparrelid, E | 1 |
| Ben-Ami, T | 1 |
| Kontny, U | 1 |
| Surun, A | 1 |
| Brecht, IB | 1 |
| Almaraz, RL | 1 |
| Dragomir, M | 1 |
| Pourtsidis, A | 1 |
| Casanova, M | 2 |
| Fresneau, B | 1 |
| Bisogno, G | 1 |
| Schneider, DT | 1 |
| Reguerre, Y | 1 |
| Bien, E | 1 |
| Stachowicz-Stencel, T | 1 |
| Österlundh, G | 1 |
| Wygoda, M | 1 |
| Janssens, GO | 1 |
| Zsiros, J | 1 |
| Jehanno, N | 1 |
| Brisse, HJ | 1 |
| Gandola, L | 1 |
| Christiansen, H | 2 |
| Claude, L | 1 |
| Ferrari, A | 2 |
| Rodriguez-Galindo, C | 3 |
| Orbach, D | 2 |
| Cavalieri, S | 1 |
| Licitra, L | 3 |
| Botticelli, A | 1 |
| Cirillo, A | 1 |
| Strigari, L | 1 |
| Valentini, F | 1 |
| Cerbelli, B | 1 |
| Scagnoli, S | 1 |
| Cerbelli, E | 1 |
| Zizzari, IG | 1 |
| Rocca, CD | 1 |
| D'Amati, G | 1 |
| Polimeni, A | 1 |
| Nuti, M | 1 |
| Merlano, MC | 1 |
| Mezi, S | 1 |
| Marchetti, P | 2 |
| Shi, CS | 1 |
| Li, JM | 1 |
| Chin, CC | 1 |
| Kuo, YH | 1 |
| Lee, YR | 1 |
| Huang, YC | 1 |
| Rani, I | 1 |
| Sharma, B | 1 |
| Kumar, S | 1 |
| Kaur, S | 1 |
| Agnihotri, N | 1 |
| Kawahira, M | 1 |
| Yokota, T | 1 |
| Hamauchi, S | 1 |
| Onozawa, Y | 1 |
| Ogawa, H | 1 |
| Onoe, T | 1 |
| Kamijo, T | 1 |
| Iida, Y | 1 |
| Nishimura, T | 1 |
| Onitsuka, T | 1 |
| Yasui, H | 1 |
| Zhuang, K | 1 |
| Zhang, L | 11 |
| Zhang, X | 2 |
| Tang, H | 1 |
| Zhang, J | 3 |
| Yan, Y | 1 |
| Han, K | 1 |
| Lee, AWM | 1 |
| Tung, SY | 7 |
| Ng, WT | 9 |
| Lee, V | 1 |
| Ngan, RKC | 1 |
| Choi, HCW | 1 |
| Chan, LLK | 1 |
| Siu, LL | 1 |
| Ng, AWY | 1 |
| Leung, TW | 7 |
| Yiu, HHY | 1 |
| O'Sullivan, B | 6 |
| Chappell, R | 7 |
| AbdelBaki, MS | 1 |
| Waguespack, SG | 1 |
| Salceda, V | 1 |
| Jones, J | 2 |
| Stapleton, SL | 1 |
| Baskin, DS | 1 |
| Okcu, MF | 1 |
| Lu, Y | 2 |
| Huang, H | 1 |
| Yang, H | 1 |
| Chen, D | 1 |
| Wu, S | 1 |
| Jiang, Z | 1 |
| Wang, R | 1 |
| Wakatsuki, K | 1 |
| Matsumoto, S | 1 |
| Migita, K | 1 |
| Ito, M | 3 |
| Kunishige, T | 1 |
| Nakade, H | 1 |
| Nakatani, M | 1 |
| Kitano, M | 1 |
| Takano, M | 2 |
| Obayashi, C | 1 |
| Sho, M | 1 |
| Cascinu, S | 4 |
| Rosati, G | 3 |
| Nasti, G | 1 |
| Lonardi, S | 1 |
| Zaniboni, A | 1 |
| Leone, F | 2 |
| Bilancia, D | 1 |
| Iaffaioli, RV | 1 |
| Zagonel, V | 1 |
| Giordano, M | 1 |
| Corsi, DC | 1 |
| Ferraú, F | 1 |
| Labianca, R | 3 |
| Ronzoni, M | 2 |
| Scartozzi, M | 2 |
| Galli, F | 1 |
| Xu, C | 1 |
| Yang, SP | 1 |
| Zhang, Y | 6 |
| Tang, LL | 4 |
| Zhou, GQ | 2 |
| Liu, X | 3 |
| Mao, YP | 5 |
| Guo, R | 2 |
| Li, WF | 3 |
| Chen, L | 5 |
| Lin, AH | 2 |
| Sun, Y | 8 |
| Ma, J | 8 |
| Xiao, N | 1 |
| Yu, K | 1 |
| Yu, S | 2 |
| Wu, J | 1 |
| Wang, J | 7 |
| Shan, S | 1 |
| Zheng, S | 1 |
| Wang, L | 3 |
| Peng, S | 1 |
| Al Mousa, A | 1 |
| Abu-Hijlih, R | 1 |
| Salem, A | 1 |
| Sultan, I | 1 |
| Mula-Hussain, L | 1 |
| Ismael, T | 1 |
| Mohamad, I | 1 |
| Vellayappan, BA | 1 |
| Soon, YY | 1 |
| Ku, GY | 1 |
| Leong, CN | 1 |
| Lu, JJ | 1 |
| Tey, JC | 1 |
| Dalenc, F | 1 |
| Ribet, V | 1 |
| Rossi, AB | 1 |
| Guyonnaud, J | 1 |
| Bernard-Marty, C | 1 |
| de Lafontan, B | 1 |
| Salas, S | 1 |
| Ranc Royo, AL | 1 |
| Sarda, C | 1 |
| Levasseur, N | 1 |
| Massabeau, C | 1 |
| Levecq, JM | 1 |
| Dulguerova, P | 1 |
| Guerrero, D | 1 |
| Sibaud, V | 1 |
| Monfort, JB | 1 |
| Mathian, A | 1 |
| Amoura, Z | 1 |
| Francès, C | 1 |
| Barbaud, A | 1 |
| Senet, P | 1 |
| Lieto, E | 1 |
| Auricchio, A | 1 |
| Cardella, F | 1 |
| Mabilia, A | 1 |
| Basile, N | 1 |
| Castellano, P | 1 |
| Orditura, M | 2 |
| Galizia, G | 1 |
| Jootun, N | 1 |
| Evans, T | 1 |
| Mak, J | 1 |
| Makin, G | 1 |
| Platell, C | 1 |
| Lièvre, A | 1 |
| Ouine, B | 1 |
| Canet, J | 1 |
| Cartier, A | 1 |
| Amar, Y | 1 |
| Cacheux, W | 2 |
| Mariani, O | 1 |
| Guimbaud, R | 1 |
| Selves, J | 1 |
| Guyetant, S | 1 |
| Bieche, I | 1 |
| Berger, F | 1 |
| de Koning, L | 1 |
| Mi, JL | 1 |
| Zhang, B | 4 |
| Pan, YF | 1 |
| Su, YX | 1 |
| Fan, JF | 1 |
| Liao, SF | 1 |
| Qin, XL | 1 |
| Yao, DC | 1 |
| Tang, HY | 1 |
| Jiang, W | 1 |
| Fokas, E | 1 |
| Ströbel, P | 1 |
| Fietkau, R | 3 |
| Ghadimi, M | 1 |
| Liersch, T | 2 |
| Grabenbauer, GG | 3 |
| Hartmann, A | 1 |
| Kaufmann, M | 1 |
| Sauer, R | 5 |
| Graeven, U | 3 |
| Hoffmanns, H | 1 |
| Raab, HR | 1 |
| Hothorn, T | 1 |
| Wittekind, C | 2 |
| Rödel, C | 4 |
| Xue, F | 1 |
| Hu, C | 3 |
| He, X | 2 |
| Ryu, H | 1 |
| Song, IC | 1 |
| Choi, YS | 1 |
| Yun, HJ | 1 |
| Jo, DY | 1 |
| Kim, JM | 1 |
| Ko, YB | 1 |
| Lee, HJ | 1 |
| Cashin, PH | 1 |
| Mahteme, H | 2 |
| Syk, I | 1 |
| Frödin, JE | 2 |
| Glimelius, B | 1 |
| Graf, W | 1 |
| Liu, GW | 1 |
| Liu, YH | 1 |
| Jiang, GS | 1 |
| Ren, WD | 1 |
| Toumi, N | 2 |
| Ben Kridis, W | 1 |
| Mnejja, W | 1 |
| Bouzguenda, R | 1 |
| Khanfir, A | 1 |
| Ghorbel, A | 3 |
| Daoud, J | 2 |
| Frikha, M | 2 |
| Qi, J | 1 |
| Yu, B | 1 |
| Peng, XH | 1 |
| Tan, JJ | 1 |
| Chen, QQ | 1 |
| Peng, XY | 1 |
| Zeng, FF | 1 |
| Fan, J | 1 |
| Fan, Y | 2 |
| Li, L | 2 |
| Xiang, Q | 1 |
| Mu, J | 1 |
| Zhou, D | 1 |
| Sun, X | 1 |
| Yang, Y | 4 |
| Ren, G | 1 |
| Tao, Q | 1 |
| Xiang, T | 1 |
| Ren, YX | 1 |
| Hao, S | 1 |
| Jin, X | 3 |
| Ye, FG | 1 |
| Gong, Y | 1 |
| Jiang, YZ | 1 |
| Shao, ZM | 2 |
| Yu, C | 1 |
| Chen, DQ | 1 |
| Liu, HX | 1 |
| Li, WB | 1 |
| Lu, JW | 1 |
| Feng, JF | 1 |
| Fanotto, V | 1 |
| Fornaro, L | 2 |
| Bordonaro, R | 2 |
| Rimassa, L | 1 |
| Di Donato, S | 1 |
| Santini, D | 1 |
| Tomasello, G | 1 |
| Silvestris, N | 1 |
| Stragliotto, S | 1 |
| Giampieri, R | 1 |
| Nichetti, F | 1 |
| Antonuzzo, L | 1 |
| Cinieri, S | 2 |
| Avallone, A | 2 |
| Pellegrino, A | 1 |
| Melisi, D | 1 |
| Vasile, E | 1 |
| Gerratana, L | 1 |
| Aprile, G | 1 |
| Phelip, JM | 1 |
| Edeline, J | 1 |
| Blanc, JF | 1 |
| Barbier, E | 1 |
| Michel, P | 1 |
| Bourgeois, V | 1 |
| Neuzillet, C | 1 |
| Malka, D | 4 |
| Manfredi, S | 1 |
| Desrame, J | 1 |
| Bang, YJ | 2 |
| Kang, YK | 3 |
| Ng, M | 1 |
| Chung, HC | 1 |
| Wainberg, ZA | 1 |
| Gendreau, S | 1 |
| Chan, WY | 1 |
| Xu, N | 1 |
| Maslyar, D | 1 |
| Meng, R | 1 |
| Chau, I | 2 |
| Ajani, JA | 4 |
| Kašperová, B | 1 |
| Jurišová, S | 1 |
| Macúch, J | 1 |
| Bumberová, M | 1 |
| Janega, P | 1 |
| Dolinský, J | 1 |
| Mego, M | 1 |
| Burnett, A | 1 |
| Lecompte, MA | 1 |
| Trabulsi, N | 1 |
| Dubé, P | 2 |
| Gervais, MK | 1 |
| Trilling, B | 1 |
| Cloutier, AS | 1 |
| Sideris, L | 4 |
| Komatsu, H | 1 |
| Izumi, N | 1 |
| Tsukioka, T | 1 |
| Inoue, H | 1 |
| Miyamoto, H | 1 |
| Nishiyama, N | 1 |
| Liu, W | 2 |
| Wang, K | 2 |
| Han, Y | 1 |
| Liang, JY | 1 |
| Li, YH | 3 |
| Xing, BC | 1 |
| Giuliani, A | 1 |
| Romanzi, F | 1 |
| Di Sibio, A | 1 |
| Calvisi, G | 1 |
| Lombardi, L | 1 |
| Marchese, M | 1 |
| Di Staso, M | 1 |
| Schietroma, M | 1 |
| Carlei, F | 1 |
| Romano, L | 1 |
| Miyazaki, T | 1 |
| Hasegawa, Y | 1 |
| Hanai, N | 1 |
| Ozawa, T | 1 |
| Hirakawa, H | 1 |
| Suzuki, A | 1 |
| Okamoto, H | 1 |
| Harata, I | 1 |
| Arredondo, J | 1 |
| Baixauli, J | 1 |
| Beorlegui, C | 1 |
| Arbea, L | 1 |
| Rodríguez, J | 2 |
| Sola, JJ | 1 |
| Chopitea, A | 2 |
| Hernández-Lizoáin, JL | 1 |
| Chen, Y | 3 |
| Liang, SB | 2 |
| Zong, JF | 1 |
| Chen, M | 2 |
| Guo, Y | 4 |
| Liu, MZ | 2 |
| El-Arab, LR | 1 |
| Swellam, M | 1 |
| El Mahdy, MM | 1 |
| Lo, AK | 1 |
| Lo, KW | 1 |
| Ko, CW | 1 |
| Young, LS | 1 |
| Dawson, CW | 1 |
| Chen, XL | 1 |
| Chen, XZ | 3 |
| Yang, C | 1 |
| Liao, YB | 1 |
| Li, H | 1 |
| Yang, K | 1 |
| Li, K | 1 |
| Hu, JK | 2 |
| Chen, ZX | 2 |
| Chen, JP | 2 |
| Zhou, ZG | 2 |
| Doganci, S | 1 |
| Kadan, M | 1 |
| Kaya, E | 1 |
| Erol, G | 1 |
| Gunay, C | 1 |
| Demirkilic, U | 1 |
| Kua, VF | 1 |
| Ismail, F | 1 |
| Chee Ee Phua, V | 1 |
| Aslan, NM | 1 |
| Mehta, S | 1 |
| Singh, G | 1 |
| Paul, BS | 1 |
| Clavarezza, M | 1 |
| Turazza, M | 1 |
| Aitini, E | 1 |
| Saracchini, S | 1 |
| Garrone, O | 1 |
| Durando, A | 1 |
| De Placido, S | 2 |
| Bisagni, G | 1 |
| Levaggi, A | 1 |
| Bighin, C | 1 |
| Restuccia, E | 1 |
| Scalamogna, R | 1 |
| Galli, A | 1 |
| Del Mastro, L | 1 |
| Mazzeo, MA | 1 |
| Linares, JA | 1 |
| López, MM | 1 |
| Bachmeier, E | 1 |
| Wietz, FM | 1 |
| Galván, V | 1 |
| Valentinuzzi, MC | 1 |
| Riveros, JA | 1 |
| Finkelberg, A | 1 |
| Himmel, M | 1 |
| Hartmann, M | 1 |
| Guntinas-Lichius, O | 1 |
| Jones, TS | 1 |
| Jones, EL | 1 |
| McManus, M | 1 |
| Shah, R | 1 |
| Gajdos, C | 1 |
| Meng, J | 1 |
| Gu, QP | 1 |
| Meng, QF | 1 |
| Li, ZP | 1 |
| Si, YM | 1 |
| Guo, W | 1 |
| Zhuang, QW | 1 |
| Deng, S | 1 |
| Hu, B | 1 |
| An, HM | 1 |
| Du, Q | 1 |
| Xu, L | 2 |
| Shen, KP | 1 |
| Shi, XF | 1 |
| Wei, MM | 1 |
| Wu, Y | 1 |
| Ryan, EM | 1 |
| Hanly, A | 1 |
| Morrin, MM | 1 |
| McNamara, DA | 1 |
| Lin, HX | 1 |
| Hua, YJ | 1 |
| Chen, QY | 3 |
| Luo, DH | 1 |
| Sun, R | 1 |
| Qiu, F | 1 |
| Mo, HY | 4 |
| Mai, HQ | 6 |
| Guo, X | 6 |
| Xian, LJ | 1 |
| Hong, MH | 5 |
| Guo, L | 3 |
| Candy, PA | 1 |
| Phillips, MR | 1 |
| Redfern, AD | 1 |
| Colley, SM | 1 |
| Davidson, JA | 1 |
| Stuart, LM | 1 |
| Wood, BA | 1 |
| Zeps, N | 1 |
| Leedman, PJ | 1 |
| Moretto, R | 1 |
| Raimondo, L | 1 |
| De Stefano, A | 1 |
| Cella, CA | 1 |
| Matano, E | 1 |
| Carlomagno, C | 1 |
| Foubert, F | 1 |
| Matysiak-Budnik, T | 1 |
| Touchefeu, Y | 1 |
| Sulzyc-Bielicka, V | 1 |
| Bielicki, D | 1 |
| Binczak-Kuleta, A | 1 |
| Kaczmarczyk, M | 1 |
| Pioch, W | 1 |
| Machoy-Mokrzynska, A | 1 |
| Ciechanowicz, A | 1 |
| Gołębiewska, M | 1 |
| Drozdzik, M | 1 |
| Zhu, AK | 1 |
| Zhou, H | 1 |
| Xia, JZ | 1 |
| Jin, HC | 1 |
| Yan, J | 1 |
| Zuo, JB | 1 |
| Zhu, X | 1 |
| Shan, T | 1 |
| Najam, R | 1 |
| Bano, N | 1 |
| Mateen, A | 1 |
| Das, R | 1 |
| Bhattacharya, K | 1 |
| Sarkar, S | 1 |
| Samanta, SK | 1 |
| Pal, BC | 1 |
| Mandal, C | 1 |
| Hequet, D | 1 |
| Marchand, E | 1 |
| Place, V | 1 |
| Fourchotte, V | 1 |
| De La Rochefordière, A | 2 |
| Dridi, S | 1 |
| Coutant, C | 2 |
| Lecuru, F | 1 |
| Bats, AS | 1 |
| Koskas, M | 1 |
| Bretel, JJ | 1 |
| Bricou, A | 1 |
| Delpech, Y | 1 |
| Barranger, E | 1 |
| Kohorn, EI | 2 |
| Likhacheva, A | 1 |
| Jhingran, A | 1 |
| Bodurka, DC | 1 |
| Sun, C | 1 |
| Sam, M | 1 |
| Eifel, PJ | 2 |
| Gao, Y | 1 |
| Huang, HQ | 1 |
| Bai, B | 1 |
| Cai, QC | 1 |
| Wang, XX | 1 |
| Cai, QQ | 1 |
| Eveno, C | 3 |
| Passot, G | 1 |
| Goéré, D | 3 |
| Soyer, P | 1 |
| Gayat, E | 2 |
| Glehen, O | 1 |
| Elias, D | 9 |
| Pocard, M | 8 |
| Schad, F | 1 |
| Atxner, J | 1 |
| Buchwald, D | 1 |
| Happe, A | 1 |
| Popp, S | 1 |
| Kröz, M | 1 |
| Matthes, H | 1 |
| Chen, X | 1 |
| Hong, Y | 1 |
| Feng, J | 2 |
| Ye, J | 1 |
| Zheng, P | 1 |
| Guan, X | 1 |
| You, X | 1 |
| Song, H | 1 |
| Du, C | 2 |
| Ying, H | 2 |
| Zhou, J | 3 |
| Jiang, J | 1 |
| Liu, C | 2 |
| Wang, X | 2 |
| Hompes, D | 1 |
| Aalbers, A | 1 |
| Boot, H | 1 |
| van Velthuysen, ML | 1 |
| Vogel, W | 1 |
| Prevoo, W | 1 |
| van Tinteren, H | 3 |
| Verwaal, V | 1 |
| An, JY | 1 |
| Li, NN | 1 |
| Geng, Q | 1 |
| Fu, L | 1 |
| Jamshed, A | 1 |
| Hussain, R | 1 |
| Iqbal, H | 1 |
| Ueno, T | 1 |
| Endo, K | 2 |
| Kondo, S | 1 |
| Wakisaka, N | 1 |
| Murono, S | 1 |
| Yoshizaki, T | 1 |
| Abdel-Fatah, TM | 1 |
| McArdle, SE | 1 |
| Johnson, C | 1 |
| Moseley, PM | 1 |
| Ball, GR | 1 |
| Pockley, AG | 1 |
| Ellis, IO | 2 |
| Rees, RC | 1 |
| Chan, SY | 1 |
| Takahashi, M | 6 |
| Niwa, K | 1 |
| Ishiyama, S | 1 |
| Sugimoto, K | 1 |
| Komiyama, H | 1 |
| Yaginuma, Y | 1 |
| Kojima, Y | 1 |
| Goto, M | 1 |
| Okuzawa, A | 1 |
| Tomiki, Y | 1 |
| Sakamoto, K | 3 |
| Zheng, J | 1 |
| Lin, J | 1 |
| Xie, B | 2 |
| Xu, T | 1 |
| Zhang, W | 3 |
| Boscolo-Rizzo, P | 1 |
| Tirelli, G | 1 |
| Mantovani, M | 1 |
| Baggio, V | 1 |
| Lupato, V | 1 |
| Spinato, G | 1 |
| Gava, A | 1 |
| Da Mosto, MC | 1 |
| Guo, XF | 1 |
| Yang, ZR | 1 |
| Lei, XF | 1 |
| Lv, XG | 1 |
| Dong, WG | 1 |
| Nöpel-Dünnebacke, S | 1 |
| Schulmann, K | 1 |
| Reinacher-Schick, A | 1 |
| Porschen, R | 2 |
| Schmiegel, W | 2 |
| Tannapfel, A | 1 |
| Stadler, ZK | 1 |
| Lee, AW | 10 |
| Ngan, RK | 4 |
| Cheng, A | 1 |
| Kwong, DL | 3 |
| Lu, TX | 5 |
| Chan, AT | 4 |
| Chan, LL | 1 |
| Yiu, H | 1 |
| Wong, F | 1 |
| Yuen, KT | 1 |
| Yau, S | 2 |
| Cheung, FY | 1 |
| Chan, OS | 2 |
| Choi, H | 1 |
| Liang, B | 1 |
| Shahbaz, M | 1 |
| Wang, Y | 5 |
| Gao, H | 1 |
| Fang, R | 1 |
| Niu, Z | 1 |
| Liu, S | 1 |
| Wang, B | 2 |
| Sun, Q | 1 |
| Niu, W | 1 |
| Liu, E | 1 |
| Niu, J | 1 |
| Duran, AO | 1 |
| Karaca, H | 2 |
| Besiroglu, M | 1 |
| Bayoglu, IV | 1 |
| Menekse, S | 1 |
| Yapici, HS | 1 |
| Yazilitas, D | 1 |
| Bahceci, A | 1 |
| Uysal, M | 1 |
| Sevinc, A | 1 |
| Hacibekiroglu, I | 1 |
| Aksoy, A | 1 |
| Tanriverdi, O | 1 |
| Arpaci, E | 1 |
| Inanc, M | 2 |
| Dane, F | 1 |
| Ozkan, M | 2 |
| Yan, CM | 1 |
| Zhao, YL | 1 |
| Cai, HY | 1 |
| Miao, GY | 1 |
| Ma, W | 1 |
| Colussi, O | 1 |
| Voron, T | 1 |
| Pozet, A | 1 |
| Sauvanet, A | 1 |
| Bachet, JB | 1 |
| Vaillant, JC | 1 |
| Rougier, P | 5 |
| Nordlinger, B | 1 |
| Berger, A | 2 |
| Dousset, B | 1 |
| André, T | 1 |
| Paye, F | 1 |
| Aparicio, T | 1 |
| Cojean Zeleck, D | 1 |
| Tchinou, L | 1 |
| Bonnetain, F | 3 |
| Wang, YJ | 1 |
| Liu, JB | 1 |
| Dou, YC | 1 |
| Normanno, N | 1 |
| Rachiglio, AM | 1 |
| Lambiase, M | 1 |
| Martinelli, E | 1 |
| Fenizia, F | 1 |
| Esposito, C | 1 |
| Roma, C | 1 |
| Troiani, T | 1 |
| Rizzi, D | 1 |
| Tatangelo, F | 1 |
| Botti, G | 1 |
| Maiello, E | 2 |
| Colucci, G | 3 |
| Ciardiello, F | 1 |
| Hsieh, TC | 1 |
| Hsieh, CY | 2 |
| Yang, TY | 1 |
| Chen, TT | 1 |
| Lin, CY | 1 |
| Lin, CC | 2 |
| Hua, CH | 1 |
| Chiu, CF | 1 |
| Yeh, SP | 1 |
| Sher, YP | 1 |
| Du, CR | 1 |
| Ying, HM | 1 |
| Kong, FF | 1 |
| Zhai, RP | 1 |
| Hu, CS | 2 |
| Yang, J | 3 |
| Li, W | 1 |
| Luo, F | 2 |
| Zhao, N | 1 |
| Zhang, D | 2 |
| Qian, J | 1 |
| Yu, Y | 1 |
| Zheng, X | 1 |
| Feng, Y | 2 |
| Liu, T | 1 |
| Chu, Y | 1 |
| Giuliani, J | 1 |
| Piacentini, P | 1 |
| Bonetti, A | 2 |
| Yang, N | 1 |
| Zhu, L | 1 |
| Tan, T | 5 |
| Hou, C | 1 |
| Doornaert, P | 1 |
| Terhaard, CH | 1 |
| Kaanders, JH | 1 |
| Du, Y | 1 |
| Cheng, X | 1 |
| Yu, P | 2 |
| Yang, L | 2 |
| Huang, L | 1 |
| Zhou, Y | 1 |
| Liang, Y | 4 |
| Bu, JG | 1 |
| Cheng, JL | 1 |
| Gao, WW | 1 |
| Xu, YC | 1 |
| Chen, BY | 1 |
| Liang, WC | 1 |
| Chen, KQ | 1 |
| Zheng, H | 1 |
| Nong, Z | 1 |
| Lu, G | 1 |
| Khan, MA | 1 |
| Rahman, A | 1 |
| Almoukirish, S | 1 |
| Jadoon, S | 1 |
| Momenah, TS | 1 |
| Liu, LT | 2 |
| Tang, LQ | 2 |
| Guo, SS | 2 |
| Zhao, C | 5 |
| Cao, KJ | 3 |
| Qian, CN | 3 |
| Zeng, MS | 4 |
| Bei, JX | 2 |
| Shao, JY | 2 |
| Komatsu, M | 2 |
| Arai, Y | 1 |
| Yabuki, K | 1 |
| Sano, D | 1 |
| Shiono, O | 2 |
| Sakuma, Y | 2 |
| Nishimura, G | 2 |
| Taguchi, T | 1 |
| Oridate, N | 1 |
| Özyar, E | 1 |
| Patte, C | 1 |
| Veyrat-Follet, C | 1 |
| Errihani, H | 1 |
| Pan, J | 1 |
| Shen, L | 1 |
| Grzegorzewski, KJ | 1 |
| Varan, A | 1 |
| Roganović, J | 1 |
| Matijašić, N | 1 |
| Mascarin, M | 1 |
| Qiu, WZ | 2 |
| Huang, PY | 3 |
| Shi, JL | 1 |
| Xia, HQ | 1 |
| Bi, T | 1 |
| Jin, F | 1 |
| Long, J | 1 |
| Li, Y | 5 |
| Gong, X | 1 |
| Luo, X | 1 |
| Li, Z | 2 |
| He, Q | 1 |
| Qu, B | 1 |
| Zielinski, V | 1 |
| Laban, S | 1 |
| Tribius, S | 1 |
| Schafhausen, P | 1 |
| Veldhoen, S | 1 |
| Knecht, R | 1 |
| Clauditz, T | 1 |
| Muenscher, A | 1 |
| Ueki, T | 1 |
| Manabe, T | 1 |
| Inoue, S | 2 |
| Ienaga, J | 1 |
| Yamanaka, N | 2 |
| Egami, T | 1 |
| Ishikawa, M | 1 |
| Konomi, H | 1 |
| Ikubo, A | 1 |
| Nagayoshi, K | 1 |
| Nakamura, M | 2 |
| Tanaka, M | 1 |
| Zhao, Q | 1 |
| Tan, BB | 1 |
| Fan, LQ | 1 |
| Yang, PG | 1 |
| Tian, Y | 1 |
| Galletti, B | 1 |
| Santoro, R | 1 |
| Mannella, VK | 1 |
| Caminiti, F | 1 |
| Bonanno, L | 1 |
| De Salvo, S | 1 |
| Cammaroto, G | 1 |
| Galletti, F | 1 |
| Serrablo, A | 1 |
| Paliogiannis, P | 1 |
| Pulighe, F | 1 |
| Moro, SS | 1 |
| Borrego-Estella, V | 1 |
| Attene, F | 1 |
| Scognamillo, F | 1 |
| Hörndler, C | 1 |
| Ma, Y | 1 |
| Lin, Y | 1 |
| Zou, B | 1 |
| Zhao, L | 1 |
| Huang, Y | 2 |
| Fang, W | 1 |
| Zhao, Y | 3 |
| Sheng, J | 1 |
| Qin, T | 1 |
| Hu, Z | 1 |
| Salamone, SJ | 1 |
| Zhao, H | 1 |
| Gichuhi, S | 1 |
| Macharia, E | 1 |
| Kabiru, J | 1 |
| Zindamoyen, AM | 1 |
| Rono, H | 1 |
| Ollando, E | 1 |
| Wachira, J | 1 |
| Munene, R | 1 |
| Maina, J | 1 |
| Onyuma, T | 1 |
| Sagoo, MS | 1 |
| Weiss, HA | 1 |
| Burton, MJ | 1 |
| Wang, D | 1 |
| Xing, Y | 1 |
| Suo, J | 1 |
| Wang, ZQ | 2 |
| Jiang, YX | 1 |
| Wang, FH | 2 |
| Luo, HY | 2 |
| Wang, DS | 1 |
| Zeng, Q | 2 |
| Wang, Z | 1 |
| Gong, Z | 1 |
| Jiang, L | 1 |
| Ma, Z | 1 |
| Qian, Y | 2 |
| Kang, H | 1 |
| Hong, S | 3 |
| Bu, Y | 1 |
| Hu, G | 1 |
| Osseis, M | 1 |
| Weyrech, J | 1 |
| Dagois, S | 1 |
| Lo Dico, R | 1 |
| Okuma, HS | 1 |
| Koizumi, F | 1 |
| Hirakawa, A | 1 |
| Nakatochi, M | 1 |
| Komori, O | 1 |
| Hashimoto, J | 1 |
| Kodaira, M | 1 |
| Yunokawa, M | 1 |
| Yamamoto, H | 2 |
| Yonemori, K | 1 |
| Shimizu, C | 1 |
| Fujiwara, Y | 2 |
| Tamura, K | 1 |
| Mohammadkhani Shali, S | 1 |
| Schmitt, V | 1 |
| Behrendt, FF | 1 |
| Winz, OH | 1 |
| Heinzel, A | 1 |
| Mottaghy, FM | 1 |
| Eble, MJ | 1 |
| Verburg, FA | 1 |
| Gracia-Cazaña, T | 1 |
| González, S | 1 |
| Gilaberte, Y | 1 |
| Yen, CF | 1 |
| Lam, HB | 1 |
| Xie, CM | 1 |
| Liu, XW | 1 |
| Chen, MY | 1 |
| Zeng, TT | 1 |
| Ban, X | 1 |
| Li, MQ | 1 |
| Zhang, BZ | 1 |
| Zhu, YH | 1 |
| Hua, WF | 1 |
| Guan, XY | 1 |
| Lv, X | 3 |
| Li, J | 1 |
| Yin, LJ | 1 |
| Xiang, YQ | 3 |
| Chua, ML | 1 |
| Tan, SH | 1 |
| Kusumawidjaja, G | 1 |
| Shwe, MT | 1 |
| Cheah, SL | 1 |
| Fong, KW | 2 |
| Soong, YL | 1 |
| Wee, JT | 1 |
| Tan, TW | 1 |
| Bossi, P | 1 |
| Bergamini, C | 1 |
| Miceli, R | 1 |
| Cova, A | 1 |
| Orlandi, E | 1 |
| Resteghini, C | 1 |
| Locati, L | 1 |
| Alfieri, S | 1 |
| Imbimbo, M | 1 |
| Granata, R | 1 |
| Mariani, L | 2 |
| Iacovelli, NA | 1 |
| Huber, V | 1 |
| Cavallo, A | 1 |
| Rivoltini, L | 1 |
| Koda, K | 1 |
| Miyauchi, H | 1 |
| Kosugi, C | 1 |
| Kaiho, T | 1 |
| Takiguchi, N | 1 |
| Kobayashi, S | 2 |
| Maruyama, T | 2 |
| Matsubara, H | 1 |
| Ou, D | 1 |
| Blanchard, P | 1 |
| El Khoury, C | 1 |
| De Felice, F | 1 |
| Even, C | 1 |
| Levy, A | 2 |
| Nguyen, F | 1 |
| Janot, F | 2 |
| Gorphe, P | 1 |
| Deutsch, E | 1 |
| Temam, S | 1 |
| Tao, Y | 1 |
| Takeyama, H | 2 |
| Shimada, T | 1 |
| Kinoshita, S | 1 |
| Uchida, K | 1 |
| Chan, DY | 1 |
| Syn, NL | 1 |
| Yap, R | 1 |
| Phua, JN | 1 |
| Soh, TI | 1 |
| Chee, CE | 1 |
| Nga, ME | 1 |
| Shabbir, A | 1 |
| So, JB | 1 |
| Yong, WP | 1 |
| Peng, H | 1 |
| Vinzens, S | 1 |
| Zindel, J | 1 |
| Zweifel, M | 1 |
| Rau, T | 1 |
| Gloor, B | 1 |
| Wochner, A | 1 |
| Ren, HY | 1 |
| Liu, F | 1 |
| Huang, GL | 1 |
| Liu, Y | 2 |
| Shen, JX | 1 |
| Zhou, P | 1 |
| Liu, WM | 1 |
| Shen, DY | 1 |
| Su, J | 1 |
| Zhu, S | 1 |
| Liu, Z | 2 |
| Song, C | 1 |
| Jouvin, I | 1 |
| Najah, H | 1 |
| Pimpie, C | 1 |
| Canet Jourdan, C | 1 |
| Kaci, R | 1 |
| Mirshahi, M | 1 |
| Ke, LR | 1 |
| Xia, WX | 2 |
| Huang, XJ | 1 |
| Yu, YH | 1 |
| Liang, H | 1 |
| Liu, GY | 1 |
| Ye, YF | 1 |
| Lundgren, JA | 1 |
| Oldfield, EH | 1 |
| Marshall, JC | 1 |
| Yao, JJ | 1 |
| Yu, XL | 1 |
| Zhang, F | 2 |
| Zhang, WJ | 1 |
| Martínez C, J | 1 |
| Jarufe C, N | 1 |
| González D, R | 1 |
| Alvarez Z, M | 1 |
| Takahashi, H | 2 |
| Yasuda, A | 1 |
| Ochi, N | 1 |
| Sakamoto, M | 1 |
| Takayama, S | 1 |
| Wakasugi, T | 1 |
| Funahashi, H | 1 |
| Sawai, H | 1 |
| Satoh, M | 1 |
| Akamo, Y | 1 |
| Pezo, RC | 1 |
| Gandhi, SJ | 1 |
| Shirley, LA | 1 |
| Pestell, RG | 1 |
| Augenlicht, LH | 2 |
| Singer, RH | 1 |
| Piqué-Duran, E | 1 |
| Pérez-Díaz, MJ | 1 |
| Pérez-Cejudo, JA | 1 |
| Ea, S | 1 |
| Giacometti, S | 1 |
| Ciccolini, J | 1 |
| Akhmedjanova, V | 1 |
| Aubert, C | 1 |
| Long, YM | 1 |
| Ye, S | 1 |
| Rong, J | 1 |
| Xie, WR | 1 |
| Xiong, HQ | 1 |
| Varadhachary, GR | 1 |
| Blais, JC | 1 |
| Hess, KR | 1 |
| Abbruzzese, JL | 3 |
| Wolff, RA | 1 |
| Specht, K | 1 |
| Harbeck, N | 3 |
| Smida, J | 1 |
| Annecke, K | 1 |
| Reich, U | 1 |
| Naehrig, J | 1 |
| Langer, R | 1 |
| Mages, J | 1 |
| Busch, R | 1 |
| Kruse, E | 1 |
| Klein-Hitpass, L | 1 |
| Schmitt, M | 1 |
| Kiechle, M | 1 |
| Hoefler, H | 1 |
| Yasuda, K | 1 |
| Kimura, T | 1 |
| Seita, M | 1 |
| Takahata, T | 1 |
| Akazai, Y | 1 |
| Fernández Sarabia, MT | 1 |
| Rodríguez García, JM | 1 |
| Cardenal Escarcena, A | 1 |
| Serrano Vicente, J | 1 |
| García Bernardo, L | 1 |
| Sokurenko, VP | 1 |
| Korytova, LI | 1 |
| Tarazov, PG | 1 |
| Suvorova, IuV | 1 |
| Puthillath, A | 1 |
| Mashtare, T | 1 |
| Wilding, G | 1 |
| Khushalani, N | 1 |
| Steinbrenner, L | 1 |
| Ross, ME | 1 |
| Romano, K | 1 |
| Wisniewski, M | 1 |
| Fakih, MG | 1 |
| Muslimov, GF | 1 |
| Michalaki, V | 2 |
| Gennatas, S | 1 |
| Gennatas, K | 1 |
| Balduzzi, A | 1 |
| Montagna, E | 2 |
| Bagnardi, V | 2 |
| Torrisi, R | 1 |
| Bertolini, F | 2 |
| Mancuso, P | 1 |
| Scarano, E | 1 |
| Viale, G | 3 |
| Veronesi, P | 3 |
| Cardillo, A | 1 |
| Orlando, L | 2 |
| Goldhirsch, A | 6 |
| Colleoni, M | 3 |
| Costantino, E | 1 |
| Maddalena, F | 1 |
| Calise, S | 1 |
| Piscazzi, A | 1 |
| Tirino, V | 1 |
| Fersini, A | 1 |
| Ambrosi, A | 1 |
| Neri, V | 1 |
| Esposito, F | 1 |
| Landriscina, M | 1 |
| Park, D | 1 |
| Kåresen, R | 1 |
| Naume, B | 1 |
| Synnestvedt, M | 1 |
| Beraki, E | 1 |
| Sauer, T | 1 |
| Maeda, S | 1 |
| Hikiba, Y | 1 |
| Nakagawa, H | 2 |
| Hayakawa, Y | 2 |
| Shibata, W | 1 |
| Yanai, A | 1 |
| Ogura, K | 1 |
| Omata, M | 1 |
| Gusella, M | 1 |
| Frigo, AC | 1 |
| Bolzonella, C | 1 |
| Marinelli, R | 1 |
| Barile, C | 1 |
| Bononi, A | 1 |
| Crepaldi, G | 1 |
| Menon, D | 1 |
| Stievano, L | 1 |
| Toso, S | 2 |
| Pasini, F | 1 |
| Ferrazzi, E | 1 |
| Padrini, R | 1 |
| Lin, YS | 1 |
| Lin, LC | 1 |
| Lin, SW | 1 |
| Welz, H | 1 |
| Pöttgen, C | 1 |
| Abu Jawad, J | 1 |
| Wierlemann, A | 1 |
| Wittig, A | 1 |
| Stüben, G | 2 |
| Budach, V | 4 |
| Lehnerdt, G | 1 |
| Jahnke, K | 3 |
| Sack, H | 3 |
| Stuschke, M | 4 |
| Lai, JI | 1 |
| Tzeng, CH | 2 |
| Chen, PM | 2 |
| Lin, JK | 2 |
| Lin, TC | 2 |
| Chen, WS | 2 |
| Jiang, JK | 2 |
| Wang, HS | 2 |
| Wang, WS | 2 |
| Vardouli, L | 1 |
| Lindqvist, C | 1 |
| Vlahou, K | 1 |
| Loskog, AS | 1 |
| Eliopoulos, AG | 1 |
| Yen, LC | 1 |
| Yeh, YS | 1 |
| Chen, CW | 1 |
| Wang, HM | 1 |
| Tsai, HL | 1 |
| Lu, CY | 2 |
| Chang, YT | 1 |
| Chu, KS | 1 |
| Lin, SR | 2 |
| Wang, JY | 2 |
| Yamashita, H | 1 |
| Okuma, K | 1 |
| Seto, Y | 1 |
| Mori, K | 2 |
| Wakui, R | 1 |
| Ohtomo, K | 1 |
| Nakagawa, K | 2 |
| Marana, HR | 1 |
| de Andrade, JM | 1 |
| Dos Reis, FJ | 1 |
| Tiezzi, DG | 1 |
| Zola, FE | 1 |
| Clagnan, WS | 1 |
| Garieri, AP | 1 |
| Hurmuzlu, M | 1 |
| Monge, OR | 1 |
| Smaaland, R | 1 |
| Viste, A | 1 |
| Choi, JY | 2 |
| Barlow, WE | 1 |
| Albain, KS | 1 |
| Hong, CC | 1 |
| Blanco, JG | 1 |
| Livingston, RB | 1 |
| Davis, W | 1 |
| Rae, JM | 1 |
| Yeh, IT | 1 |
| Hutchins, LF | 1 |
| Ravdin, PM | 1 |
| Martino, S | 1 |
| Lyss, AP | 1 |
| Osborne, CK | 1 |
| Abeloff, MD | 1 |
| Hayes, DF | 1 |
| Ambrosone, CB | 1 |
| Cordio, S | 1 |
| Caputo, G | 1 |
| Novello, G | 1 |
| Reggiardo, G | 1 |
| Manzione, L | 2 |
| Oliva, C | 1 |
| Bergnolo, P | 1 |
| Inguì, M | 1 |
| Bianco, L | 1 |
| Pochettino, P | 1 |
| Cutin, SC | 1 |
| Boglione, A | 1 |
| Dal Canton, O | 1 |
| Garetto, F | 1 |
| Comandone, A | 1 |
| Ghiringhelli, F | 1 |
| Guiu, B | 1 |
| Chauffert, B | 1 |
| Ladoire, S | 1 |
| Khademi, B | 1 |
| Moradi, A | 1 |
| Hoseini, S | 1 |
| Mohammadianpanah, M | 1 |
| Hasenberg, T | 1 |
| Essenbreis, M | 1 |
| Herold, A | 1 |
| Post, S | 1 |
| Shang, E | 1 |
| Xie, P | 1 |
| Yue, JB | 1 |
| Zhao, HX | 1 |
| Sun, XD | 1 |
| Kong, L | 1 |
| Fu, Z | 1 |
| Yu, JM | 1 |
| Haramoto, M | 1 |
| Kohno, M | 1 |
| Nakajima, O | 1 |
| Horibe, T | 1 |
| Kiyohara, M | 1 |
| Fukazawa, H | 1 |
| Togawa, T | 2 |
| Kawakami, K | 1 |
| Mattioli, R | 1 |
| Gridelli, C | 1 |
| Castellanos, J | 1 |
| Duque, A | 1 |
| Falcone, A | 3 |
| Mansutti, M | 1 |
| Bacon, P | 1 |
| Lawrinson, S | 1 |
| Skacel, T | 1 |
| Casas, A | 1 |
| Lee, JK | 1 |
| Kim, YC | 1 |
| Qi, Y | 1 |
| Theodorescu, D | 1 |
| Symmans, WF | 2 |
| Baggerly, K | 1 |
| Rouzier, R | 1 |
| Pusztai, L | 2 |
| Biffi, R | 1 |
| Fazio, N | 2 |
| Luca, F | 1 |
| Chiappa, A | 1 |
| Andreoni, B | 1 |
| Zampino, MG | 1 |
| Roth, A | 1 |
| Schuller, JC | 1 |
| Fiori, G | 1 |
| Orsi, F | 1 |
| Bonomo, G | 1 |
| Crosta, C | 1 |
| Huber, O | 1 |
| Patel, BB | 1 |
| Majumdar, AP | 1 |
| Domingues, AP | 1 |
| Mota, F | 1 |
| Durão, M | 1 |
| Frutuoso, C | 1 |
| Amaral, N | 1 |
| de Oliveira, CF | 1 |
| Richetti, A | 1 |
| Fogliata, A | 1 |
| Clivio, A | 1 |
| Nicolini, G | 1 |
| Pesce, G | 1 |
| Salati, E | 1 |
| Vanetti, E | 1 |
| Cozzi, L | 1 |
| Sutherland, S | 1 |
| Ashley, S | 1 |
| Miles, D | 2 |
| Chan, S | 1 |
| Wardley, A | 2 |
| Davidson, N | 1 |
| Bhatti, R | 1 |
| Shehata, M | 1 |
| Nouras, H | 1 |
| Camburn, T | 1 |
| Johnston, SR | 1 |
| Ferrari, G | 1 |
| Gemignani, F | 1 |
| Macaluso, C | 1 |
| Zarate, R | 1 |
| Bandres, E | 1 |
| Patiño-Garcia, A | 1 |
| Ponz-Sarvise, M | 1 |
| Viudez, A | 1 |
| Ramirez, N | 1 |
| Bitarte, N | 1 |
| Gacía-Foncillas, J | 1 |
| Møller, AK | 1 |
| Pedersen, KD | 1 |
| Abildgaard, J | 1 |
| Petersen, BL | 1 |
| Daugaard, G | 1 |
| Ghorbel, L | 1 |
| Ben Salah, H | 1 |
| Khabir, A | 1 |
| Karray, H | 1 |
| Gargouri, R | 1 |
| Boudawara, T | 1 |
| Northover, J | 1 |
| Glynne-Jones, R | 2 |
| Sebag-Montefiore, D | 1 |
| James, R | 1 |
| Meadows, H | 1 |
| Wan, S | 1 |
| Jitlal, M | 1 |
| Ledermann, J | 1 |
| Matsushita, S | 1 |
| Ikeda, R | 1 |
| Nishizawa, Y | 2 |
| Che, XF | 1 |
| Furukawa, T | 2 |
| Miyadera, K | 2 |
| Tabata, S | 1 |
| Ushiyama, M | 1 |
| Tajitsu, Y | 1 |
| Yamamoto, M | 1 |
| Takeda, Y | 1 |
| Minami, K | 1 |
| Mataki, H | 1 |
| Kanzaki, T | 1 |
| Yamada, K | 1 |
| Kanekura, T | 1 |
| Akiyama, S | 1 |
| Correale, P | 4 |
| Rotundo, MS | 1 |
| Del Vecchio, MT | 2 |
| Remondo, C | 1 |
| Migali, C | 1 |
| Ginanneschi, C | 1 |
| Tsang, KY | 1 |
| Licchetta, A | 1 |
| Mannucci, S | 1 |
| Loiacono, L | 1 |
| Tassone, P | 1 |
| Francini, G | 3 |
| Tagliaferri, P | 1 |
| Morganti, AG | 1 |
| Picardi, V | 1 |
| Ippolito, E | 1 |
| Massaccesi, M | 1 |
| Macchia, G | 1 |
| Deodato, F | 1 |
| Mattiucci, GC | 1 |
| Caravatta, L | 1 |
| Di Lullo, L | 1 |
| Giglio, G | 1 |
| Tambaro, R | 1 |
| Mignogna, S | 1 |
| Caprino, P | 1 |
| Ingrosso, M | 1 |
| Sofo, L | 1 |
| Cellini, N | 1 |
| Valentini, V | 1 |
| Tanizaki, J | 1 |
| Okamoto, I | 1 |
| Takezawa, K | 1 |
| Tsukioka, S | 1 |
| Uchida, J | 1 |
| Kiniwa, M | 1 |
| Fukuoka, M | 1 |
| Gao, J | 1 |
| Hu, JY | 1 |
| Xia, YF | 1 |
| Yi, W | 2 |
| Tao, YL | 1 |
| Li, G | 3 |
| Lee, MC | 2 |
| Hung, WM | 2 |
| Choi, CW | 4 |
| Lee, KC | 1 |
| Manterola, C | 1 |
| Vial, M | 1 |
| Roa, JC | 1 |
| Clavel, S | 1 |
| Fortin, B | 1 |
| Després, P | 1 |
| Donath, D | 1 |
| Soulières, D | 1 |
| Khaouam, N | 1 |
| Charpentier, D | 1 |
| Bélair, M | 1 |
| Guertin, L | 1 |
| Nguyen-Tan, PF | 1 |
| Chen, MH | 2 |
| Pang, R | 1 |
| Law, WL | 1 |
| Chu, AC | 1 |
| Poon, JT | 1 |
| Lam, CS | 1 |
| Chow, AK | 1 |
| Ng, L | 1 |
| Cheung, LW | 1 |
| Lan, XR | 1 |
| Lan, HY | 2 |
| Tan, VP | 1 |
| Yau, TC | 1 |
| Poon, RT | 1 |
| Wong, BC | 1 |
| Wan, YW | 1 |
| Rathnagiriswaran, S | 1 |
| Castranova, V | 1 |
| Guo, NL | 1 |
| Hashiguchi, K | 1 |
| Kitajima, Y | 1 |
| Kai, K | 1 |
| Hiraki, M | 1 |
| Nakamura, J | 1 |
| Tokunaga, O | 1 |
| Noshiro, H | 1 |
| Miyazaki, K | 1 |
| Chan, SH | 1 |
| Cheung, FM | 1 |
| Cheung, KN | 1 |
| Yiu, KH | 1 |
| Nonaka, K | 2 |
| Sha, S | 1 |
| Chua, DT | 8 |
| Tung, R | 3 |
| Siu, L | 5 |
| Sze, WK | 1 |
| Au, GK | 6 |
| Law, SC | 2 |
| Yau, TK | 5 |
| Au, JS | 2 |
| Sze, WM | 4 |
| Fung, KK | 2 |
| Lau, JT | 2 |
| Lau, WH | 5 |
| Fariña-Sarasqueta, A | 1 |
| van Lijnschoten, G | 1 |
| Rutten, HJ | 2 |
| van den Brule, AJ | 1 |
| Forrest, JL | 1 |
| Ackerman, I | 1 |
| Barbera, L | 1 |
| Barnes, EA | 1 |
| Davidson, M | 1 |
| Kiss, A | 1 |
| Thomas, G | 1 |
| Kau, HC | 1 |
| Tsai, CC | 1 |
| Heinrich, N | 1 |
| Born, M | 1 |
| Hoebert, E | 1 |
| Verrel, F | 1 |
| Simon, A | 1 |
| Bode, U | 1 |
| Fleischhack, G | 1 |
| Van der Speeten, K | 1 |
| Stuart, OA | 1 |
| Chang, D | 1 |
| Sugarbaker, PH | 5 |
| Benoit, A | 1 |
| Ducray, F | 1 |
| Cartalat-Carel, S | 1 |
| Psimaras, D | 1 |
| Ricard, D | 1 |
| Honnorat, J | 1 |
| Jeong, JH | 1 |
| Jung, SY | 1 |
| Park, IH | 1 |
| Lee, KS | 1 |
| Kang, HS | 1 |
| Kim, SW | 1 |
| Kwon, Y | 1 |
| Kim, EA | 1 |
| Ko, KL | 1 |
| Nam, BH | 1 |
| Lee, S | 2 |
| Ro, J | 1 |
| Jegannathen, A | 1 |
| Mais, K | 1 |
| Sykes, A | 1 |
| Lee, L | 1 |
| Yap, B | 1 |
| Birzgalis, A | 1 |
| Homer, J | 1 |
| Ryder, WD | 1 |
| Slevin, N | 1 |
| Fu, YT | 3 |
| Leung, SF | 3 |
| Tan, EH | 4 |
| Stoiber, N | 1 |
| Hauser, N | 1 |
| Stoiber, B | 1 |
| Hohl, MK | 1 |
| Sohn, C | 1 |
| Eichbaum, MH | 1 |
| Na, YS | 1 |
| Kim, SM | 1 |
| Jung, KA | 1 |
| Yang, SJ | 1 |
| Hong, YS | 1 |
| Ryu, MH | 3 |
| Ro, S | 1 |
| Cho, DH | 1 |
| Kim, JC | 1 |
| Jin, DH | 1 |
| Lee, JS | 5 |
| Kim, TW | 3 |
| Huang, MY | 2 |
| Huang, ML | 1 |
| Chen, MJ | 1 |
| Chen, CF | 1 |
| Tsai, PC | 1 |
| Chuang, SC | 1 |
| Hou, MF | 2 |
| Saif, MW | 2 |
| Kaley, K | 1 |
| Obi, EE | 1 |
| McDonald, A | 1 |
| Kemp, E | 1 |
| Yamauchi, M | 1 |
| Okamoto, Y | 1 |
| Doi, M | 1 |
| Shinozaki, K | 1 |
| Kogashiwa, Y | 1 |
| Yamauchi, K | 1 |
| Nagafuji, H | 1 |
| Matsuda, T | 2 |
| Tsubosaka, T | 1 |
| Karaho, T | 1 |
| Kohno, N | 1 |
| Chan, LK | 1 |
| Xu, BH | 1 |
| Zhang, P | 1 |
| Song, X | 1 |
| Zhao, Z | 1 |
| Barber, B | 1 |
| Gregory, C | 1 |
| Wang, PF | 1 |
| Long, SR | 1 |
| Lim, YC | 1 |
| Oh, SY | 2 |
| Cha, YY | 1 |
| Kim, SH | 3 |
| Kim, H | 1 |
| Pelz, JO | 1 |
| Chua, TC | 1 |
| Esquivel, J | 1 |
| Stojadinovic, A | 1 |
| Doerfer, J | 1 |
| Morris, DL | 3 |
| Maeder, U | 1 |
| Germer, CT | 1 |
| Kerscher, AG | 1 |
| Choi, MS | 1 |
| Kuh, HJ | 1 |
| Oberholzer, K | 1 |
| Menig, M | 1 |
| Kreft, A | 1 |
| Schneider, A | 1 |
| Junginger, T | 1 |
| Heintz, A | 1 |
| Kreitner, KF | 1 |
| Hötker, AM | 1 |
| Hansen, T | 1 |
| Düber, C | 1 |
| Schmidberger, H | 1 |
| Kawabata, R | 1 |
| Oie, S | 1 |
| Oka, T | 1 |
| Kanayama, H | 1 |
| Itoh, K | 1 |
| Chilimoniuk, M | 1 |
| Olszewska, E | 1 |
| Maksimowicz, T | 1 |
| Edlund, P | 1 |
| Ahlgren, J | 1 |
| Bjerre, K | 1 |
| Andersson, M | 1 |
| Bergh, J | 2 |
| Mouridsen, H | 1 |
| Holmberg, SB | 1 |
| Bengtsson, NO | 1 |
| Jakobsen, E | 1 |
| Møller, S | 1 |
| Lindman, H | 1 |
| Blomqvist, C | 1 |
| Iiristo, M | 1 |
| Wiklund, T | 1 |
| Wilking, N | 1 |
| Brandberg, Y | 1 |
| Backshall, A | 1 |
| Sharma, R | 1 |
| Clarke, SJ | 1 |
| Keun, HC | 1 |
| Nishi, T | 1 |
| Hamamoto, Y | 1 |
| Warita, E | 1 |
| Miyamoto, J | 1 |
| Akutsu, N | 1 |
| Yamanaka, Y | 1 |
| Nagase, M | 1 |
| Fujii, H | 1 |
| Radhakrishnan, V | 1 |
| Bakhshi, S | 1 |
| Eich, HT | 1 |
| Stepien, A | 1 |
| Zimmermann, C | 1 |
| Hellmich, M | 1 |
| Metzger, R | 1 |
| Hölscher, A | 1 |
| Müller, RP | 1 |
| Yeh, CT | 1 |
| Chen, HC | 1 |
| Sung, CM | 1 |
| Hsu, CL | 1 |
| Pan, KT | 1 |
| Tseng, JH | 1 |
| Hung, CF | 1 |
| Deenen, MJ | 1 |
| Tol, J | 2 |
| Burylo, AM | 1 |
| Doodeman, VD | 1 |
| de Boer, A | 1 |
| Vincent, A | 1 |
| Guchelaar, HJ | 1 |
| Smits, PH | 1 |
| Beijnen, JH | 1 |
| Punt, CJ | 4 |
| Schellens, JH | 1 |
| Cats, A | 2 |
| Specenier, P | 1 |
| Vermorken, JB | 2 |
| Showalter, TN | 1 |
| Zhan, T | 1 |
| Anne, PR | 1 |
| Chervoneva, I | 1 |
| Mitchell, EP | 1 |
| Yeo, CJ | 1 |
| Rosato, EL | 1 |
| Kennedy, EP | 1 |
| Berger, AC | 1 |
| Guigay, J | 1 |
| Mesia, R | 1 |
| Trigo, JM | 1 |
| Keilholz, U | 1 |
| Kerber, A | 1 |
| Bethe, U | 1 |
| Picard, M | 1 |
| Brummendorf, TH | 1 |
| Yang, JP | 1 |
| Zhong, W | 1 |
| Yu, D | 1 |
| Wen, LJ | 1 |
| Jin, CS | 1 |
| Dechaphunkul, T | 1 |
| Pruegsanusak, K | 2 |
| Sangthawan, D | 1 |
| Sunpaweravong, P | 1 |
| Hwang, WL | 1 |
| Yang, MH | 1 |
| Tsai, ML | 1 |
| Su, SH | 1 |
| Chang, SC | 1 |
| Teng, HW | 1 |
| Yang, SH | 1 |
| Lan, YT | 1 |
| Chiou, SH | 1 |
| Wang, HW | 1 |
| Wahba, HA | 1 |
| El-Hadaad, HA | 1 |
| Abd-Ellatif, EA | 1 |
| Higashiyama, A | 1 |
| Kudo, M | 1 |
| Nagasako, T | 1 |
| Kawamura, N | 1 |
| Abiko, S | 1 |
| Yamamoto, Y | 1 |
| Gotoh, J | 1 |
| Tamaki, T | 1 |
| Meguro, J | 1 |
| Yonekawa, M | 1 |
| Kawamura, A | 1 |
| Tanino, M | 1 |
| Stintzing, S | 1 |
| Fischer von Weikersthal, L | 1 |
| Vehling-Kaiser, U | 1 |
| Stauch, M | 1 |
| Hass, HG | 1 |
| Dietzfelbinger, H | 1 |
| Oruzio, D | 1 |
| Klein, S | 1 |
| Zellmann, K | 1 |
| Decker, T | 1 |
| Schulze, M | 1 |
| Abenhardt, W | 1 |
| Puchtler, G | 1 |
| Kappauf, H | 1 |
| Mittermüller, J | 1 |
| Haberl, C | 1 |
| Giessen, C | 1 |
| Moosmann, N | 1 |
| Heinemann, V | 1 |
| Fedele, P | 1 |
| Marino, A | 1 |
| Schiavone, P | 1 |
| Nacci, A | 1 |
| Sponziello, F | 1 |
| Rizzo, P | 1 |
| Calvani, N | 1 |
| Mazzoni, E | 1 |
| Cinefra, M | 1 |
| Tanaka, K | 4 |
| Sugitani, I | 1 |
| Fujimoto, Y | 1 |
| Schauer, M | 1 |
| Knoefel, WT | 1 |
| Friess, H | 1 |
| Theisen, J | 1 |
| Kato, T | 1 |
| Muro, K | 2 |
| Yamaguchi, K | 1 |
| Bando, H | 2 |
| Hazama, S | 1 |
| Amagai, K | 1 |
| Baba, H | 3 |
| Denda, T | 1 |
| Shi, X | 1 |
| Fukase, K | 1 |
| Skamoto, J | 1 |
| Mishima, H | 1 |
| Brixi-Benmansour, H | 1 |
| Jouve, JL | 1 |
| Mitry, E | 1 |
| Landi, B | 2 |
| Hentic, O | 1 |
| Bedenne, L | 1 |
| Cadiot, G | 1 |
| Klaver, YL | 2 |
| Hendriks, T | 1 |
| Lomme, RM | 1 |
| Bleichrodt, RP | 3 |
| de Hingh, IH | 2 |
| Opdam, FL | 1 |
| Swen, JJ | 1 |
| Wessels, JA | 1 |
| Gelderblom, H | 1 |
| van Kuilenburg, AB | 1 |
| Largiadèr, CR | 1 |
| Végran, F | 1 |
| Boidot, R | 1 |
| Cadouot, M | 1 |
| Chevrier, S | 1 |
| Lizard-Nacol, S | 1 |
| Edhemovic, I | 1 |
| Gadzijev, EM | 1 |
| Brecelj, E | 1 |
| Miklavcic, D | 1 |
| Kos, B | 1 |
| Zupanic, A | 1 |
| Mali, B | 1 |
| Jarm, T | 1 |
| Pavliha, D | 1 |
| Marcan, M | 1 |
| Gasljevic, G | 1 |
| Gorjup, V | 1 |
| Music, M | 1 |
| Vavpotic, TP | 1 |
| Cemazar, M | 1 |
| Snoj, M | 1 |
| Sersa, G | 1 |
| Zhuchenko, AP | 2 |
| Kalganov, ID | 2 |
| Filon, AF | 2 |
| Pallis, AG | 1 |
| Boukovinas, I | 1 |
| Ardavanis, A | 1 |
| Varthalitis, I | 2 |
| Malamos, N | 2 |
| Georgoulias, V | 2 |
| Mavroudis, D | 2 |
| Hinchliffe, E | 1 |
| Allcock, RL | 1 |
| Mansoor, W | 1 |
| Myers, MA | 1 |
| Zapf, I | 1 |
| Tizedes, G | 1 |
| Pavlovics, G | 1 |
| Kovács, G | 1 |
| Kálmán, E | 1 |
| Szalai, G | 1 |
| Kövér, E | 1 |
| Farkas, R | 1 |
| Horváth, OP | 2 |
| Badri, T | 1 |
| Hammami, H | 1 |
| Lachkham, A | 1 |
| Benmously-Mlika, R | 1 |
| Mokhtar, I | 1 |
| Fenniche, S | 1 |
| Rosenberg, L | 1 |
| Weissler, M | 1 |
| Hayes, DN | 1 |
| Shockley, W | 1 |
| Zanation, A | 1 |
| Rosenman, J | 1 |
| Chera, B | 1 |
| Hu, GQ | 1 |
| Cheng, ZB | 1 |
| Li, WX | 1 |
| Chen, YY | 1 |
| Xie, FY | 2 |
| Xu, TT | 1 |
| Li, B | 1 |
| Long, GX | 1 |
| Wang, SY | 1 |
| Zheng, BM | 1 |
| Chen, YM | 1 |
| Regierer, AC | 1 |
| Reinecke, F | 1 |
| Weigel, A | 1 |
| Dieing, A | 1 |
| Lehenbauer-Dehm, S | 2 |
| Schwarzlose-Schwarck, S | 1 |
| Possinger, K | 2 |
| Eucker, J | 1 |
| Zheng, G | 1 |
| Xiong, Y | 1 |
| Yi, S | 1 |
| Peng, B | 1 |
| Zhang, Q | 1 |
| He, Z | 1 |
| Yonemura, Y | 1 |
| Ishibashi, H | 1 |
| Sako, S | 1 |
| Kitai, T | 1 |
| Mizumoto, A | 1 |
| Hirano, M | 1 |
| Ichinose, M | 1 |
| Takao, N | 1 |
| Matsuda, N | 1 |
| Ozamto, Y | 1 |
| Chang-Yun, L | 1 |
| Elnemr, A | 1 |
| Xiao-Jun, Y | 1 |
| Hecht, JR | 1 |
| Farrell, JJ | 1 |
| Senzer, N | 1 |
| Nemunaitis, J | 1 |
| Rosemurgy, A | 1 |
| Chung, T | 2 |
| Hanna, N | 1 |
| Chang, KJ | 1 |
| Javle, M | 1 |
| Posner, M | 1 |
| Waxman, I | 1 |
| Reid, A | 1 |
| Erickson, R | 1 |
| Canto, M | 1 |
| Chak, A | 1 |
| Blatner, G | 1 |
| Kovacevic, M | 1 |
| Thornton, M | 1 |
| Zielinski, C | 1 |
| Martin, M | 1 |
| Vrdoljak, E | 1 |
| Robert, N | 1 |
| Ferrero, A | 1 |
| Langella, S | 1 |
| Russolillo, N | 1 |
| Vigano', L | 1 |
| Lo Tesoriere, R | 1 |
| Capussotti, L | 1 |
| Jin, Y | 3 |
| Cai, YC | 2 |
| Cao, Y | 2 |
| Cai, XY | 2 |
| Tan, YT | 1 |
| Shi, YX | 2 |
| Jiang, WQ | 2 |
| Tsukuda, M | 1 |
| Matsuda, H | 1 |
| Horiuchi, C | 1 |
| Taguch, T | 1 |
| Mori, M | 1 |
| Niho, T | 1 |
| Ishitoya, J | 1 |
| Hirama, M | 1 |
| Grenader, T | 1 |
| Buehrlen, M | 1 |
| Zwaan, CM | 1 |
| Granzen, B | 2 |
| Lassay, L | 2 |
| Deutz, P | 1 |
| Vorwerk, P | 1 |
| Staatz, G | 1 |
| Gademann, G | 2 |
| Oldenburger, F | 1 |
| Tamm, M | 1 |
| Mertens, R | 2 |
| Crea, F | 1 |
| Masi, G | 1 |
| Paolicchi, E | 1 |
| Loupakis, F | 1 |
| Graziano, F | 1 |
| Salvatore, L | 1 |
| Ricci, V | 1 |
| Cremolini, C | 1 |
| Schirripa, M | 1 |
| Danesi, R | 2 |
| Aliev, DA | 1 |
| Isaev, IG | 1 |
| Kazieva, RR | 1 |
| Ferrand, FR | 1 |
| Gontier, E | 1 |
| Guymar, S | 1 |
| Fagot, T | 1 |
| Ceccaldi, B | 1 |
| Malfuson, JV | 1 |
| de Revel, T | 1 |
| Takara, K | 1 |
| Shin, Y | 1 |
| Obata, Y | 1 |
| Kitada, N | 1 |
| Ohnishi, N | 1 |
| Yokoyama, T | 1 |
| Chen, YG | 1 |
| Kao, WY | 1 |
| Tsai, SH | 1 |
| Setton, J | 1 |
| Wolden, S | 1 |
| Caria, N | 1 |
| Lee, N | 1 |
| Hidaka, T | 1 |
| Fujimura, T | 1 |
| Watabe, A | 1 |
| Hashimoto, A | 2 |
| Haga, T | 1 |
| Onami, K | 1 |
| Mizuashi, M | 1 |
| Aiba, S | 1 |
| Cancello, G | 1 |
| Pastrello, D | 1 |
| Dellapasqua, S | 1 |
| Perri, G | 1 |
| Luini, A | 2 |
| Intra, M | 2 |
| Calleri, A | 1 |
| Rampinelli, C | 1 |
| Cheuk, DK | 1 |
| Sabin, ND | 1 |
| Hossain, M | 1 |
| Wozniak, A | 1 |
| Naik, M | 1 |
| Krasin, MJ | 1 |
| Shulkin, BL | 1 |
| Gong, C | 1 |
| Wang, C | 2 |
| Wu, Q | 1 |
| Qian, Z | 1 |
| Simkens, LH | 1 |
| Lemmens, VE | 1 |
| Koopman, M | 3 |
| Teerenstra, S | 1 |
| Er, O | 1 |
| Berk, V | 1 |
| Saraymen, R | 1 |
| Elmalı, F | 1 |
| Razis, E | 1 |
| Kalogeras, KT | 1 |
| Kotoula, V | 1 |
| Eleftheraki, AG | 1 |
| Nikitas, N | 1 |
| Kronenwett, R | 1 |
| Timotheadou, E | 2 |
| Christodoulou, C | 1 |
| Pectasides, D | 2 |
| Gogas, H | 2 |
| Wirtz, RM | 1 |
| Makatsoris, T | 1 |
| Bafaloukos, D | 4 |
| Aravantinos, G | 2 |
| Televantou, D | 1 |
| Pavlidis, N | 2 |
| Fountzilas, G | 3 |
| Gu, MF | 1 |
| Liu, LZ | 2 |
| He, LJ | 1 |
| Yuan, WX | 1 |
| Zhang, R | 1 |
| Luo, GY | 1 |
| Xu, GL | 1 |
| Zhang, HM | 1 |
| Yan, CX | 1 |
| Li, JJ | 1 |
| Jin, K | 1 |
| Lan, H | 1 |
| He, K | 1 |
| Han, N | 1 |
| Teng, L | 1 |
| Cao, F | 1 |
| Tursi, A | 1 |
| Xia, XY | 1 |
| Zhang, WD | 1 |
| Hu, WH | 2 |
| Takanashi, K | 1 |
| Katsuki, S | 1 |
| Fujita, T | 2 |
| Waga, E | 1 |
| Shimodate, Y | 1 |
| Sasaki, K | 1 |
| Someya, T | 1 |
| Ohno, K | 2 |
| Fujita, M | 1 |
| Yamazaki, H | 1 |
| Ota, Y | 1 |
| Aoki, T | 1 |
| Kaneko, A | 1 |
| Nishino, H | 1 |
| Takanosawa, M | 1 |
| Kawada, K | 1 |
| Kanazawa, T | 1 |
| Ichimura, K | 1 |
| Takahashi, S | 1 |
| Nakazawa, M | 1 |
| Pan, XB | 1 |
| Zhu, XD | 1 |
| Valentino, JD | 1 |
| Elliott, VA | 1 |
| Zaytseva, YY | 1 |
| Rychahou, PG | 1 |
| Mustain, WC | 1 |
| Gao, T | 1 |
| Evers, BM | 1 |
| Yan, S | 1 |
| Jiang, X | 1 |
| Yan, D | 1 |
| Wang, YX | 1 |
| Bollet, MA | 1 |
| Servois, V | 1 |
| Zefkili, S | 1 |
| Farkhondeh, F | 2 |
| Baranger, B | 1 |
| Mariani, P | 1 |
| Kulcsár, G | 1 |
| Gaál, D | 1 |
| Kulcsár, PI | 1 |
| Schulcz, Á | 1 |
| Czömpöly, T | 1 |
| Lin, G | 1 |
| Lin, MC | 1 |
| Lin, S | 2 |
| Yao, H | 1 |
| Xu, G | 1 |
| Ng, SS | 1 |
| Chen, S | 1 |
| Yu, J | 1 |
| Yang, B | 1 |
| Golden, DW | 2 |
| Novak, CJ | 1 |
| Minsky, BD | 1 |
| Liauw, SL | 1 |
| Mourad, WF | 1 |
| Hauerstock, D | 1 |
| Shourbaji, RA | 1 |
| Hu, KS | 1 |
| Culliney, B | 1 |
| Jacobson, A | 1 |
| Tran, T | 1 |
| Manolidis, S | 1 |
| Schantz, S | 1 |
| Urken, M | 1 |
| Persky, M | 1 |
| Harrison, LB | 1 |
| Shah, SM | 1 |
| Drage, MG | 1 |
| Lichtman, AH | 1 |
| Haddad, RI | 1 |
| Croitoru, A | 1 |
| Gramaticu, I | 1 |
| Dinu, I | 1 |
| Gheorghe, L | 1 |
| Alexandrescu, S | 1 |
| Buica, F | 1 |
| Luca, I | 1 |
| Becheanu, G | 1 |
| Herlea, V | 1 |
| Simionov, I | 1 |
| Hrehoret, D | 1 |
| Lupescu, I | 1 |
| Popescu, I | 1 |
| Diculescu, M | 1 |
| Kim, KC | 1 |
| Yook, JH | 2 |
| Eisenbraun, J | 1 |
| Kim, BS | 2 |
| Huber, R | 1 |
| Tenti, S | 1 |
| Conca, R | 1 |
| Pastina, P | 1 |
| Fioravanti, A | 1 |
| Palomo, AG | 1 |
| Glogowska, I | 1 |
| Sommer, H | 1 |
| Kilar, E | 1 |
| Vega, JM | 1 |
| Torrecillas, L | 1 |
| Delozier, T | 1 |
| Ettl, J | 1 |
| Finek, J | 1 |
| Rocha Lima, CM | 1 |
| Bayraktar, S | 1 |
| Flores, AM | 1 |
| MacIntyre, J | 1 |
| Montero, A | 1 |
| Baranda, JC | 1 |
| Wallmark, J | 1 |
| Portera, C | 1 |
| Raja, R | 1 |
| Stern, H | 1 |
| Royer-Joo, S | 1 |
| Amler, LC | 1 |
| Holma, R | 1 |
| Korpela, R | 1 |
| Sairanen, U | 1 |
| Blom, M | 1 |
| Rautio, M | 1 |
| Poussa, T | 1 |
| Saxelin, M | 1 |
| Osterlund, P | 1 |
| Rudra, S | 1 |
| Witt, ME | 2 |
| Nwizu, T | 1 |
| Cohen, EE | 1 |
| Blair, E | 1 |
| Stenson, KM | 1 |
| Vokes, EE | 8 |
| Haraf, DJ | 5 |
| Bates, DO | 1 |
| Catalano, PJ | 2 |
| Symonds, KE | 1 |
| Varey, AH | 1 |
| Ramani, P | 1 |
| O'Dwyer, PJ | 2 |
| Giantonio, BJ | 2 |
| Meropol, NJ | 5 |
| Benson, AB | 2 |
| Harper, SJ | 1 |
| Can, G | 1 |
| Akpinar, B | 1 |
| Baran, Y | 1 |
| Zhivotovsky, B | 1 |
| Olsson, M | 1 |
| Brieau, B | 1 |
| Roussel, H | 1 |
| Markoutsaki, T | 1 |
| Dubreuil, O | 1 |
| Trouilloud, I | 1 |
| Lepère, C | 1 |
| Vaillant, JN | 1 |
| Zaanan, A | 1 |
| Chen, C | 1 |
| An, X | 1 |
| Xue, C | 1 |
| Yu, QT | 1 |
| Pan, JJ | 1 |
| Song, XQ | 1 |
| Lin, SJ | 1 |
| Wu, JX | 1 |
| Zhang, JW | 1 |
| Zhao, HY | 1 |
| Xu, F | 1 |
| Liu, JL | 1 |
| Hu, ZH | 1 |
| Zhao, LP | 1 |
| Zhao, YY | 1 |
| Wu, X | 1 |
| Ma, YX | 1 |
| Park, JM | 1 |
| Huang, S | 1 |
| Wu, TT | 2 |
| Foster, NR | 1 |
| Sinicrope, FA | 1 |
| Rana, SV | 1 |
| Steger, F | 1 |
| Hautmann, MG | 1 |
| Kölbl, O | 1 |
| Li, SW | 1 |
| Wang, H | 1 |
| Liu, ML | 1 |
| Zhang, HB | 1 |
| Ye, X | 1 |
| Shao, L | 1 |
| Lin, BC | 1 |
| He, CX | 1 |
| Zhang, BB | 1 |
| Zhang, YP | 1 |
| Peerawong, T | 1 |
| Phungrassami, T | 1 |
| Sangthong, R | 1 |
| Ishida, H | 1 |
| Kumamoto, K | 1 |
| Ishibashi, K | 1 |
| Hatano, S | 1 |
| Matsuzawa, T | 1 |
| Okada, N | 1 |
| Kumagai, Y | 1 |
| Haga, N | 1 |
| López, R | 1 |
| Méndez, CM | 1 |
| Fernández, MJ | 1 |
| Reinoso, CR | 1 |
| Aldana, GQ | 1 |
| Fernández, MS | 1 |
| DE LA Cámara Gómez, J | 1 |
| López, MR | 1 |
| Vázquez, MR | 1 |
| Folgar, SC | 1 |
| Lee, KD | 1 |
| Liu, TW | 1 |
| Wu, CW | 1 |
| Tiu, CM | 1 |
| Liu, JM | 1 |
| Chung, TR | 1 |
| Chang, JY | 1 |
| Whang-Peng, J | 2 |
| Chen, LT | 2 |
| Rigas, A | 1 |
| Dervenis, C | 1 |
| Giannakou, N | 1 |
| Kozoni, V | 1 |
| Shiff, SJ | 1 |
| Rigas, B | 1 |
| Yao, K | 1 |
| Inagi, K | 1 |
| Nakayama, M | 1 |
| Makoshi, T | 1 |
| Nagai, H | 1 |
| Okamoto, M | 1 |
| Bogenrieder, T | 1 |
| Weitzel, C | 1 |
| Schölmerich, J | 1 |
| Landthaler, M | 1 |
| Stolz, W | 1 |
| Brickelmaier, M | 1 |
| Carmillo, A | 1 |
| Goelz, S | 1 |
| Barsoum, J | 1 |
| Qin, XQ | 1 |
| El Otmany, A | 1 |
| Bonnay, M | 1 |
| Paci, A | 1 |
| Ducreux, M | 4 |
| Antoun, S | 1 |
| Lasser, P | 6 |
| Laurent, S | 1 |
| Bourget, P | 1 |
| Dietz, A | 1 |
| Vanselow, B | 1 |
| Rudat, V | 1 |
| Conradt, C | 1 |
| Weidauer, H | 1 |
| Kallinowski, F | 1 |
| Dollner, R | 1 |
| Schneider, T | 1 |
| Osl, F | 1 |
| Friess, T | 1 |
| Stockinger, H | 1 |
| Scheuer, WV | 1 |
| Ogura, O | 1 |
| Kanzaki, A | 2 |
| Ogura, T | 1 |
| Toi, M | 3 |
| Takebayashi, Y | 2 |
| Higashimoto, M | 1 |
| Shimakawa, T | 1 |
| Konno, S | 1 |
| Naritaka, Y | 1 |
| Nitta, Y | 1 |
| Mori, S | 1 |
| Shirata, S | 1 |
| Yoshida, A | 1 |
| Terada, K | 1 |
| Sugiyama, T | 1 |
| Ogawa, K | 1 |
| Bagatzounis, A | 1 |
| Erakleous, E | 1 |
| Michaelides, I | 1 |
| Locati, LD | 1 |
| Cavina, R | 1 |
| Garassino, I | 1 |
| Mattavelli, F | 1 |
| Pizzi, N | 1 |
| Quattrone, P | 1 |
| Valagussa, P | 2 |
| Gianni, L | 2 |
| Bonadonna, G | 2 |
| Solero, CL | 1 |
| Cantu, G | 1 |
| Nemoto, H | 1 |
| Takeuchi, S | 1 |
| Nagasaki, H | 1 |
| Yoshizawa, Y | 1 |
| Kikuchi, H | 1 |
| Yagi, H | 1 |
| Midorikawa, T | 1 |
| Sanada, Y | 1 |
| Kumada, K | 1 |
| Iwashige, M | 1 |
| Takizawa, K | 1 |
| Tate, G | 1 |
| Oh, JL | 1 |
| Kies, MS | 1 |
| Mittal, BB | 1 |
| Weichselbaum, RR | 5 |
| Smith, T | 1 |
| Kau, SW | 1 |
| McConathy, JM | 1 |
| Esteva, FJ | 1 |
| Kuerer, HM | 1 |
| Buzdar, AU | 7 |
| Hortobagyi, GN | 4 |
| Uchida, H | 1 |
| Shinoura, N | 1 |
| Kitayama, J | 2 |
| Watanabe, T | 2 |
| Nagawa, H | 3 |
| Hamada, H | 1 |
| Sham, JS | 6 |
| Kwong, PW | 3 |
| Hung, KN | 1 |
| Leung, LH | 2 |
| Burmeister, BH | 1 |
| Schache, D | 1 |
| Burmeister, EA | 1 |
| Bell, A | 1 |
| Poulsen, MG | 1 |
| Walpole, ET | 1 |
| Mackintosh, J | 1 |
| Lin, JC | 5 |
| Jan, JS | 5 |
| Chen, KY | 3 |
| Hsu, CY | 4 |
| Liang, WM | 2 |
| Wang, WY | 2 |
| Capotorto, AM | 1 |
| Pavesi, L | 1 |
| Pedrazzoli, P | 1 |
| Da Prada, GA | 1 |
| Zamagni, C | 1 |
| Massidda, B | 2 |
| Farris, A | 2 |
| Martoni, A | 1 |
| Lelli, G | 1 |
| Robustelli della Cuna, G | 1 |
| Harney, J | 1 |
| Goodchild, K | 1 |
| Phillips, H | 1 |
| Hoskin, PJ | 1 |
| Saunders, MI | 1 |
| Mukherjee, S | 1 |
| Aston, D | 1 |
| Minett, M | 1 |
| Brewster, AE | 2 |
| Crosby, TD | 2 |
| Klump, B | 1 |
| Nehls, O | 1 |
| Okech, T | 1 |
| Hsieh, CJ | 1 |
| Gaco, V | 1 |
| Gittinger, FS | 1 |
| Sarbia, M | 1 |
| Borchard, F | 1 |
| Greschniok, A | 1 |
| Gruenagel, HH | 1 |
| Gregor, M | 1 |
| Petty, RD | 1 |
| Nicolson, MC | 2 |
| Skaria, S | 1 |
| Sinclair, TS | 1 |
| Samuel, LM | 2 |
| Koruth, M | 1 |
| Hashitani, S | 1 |
| Urade, M | 1 |
| Nishimura, N | 1 |
| Maeda, T | 2 |
| Takaoka, K | 1 |
| Noguchi, K | 1 |
| Sakurai, K | 1 |
| Uetsuka, H | 1 |
| Haisa, M | 1 |
| Kimura, M | 2 |
| Gunduz, M | 1 |
| Kaneda, Y | 1 |
| Ohkawa, T | 2 |
| Takaoka, M | 1 |
| Murata, T | 1 |
| Nobuhisa, T | 1 |
| Yamatsuji, T | 1 |
| Matsuoka, J | 1 |
| Tanaka, N | 1 |
| Naomoto, Y | 1 |
| Salnikov, AV | 1 |
| Iversen, VV | 1 |
| Koisti, M | 1 |
| Sundberg, C | 1 |
| Johansson, L | 1 |
| Stuhr, LB | 1 |
| Sjöquist, M | 1 |
| Ahlström, H | 1 |
| Reed, RK | 1 |
| Rubin, K | 1 |
| KHO, MC | 1 |
| PARSONNET, V | 1 |
| DEREN, TL | 1 |
| WILSON, WL | 2 |
| HELSPER, JT | 1 |
| SHARP, GS | 2 |
| BENEFIEL, WW | 1 |
| LYTTON, B | 1 |
| MARK, JB | 1 |
| HARVARD, BM | 1 |
| MCNAIR, TJ | 1 |
| WIBIN, FA | 1 |
| HOPPE, ET | 1 |
| SCHMIDT, JL | 1 |
| DEPEYSTER, JA | 1 |
| OKADA, TA | 1 |
| ROBERTS, E | 1 |
| JOHNSON, RO | 4 |
| KISKEN, WA | 3 |
| CURRERI, AR | 6 |
| SKOLD, O | 1 |
| MAGNUSSON, PH | 1 |
| REVESZ, L | 1 |
| BOTIGLIERI, NG | 1 |
| WOLBERG, WH | 1 |
| WOODRUFF, MW | 1 |
| MURPHY, WT | 1 |
| HODSON, JM | 1 |
| LINDNER, A | 2 |
| KUTKAM, T | 1 |
| SANKARANARAYANAN, K | 1 |
| RUCKER, R | 1 |
| ARRADONDO, J | 1 |
| DIPAOLO, JA | 1 |
| MALKASIAN, GD | 2 |
| DECKER, DG | 2 |
| MUSSEY, E | 1 |
| JOHNSON, CE | 1 |
| LANGE, RD | 1 |
| CHAN, DP | 1 |
| HO, JH | 1 |
| WOO, AW | 1 |
| ARONOVITCH, M | 1 |
| BOUCHARD, J | 1 |
| GROSZMAN, M | 1 |
| MEAKINSS, JF | 1 |
| HAZEL, J | 1 |
| JALIL, A | 1 |
| GOLLIN, FF | 1 |
| ANSFIELD, FJ | 2 |
| VERMUND, H | 1 |
| GOLDENBERG, IS | 1 |
| HAYES, MA | 1 |
| HARROLD, MW | 1 |
| EDWARDS, CN | 1 |
| GRAVEY, FK | 1 |
| RIEHL, JL | 1 |
| BROWN, WJ | 1 |
| SMITH, SJ | 1 |
| BUSCH, H | 1 |
| HAKIM, P | 1 |
| PACE, WG | 1 |
| KNOERNSCHILD, H | 1 |
| CRESSY, NL | 2 |
| SCHELL, HW | 2 |
| ESQUIVEL, EL | 1 |
| MACKENZIE, AR | 1 |
| WHITMORE, WF | 1 |
| HEIDELBERGER, C | 1 |
| BOOHAR, J | 1 |
| BIRNIE, GD | 1 |
| Poindessous, V | 1 |
| Koeppel, F | 1 |
| Raymond, E | 2 |
| Cvitkovic, E | 6 |
| Waters, SJ | 1 |
| Larsen, AK | 1 |
| Belhadj, N | 1 |
| Gargouri, D | 1 |
| Kharrat, J | 1 |
| Ben Hriz, F | 1 |
| Kochlef, A | 1 |
| Kilani, A | 1 |
| Romani, M | 1 |
| Cherif, R | 1 |
| Khlifi, S | 1 |
| Ben Maamer, A | 1 |
| Letaief, A | 1 |
| Chauveinc, L | 2 |
| Buthaud, X | 1 |
| Falcou, MC | 1 |
| Mosseri, V | 2 |
| Pierga, JY | 2 |
| Girodet, J | 1 |
| Salmon, RJ | 1 |
| Konishi, N | 1 |
| Ohmori, Y | 1 |
| Kobayashi, M | 4 |
| Mohri, Y | 1 |
| Tonouchi, H | 1 |
| Kusunoki, M | 2 |
| Giglio, P | 1 |
| Tremont-Lukats, IW | 1 |
| Groves, MD | 1 |
| Borley, A | 1 |
| Perschky, L | 1 |
| Kehagioglou, P | 1 |
| Court, J | 1 |
| Maughan, TS | 1 |
| Tamatani, T | 1 |
| Azuma, M | 1 |
| Ashida, Y | 1 |
| Motegi, K | 2 |
| Takashima, R | 1 |
| Harada, K | 1 |
| Kawaguchi, S | 1 |
| Sato, M | 3 |
| Bajetta, E | 1 |
| Di Bartolomeo, M | 1 |
| Cassata, A | 1 |
| Artale, S | 1 |
| Frustaci, S | 1 |
| Pinotti, G | 2 |
| Carreca, I | 1 |
| Biasco, G | 2 |
| Bonaglia, L | 1 |
| Marini, G | 1 |
| Iannelli, A | 1 |
| Cortinovis, D | 1 |
| Ferrario, E | 1 |
| Beretta, E | 1 |
| Lambiase, A | 1 |
| Buzzoni, R | 1 |
| Kalofonos, HP | 2 |
| Skarlos, D | 3 |
| Papakostas, P | 2 |
| Bamias, A | 1 |
| Janinis, J | 1 |
| Kouvatseas, G | 1 |
| Stavropoulos, M | 1 |
| Economopulos, T | 1 |
| Shields, AF | 1 |
| Zalupski, MM | 1 |
| Marshall, JL | 1 |
| Verwaal, VJ | 2 |
| Ruth, SV | 1 |
| Zoetmulder, FA | 2 |
| Mizutani, Y | 1 |
| Wada, H | 1 |
| Fukushima, M | 3 |
| Yoshida, O | 1 |
| Nakanishi, H | 1 |
| Li, YN | 1 |
| Miki, T | 1 |
| Morant, R | 3 |
| Bernhard, J | 1 |
| Dietrich, D | 1 |
| Gillessen, S | 1 |
| Bonomo, M | 1 |
| Borner, M | 1 |
| Bauer, J | 2 |
| Cerny, T | 1 |
| Rochlitz, C | 1 |
| Wernli, M | 1 |
| Gschwend, A | 1 |
| Hanselmann, S | 2 |
| Hering, F | 1 |
| Schmid, HP | 1 |
| Roth, AD | 1 |
| Maibach, R | 1 |
| Sessa, C | 1 |
| Stupp, R | 1 |
| Herrmann, R | 2 |
| Borner, MM | 2 |
| de Braud, F | 1 |
| Edè, C | 1 |
| Ben Hassouna, D | 1 |
| Boige, V | 2 |
| Côté, JF | 1 |
| Delperro, JR | 1 |
| Benhamou, E | 1 |
| Baton, O | 1 |
| Giovannini, M | 1 |
| Oman, M | 1 |
| Tölli, J | 1 |
| Naredi, P | 1 |
| Hafström, LO | 1 |
| Gal, R | 1 |
| Sadikov, E | 1 |
| Sulkes, J | 1 |
| Klein, B | 1 |
| Koren, R | 1 |
| Eng, C | 1 |
| Kindler, HL | 1 |
| Nattam, S | 1 |
| Ansari, RH | 1 |
| Kasza, K | 1 |
| Wade-Oliver, K | 1 |
| Ceyhan, C | 1 |
| Meydan, N | 1 |
| Barutca, S | 1 |
| Tekten, T | 1 |
| Onbasili, AO | 1 |
| Ozturk, B | 1 |
| Unal, S | 1 |
| Bayrak, I | 1 |
| van Ruth, S | 1 |
| Melisko, ME | 1 |
| Fox, R | 1 |
| Venook, A | 1 |
| Lerouge, D | 1 |
| Touboul, E | 1 |
| Lefranc, JP | 1 |
| Uzan, S | 1 |
| Jannet, D | 1 |
| Moureau-Zabotto, L | 1 |
| Genestie, C | 1 |
| Antoine, M | 1 |
| Jamali, M | 1 |
| Cheng, AC | 2 |
| Wu, PM | 2 |
| Law, MW | 1 |
| Kwok, CC | 1 |
| Yau, CC | 2 |
| Wan, KY | 1 |
| Chan, RT | 1 |
| Choy, DD | 1 |
| Kershaw, MH | 1 |
| Jackson, JT | 1 |
| Haynes, NM | 1 |
| Teng, MW | 1 |
| Moeller, M | 1 |
| Street, SE | 1 |
| Cameron, R | 1 |
| Tanner, JE | 1 |
| Trapani, JA | 1 |
| Smyth, MJ | 1 |
| Darcy, PK | 1 |
| Poon, D | 1 |
| Yap, SP | 1 |
| Wong, ZW | 1 |
| Cheung, YB | 1 |
| Leong, SS | 1 |
| Wee, J | 1 |
| Chua, ET | 1 |
| Liljefors, M | 1 |
| Ragnhammar, P | 1 |
| Nilsson, B | 1 |
| Ullenhag, G | 1 |
| Mellstedt, H | 1 |
| Singhal, V | 1 |
| Singh, JP | 1 |
| Lyall, A | 1 |
| Saxena, S | 1 |
| Bansal, A | 1 |
| Costa, NM | 1 |
| Rodrigues, H | 1 |
| Pereira, H | 1 |
| Pardal, F | 1 |
| Matos, E | 1 |
| Noguchi, T | 2 |
| Tanimoto, K | 1 |
| Shimokuni, T | 1 |
| Ukon, K | 1 |
| Tsujimoto, H | 2 |
| Kawahara, K | 1 |
| Hiyama, K | 1 |
| Nishiyama, M | 1 |
| Denis, F | 1 |
| Desbiez-Bourcier, AV | 1 |
| Chapiron, C | 1 |
| Arbion, F | 1 |
| Body, G | 2 |
| Brunereau, L | 1 |
| Inoue, Y | 1 |
| Shirane, M | 1 |
| Miki, C | 1 |
| Hiro, J | 1 |
| Yanagi, H | 1 |
| Rahman, R | 1 |
| Latonen, L | 1 |
| Wiman, KG | 1 |
| Lukaschek, J | 1 |
| Nufer, M | 1 |
| Maurer, D | 1 |
| Asanger, M | 1 |
| Honegger, H | 1 |
| Widmer, L | 1 |
| Malet-Martino, M | 1 |
| Legay, R | 1 |
| Martino, R | 1 |
| Popiela, T | 2 |
| Kulig, J | 2 |
| Czupryna, A | 1 |
| Szczepanik, AM | 1 |
| Zembala, M | 1 |
| Wofford, M | 1 |
| Castleberry, RP | 1 |
| Swanson, GP | 1 |
| London, WB | 1 |
| Fontanesi, J | 1 |
| Pappo, AS | 1 |
| Douglass, EC | 2 |
| Kecmanovic, DM | 1 |
| Pavlov, MJ | 1 |
| Ceranic, MS | 1 |
| Sepetkovski, AV | 1 |
| Kovacevic, PA | 1 |
| Stamenkovic, AB | 1 |
| Yasuno, M | 1 |
| Mori, T | 2 |
| Koike, M | 1 |
| Takahashi, K | 1 |
| Takizawa, T | 1 |
| Shimizu, S | 1 |
| Yamaguchi, T | 1 |
| Matsumoto, H | 1 |
| Budach, W | 1 |
| Baumann, M | 1 |
| Geismar, D | 1 |
| Grabenbauer, G | 1 |
| Lammert, I | 1 |
| Stueben, G | 1 |
| Herrmann, T | 1 |
| Bamberg, M | 1 |
| Wust, P | 1 |
| Hinkelbein, W | 1 |
| Wernecke, KD | 1 |
| Alieva, SB | 1 |
| Tkachëv, SI | 1 |
| Matiakin, EG | 1 |
| Kondrat'eva, AP | 1 |
| Zimina, NA | 1 |
| Sakharovskaia, VG | 1 |
| Iachmeneva, NF | 1 |
| Romanov, IS | 1 |
| Chun, JH | 1 |
| Kim, HK | 1 |
| Hwangbo, B | 1 |
| Lee, HG | 1 |
| Park, SR | 1 |
| Choi, IJ | 1 |
| Kim, CG | 1 |
| Ryu, KW | 1 |
| Kim, YW | 1 |
| Bae, JM | 1 |
| Iwata, H | 1 |
| Nakamura, S | 1 |
| Shin, E | 1 |
| Masuda, N | 1 |
| Ohno, S | 2 |
| Takatsuka, Y | 2 |
| Hisamatsu, K | 1 |
| Yamazaki, K | 1 |
| Kusama, M | 1 |
| Kaise, H | 1 |
| Sato, Y | 3 |
| Kuroi, K | 1 |
| Akiyama, F | 1 |
| Tsuda, H | 1 |
| Kurosumi, M | 1 |
| Comella, P | 2 |
| Palmeri, S | 4 |
| Lucia, LD | 1 |
| Natale, D | 1 |
| Maiorino, L | 1 |
| Tafuto, S | 1 |
| Cataldis, GD | 1 |
| Casaretti, R | 3 |
| Gebbia, V | 7 |
| Giuliani, F | 1 |
| Paoletti, G | 1 |
| Gebbia, N | 5 |
| Borsellino, N | 1 |
| Cartenì, G | 1 |
| Pezzella, G | 2 |
| Romito, S | 1 |
| Lopez, M | 1 |
| Izawa, H | 1 |
| Damdinsuren, B | 1 |
| Ikeda, K | 1 |
| Tsujie, M | 1 |
| Suzuki, R | 1 |
| Kitani, K | 1 |
| Seki, Y | 1 |
| Hayashi, T | 1 |
| Takemasa, I | 1 |
| Ikeda, M | 3 |
| Ohue, M | 1 |
| Sekimoto, M | 1 |
| Monden, T | 2 |
| Monden, M | 1 |
| Di Battista, M | 1 |
| Derenzini, E | 1 |
| Liberale, G | 1 |
| Sabourin, JC | 2 |
| Park, SH | 1 |
| Bang, SM | 1 |
| Cho, EK | 1 |
| Shin, DB | 1 |
| Lee, JH | 2 |
| Lee, WK | 1 |
| Chung, M | 1 |
| Wong, DH | 1 |
| Chan, EW | 1 |
| Yeung, RM | 1 |
| Tong, M | 1 |
| Soong, IS | 1 |
| Pang, ES | 2 |
| O, SK | 1 |
| Zheng, W | 1 |
| Di Genova, G | 1 |
| Savellini, GG | 1 |
| La Placa, M | 1 |
| Terrosi, C | 1 |
| Vestri, M | 1 |
| Urso, R | 1 |
| Lemonnier, F | 1 |
| Aquino, A | 2 |
| Bonmassar, E | 1 |
| Giorgi, G | 2 |
| Cusi, MG | 2 |
| Ng, WM | 1 |
| Lui, WM | 1 |
| Wei, W | 1 |
| Au, G | 1 |
| Haimi, M | 1 |
| Arush, MW | 1 |
| Bar-Sela, G | 1 |
| Gez, E | 1 |
| Bernstein, Z | 1 |
| Postovsky, S | 1 |
| Barak, AB | 1 |
| Kuten, A | 1 |
| Videnovic, A | 1 |
| Semenov, I | 1 |
| Chua-Adajar, R | 1 |
| Baddi, L | 1 |
| Blumenthal, DT | 1 |
| Beck, AC | 1 |
| Simuni, T | 1 |
| Futterer, S | 1 |
| Gradishar, W | 1 |
| Tellez, C | 1 |
| Raizer, JJ | 1 |
| Martus, P | 2 |
| Papadoupolos, T | 1 |
| Füzesi, L | 1 |
| Klimpfinger, M | 1 |
| Hohenberger, W | 1 |
| Raab, R | 1 |
| Farrell, PJ | 1 |
| Douek, M | 1 |
| Tobias, J | 1 |
| Bujko, K | 1 |
| Nowacki, MP | 1 |
| Nasierowska-Guttmejer, A | 1 |
| Kepka, L | 1 |
| Winkler-Spytkowska, B | 1 |
| Suwiński, R | 1 |
| Oledzki, J | 1 |
| Stryczyńska, G | 1 |
| Wieczorek, A | 1 |
| Serkies, K | 1 |
| Rogowska, D | 1 |
| Tokar, P | 1 |
| Prausová, J | 1 |
| Kubácková, K | 1 |
| Linke, Z | 1 |
| Kubala, E | 1 |
| Pipková, R | 1 |
| Hladíková, J | 1 |
| Barbado, M | 1 |
| Preisser, L | 1 |
| Boisdron-Celle, M | 1 |
| Verriele, V | 1 |
| Lorimier, G | 1 |
| Gamelin, E | 1 |
| Morel, A | 1 |
| Recchia, F | 1 |
| Saggio, G | 1 |
| Amiconi, G | 1 |
| Di Blasio, A | 1 |
| Cesta, A | 1 |
| Candeloro, G | 1 |
| Rea, S | 1 |
| Izzo, JG | 1 |
| Malhotra, U | 1 |
| Ensor, J | 1 |
| Luthra, R | 1 |
| Swisher, SG | 1 |
| Liao, Z | 1 |
| Chao, KS | 1 |
| Hittelman, WN | 1 |
| Aggarwal, BB | 1 |
| Khader, A | 1 |
| Gritli, S | 1 |
| Boussen, I | 1 |
| Oueslati, Z | 1 |
| Ferjaoui, M | 1 |
| Nouira, R | 1 |
| Ladgham, A | 1 |
| Boussen, H | 2 |
| Koppe, MJ | 1 |
| Boerman, OC | 1 |
| Oyen, WJ | 1 |
| Curtis, BR | 1 |
| Kaliszewski, J | 1 |
| Marques, MB | 1 |
| Nabelle, L | 1 |
| Blank, J | 1 |
| McFarland, JG | 1 |
| Aster, RH | 1 |
| Ceelen, WP | 1 |
| Okita, A | 1 |
| Tsukuda, K | 1 |
| Murakami, M | 1 |
| Ota, T | 1 |
| Doihara, H | 1 |
| Suda, M | 1 |
| Nakano, T | 1 |
| Matsuoka, K | 1 |
| Suzuki, E | 1 |
| Naito, M | 1 |
| Andou, A | 1 |
| Shimizu, N | 1 |
| Nieto, Y | 1 |
| Santisteban, M | 1 |
| Aramendía, JM | 1 |
| Fernández-Hidalgo, O | 1 |
| García-Manero, M | 1 |
| López, G | 1 |
| Ducreux, MP | 1 |
| Leboulleux, S | 1 |
| Kergoat, P | 1 |
| Dromain, C | 1 |
| de Baere, T | 1 |
| Duvillard, P | 1 |
| Schlumberger, M | 3 |
| Baudin, E | 1 |
| Kobayashi, K | 1 |
| Tsuji, A | 1 |
| Morita, S | 2 |
| Horimi, T | 1 |
| Shirasaka, T | 1 |
| Kanematsu, T | 1 |
| Cassidy, J | 2 |
| Khanna, A | 1 |
| Walker, GR | 1 |
| Livingstone, AS | 1 |
| Arheart, KL | 1 |
| Rocha-Lima, C | 1 |
| Koniaris, LG | 1 |
| Shirado, A | 1 |
| Uto, H | 1 |
| Kusumoto, K | 1 |
| Kurogi, J | 1 |
| Sakamoto, H | 1 |
| Hasuike, S | 1 |
| Nagata, K | 1 |
| Hayashi, K | 1 |
| Iwamitsu, A | 1 |
| Hori, T | 1 |
| Ibusuki, K | 1 |
| Ido, A | 1 |
| Tsubouchi, H | 1 |
| Antonini, NF | 2 |
| Douma, J | 1 |
| Wals, J | 1 |
| Honkoop, AH | 1 |
| Erdkamp, FL | 2 |
| de Jong, RS | 1 |
| Rodenburg, CJ | 2 |
| Vreugdenhil, G | 1 |
| Akkermans-Vogelaar, JM | 1 |
| Levy, DE | 1 |
| Pierard, S | 1 |
| Gregoire, V | 1 |
| Weynand, B | 1 |
| Machiels, JP | 1 |
| Xu, SL | 1 |
| Kwan, WH | 2 |
| Chan, PT | 1 |
| Liu, XF | 1 |
| Murillo-Ortiz, B | 1 |
| Astudillo-De la Vega, H | 1 |
| Castillo-Medina, S | 1 |
| Malacara, JM | 1 |
| Benitez-Bribiesca, L | 1 |
| Tempestini, A | 1 |
| Caciagli, B | 1 |
| Morganti, M | 1 |
| Witort, E | 1 |
| Nobili, S | 1 |
| Papucci, L | 1 |
| Schiavone, N | 1 |
| Donnini, M | 1 |
| Landini, I | 1 |
| Lapucci, A | 1 |
| Perna, F | 1 |
| Lulli, M | 1 |
| Mazzei, T | 1 |
| Sobrero, A | 1 |
| Mini, E | 1 |
| Capaccioli, S | 1 |
| Ichikawa, W | 1 |
| Leonard, R | 1 |
| O'Shaughnessy, J | 1 |
| Vukelja, S | 1 |
| Gorbounova, V | 1 |
| Chan-Navarro, CA | 1 |
| Maraninchi, D | 1 |
| Barak-Wigler, N | 1 |
| McKendrick, JJ | 1 |
| Harker, WG | 1 |
| Bexon, AS | 1 |
| Twelves, C | 1 |
| Zurabiani, TA | 1 |
| Charkviani, LI | 1 |
| Gersamia, GK | 1 |
| Huang, CJ | 1 |
| Lin, SD | 1 |
| Chuang, HY | 1 |
| Fu, OY | 1 |
| Lian, SL | 1 |
| Allen, JA | 1 |
| Adlakha, A | 1 |
| Bergethon, PR | 1 |
| Li, M | 1 |
| Zhou, S | 1 |
| Li, P | 1 |
| McNutt, MA | 1 |
| Amatori, F | 1 |
| Di Paolo, A | 1 |
| Del Tacca, M | 1 |
| Fontanini, G | 1 |
| Vannozzi, F | 1 |
| Boldrini, L | 1 |
| Bocci, G | 1 |
| Lastella, M | 1 |
| Kaufmann, P | 1 |
| Dauphine, CE | 1 |
| Vargas, MP | 1 |
| Burla, ML | 1 |
| Isaac, NM | 1 |
| Gonzalez, KD | 1 |
| Rosing, D | 1 |
| Vargas, HI | 1 |
| Rocca, A | 1 |
| Peruzzotti, G | 1 |
| Ghisini, R | 1 |
| Pietri, E | 1 |
| Curigliano, G | 1 |
| Giovanardi, F | 1 |
| Maisonneuve, P | 1 |
| Raynard, B | 2 |
| Rouquie, D | 1 |
| Ciuchendea, R | 1 |
| Mariani, G | 1 |
| Petrelli, F | 1 |
| Zambetti, M | 2 |
| Moliterni, A | 1 |
| Fasolo, A | 1 |
| Marchiano, A | 1 |
| Resnik, KS | 1 |
| DiLeonardo, M | 1 |
| Gibbons, G | 1 |
| Gennatas, C | 1 |
| Papaxoinis, G | 1 |
| Mouratidou, D | 1 |
| Andreadis, C | 1 |
| Tsavaris, N | 1 |
| Pafiti, A | 1 |
| Lowy, AM | 1 |
| Firdaus, I | 1 |
| Roychowdhury, D | 1 |
| Redmond, K | 1 |
| Howington, JA | 1 |
| Sussman, JJ | 1 |
| Safa, M | 1 |
| Ahmad, SA | 1 |
| Reed, MF | 1 |
| Rose, P | 1 |
| James, L | 1 |
| Jazieh, AR | 1 |
| Stadler, P | 1 |
| Putnik, K | 1 |
| Kreimeyer, T | 1 |
| Sprague, LD | 1 |
| Koelbl, O | 1 |
| Schäfer, C | 1 |
| Kanoh, T | 1 |
| Ohnishi, T | 1 |
| Tono, T | 2 |
| Takemoto, H | 1 |
| Shiozaki, K | 1 |
| Kimura, Y | 1 |
| Iwazawa, T | 1 |
| Nakano, Y | 1 |
| Yano, H | 1 |
| Tegze, B | 1 |
| Tulassay, Z | 1 |
| Gyôrffy, B | 1 |
| Taomoto, J | 1 |
| Yoshida, K | 1 |
| Wada, Y | 1 |
| Tanabe, K | 1 |
| Konishi, K | 1 |
| Tahara, H | 1 |
| Pérez, J | 1 |
| Rodríguez, MJ | 1 |
| Campaña, O | 1 |
| Veiras, S | 1 |
| Lorenzo, D | 1 |
| Lamas, M | 1 |
| Alvarez, J | 1 |
| Blot, F | 1 |
| Billard, V | 1 |
| Kohneh-Shahri, N | 1 |
| Sameshima, S | 1 |
| Horikoshi, H | 1 |
| Tomozawa, S | 1 |
| Hirayama, I | 1 |
| Sawada, T | 1 |
| Ember, A | 1 |
| Yousuf, AF | 1 |
| Kalmár, K | 1 |
| Papp, A | 1 |
| Esik, O | 1 |
| Tang, XY | 1 |
| Zhu, YQ | 1 |
| Tao, WH | 1 |
| Wei, B | 1 |
| Lin, XL | 1 |
| Bijelic, L | 1 |
| Yan, TD | 1 |
| Kerbrat, P | 1 |
| Roché, H | 1 |
| Bonneterre, J | 1 |
| Veyret, C | 1 |
| Lortholary, A | 1 |
| Monnier, A | 1 |
| Fumoleau, P | 1 |
| Fargeot, P | 1 |
| Namer, M | 1 |
| Chollet, P | 2 |
| Goudier, MJ | 1 |
| Audhuy, B | 1 |
| Simon, H | 1 |
| Montcuquet, P | 1 |
| Eymard, JC | 1 |
| Walter, S | 1 |
| Clavère, P | 2 |
| Guastalla, JP | 1 |
| Emmanouilides, C | 1 |
| Sfakiotaki, G | 1 |
| Androulakis, N | 1 |
| Kalbakis, K | 1 |
| Christophylakis, C | 1 |
| Kalykaki, A | 1 |
| Vamvakas, L | 1 |
| Kotsakis, A | 1 |
| Agelaki, S | 1 |
| Diamandidou, E | 1 |
| Touroutoglou, N | 1 |
| Chatzidakis, A | 1 |
| Souglakos, J | 1 |
| Zhang, S | 1 |
| Ding, F | 1 |
| Luo, A | 1 |
| Chen, A | 1 |
| Yu, Z | 1 |
| Ren, S | 1 |
| Ekenel, M | 1 |
| Hormigo, AM | 1 |
| Peak, S | 1 |
| Deangelis, LM | 1 |
| Abrey, LE | 1 |
| Folprecht, G | 1 |
| Köhne, CH | 1 |
| Lutz, MP | 2 |
| Vázquez-Bayo, C | 1 |
| Rodríguez-Bujaldón, AL | 1 |
| Jiménez-Puya, R | 1 |
| Galán-Gutiérrez, M | 1 |
| Moreno-Giménez, JC | 1 |
| Gao, JM | 1 |
| Gao, YH | 1 |
| Zhang, H | 2 |
| Li, YM | 1 |
| Kusaba, H | 1 |
| Shibata, Y | 1 |
| Arita, S | 1 |
| Ariyama, H | 1 |
| Baba, E | 1 |
| Mitsugi, K | 1 |
| Harada, M | 1 |
| Nakano, S | 1 |
| Loven, D | 1 |
| Be'ery, E | 1 |
| Yerushalmi, R | 1 |
| Koren, C | 1 |
| Sulkes, A | 1 |
| Lavi, I | 1 |
| Shaked, Y | 1 |
| Fenig, E | 1 |
| Li, CM | 1 |
| Ninomiya, M | 1 |
| Kondo, K | 1 |
| Matsuo, K | 1 |
| Hirabayashi, N | 1 |
| Kojima, H | 1 |
| Kawamura, S | 1 |
| Ando, T | 2 |
| Musha, N | 1 |
| Konno, H | 1 |
| Nagata, N | 1 |
| Usuki, H | 1 |
| Miyashita, Y | 1 |
| Oba, K | 1 |
| Sakamoto, J | 1 |
| Topkan, E | 1 |
| Karaoglu, A | 1 |
| Czaykowski, PM | 1 |
| Jiang, AC | 1 |
| Dong, P | 1 |
| Wan, Y | 1 |
| Yu, ZW | 1 |
| Liu, J | 1 |
| Li, X | 1 |
| Cheng, YN | 1 |
| Cui, SX | 1 |
| Xu, WF | 1 |
| Tian, ZG | 1 |
| Makuuchi, M | 1 |
| Tang, W | 1 |
| Qu, XJ | 1 |
| Cho, YH | 1 |
| Lee, SH | 1 |
| Kim, DW | 1 |
| Wu, HG | 3 |
| Hah, JH | 1 |
| Rhee, CS | 1 |
| Sung, MW | 3 |
| Kim, KH | 3 |
| Heo, DS | 3 |
| Benjapibal, M | 1 |
| Thirapakawong, C | 1 |
| Leelaphatanadit, C | 1 |
| Therasakvichya, S | 1 |
| Inthasorn, P | 1 |
| Dafni, U | 1 |
| Linardou, H | 1 |
| Briasoulis, E | 1 |
| Samantas, E | 1 |
| Stathopoulos, GP | 1 |
| Karina, M | 1 |
| Papadimitriou, C | 1 |
| Pisanidis, N | 1 |
| Markopoulos, C | 1 |
| Tzorakoeleftherakis, E | 1 |
| Dimitrakakis, K | 1 |
| Makrantonakis, P | 1 |
| Xiros, N | 1 |
| Polichronis, A | 1 |
| Karanikiotis, C | 1 |
| Dimopoulos, AM | 1 |
| Ponzanelli, A | 1 |
| Vigo, V | 1 |
| Marcenaro, M | 1 |
| Bacigalupo, A | 1 |
| Gatteschi, B | 1 |
| Ravetti, JL | 1 |
| Corvò, R | 3 |
| Benasso, M | 2 |
| Cohen, MS | 1 |
| Triaca, V | 1 |
| Billmeyer, B | 1 |
| Hanley, RS | 1 |
| Girshovich, L | 1 |
| Shuster, T | 1 |
| Oberfield, RA | 1 |
| Zinman, L | 1 |
| Gluz, O | 1 |
| Nitz, UA | 1 |
| Ting, E | 1 |
| Kates, R | 1 |
| Herr, A | 1 |
| Lindemann, W | 1 |
| Jackisch, C | 1 |
| Berdel, WE | 1 |
| Kirchner, H | 1 |
| Metzner, B | 1 |
| Werner, F | 1 |
| Schütt, G | 1 |
| Frick, M | 1 |
| Poremba, C | 1 |
| Diallo-Danebrock, R | 1 |
| Mohrmann, S | 1 |
| Ishiguro, H | 1 |
| Kuwabara, Y | 1 |
| Mitsui, A | 1 |
| Sugito, N | 1 |
| Mori, R | 1 |
| Ogawa, R | 1 |
| Katada, T | 1 |
| Fujii, Y | 1 |
| Schmid, P | 1 |
| Kühnhardt, D | 1 |
| Kiewe, P | 1 |
| Schippinger, W | 1 |
| Greil, R | 1 |
| Lange, W | 1 |
| Preiss, J | 1 |
| Niederle, N | 1 |
| Brossart, P | 1 |
| Freier, W | 1 |
| Kümmel, S | 1 |
| Van de Velde, H | 1 |
| Regierer, A | 1 |
| Kwon, HC | 1 |
| Lee, DM | 1 |
| Yoo, HS | 1 |
| Jang, JS | 1 |
| Kim, MC | 1 |
| Jeong, JS | 1 |
| Kim, HJ | 1 |
| Jo, JC | 1 |
| Lee, JL | 1 |
| Sym, SJ | 1 |
| Lee, SS | 1 |
| Chang, HM | 2 |
| Song, CH | 1 |
| Park, CI | 2 |
| Kang, HJ | 1 |
| Sohn, HJ | 1 |
| Oh, ST | 1 |
| Creemers, GJ | 1 |
| Schrama, JG | 1 |
| Vos, AH | 1 |
| Mol, L | 1 |
| Rosa, DD | 1 |
| Awada, A | 1 |
| Mano, MS | 1 |
| Selleslags, J | 1 |
| Lebrun, F | 1 |
| Gil, T | 1 |
| Piccart, MJ | 1 |
| D'Hondt, V | 1 |
| Li, LF | 1 |
| Xu, XJ | 1 |
| Liu, ZB | 1 |
| Shen, ZZ | 1 |
| Jin, WR | 1 |
| Lau, KY | 1 |
| Chan, CC | 1 |
| Cheng, PT | 1 |
| Benedix, F | 1 |
| Schmidt, C | 1 |
| Schulz, HU | 1 |
| Lippert, H | 1 |
| Meyer, F | 1 |
| Pech, M | 1 |
| Traina, TA | 1 |
| Theodoulou, M | 1 |
| Feigin, K | 1 |
| Patil, S | 1 |
| Tan, KL | 1 |
| Edwards, C | 2 |
| Dugan, U | 1 |
| Norton, L | 2 |
| Hudis, C | 1 |
| Fabrício, Vde C | 1 |
| Amado, F | 1 |
| Del Giglio, A | 1 |
| Qin, L | 1 |
| Weng, GX | 1 |
| Li, MZ | 1 |
| Kong, QL | 1 |
| Zeng, YX | 1 |
| Liao, DF | 1 |
| Song, LB | 1 |
| Beriwal, S | 1 |
| Coon, D | 1 |
| Heron, DE | 1 |
| Kelley, JL | 1 |
| Edwards, RP | 1 |
| Sukumvanich, P | 1 |
| Zorn, KK | 1 |
| Krivak, TC | 1 |
| Kaufman, JJ | 1 |
| Langdon, EA | 1 |
| Stein, JJ | 1 |
| Burt, FB | 1 |
| Brocard, H | 1 |
| Akoun, G | 1 |
| Turpin, G | 1 |
| Gendre, JP | 1 |
| Szepesi, T | 1 |
| Szalay, S | 1 |
| Breitenecker, G | 1 |
| Schratter-Sehn, A | 1 |
| Rogan, AM | 1 |
| Riss, T | 1 |
| Wittich, G | 1 |
| Heckenthaler, W | 1 |
| Fasching, W | 1 |
| Scheiber, V | 1 |
| Dolnick, BJ | 1 |
| Pink, JJ | 1 |
| Markman, M | 1 |
| Presant, CA | 1 |
| Ardalan, B | 1 |
| Multhauf, P | 1 |
| Chan, C | 1 |
| Staples, R | 1 |
| Green, L | 1 |
| Browning, S | 1 |
| Carr, BI | 1 |
| Chang, FF | 1 |
| Thayer, W | 1 |
| Bukowski, RM | 1 |
| Hermann, RE | 1 |
| Theodors, A | 1 |
| deKernion, JB | 1 |
| Konno, A | 1 |
| Togawa, K | 1 |
| Carmo-Pereira, J | 1 |
| Costa, FO | 1 |
| Henriques, E | 1 |
| Ricardo, JA | 1 |
| Kopper, L | 2 |
| Magyarosy, E | 1 |
| Jeney, A | 1 |
| Lapis, K | 1 |
| Szabolcs, A | 1 |
| Otvös, L | 1 |
| Teufel, G | 1 |
| Kiseleva, ES | 1 |
| Pitskhelauri, VG | 1 |
| Trakhtenberg, AKh | 1 |
| Bidiak, IP | 1 |
| Zholkiver, KI | 1 |
| Kano, T | 1 |
| Kumashiro, R | 1 |
| Masuda, H | 1 |
| Tamada, R | 1 |
| Inokuchi, K | 1 |
| Bruntsch, U | 1 |
| Gallmeier, WM | 1 |
| Ray, GR | 1 |
| Fish, VJ | 1 |
| Marmor, JB | 1 |
| Rogoway, W | 1 |
| Kushlan, P | 1 |
| Arnold, C | 1 |
| Lee, RH | 1 |
| Marzoni, F | 1 |
| Akiyoshi, T | 1 |
| Kawaguchi, M | 1 |
| Arinaga, S | 1 |
| Miyazaki, S | 1 |
| Koba, F | 1 |
| Wada, T | 1 |
| Tsuji, H | 1 |
| Shlemkevich, MP | 2 |
| Shiian, DN | 4 |
| Berger, SH | 1 |
| Hakala, MT | 3 |
| Tashiro, K | 1 |
| Machida, T | 1 |
| Masuda, F | 1 |
| Ohishi, Y | 1 |
| Moresco, L | 1 |
| Quidaciolu, F | 1 |
| Ingravaglieri, E | 1 |
| Sorice, G | 1 |
| Yin, MB | 1 |
| Zakrzewski, SF | 1 |
| Gnatyshak, AI | 2 |
| Grigorova, TM | 1 |
| Vartanian, LG | 1 |
| Marenich, AF | 1 |
| Narisawa, T | 1 |
| Tani, M | 1 |
| Takahashi, T | 3 |
| Greco, FA | 2 |
| Julian, CG | 1 |
| Richardson, RL | 1 |
| Burnett, L | 1 |
| Hande, KR | 2 |
| Oldham, RK | 1 |
| Montague, ED | 2 |
| Barker, JL | 1 |
| Blumenschein, GR | 2 |
| Arakawa, M | 1 |
| Shimizu, F | 1 |
| Sasagawa, K | 1 |
| Inomata, T | 1 |
| Shinkai, K | 1 |
| Blokhina, NG | 1 |
| Sorokina, GA | 1 |
| Casper, ES | 1 |
| Vale, K | 1 |
| Williams, LJ | 1 |
| Martin, DS | 1 |
| Young, CW | 1 |
| Cummings, BJ | 1 |
| Servadio, C | 1 |
| Mukamel, E | 1 |
| Lurie, H | 1 |
| Nissenkorn, I | 1 |
| Israël, L | 4 |
| Lepage, E | 1 |
| Breau, JL | 2 |
| Aguilera, J | 1 |
| Lee, YT | 1 |
| Evans, RM | 1 |
| Laskin, JD | 1 |
| Green, SJ | 1 |
| Edmonson, JH | 1 |
| Jefferies, JA | 1 |
| Webb, MJ | 1 |
| Aroney, RS | 1 |
| Levi, JA | 1 |
| Dalley, DN | 1 |
| Miller, AB | 1 |
| Klaassen, DJ | 2 |
| Boyes, DA | 1 |
| Dodds, DJ | 1 |
| Gerulath, A | 1 |
| Kirk, ME | 1 |
| Levitt, M | 1 |
| Pearson, JG | 1 |
| Wall, C | 1 |
| Gewirtz, AM | 1 |
| Cadman, E | 2 |
| Weiss, GR | 2 |
| Ervin, TJ | 1 |
| Meshad, MW | 1 |
| Kufe, DW | 1 |
| Herr, HW | 1 |
| Zylberberg, B | 1 |
| Salat-Baroux, J | 1 |
| Ravina, JH | 1 |
| Dormont, D | 1 |
| Amiel, JP | 1 |
| Diebold, P | 1 |
| Izrael, V | 1 |
| Harvey, HA | 1 |
| Lipton, A | 1 |
| Lawrence, BV | 1 |
| White, DS | 1 |
| Wells, SA | 1 |
| Blumenschein, G | 1 |
| Lee, D | 1 |
| Sorbe, B | 1 |
| Frankendal, B | 1 |
| Gutsche, W | 1 |
| Wohlrabe, K | 1 |
| Jungstand, W | 1 |
| Fleck, WF | 1 |
| Huguier, M | 1 |
| Destroyes, JP | 1 |
| Baschet, C | 1 |
| Le Henand, F | 1 |
| Bernard, PF | 1 |
| Benz, C | 1 |
| Schoenberg, M | 1 |
| Choti, M | 1 |
| Kamphuis, JT | 1 |
| Huider, MC | 1 |
| Ras, GJ | 1 |
| Verhagen, CA | 1 |
| Kateman, I | 1 |
| Vreeswijk, JH | 1 |
| Burghouts, JT | 1 |
| Untch, M | 1 |
| Pache, L | 1 |
| Eiermann, W | 1 |
| Weissman, DE | 1 |
| Gedney, C | 1 |
| Chambers, SK | 1 |
| Lamb, L | 1 |
| Schwartz, PE | 1 |
| Chambers, JT | 1 |
| Callari, A | 1 |
| Testa, A | 3 |
| Cusimano, MP | 1 |
| Cipolla, C | 1 |
| Amato, C | 1 |
| Cannata, G | 1 |
| Latteri, MA | 1 |
| Garascia, C | 1 |
| Allen, BJ | 1 |
| Parker, D | 1 |
| Wright, AL | 1 |
| Dogliotti, L | 2 |
| Berruti, A | 1 |
| Pia, A | 1 |
| Paccotti, P | 1 |
| Alì, A | 1 |
| Angeli, A | 1 |
| Reich, DS | 1 |
| Palmer, CA | 1 |
| Peters, GE | 1 |
| Schwartz, EL | 2 |
| Baptiste, N | 1 |
| Megati, S | 1 |
| Wadler, S | 5 |
| Otter, BA | 1 |
| Zerillo, G | 2 |
| Restivo, G | 1 |
| Speciale, R | 1 |
| Cupido, G | 1 |
| Lo Bue, P | 1 |
| Ingria, F | 2 |
| Gallina, S | 1 |
| Spatafora, G | 2 |
| Barberi-Heyob, M | 2 |
| Merlin, JL | 2 |
| Vigneron, M | 1 |
| Conroy, T | 1 |
| Bondar', GV | 1 |
| Zabudkin, AF | 1 |
| Bukhteev, SV | 1 |
| Imai, T | 1 |
| Kodama, S | 1 |
| Yanase, T | 1 |
| Ikarashi, H | 1 |
| Kazama, Y | 1 |
| Look, KY | 2 |
| Muss, HB | 3 |
| Blessing, JA | 2 |
| Morris, M | 2 |
| Romani, R | 1 |
| Dhot, PS | 1 |
| Sharma, MC | 1 |
| Kumar, L | 1 |
| Saxena, R | 1 |
| Sataloff, DM | 1 |
| Mason, BA | 1 |
| Prestipino, AJ | 1 |
| Seinige, UL | 1 |
| Lieber, CP | 1 |
| Baloch, Z | 1 |
| Chandrasekaran, B | 1 |
| Kute, TE | 1 |
| Duch, DS | 1 |
| Kawai, M | 1 |
| Kikkawa, F | 1 |
| Hattori, S | 1 |
| Ohta, M | 2 |
| Arii, Y | 1 |
| Tomoda, Y | 1 |
| Pratt, CB | 2 |
| Meyer, WH | 1 |
| Howlett, N | 1 |
| Bowman, LC | 1 |
| Poe, D | 1 |
| Mounce, K | 1 |
| Kun, LE | 1 |
| Houghton, JA | 1 |
| Fine, S | 1 |
| Erlichman, C | 1 |
| Kaizer, L | 1 |
| Warr, D | 1 |
| Gadalla, T | 1 |
| Laccourreye, O | 1 |
| Weinstein, G | 1 |
| Brasnu, D | 2 |
| Bassot, V | 2 |
| Cauchois, R | 1 |
| Jouffre, V | 1 |
| Garcia, D | 1 |
| Laccourreye, H | 2 |
| Cocconi, G | 2 |
| Bella, M | 1 |
| Zironi, S | 1 |
| Algeri, R | 1 |
| Di Costanzo, F | 2 |
| De Lisi, V | 2 |
| Luppi, G | 1 |
| Mazzocchi, B | 1 |
| Rodinò, C | 2 |
| Soldani, M | 2 |
| Resbeut, M | 1 |
| Cowen, D | 1 |
| Viens, P | 1 |
| Noirclerc, M | 1 |
| Perez, T | 1 |
| Gouvernet, J | 1 |
| Delpero, JR | 1 |
| Gamerre, M | 1 |
| Boubli, L | 1 |
| Houvenaeghel, G | 1 |
| Castoldi, MC | 1 |
| Dellafiore, L | 1 |
| Pancera, G | 1 |
| Panzer, M | 1 |
| Hültenschmidt, B | 1 |
| Döker, R | 1 |
| Huber, K | 1 |
| Kuhne-Velte, HJ | 1 |
| Hutter, M | 1 |
| Rühl, U | 1 |
| Wendt, T | 2 |
| Okuyama, T | 1 |
| Maehara, Y | 1 |
| Adachi, Y | 1 |
| Kuwano, M | 1 |
| Sugimachi, K | 1 |
| Yu, KH | 1 |
| Teo, PM | 3 |
| Lee, WY | 2 |
| Choi, PH | 2 |
| Johnson, PJ | 3 |
| Forman, WB | 1 |
| Rastogi, N | 1 |
| Chag, M | 1 |
| Ayyagari, S | 1 |
| Prat, F | 1 |
| Sibille, A | 1 |
| Luccioni, C | 1 |
| Pansu, D | 1 |
| Chapelon, JY | 1 |
| Beaumatin, J | 1 |
| Ponchon, T | 1 |
| Cathignol, D | 1 |
| Scheithauer, W | 1 |
| Depisch, D | 1 |
| Kornek, G | 1 |
| Pidlich, J | 1 |
| Rosen, H | 1 |
| Karall, M | 1 |
| Prochaska, M | 1 |
| Ernst, A | 1 |
| Sebesta, C | 1 |
| Eckhardt, S | 1 |
| Velikova, M | 2 |
| Tsvekova, V | 1 |
| Koĭnov, K | 2 |
| Wagner, JP | 1 |
| Mahe, MA | 1 |
| Romestaing, P | 1 |
| Rocher, FP | 1 |
| Berger, C | 1 |
| Trillet-Lenoir, V | 1 |
| Gerard, JP | 1 |
| Brunetti, I | 1 |
| Bertuccelli, M | 1 |
| Cianci, C | 1 |
| Ricci, S | 1 |
| Conte, PF | 3 |
| Milano, G | 3 |
| Fischel, JL | 2 |
| Etienne, MC | 2 |
| Renée, N | 3 |
| Formento, P | 2 |
| Thyss, A | 2 |
| Gaspard, MH | 1 |
| Thill, L | 1 |
| Cupissol, D | 1 |
| Rasi, G | 1 |
| Silecchia, G | 1 |
| Sinibaldi-Vallebona, P | 1 |
| Spaziani, E | 1 |
| Pierimarchi, P | 1 |
| Sivilia, M | 1 |
| Tremiterra, S | 1 |
| Garaci, E | 1 |
| Chen, JA | 1 |
| Balaban, EP | 1 |
| Graham, M | 1 |
| Perkins, S | 1 |
| Sheehan, RG | 1 |
| Frenkel, EP | 1 |
| Ross, M | 1 |
| Bull, J | 1 |
| Pruitt, B | 1 |
| Periman, P | 1 |
| Ruud, C | 1 |
| Yiu, HY | 1 |
| Lee, WM | 1 |
| Rose, PG | 2 |
| Goff, BA | 1 |
| Goodman, A | 1 |
| Muntz, HG | 1 |
| Fuller, AF | 2 |
| Nikrui, N | 1 |
| Rice, LW | 1 |
| Rosen, A | 1 |
| Scher, N | 1 |
| Haraf, D | 1 |
| Panje, WR | 4 |
| de Souza, P | 1 |
| Tomio, L | 1 |
| Zorat, PL | 1 |
| Paccagnella, A | 1 |
| Segati, R | 1 |
| Loreggian, L | 1 |
| Lora, O | 1 |
| Friso, ML | 1 |
| Chiarion-Sileni, V | 1 |
| Favaretto, A | 1 |
| Fede, A | 1 |
| Wiegel, T | 1 |
| Lorenzen, J | 1 |
| Brockmann, WP | 1 |
| Lopez, B | 1 |
| Schwarz, R | 1 |
| Hübener, KH | 1 |
| Park, TK | 1 |
| Lee, SK | 1 |
| Kim, SN | 1 |
| Hwang, TS | 1 |
| Kim, GE | 1 |
| Suh, CO | 1 |
| Loh, JK | 1 |
| Calais, G | 2 |
| Descamps, P | 1 |
| Chapet, S | 1 |
| Turgeon, V | 1 |
| Reynaud-Bougnoux, A | 1 |
| Lemarié, E | 1 |
| Fignon, A | 1 |
| Bougnoux, P | 1 |
| Lansac, J | 1 |
| Hidalgo, OF | 1 |
| Rebollo, J | 1 |
| Vieitez, JM | 1 |
| Bilbao, I | 1 |
| Tangco, E | 1 |
| Abuchaibe, O | 1 |
| Pardo, F | 1 |
| Nio, Y | 1 |
| Tseng, CC | 1 |
| Shiraishi, T | 1 |
| Tsubono, M | 1 |
| Kawabata, K | 1 |
| Masai, Y | 1 |
| Hayashi, H | 1 |
| Fukumoto, M | 1 |
| Nio, M | 1 |
| Smith, RD | 1 |
| Hall, J | 1 |
| Gurney, H | 1 |
| Harnett, PR | 1 |
| Arrigoni, F | 1 |
| Ventriglia, L | 1 |
| Saturno, F | 1 |
| Poletti, EM | 1 |
| Sacco, R | 1 |
| Cao, S | 1 |
| Baccanari, DP | 1 |
| Joyner, SS | 1 |
| Davis, ST | 1 |
| Rustum, YM | 3 |
| Spector, T | 2 |
| Tausch-Treml, R | 1 |
| Baumgart, F | 1 |
| Ziessow, D | 1 |
| Köpf-Maier, P | 1 |
| Bovo, G | 1 |
| Brivio, F | 1 |
| Brenna, A | 1 |
| Fumagalli, L | 1 |
| Perego, P | 1 |
| Brivio, O | 1 |
| Uggeri, F | 1 |
| Lavorato, F | 1 |
| Bratina, G | 1 |
| Denehy, TR | 1 |
| Eastman, R | 1 |
| SanFilippo, L | 1 |
| Gregori, CA | 1 |
| Breen, JL | 1 |
| Bonnefoi, H | 2 |
| Smith, IE | 2 |
| O'Brien, ME | 1 |
| Seymour, MT | 1 |
| Powles, TJ | 1 |
| Allum, WH | 1 |
| Ebbs, S | 1 |
| Baum, M | 1 |
| Eatock, MM | 1 |
| Carlin, W | 1 |
| Dunlop, DJ | 1 |
| Soukop, M | 1 |
| Watson, DG | 1 |
| Haaz, MC | 1 |
| Petrelli, NJ | 3 |
| Rodriguez-Bigas, M | 1 |
| Blumenson, LE | 1 |
| Frank, C | 1 |
| Berghorn, E | 1 |
| Creaven, PJ | 2 |
| Stahl, M | 1 |
| Wilke, H | 1 |
| Fink, U | 1 |
| Walz, MK | 1 |
| Siewert, JR | 1 |
| Molls, M | 1 |
| Fett, W | 1 |
| Makoski, HB | 1 |
| Breuer, N | 1 |
| Schmidt, U | 1 |
| Niebel, W | 1 |
| Eigler, FW | 1 |
| Seeber, S | 1 |
| Thomas, PR | 2 |
| Angelini, F | 1 |
| Cavicchi, F | 1 |
| Gilli, G | 1 |
| Tonato, M | 1 |
| Finardi, C | 1 |
| Chi, KH | 1 |
| Chan, WK | 1 |
| Shu, CH | 2 |
| Law, CK | 1 |
| Chen, SY | 1 |
| Yen, SH | 1 |
| Temeck, BK | 1 |
| Liebmann, JE | 1 |
| Theodossiou, C | 1 |
| Steinberg, SM | 3 |
| Cook, JA | 1 |
| Metz, DC | 1 |
| Shawker, TH | 1 |
| Allegra, CJ | 2 |
| Russo, A | 3 |
| Pass, HI | 1 |
| Landoni, F | 1 |
| Maneo, A | 1 |
| Zanetta, G | 1 |
| Colombo, A | 1 |
| Nava, S | 1 |
| Placa, F | 1 |
| Tancini, G | 1 |
| Mangioni, C | 1 |
| Wilson, RH | 1 |
| Houston, RF | 1 |
| Moorehead, RJ | 1 |
| Feliu, J | 1 |
| González Barón, M | 1 |
| García-Girón, C | 1 |
| Espinosa, E | 1 |
| García-Alfonso, P | 1 |
| Belón, J | 1 |
| Blanco, E | 1 |
| Garrido, P | 1 |
| Ordónez, A | 1 |
| Gómez-Navarro, J | 1 |
| Zamora, P | 1 |
| Suzuki, K | 2 |
| Dozois, RR | 1 |
| Devine, RM | 1 |
| Nelson, H | 1 |
| Weaver, AL | 1 |
| Gunderson, LL | 2 |
| Ilstrup, DM | 1 |
| Plasswilm, L | 1 |
| Seegenschmiedt, MH | 1 |
| Ganssauge, F | 1 |
| Furuse, S | 1 |
| Mizushima, Y | 1 |
| Mino, T | 1 |
| Yoshida, Y | 1 |
| Asou, S | 1 |
| Wakagi, K | 1 |
| Chow, LT | 1 |
| Cakmakli, S | 1 |
| Ersöz, S | 1 |
| Karaayvaz, M | 1 |
| Arat, AR | 1 |
| Yeo, W | 1 |
| Kaern, J | 2 |
| Tropé, C | 2 |
| Sundfoer, K | 1 |
| Kristensen, GB | 1 |
| Roca, E | 1 |
| Pennella, E | 1 |
| Sardi, M | 1 |
| Carraro, S | 1 |
| Barugel, M | 1 |
| Milano, C | 1 |
| Fiorini, A | 1 |
| Giglio, R | 1 |
| Gonzalez, G | 1 |
| Kneitschel, R | 1 |
| Aman, E | 1 |
| Jarentchuk, A | 1 |
| Blajman, C | 1 |
| Nadal, J | 1 |
| Santarelli, MT | 1 |
| Navigante, A | 1 |
| Tsavaris, NB | 1 |
| Tentas, K | 1 |
| Kosmidis, P | 2 |
| Mylonakis, N | 1 |
| Sakelaropoulos, N | 1 |
| Kosmas, C | 1 |
| Lisaios, B | 1 |
| Soumilas, A | 1 |
| Mandrekois, D | 1 |
| Tsetis, A | 1 |
| Klonaris, C | 1 |
| Majello, E | 1 |
| Giuseppe, S | 1 |
| Giotta, F | 1 |
| Riccardi, F | 1 |
| Fortunato, S | 1 |
| Chen, FC | 1 |
| Mackay, JR | 1 |
| Woods, RJ | 1 |
| Del Ferro, E | 1 |
| Ligi, M | 1 |
| Catalano, G | 4 |
| Fox, ME | 1 |
| Lemmon, MJ | 1 |
| Mauchline, ML | 1 |
| Davis, TO | 1 |
| Giaccia, AJ | 1 |
| Minton, NP | 1 |
| Brown, JM | 1 |
| Hagiwara, A | 1 |
| Sawai, K | 1 |
| Sakakura, C | 1 |
| Imanishi, T | 1 |
| Ohgaki, M | 1 |
| Yamazaki, J | 1 |
| Muranishi, S | 1 |
| Yamamoto, A | 1 |
| Giralt, EG | 1 |
| de Crevoisier, R | 1 |
| Mazeron, JJ | 1 |
| Sugamura, K | 1 |
| Makino, M | 1 |
| Shirai, H | 1 |
| Kimura, O | 1 |
| Maeta, M | 1 |
| Itoh, H | 1 |
| Kaibara, N | 1 |
| Webb, A | 2 |
| Cunningham, D | 4 |
| Scarffe, JH | 1 |
| Harper, P | 1 |
| Norman, A | 3 |
| Joffe, JK | 1 |
| Hughes, M | 1 |
| Mansi, J | 1 |
| Findlay, M | 1 |
| Hill, A | 1 |
| Oates, J | 1 |
| Nicolson, M | 1 |
| Hickish, T | 1 |
| O'Brien, M | 1 |
| Iveson, T | 1 |
| Watson, M | 1 |
| Underhill, C | 1 |
| Meehan, M | 1 |
| Hainsworth, JD | 1 |
| Jolivet, J | 1 |
| Birch, R | 1 |
| Hopkins, LG | 1 |
| Fandi, A | 4 |
| Taamma, A | 3 |
| Azli, N | 3 |
| Bachouchi, M | 2 |
| Yanes, B | 1 |
| Armand, JP | 5 |
| Corner, G | 1 |
| Richards, C | 1 |
| Ryan, L | 1 |
| Multani, AS | 1 |
| Pathak, S | 1 |
| Benson, A | 1 |
| Haller, D | 1 |
| Heerdt, BG | 1 |
| Cremona, F | 1 |
| Izzo, F | 1 |
| Ruffolo, F | 1 |
| Palaia, R | 1 |
| Parisi, V | 1 |
| Sanz-Altamira, PM | 1 |
| Spence, LD | 1 |
| Huberman, MS | 1 |
| Posner, MR | 1 |
| Steele, G | 1 |
| Perry, LJ | 1 |
| Stuart, KE | 1 |
| Fonseca, E | 1 |
| Cruz, JJ | 1 |
| Rodríguez, CA | 1 |
| Gómez-Bernal, A | 1 |
| Martín, G | 1 |
| Sánchez, P | 1 |
| Nieto, A | 1 |
| Soria, P | 1 |
| Vega, MJ | 1 |
| Muñoz, A | 1 |
| Pardal, JL | 1 |
| Aranda, E | 1 |
| Cervantes, A | 1 |
| Carrato, A | 1 |
| Antón-Torres, A | 1 |
| Massutí, T | 1 |
| Fernández-Martos, C | 1 |
| Díaz-Rubio, E | 1 |
| Stehman, FB | 1 |
| Bundy, BN | 2 |
| Kucera, PR | 1 |
| Deppe, G | 2 |
| Reddy, S | 1 |
| O'Connor, DM | 1 |
| Demicheli, R | 1 |
| De Candis, D | 1 |
| Antonelli, G | 1 |
| Giacobone, A | 1 |
| Terenziani, M | 1 |
| Laffranchi, A | 1 |
| Garbagnati, F | 1 |
| Biasi, S | 1 |
| Keilholz, L | 1 |
| Kessler, H | 1 |
| Allal, AS | 1 |
| Bieri, S | 1 |
| Miralbell, R | 1 |
| Dulguerov, P | 1 |
| Bardina, A | 1 |
| Lehmann, W | 1 |
| Kurtz, JM | 1 |
| Grandi, AM | 1 |
| Morandi, E | 1 |
| Zanzi, P | 1 |
| Bulgheroni, P | 1 |
| Guasti, L | 1 |
| Bertolini, A | 1 |
| Venco, A | 1 |
| Hess, CF | 1 |
| Heimann, G | 1 |
| Willett, CG | 1 |
| Bandealy, MT | 1 |
| Gonin, R | 1 |
| Loehrer, PJ | 1 |
| Monaco, F | 1 |
| Einhorn, LH | 1 |
| Jouve, M | 1 |
| Asselain, B | 1 |
| Livartowski, A | 1 |
| Beuzeboc, P | 1 |
| Diéras, V | 1 |
| Scholl, S | 1 |
| Dorval, T | 1 |
| Palangié, T | 1 |
| Garcia-Giralt, E | 1 |
| Pouillart, P | 1 |
| Mackean, MJ | 1 |
| Jodrell, DI | 1 |
| Paul, J | 1 |
| Reed, NS | 1 |
| Canney, PA | 1 |
| Yosef, H | 1 |
| Habeshaw, T | 1 |
| Robertson, AG | 1 |
| McInnes, A | 1 |
| Twelves, CJ | 1 |
| Castiglione, M | 1 |
| Bacchi, M | 1 |
| Weber, W | 1 |
| Fey, MF | 1 |
| Pagani, O | 1 |
| Leyvraz, S | 1 |
| Pestalozzi, B | 1 |
| Moehler, M | 1 |
| Dimitrakopoulou-Strauss, A | 1 |
| Gutzler, F | 1 |
| Raeth, U | 1 |
| Strauss, LG | 2 |
| Stremmel, W | 1 |
| Hoffman, PC | 1 |
| Ferguson, MK | 1 |
| Drinkard, LC | 1 |
| Clavero-Fabri, MC | 1 |
| Villing, AL | 1 |
| Fassone, F | 1 |
| Fandi, L | 1 |
| Zarba, J | 1 |
| Julieron, M | 1 |
| Germain, MA | 1 |
| Schwaab, G | 2 |
| Marandas, P | 1 |
| Bourgain, JL | 1 |
| Wibault, P | 3 |
| Luboinski, B | 1 |
| Busse, PM | 1 |
| Ng, A | 1 |
| Recht, A | 1 |
| Pribylová, O | 1 |
| Petruzelka, L | 1 |
| Honová, H | 1 |
| Fischer, J | 1 |
| Bustová, I | 1 |
| Siffnerová, H | 1 |
| Kůta, M | 1 |
| Miller, V | 1 |
| Hacklová, M | 1 |
| Machácek, J | 1 |
| Kohoutek, M | 1 |
| Vodvárka, P | 1 |
| Kyselá, T | 1 |
| Tajblová, J | 1 |
| Suk, J | 1 |
| Dorazilová, V | 1 |
| Dunst, J | 1 |
| Narimatsu, M | 1 |
| Nagayama, Y | 1 |
| Akino, K | 1 |
| Yasuda, M | 1 |
| Yamamoto, T | 2 |
| Yang, TT | 1 |
| Ohtsuru, A | 1 |
| Namba, H | 1 |
| Yamashita, S | 1 |
| Ayabe, H | 1 |
| Niwa, M | 1 |
| Arnaud, JP | 1 |
| Maeda, M | 1 |
| Koike, H | 1 |
| Kasai, H | 1 |
| Pinder, SE | 1 |
| Murray, S | 1 |
| Trihia, H | 1 |
| Elston, CW | 1 |
| Gelber, RD | 1 |
| Lindtner, J | 1 |
| Cortés-Funes, H | 2 |
| Simoncini, E | 1 |
| Byrne, MJ | 1 |
| Golouh, R | 1 |
| Rudenstam, CM | 1 |
| Castiglione-Gertsch, M | 1 |
| Gusterson, BA | 1 |
| Onda, T | 1 |
| Yoshikawa, H | 1 |
| Yasugi, T | 1 |
| Mishima, M | 1 |
| Nakagawa, S | 1 |
| Yamada, M | 1 |
| Matsumoto, K | 1 |
| Taketani, Y | 1 |
| Konishi, I | 1 |
| Nanbu, K | 1 |
| Mandai, M | 1 |
| Tsuruta, Y | 1 |
| Kataoka, N | 1 |
| Nagata, Y | 1 |
| Nakanishi, F | 1 |
| Shijubo, N | 1 |
| Shiratori, M | 1 |
| Honma, S | 1 |
| Zhi, J | 1 |
| Satoh, H | 1 |
| Koss-Twardy, SG | 1 |
| Passe, SM | 1 |
| Patel, IH | 1 |
| Pazdur, R | 3 |
| Kumagai, K | 2 |
| Shimizu, K | 1 |
| Masuo, K | 1 |
| Yamagata, K | 1 |
| Tanaka, T | 1 |
| Evrard, A | 1 |
| Cuq, P | 1 |
| Robert, B | 1 |
| Vian, L | 1 |
| Pèlegrin, A | 1 |
| Cano, JP | 1 |
| Frontini, L | 2 |
| Comella, G | 2 |
| Barni, S | 2 |
| Battelli, N | 1 |
| Zonato, S | 1 |
| Pirovano, M | 1 |
| Cellerino, R | 1 |
| Lu, J | 1 |
| Grigsby, PW | 2 |
| Levenback, C | 1 |
| Stevens, RE | 1 |
| Rotman, M | 1 |
| Gershenson, DM | 1 |
| Mutch, DG | 1 |
| Watkins, EB | 1 |
| Thigpen, JT | 1 |
| Maiman, MA | 1 |
| Clarke-Pearson, DL | 1 |
| Insalaco, S | 1 |
| Samonis, G | 1 |
| Katsifis, G | 1 |
| Bakoyiannis, C | 1 |
| Guzel, Z | 1 |
| Bedford, JL | 1 |
| Childs, PJ | 1 |
| Nahum, AE | 1 |
| Webb, S | 1 |
| Oldham, M | 1 |
| Tait, D | 1 |
| Kern, W | 1 |
| Braess, J | 1 |
| Böttger, B | 1 |
| Kaufmann, CC | 1 |
| Hiddemann, W | 1 |
| Schleyer, E | 1 |
| Hennequin, C | 1 |
| Maylin, C | 1 |
| Rao, BN | 1 |
| Merchant, TE | 1 |
| Shah, A | 1 |
| Avery, L | 1 |
| Cain, A | 1 |
| Bodner, S | 1 |
| Poquette, C | 1 |
| Tan, M | 1 |
| Tominaga, K | 1 |
| Arakawa, T | 1 |
| Imano, M | 1 |
| Kato, M | 1 |
| Hamaguchi, Y | 2 |
| Takaishi, O | 1 |
| Fukuda, T | 1 |
| Higuchi, K | 1 |
| Osugi, H | 1 |
| Chono, S | 1 |
| Kuroki, T | 1 |
| Rayson, D | 1 |
| Adjei, AA | 1 |
| Suman, VJ | 1 |
| Wold, LE | 1 |
| Ingle, JN | 1 |
| Hasbini, A | 2 |
| Mahjoubi, R | 1 |
| Chouaki, N | 2 |
| Lianes, P | 1 |
| Alonso, S | 1 |
| Lévi, F | 1 |
| Zidani, R | 1 |
| Brienza, S | 1 |
| Perpoint, B | 1 |
| Rotarski, M | 1 |
| Letourneau, Y | 1 |
| Llory, JF | 1 |
| Le Rol, A | 1 |
| Focan, C | 2 |
| Martenson, JA | 1 |
| Shanahan, TG | 1 |
| O'Connell, MJ | 4 |
| Cobau, CD | 1 |
| Schroeder, G | 1 |
| Burch, PA | 1 |
| Levitt, R | 1 |
| Rowland, KM | 1 |
| Ishikawa, T | 1 |
| Kamiyama, M | 1 |
| Hisatomi, H | 1 |
| Ichikawa, Y | 1 |
| Momiyama, N | 1 |
| Hasegawa, S | 1 |
| Narita, T | 1 |
| Shimada, H | 1 |
| Cavaliere, F | 2 |
| Di Filippo, F | 2 |
| Cosimelli, M | 2 |
| Aloe, L | 2 |
| Arcuri, E | 2 |
| Anzà, M | 1 |
| Callopoli, A | 2 |
| Di Lauro, L | 1 |
| Morace, E | 1 |
| Botti, C | 2 |
| Natoli, S | 1 |
| Tedesco, M | 2 |
| Giunta, S | 2 |
| Cavaliere, R | 2 |
| Harper-Wynne, C | 1 |
| English, J | 1 |
| Meyer, L | 1 |
| Bower, M | 1 |
| Archer, C | 1 |
| Sinnett, HD | 1 |
| Lowdell, C | 1 |
| Coombes, RC | 1 |
| Lim, WT | 1 |
| Koo, WH | 1 |
| Au, E | 1 |
| Khoo, KS | 1 |
| Couteau, C | 1 |
| Kuropkat, C | 1 |
| Griem, K | 1 |
| Clark, J | 1 |
| Rodriguez, ER | 1 |
| Hutchinson, J | 1 |
| Taylor, SG | 1 |
| Wolmark, N | 1 |
| Rockette, H | 1 |
| Mamounas, E | 1 |
| Wieand, S | 1 |
| Wickerham, DL | 1 |
| Bear, HD | 1 |
| Atkins, JN | 1 |
| Dimitrov, NV | 1 |
| Glass, AG | 1 |
| Fisher, ER | 1 |
| Fisher, B | 1 |
| Horie, H | 1 |
| Kashiwagi, H | 1 |
| Konishi, F | 1 |
| Furuta, K | 1 |
| Ozawa, A | 1 |
| Kanazawa, K | 1 |
| Jakesz, R | 1 |
| Hausmaninger, H | 1 |
| Haider, K | 1 |
| Kubista, E | 1 |
| Samonigg, H | 1 |
| Gnant, M | 1 |
| Manfreda, D | 1 |
| Tschurtschenthaler, G | 1 |
| Kolb, R | 1 |
| Stierer, M | 1 |
| Fridrik, M | 1 |
| Mlineritsch, B | 1 |
| Steindorfer, P | 1 |
| Mittlböck, M | 1 |
| Steger, G | 1 |
| Damle, S | 1 |
| Haynes, H | 1 |
| Kaleya, R | 1 |
| Schechner, R | 1 |
| Berkenblit, R | 1 |
| Ladner, RD | 1 |
| Murgo, A | 1 |
| Yoshioka, T | 1 |
| Gamoh, M | 1 |
| Shineha, R | 1 |
| Ishibashi, S | 1 |
| Shibata, H | 1 |
| Suzuki, T | 1 |
| Murakawa, Y | 1 |
| Kato, S | 2 |
| Shimodaira, H | 1 |
| Ishioka, C | 1 |
| Kanamaru, R | 1 |
| Chie, EK | 1 |
| Anderson, SH | 1 |
| Hudson-Peacock, M | 1 |
| Muller, AF | 1 |
| Elsaleh, H | 1 |
| Powell, B | 1 |
| Soontrapornchai, P | 1 |
| Joseph, D | 1 |
| Goria, F | 1 |
| Spry, N | 1 |
| Iacopetta, B | 1 |
| Björk-Eriksson, T | 1 |
| West, C | 1 |
| Karlsson, E | 1 |
| Mercke, C | 1 |
| Wilson, J | 1 |
| Carder, P | 1 |
| Gooi, J | 1 |
| Nishikawa, H | 1 |
| Baker, SD | 1 |
| Diasio, RB | 1 |
| O'Reilly, S | 1 |
| Lucas, VS | 1 |
| Khor, SP | 1 |
| Sartorius, SE | 1 |
| Donehower, RC | 1 |
| Grochow, LB | 1 |
| Hohneker, JA | 1 |
| Rowinsky, EK | 1 |
| Vlastos, G | 1 |
| Mirza, NQ | 1 |
| Lenert, JT | 1 |
| Hunt, KK | 1 |
| Ames, FC | 2 |
| Feig, BW | 1 |
| Ross, MI | 1 |
| Singletary, SE | 3 |
| Prasad, S | 1 |
| Kamath, GG | 1 |
| Phillips, RP | 1 |
| Hasuike, Y | 1 |
| Ohzato, H | 1 |
| Kikkawa, N | 1 |
| Leder, GH | 1 |
| Pillasch, J | 1 |
| Kornmann, M | 1 |
| Danenberg, PV | 1 |
| Link, KH | 1 |
| Hara, Y | 1 |
| Kawasaki, T | 1 |
| Yabata, E | 1 |
| Gen, T | 1 |
| Jibiki, M | 1 |
| Kudoh, A | 1 |
| Noguchi, N | 1 |
| Igarashi, K | 2 |
| Kikuchi, M | 2 |
| Takenoue, T | 1 |
| Matsuda, K | 1 |
| Fujii, S | 1 |
| Nita, ME | 1 |
| Hatano, K | 1 |
| Tsuruo, T | 1 |
| Muto, T | 1 |
| Morgan, RJ | 1 |
| Braly, P | 2 |
| Leong, L | 1 |
| Shibata, S | 1 |
| Margolin, K | 1 |
| Somlo, G | 1 |
| McNamara, M | 1 |
| Longmate, J | 1 |
| Schinke, S | 1 |
| Raschko, J | 1 |
| Nagasawa, S | 1 |
| Kogut, N | 1 |
| Najera, L | 1 |
| Johnson, D | 1 |
| Doroshow, JH | 2 |
| De Vita, F | 1 |
| De Lucia, L | 1 |
| Rivellini, F | 1 |
| Chaouche, M | 1 |
| Pasturaud, AL | 1 |
| Kamioner, D | 1 |
| Grandjean, M | 1 |
| Franiatte, J | 1 |
| Tourani, JM | 1 |
| Yau, JC | 1 |
| Gertler, SZ | 1 |
| Hanson, J | 1 |
| Verma, S | 1 |
| Grimard, LJ | 1 |
| Malik, ST | 1 |
| Aref, IM | 1 |
| Cross, PW | 1 |
| Tomiak, EM | 1 |
| Stewart, DJ | 1 |
| St Cyr, DA | 1 |
| Huan, SD | 1 |
| Cooper, JS | 1 |
| Lee, H | 1 |
| Torrey, M | 1 |
| Hochster, H | 1 |
| Tang, SG | 1 |
| See, LC | 1 |
| Chen, WC | 1 |
| Tsang, S | 1 |
| Chang, JT | 1 |
| Hong, JH | 1 |
| Cameron, DA | 1 |
| Gregory, WM | 1 |
| Bowman, A | 1 |
| Anderson, ED | 1 |
| Levack, P | 1 |
| Forouhi, P | 1 |
| Leonard, RC | 1 |
| Braybrooke, JP | 1 |
| Propper, DJ | 1 |
| O'Byrne, KJ | 1 |
| Koukourakis, MI | 1 |
| Patterson, AV | 1 |
| Houlbrook, S | 1 |
| Love, SD | 1 |
| Varcoe, S | 1 |
| Taylor, M | 1 |
| Ganesan, TS | 1 |
| Talbot, DC | 1 |
| Harris, AL | 1 |
| Zubizarreta, PA | 1 |
| D'Antonio, G | 1 |
| Raslawski, E | 1 |
| Gallo, G | 1 |
| Preciado, MV | 1 |
| Casak, SJ | 1 |
| Scopinaro, M | 1 |
| Morales, G | 1 |
| Sackmann-Muriel, F | 1 |
| Pritchard, DM | 1 |
| Print, C | 1 |
| O'Reilly, L | 1 |
| Adams, JM | 1 |
| Potten, CS | 1 |
| Hickman, JA | 1 |
| Giannarelli, D | 1 |
| Aromatario, C | 1 |
| Consolo, S | 1 |
| Laurenzi, L | 1 |
| Di Angelo, P | 1 |
| Madajewicz, S | 1 |
| Hentschel, P | 1 |
| Burns, P | 1 |
| Caruso, R | 1 |
| Fiore, J | 1 |
| Fried, M | 1 |
| Malhotra, H | 1 |
| Ostrow, S | 1 |
| Sugarman, S | 1 |
| Viola, M | 1 |
| Mirjolet, JF | 1 |
| Didelot, C | 1 |
| Peyrat, JP | 1 |
| Abecassis, J | 1 |
| Millon, R | 1 |
| Pestieau, SR | 1 |
| Ho, JC | 1 |
| Lam, WK | 1 |
| Ooi, GC | 1 |
| Lam, B | 1 |
| Tsang, KW | 1 |
| Montana, GS | 1 |
| Thomas, GM | 1 |
| Moore, DH | 1 |
| Saxer, A | 1 |
| Mangan, CE | 1 |
| Lentz, SS | 1 |
| Averette, HE | 1 |
| Sanguineti, G | 2 |
| D'Amico, M | 1 |
| Ricci, I | 1 |
| Numico, G | 1 |
| Guarneri, D | 1 |
| Vitale, V | 2 |
| Pallestrini, E | 1 |
| Santelli, A | 1 |
| Rosso, R | 3 |
| Mori, H | 1 |
| Honda, K | 1 |
| Ishida, R | 1 |
| Nohira, T | 1 |
| Tomoda, A | 1 |
| Abe, S | 1 |
| Kubota, T | 2 |
| Otani, Y | 1 |
| Watanabe, M | 1 |
| Kumai, K | 1 |
| Kitajima, M | 1 |
| Cheng, SH | 1 |
| Jian, JJ | 1 |
| Tsai, SY | 1 |
| Yen, KL | 1 |
| Chu, NM | 1 |
| Chan, KY | 1 |
| Tan, TD | 1 |
| Cheng, JC | 1 |
| Leu, SY | 1 |
| Huang, AT | 1 |
| Dowell, JE | 1 |
| Garrett, AM | 1 |
| Shyr, Y | 1 |
| Johnson, DH | 1 |
| Berner, J | 1 |
| Tenderenda, M | 1 |
| Pasz, S | 1 |
| Berner, A | 1 |
| Piekarski, J | 1 |
| Kołodziejczyk, P | 1 |
| Huang, TS | 1 |
| Lee, CC | 1 |
| Min, HQ | 1 |
| Mao, ZD | 1 |
| Cui, NJ | 1 |
| Witte, RS | 1 |
| Cnaan, A | 1 |
| Mansour, EG | 1 |
| Barylak, E | 1 |
| Harris, JE | 1 |
| Schutt, AJ | 1 |
| Niedzwiecki, D | 2 |
| Hollis, D | 1 |
| Schilsky, RL | 2 |
| Mayer, RJ | 2 |
| Strickland, AH | 1 |
| Karapetis, CS | 2 |
| Yip, D | 2 |
| Harper, PG | 2 |
| Karayannopoulou, M | 1 |
| Kaldrymidou, E | 1 |
| Constantinidis, TC | 1 |
| Dessiris, A | 1 |
| Tebbutt, NC | 1 |
| Hill, M | 2 |
| Lew, JI | 1 |
| Gooding, WE | 1 |
| Ribeiro, U | 1 |
| Safatle-Ribeiro, AV | 1 |
| Posner, MC | 1 |
| Fischer, M | 1 |
| Klahold, M | 1 |
| Ijiri, R | 1 |
| Onuma, K | 1 |
| Kato, K | 1 |
| Toyoda, Y | 1 |
| Nagashima, Y | 1 |
| Ito, Y | 1 |
| Abiko, Y | 1 |
| Tanaka, Y | 1 |
| Tas, F | 1 |
| Basaran, M | 1 |
| Aydiner, A | 1 |
| Eralp, Y | 1 |
| Topuz, E | 1 |
| El-Weshi, A | 1 |
| Khafaga, Y | 1 |
| Allam, A | 1 |
| Ibrahim, E | 1 |
| El-Serafi, M | 1 |
| El-Badawi, S | 1 |
| Zhou, C | 1 |
| Jia, J | 1 |
| Huang, T | 1 |
| Reimer, P | 1 |
| Rückle-Lanz, H | 1 |
| Waters, JS | 1 |
| Massey, A | 1 |
| Sabatino, M | 1 |
| Micheli, L | 1 |
| Nencini, C | 1 |
| Pozzessere, D | 1 |
| Petrioli, R | 1 |
| De Vecchis, L | 1 |
| Turriziani, M | 1 |
| Prete, SP | 1 |
| Sanguedolce, R | 1 |
| Rausa, L | 4 |
| Virik, K | 1 |
| Strickland, A | 1 |
| Ryder, K | 1 |
| Cowling, M | 1 |
| Adler, G | 1 |
| Yang, Q | 1 |
| Barbareschi, M | 1 |
| Mori, I | 1 |
| Mauri, F | 1 |
| Muscarà, M | 1 |
| Nakamura, Y | 1 |
| Yoshimura, G | 1 |
| Sakurai, T | 1 |
| Caffo, O | 1 |
| Galligioni, E | 1 |
| Dalla Palma, P | 1 |
| Kakudo, K | 1 |
| Wei, YH | 1 |
| Dhar, DK | 1 |
| Kubota, H | 1 |
| Yamanoi, A | 1 |
| Ono, T | 1 |
| Yashimura, H | 1 |
| Tachibana, M | 1 |
| Kohno, H | 1 |
| Nagasue, N | 1 |
| Kiss, I | 1 |
| Marková, J | 1 |
| Tomásek, J | 1 |
| Vyzula, R | 1 |
| Válek, V | 1 |
| Boudný, J | 1 |
| Kala, Z | 1 |
| Hanke, I | 1 |
| Ostrízek, T | 1 |
| Leypold, J | 1 |
| Lazaris, AC | 1 |
| Kavantzas, NG | 1 |
| Zorzos, HS | 1 |
| Tsavaris, NV | 1 |
| Davaris, PS | 1 |
| Baldelli, AM | 1 |
| Catalano, V | 1 |
| Giordani, P | 1 |
| Beretta, GD | 1 |
| Silva, RR | 1 |
| Gasparini, G | 1 |
| Mari, D | 1 |
| Maisano, R | 1 |
| Salvagni, S | 1 |
| Curti, C | 1 |
| Basaki, Y | 1 |
| Chikahisa, L | 1 |
| Aoyagi, K | 1 |
| Yonekura, K | 1 |
| Okabe, S | 1 |
| Wierzba, K | 1 |
| Yamada, Y | 3 |
| Feng, WH | 1 |
| Israel, B | 1 |
| Raab-Traub, N | 1 |
| Busson, P | 1 |
| Kenney, SC | 1 |
| Gruenberger, T | 1 |
| Zhao, J | 1 |
| King, J | 1 |
| Clingan, PR | 1 |
| Namiki, Y | 1 |
| Shirao, K | 1 |
| Shimada, Y | 1 |
| Matsumura, Y | 1 |
| Gotoh, M | 1 |
| Hamaguchi, T | 1 |
| Mizuno, T | 1 |
| Ura, T | 1 |
| Macdonald, AG | 1 |
| Hutcheon, AW | 1 |
| Ahmed, FY | 1 |
| Sikma, MA | 1 |
| Coenen, JL | 1 |
| Kloosterziel, C | 1 |
| Hasselt, BA | 1 |
| Ruers, TJ | 1 |
| Hareyama, M | 1 |
| Sakata, K | 1 |
| Shirato, H | 1 |
| Nishioka, T | 1 |
| Nishio, M | 1 |
| Saitoh, A | 1 |
| Oouchi, A | 1 |
| Fukuda, S | 1 |
| Himi, T | 1 |
| Elias, AD | 1 |
| Ibrahim, J | 1 |
| Richardson, P | 1 |
| Avigan, D | 1 |
| Joyce, R | 1 |
| Reich, E | 1 |
| McCauley, M | 1 |
| Wheeler, C | 1 |
| Frei, E | 1 |
| Prasad, U | 1 |
| Wahid, MI | 1 |
| Jalaludin, MA | 1 |
| Abdullah, BJ | 1 |
| Paramsothy, M | 1 |
| Abdul-Kareem, S | 1 |
| Tattersall, S | 1 |
| Ryall, RD | 1 |
| Starichkov, MS | 1 |
| Nivinskaia, MM | 1 |
| Bychkov, MB | 1 |
| Lichinitser, MR | 2 |
| Chebotareva, LI | 1 |
| Depierre, A | 1 |
| Newman, CE | 1 |
| Ford, CH | 1 |
| Brockman, RW | 1 |
| Shaddix, SC | 1 |
| Rose, LM | 1 |
| McBride, CM | 2 |
| Nüvemann, M | 1 |
| Fernholz, HJ | 1 |
| Frik, W | 1 |
| Oda, Y | 1 |
| Tokuriki, Y | 1 |
| Tsuda, E | 1 |
| Handa, H | 1 |
| Kieler, J | 1 |
| Kingston, RD | 1 |
| Ellis, DJ | 1 |
| Powell, J | 1 |
| Brookes, VS | 1 |
| Waterhouse, JA | 1 |
| Hurst, MD | 1 |
| Smith, JA | 1 |
| Weiss, RB | 1 |
| DeVita, VT | 1 |
| Görlich, M | 1 |
| Heise, E | 1 |
| Számel, I | 1 |
| Kerpel-Fronius, S | 1 |
| Majima, S | 1 |
| Watanabe, S | 1 |
| Nakao, E | 1 |
| Ueda, T | 1 |
| Morisawa, K | 1 |
| Cho, K | 1 |
| Nishioka, B | 1 |
| Fujita, Y | 1 |
| Barkin, JS | 2 |
| Kalser, MH | 1 |
| Kaplan, R | 1 |
| Redlhammer, D | 1 |
| Heal, A | 1 |
| Morita, M | 1 |
| Miyakawa, K | 1 |
| Garibjanian, BT | 1 |
| Johnson, RK | 1 |
| Kline, I | 1 |
| Vadlamudi, S | 1 |
| Gang, M | 1 |
| Venditti, JM | 1 |
| Goldin, A | 1 |
| Inoguchi, T | 1 |
| Yamasaki, I | 1 |
| Yazuka, K | 1 |
| Kita, T | 2 |
| Kuwano, K | 1 |
| Ramming, KP | 2 |
| Sparks, FC | 2 |
| Eilber, FR | 1 |
| Morton, DL | 2 |
| Mavligit, GM | 1 |
| Gutterman, JU | 2 |
| Malahy, MA | 1 |
| Burgess, MA | 1 |
| Jubert, A | 1 |
| Hersh, EM | 1 |
| Scott, WW | 3 |
| Gibbons, RP | 3 |
| Johnson, DE | 3 |
| Prout, GR | 4 |
| Schmidt, JD | 3 |
| Saroff, J | 2 |
| Murphy, GP | 4 |
| Abisatov, KhA | 1 |
| Khan, SV | 1 |
| Wile, AG | 1 |
| Silver, HK | 1 |
| Wolk, RW | 1 |
| Steel, GG | 1 |
| Ostuni, JA | 1 |
| Roginsky, MS | 1 |
| Falk, RE | 1 |
| MacGregor, AB | 1 |
| Landi, S | 1 |
| Ambus, U | 1 |
| Langer, B | 1 |
| Valdivieso, M | 1 |
| Bodey, GP | 1 |
| Gottlieb, JA | 2 |
| Freireich, EJ | 1 |
| Fritz, P | 1 |
| Schraube, P | 1 |
| Oberle, J | 1 |
| Wannenmacher, M | 1 |
| Friedl, P | 1 |
| Mick, R | 2 |
| McEvilly, JM | 1 |
| Rahal, M | 1 |
| Eschwege, F | 1 |
| Gasmi, J | 1 |
| DeGeest, K | 1 |
| Kakizaki, K | 1 |
| Yamauchi, H | 1 |
| Laurie, JA | 3 |
| Hahn, RG | 1 |
| Therneau, TM | 1 |
| Patel, SR | 1 |
| Mailliard, JA | 1 |
| Windschitl, HE | 2 |
| Twito, DI | 1 |
| Morton, RF | 1 |
| Krook, JE | 2 |
| Seifert, E | 1 |
| Schadel, A | 1 |
| Haberkorn, U | 1 |
| MacVicar, D | 1 |
| Husband, JE | 1 |
| Taylor, R | 1 |
| Menzies-Gow, N | 1 |
| Cimino, A | 1 |
| Pastorello, T | 1 |
| Ferrara, P | 1 |
| Sener, SF | 1 |
| Imperato, JP | 1 |
| Khandekar, JD | 1 |
| Ragin, A | 1 |
| Beck, J | 1 |
| Merkel, DE | 1 |
| Sbalzarini, G | 1 |
| Pandolfi, C | 1 |
| Labadini, A | 1 |
| Sidorova, NA | 1 |
| Volchenko, NN | 2 |
| Saribekian, EK | 1 |
| Coia, LR | 1 |
| Engstrom, PF | 1 |
| Paul, AR | 1 |
| Stafford, PM | 1 |
| Hanks, GE | 1 |
| De Besi, P | 1 |
| Busnardo, B | 1 |
| Girelli, ME | 1 |
| Nacamulli, D | 1 |
| Simioni, N | 1 |
| Casara, D | 1 |
| Zorat, P | 1 |
| Fiorentino, MV | 2 |
| Hiehle, JF | 1 |
| Levine, MS | 1 |
| Dawson, NA | 1 |
| Costanza, ME | 1 |
| Korzun, AH | 1 |
| Clamon, GH | 1 |
| Pollak, M | 1 |
| Vogelzang, NJ | 1 |
| Carey, RW | 2 |
| Grem, JL | 1 |
| Tsekova, V | 1 |
| Pflüger, KH | 1 |
| Havemann, K | 1 |
| Rothmund, M | 1 |
| Fujita, S | 1 |
| Kodaira, S | 1 |
| Josui, K | 1 |
| Arisawa, Y | 1 |
| Suto, A | 1 |
| Ishibiki, K | 1 |
| Abe, O | 1 |
| Mabuchi, K | 1 |
| Raber, MN | 1 |
| Faintuch, J | 1 |
| Sumrall, C | 1 |
| Frost, P | 1 |
| Rustum, Y | 1 |
| Creaven, P | 1 |
| Petrelli, N | 1 |
| Bready, B | 1 |
| Moore, DF | 1 |
| Villar-Grimalt, A | 1 |
| Candel, MT | 1 |
| Delgado, F | 1 |
| García-Reinoso, J | 1 |
| Sanchis, C | 1 |
| Viciano, V | 1 |
| Asencio, F | 1 |
| Martínez-Abad, M | 1 |
| Aguilo, J | 1 |
| Sánchez, JJ | 1 |
| Frank, GA | 1 |
| Borisov, VI | 1 |
| Schreer, I | 1 |
| Frischbier, HJ | 1 |
| Maass, H | 1 |
| Stegner, HE | 1 |
| Robbins, KT | 1 |
| Varki, NM | 1 |
| Storniolo, AM | 1 |
| Hoffman, H | 1 |
| Hoffman, RM | 1 |
| Brugieres, L | 1 |
| Gicquel, C | 1 |
| Travagli, JP | 1 |
| Droz, JP | 3 |
| Parmentier, C | 2 |
| Hryniuk, WM | 1 |
| Moertel, CG | 2 |
| Poon, MA | 1 |
| Schiller, JH | 1 |
| Bittner, G | 1 |
| Matsuno, S | 1 |
| Hisano, H | 1 |
| Kobari, M | 1 |
| Akaishi, S | 1 |
| Lisetskiĭ, VA | 1 |
| Evtushenko, GV | 1 |
| Dotsenko, IuS | 1 |
| Svintsitskiĭ, VS | 1 |
| Lund, B | 1 |
| Hansen, M | 1 |
| Hansen, HH | 1 |
| Thomsen, HK | 1 |
| Sørensen, BL | 1 |
| Nielsen, NC | 1 |
| Lundvall, F | 1 |
| Maloisel, F | 1 |
| Dufour, P | 1 |
| Bergerat, JP | 1 |
| Herbrecht, R | 1 |
| Duclos, B | 1 |
| Boilletot, A | 1 |
| Giron, C | 1 |
| Jaeck, D | 1 |
| Haennel, P | 1 |
| Jung, G | 1 |
| Fornasiero, A | 1 |
| Daniele, O | 1 |
| Ghiotto, C | 1 |
| Aversa, SM | 1 |
| Morandi, P | 1 |
| Rouëssé, J | 1 |
| Friedman, S | 1 |
| Mouriesse, H | 1 |
| Sarrazin, D | 1 |
| Spielmann, M | 1 |
| Roullet, B | 1 |
| Labadie, M | 1 |
| Taper, H | 1 |
| Lans, M | 1 |
| Economidou-Karaoglou, A | 1 |
| Dewez, B | 1 |
| Roberfroid, M | 1 |
| Berdah, JF | 1 |
| Bachellerie-Rhein, B | 1 |
| Kjørstad, KE | 1 |
| Nordal, R | 1 |
| Sundfør, K | 1 |
| Vergote, I | 1 |
| Vossli, S | 1 |
| Abeler, V | 1 |
| Sandvei, R | 1 |
| Koh, EH | 1 |
| McNeese, MD | 2 |
| Frye, D | 1 |
| Holmes, FA | 1 |
| Fraschini, G | 1 |
| Hug, V | 1 |
| Theriault, RL | 1 |
| Futami, H | 1 |
| Jansen, R | 1 |
| MacPhee, MJ | 1 |
| Keller, J | 1 |
| McCormick, K | 1 |
| Longo, DL | 1 |
| Oppenheim, JJ | 1 |
| Ruscetti, FW | 1 |
| Wiltrout, RH | 1 |
| Barth, V | 1 |
| Schönfelder, M | 1 |
| Hirsh, A | 1 |
| Alhalel, A | 1 |
| Weiss, A | 1 |
| Brener, H | 1 |
| Avni, I | 1 |
| Fleming, TR | 3 |
| Macdonald, JS | 2 |
| Haller, DG | 1 |
| Goodman, PJ | 1 |
| Ungerleider, JS | 1 |
| Emerson, WA | 1 |
| Tormey, DC | 1 |
| Glick, JH | 1 |
| Green, S | 1 |
| Hannigan, EV | 1 |
| Boutselis, JG | 1 |
| Surwit, EA | 1 |
| Wallace, DL | 1 |
| Alberts, DS | 2 |
| Visser, GW | 1 |
| Gorree, GC | 1 |
| Peters, GJ | 4 |
| Herscheid, JD | 1 |
| Guenzi, M | 1 |
| Scarpati, D | 3 |
| Gardin, G | 1 |
| Kemeny, N | 1 |
| Israel, K | 1 |
| Chapman, D | 1 |
| Botet, J | 1 |
| Minsky, B | 1 |
| Vinciguerra, V | 1 |
| Rosenbluth, R | 1 |
| Bosselli, B | 1 |
| Cochran, C | 1 |
| Wiernik, PH | 2 |
| Stolwijk, C | 1 |
| Wagener, DJ | 1 |
| Van den Broek, P | 1 |
| Levendag, PC | 1 |
| Kazem, I | 1 |
| Bruaset, I | 1 |
| De Mulder, PH | 1 |
| Wright, JC | 1 |
| Rahima, M | 1 |
| Rakowsky, E | 1 |
| Barzilay, J | 1 |
| Sidi, J | 1 |
| von der Maase, H | 1 |
| Tallroth, E | 1 |
| Wallin, G | 1 |
| Lundell, G | 1 |
| Löwhagen, T | 1 |
| Einhorn, J | 1 |
| Goga, D | 1 |
| Le Flock, O | 1 |
| Ballon, G | 1 |
| Al-Kourainy, K | 1 |
| Crissman, J | 1 |
| Ensley, J | 1 |
| Kish, J | 1 |
| Kelly, J | 1 |
| Al-Sarraf, M | 1 |
| Bonfils, P | 1 |
| Ménard, M | 1 |
| Fabre, A | 1 |
| Airoldi, M | 1 |
| Pedani, F | 1 |
| Brando, V | 1 |
| Gabriele, P | 1 |
| Giordano, C | 1 |
| Thoms, WW | 1 |
| Fletcher, GH | 1 |
| Oswald, MJ | 1 |
| Rios, AA | 1 |
| Ende, K | 1 |
| Faintuch, JS | 1 |
| Saks, S | 1 |
| Levin, B | 1 |
| Sipilä, P | 1 |
| Kivinen, S | 1 |
| Gröhn, P | 1 |
| Vesala, J | 1 |
| Heinonen, E | 1 |
| Kikuchi, Y | 1 |
| Oomori, K | 1 |
| Iwano, I | 1 |
| Kizawa, I | 1 |
| Miyauchi, M | 1 |
| Kuki, E | 1 |
| Bruckner, HW | 2 |
| Kalman, J | 1 |
| Spigelman, M | 1 |
| Gorbaty, MI | 1 |
| Butwell, N | 1 |
| Storch, J | 1 |
| McKenna, A | 1 |
| Tveit, KM | 1 |
| Karlsen, KO | 1 |
| Fosså, SD | 1 |
| Flokkmann, A | 1 |
| Guldvog, I | 1 |
| Haffner, J | 1 |
| San Martín, S | 1 |
| Armando, S | 1 |
| Arraztoa, J | 1 |
| Morales, Y | 1 |
| Braakhuis, BJ | 1 |
| de Bruijn, EA | 1 |
| Laurensse, EJ | 2 |
| van Walsum, M | 1 |
| Pinedo, HM | 3 |
| Treat, J | 1 |
| Falchuk, SC | 1 |
| Woolley, PV | 1 |
| Ahlgren, JD | 1 |
| Neefe, JR | 1 |
| Smith, FP | 1 |
| Schein, PS | 1 |
| Stewart, HJ | 1 |
| Prescott, RJ | 1 |
| Forrest, PA | 1 |
| Cheson, BD | 1 |
| Goldman, M | 1 |
| Lyver, A | 1 |
| Rader, M | 1 |
| Zimmerman, M | 1 |
| Itri, L | 1 |
| Weinberg, V | 1 |
| Greenhalgh, DA | 1 |
| Parish, JH | 1 |
| Kim, TH | 1 |
| McLaren, J | 1 |
| Alvarado, CS | 1 |
| Wyly, JB | 1 |
| Crocker, I | 1 |
| Winn, K | 1 |
| Singhapakdi, S | 1 |
| Ragab, A | 1 |
| Weh, HJ | 2 |
| Platz, D | 1 |
| Garbrecht, M | 1 |
| Kremer, B | 2 |
| Henne-Bruns, D | 2 |
| Crone-Münzebrock, W | 1 |
| Hossfeld, DK | 1 |
| Kuske, RR | 2 |
| Perez, CA | 2 |
| Lovett, RD | 1 |
| Jacobs, AJ | 1 |
| Galakatos, AE | 1 |
| Camel, HM | 1 |
| Kao, MS | 1 |
| Awan, AM | 1 |
| Moran, WJ | 1 |
| Goldman, MD | 1 |
| Tybor, AG | 1 |
| Schoen, HD | 1 |
| Lindeløv, B | 1 |
| Hansen, HS | 1 |
| Effenberger, T | 1 |
| Fields, JN | 1 |
| Fineberg, BB | 1 |
| Bartlett, N | 1 |
| Swanson, JD | 1 |
| Sykes, E | 1 |
| Teo, P | 1 |
| Tsao, SY | 1 |
| Shiu, W | 1 |
| Leung, WT | 1 |
| Tsang, V | 1 |
| Lui, C | 1 |
| Ang, PT | 1 |
| Smith, TL | 1 |
| Kau, S | 1 |
| Wang, ZY | 1 |
| Herrera, L | 1 |
| Mittelman, A | 1 |
| Venturini, M | 2 |
| Merlano, M | 2 |
| Michelotti, A | 2 |
| Martorana, G | 2 |
| Curotto, A | 2 |
| Orsatti, M | 1 |
| Giuliani, L | 1 |
| Donegan, WL | 1 |
| Fujimoto, S | 1 |
| Shrestha, RD | 1 |
| Miyazaki, M | 1 |
| Endoh, F | 1 |
| Togawa, Y | 1 |
| Okui, K | 1 |
| van Dijk, J | 1 |
| van Groeningen, C | 1 |
| Leyva, A | 1 |
| Lankelma, J | 1 |
| Valone, FH | 1 |
| Kohler, M | 1 |
| Fisher, K | 1 |
| Hannigan, J | 1 |
| Flam, M | 1 |
| Gandara, D | 1 |
| Hendrickson, C | 1 |
| Richman, E | 1 |
| Yu, KP | 1 |
| Berne, M | 1 |
| Gustavsson, B | 1 |
| Almersjö, O | 1 |
| Spears, P | 1 |
| Sundström, E | 1 |
| Park, JG | 1 |
| Collins, JM | 1 |
| Gazdar, AF | 1 |
| Greene, RF | 1 |
| Kramer, BS | 1 |
| Sertoli, MR | 1 |
| Bruzzone, M | 1 |
| Rubagotti, A | 1 |
| Bentivoglio, G | 1 |
| Conio, A | 1 |
| Pescetto, G | 1 |
| Sillman, FH | 1 |
| Sedlis, A | 1 |
| Boyce, JG | 1 |
| Okawa, T | 1 |
| Mikuriya, S | 1 |
| Hashimoto, S | 1 |
| Amino, S | 1 |
| Horiuchi, J | 1 |
| Ebata, K | 1 |
| Kaneda, K | 2 |
| Bennett, JM | 1 |
| Wolff, S | 1 |
| Krementz, ET | 3 |
| Cartwright, K | 1 |
| Dukart, G | 1 |
| Reisman, A | 1 |
| Schoch, I | 1 |
| Nadal, JC | 1 |
| Van Groeningen, CJ | 1 |
| Aoki, N | 1 |
| Belinson, JL | 1 |
| Pretorius, RG | 1 |
| McClure, M | 1 |
| Ashikaga, T | 1 |
| de Gramont, A | 1 |
| Drolet, Y | 1 |
| Louvet, C | 1 |
| Dray, C | 1 |
| Krulik, M | 1 |
| Pigné, A | 1 |
| Lavoie, A | 1 |
| Painchaud, M | 1 |
| Blouin, R | 1 |
| Tessier, C | 1 |
| Laufman, LR | 1 |
| Green, JB | 1 |
| O'Toole, R | 1 |
| Hilgers, RD | 1 |
| Young, DC | 1 |
| Lin, F | 1 |
| Rivkin, SE | 1 |
| Pasterz, R | 1 |
| Savaraj, N | 1 |
| Burgess, M | 1 |
| Zhero, SV | 1 |
| Ganina, KP | 1 |
| Jain, S | 1 |
| Seymour, AE | 1 |
| Wu, BZ | 1 |
| Uekado, Y | 1 |
| Shinka, T | 1 |
| Hirano, A | 1 |
| Noguchi, S | 1 |
| Miyauchi, K | 1 |
| Koyama, H | 1 |
| Terasawa, T | 1 |
| Giberti, C | 1 |
| Bonamini, A | 1 |
| Pizzorno, R | 1 |
| Oneto, F | 1 |
| Heintz, AP | 1 |
| Van Oosterom, AT | 1 |
| Trimbos, JB | 1 |
| Schaberg, A | 1 |
| Van der Velde, EA | 1 |
| Nooy, M | 1 |
| Peek, U | 1 |
| Yamamura, Y | 1 |
| Nakazato, H | 1 |
| Koike, A | 1 |
| Ichihashi, H | 1 |
| Petursson, SR | 1 |
| Dusková, M | 1 |
| Kanno, A | 1 |
| Tanaka, S | 1 |
| Ito, T | 1 |
| Ban, K | 1 |
| Oshita, H | 1 |
| Fukata, D | 1 |
| Sakai, N | 1 |
| Kashizuka, T | 1 |
| Hatoh, T | 1 |
| Stablein, DM | 1 |
| Nauta, RJ | 1 |
| Brun, B | 1 |
| Otmezguine, Y | 1 |
| Feuilhade, F | 1 |
| Julien, M | 1 |
| Lebourgeois, JP | 1 |
| Calitchi, E | 1 |
| Roucayrol, AM | 1 |
| Ganem, G | 1 |
| Huart, J | 1 |
| Pierquin, B | 1 |
| Ostronoff, M | 1 |
| Bellaiche, M | 1 |
| Sethi, VK | 1 |
| Chia, KB | 1 |
| Chua, EJ | 1 |
| Khor, TH | 1 |
| Tan, BC | 1 |
| Tan, TM | 1 |
| Mishina, H | 1 |
| Okuyama, S | 1 |
| Scanlon, KJ | 1 |
| Newman, EM | 1 |
| Priest, DG | 1 |
| Mendoza, EA | 1 |
| Thomas, LC | 1 |
| Sutherland, CM | 1 |
| Stablein, D | 1 |
| Novak, J | 1 |
| Mayer, R | 1 |
| Everson, LK | 2 |
| Cullinan, S | 1 |
| Wieand, HS | 1 |
| Arbuck, SG | 1 |
| Douglass, HO | 1 |
| Trave, F | 1 |
| Huben, RP | 1 |
| Priore, R | 1 |
| Appelqvist, P | 1 |
| Salmo, M | 1 |
| Leivonen, M | 1 |
| Kalima, T | 1 |
| Saario, I | 1 |
| Tolppanen, EM | 1 |
| Theodore, C | 1 |
| Piot, G | 1 |
| Herait, P | 1 |
| Ruffie, P | 1 |
| Carde, P | 1 |
| Drexler, LJ | 1 |
| Mitre, RJ | 1 |
| Madan, E | 1 |
| Zidar, BL | 1 |
| Doroshow, J | 1 |
| Hoff, S | 1 |
| Gribel', NV | 1 |
| Pashinskiĭ, VG | 1 |
| Orzechowska-Juzwenko, K | 1 |
| Wiela, A | 1 |
| Cieślińska, A | 1 |
| Roszkowska, E | 1 |
| Jett, JR | 1 |
| Dalton, RJ | 1 |
| Marschke, RF | 1 |
| Cullinan, SA | 1 |
| Brunk, FS | 1 |
| Fastenberg, NA | 1 |
| Martin, RG | 1 |
| Jessup, JM | 1 |
| Krane, IM | 1 |
| Budzik, GP | 1 |
| Donahoe, PK | 1 |
| Vallicioni, J | 1 |
| Schneider, M | 1 |
| Demard, F | 1 |
| Morere, JF | 1 |
| Piver, MS | 1 |
| Lele, SB | 1 |
| Patsner, B | 1 |
| Emrich, LJ | 1 |
| Lobova, TG | 1 |
| Dobrynin, IaV | 1 |
| Nikolaeva, TG | 1 |
| Zharkov, SA | 1 |
| Weiden, PL | 1 |
| Einstein, AB | 1 |
| Rudolph, RH | 1 |
| Leidi, L | 1 |
| Maina, G | 1 |
| Rappelli, F | 1 |
| Cocola, L | 1 |
| Durando, C | 1 |
| Hughes, RR | 1 |
| Hellriegel, W | 1 |
| Lemon, HM | 1 |
| Foley, JF | 1 |
| Paustian, FF | 1 |
| Kessinger, A | 1 |
| Delevan, J | 1 |
| McLaughlin, CW | 1 |
| Green, N | 1 |
| Beron, E | 1 |
| Melbye, RW | 1 |
| George, FW | 1 |
| Richard, JM | 1 |
| Sancho, H | 1 |
| Erez, S | 1 |
| Kaplan, AL | 1 |
| Wall, JA | 1 |
| Mackman, S | 2 |
| Villasanta, U | 1 |
| Bloedorn, FG | 1 |
| Kissel, P | 1 |
| Bessot, M | 1 |
| Duprez, A | 1 |
| Wheeler, GP | 1 |
| Bowdon, BJ | 1 |
| Adamson, DJ | 1 |
| Vail, MH | 1 |
| Ringkjob, R | 1 |
| Rottenberg, VI | 1 |
| Knysh, VI | 1 |
| Izsak, FC | 1 |
| Eylan, E | 1 |
| Gazith, A | 1 |
| Shapiro, J | 1 |
| Naharin, S | 1 |
| Raanani, C | 1 |
| Nitze, HR | 3 |
| Ganzer, U | 3 |
| Vosteen, KH | 3 |
| Wright, PF | 1 |
| Gharpure, MA | 1 |
| Hodes, DS | 1 |
| Chanock, RM | 1 |
| van der Merwe, AM | 1 |
| Falkson, G | 1 |
| Sandison, AG | 1 |
| van Dyk, JJ | 1 |
| Falkson, HC | 1 |
| Patrassi, N | 1 |
| Basoli, A | 1 |
| Mineo, TC | 1 |
| Carboni, M | 1 |
| Simpson, RW | 1 |
| Obijeski, JF | 1 |
| Carter, SK | 1 |
| Elias, EG | 1 |
| Byland, W | 1 |
| Nagel, G | 1 |
| Senn, HJ | 1 |
| Hecker, D | 1 |
| Klug, H | 1 |
| Tanneberger, S | 1 |
| Rose, H | 1 |
| Ueda, G | 1 |
| Hayakawa, K | 1 |
| Yoshinare, S | 1 |
| Yamazaki, M | 1 |
| Knock, FE | 1 |
| Galt, RM | 1 |
| Oester, YT | 1 |
| Sylvester, R | 1 |
| Lokich, JJ | 1 |
| Skarin, AT | 1 |
| Bernard, LJ | 1 |
| Allen, M | 1 |
| Birchette, C | 1 |
| Royal, J | 1 |
| Walker, M | 1 |
| Waddell, WR | 2 |
| Grover, FL | 1 |
| Carr, DT | 1 |
| Childs, DS | 1 |
| Lee, RE | 1 |
| Nevin, JE | 1 |
| Melnick, I | 1 |
| Baggerly, JT | 1 |
| Hoffman, A | 1 |
| Landes, RR | 1 |
| Easley, C | 1 |
| Ammon, J | 1 |
| Hermann, HJ | 1 |
| Janssen, B | 1 |
| Schmidt, L | 1 |
| Günther, W | 1 |
| Bulbuk, GA | 1 |
| Nordman, E | 1 |
| Kauppinen, C | 1 |
| Wallgren, A | 1 |
| Norin, T | 1 |
| Spigel, SC | 1 |
| Coltman, CA | 1 |
| Costanzi, JJ | 1 |
| Bross, ID | 1 |
| Slack, NH | 1 |
| Ausman, RK | 1 |
| Alberto, P | 1 |
| Nathanson, L | 1 |
| Hall, TC | 1 |
| Schilling, A | 1 |
| Miller, S | 1 |
| Burdette, WJ | 1 |
| Healy, JB | 1 |
| Kokame, GM | 1 |
| Molina, C | 1 |
| Cheminat, JC | 1 |
| Passemard, N | 1 |
| Adam, J | 1 |
| Migueres, J | 1 |
| Jover, A | 1 |
| Mignon, A | 1 |
| Tournant, A | 1 |
| Meyer, A | 1 |
| Tsuya, A | 1 |
| Okano, S | 1 |
| Goto, H | 1 |
| Rutledge, F | 1 |
| Zingg, E | 1 |
| Poliak, NR | 1 |
| Goldfinger, D | 1 |
| McGinniss, MH | 1 |
| Lleander, VC | 1 |
| Goldstein, G | 1 |
| Horsley, JS | 1 |
| Litwin, MS | 1 |
| Ryan, RF | 1 |
| Reed, RJ | 1 |
| Chevrel, B | 1 |
| Chevrel, JP | 1 |
| Obert, G | 1 |
| Tripier, F | 1 |
| Guir, J | 1 |
| Holland, JF | 1 |
| Sheehe, PR | 1 |
| Graham, S | 1 |
| Wilson, CB | 1 |
| Winternitz, WW | 1 |
| Rush, BF | 1 |
| Walton, KN | 1 |
| Maddy, JA | 1 |
| Toriyama, K | 1 |
| Maeda, H | 1 |
| Landes, E | 1 |
| Thivolet, J | 1 |
| Bondet, P | 1 |
| Perrot, H | 1 |
| Claudy, A | 1 |
| Rapoport, AH | 1 |
| Burleson, RL | 1 |
| Borczewski, S | 1 |
| Zurakowski, W | 1 |
| Serpick, AA | 1 |
| Karrer, K | 1 |
| Kühböck, J | 1 |
| Rousselot, LM | 1 |
| Cole, DR | 1 |
| Grossi, CE | 1 |
| Conte, AJ | 1 |
| Gonzalez, EM | 1 |
| Pasternack, BS | 1 |
| Reboul, AR | 1 |
| Lewest, G | 1 |
| Morere, P | 1 |
| Chauvet, MC | 1 |
| Vaudour, P | 1 |
| Maisse, P | 1 |
| Stain, JP | 1 |
| Lenail, C | 1 |
| Wirtanen, GW | 1 |
| Bernhardt, LC | 1 |
| Ramirez, G | 1 |
| Bernard, E | 1 |
| Grant, JP | 1 |
| Harper PV FERGUSON, DJ | 1 |
| Gasparri, F | 1 |
| Periti, P | 1 |
| De Laurentiis, G | 1 |
| Boffi, L | 1 |
| Favi, P | 1 |
| Sbaragli, F | 1 |
| Nance, FC | 1 |
| MacVaugh, H | 1 |
| Fitts, WT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial[NCT00847912] | Phase 4 | 954 participants (Actual) | Interventional | 2009-06-26 | Completed | ||
| Diagnostic Value of Intraoperative Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases During Staging Laparoscopy for Gastric Adenocarcinoma: a Prospective, Multicentric Study.[NCT05687617] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-12-15 | Recruiting | ||
| A Randomized, Phase II, Placebo-controlled Study of Ipatasertib (GDC-0068), an Inhibitor to Akt, in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma[NCT01896531] | Phase 2 | 153 participants (Actual) | Interventional | 2013-08-14 | Completed | ||
| Phase II, Open Label, Neoadjuvant Study of Bevacizumab in Patients With Inflammatory or Locally Advanced Breast Cancer[NCT00559845] | Phase 2 | 56 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Pilot Study of Teng-Long-Bu-Zhong-Tang Based Herbal Therapy in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer[NCT01975454] | Phase 1/Phase 2 | 62 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Randomized Controlled Trial of the Efficacy of Adjuvant Chemotherapy in Patients With Residual Lesions After Concurrent Radiochemotherapy for Locally Advanced Cervical Cancer[NCT04409860] | 120 participants (Anticipated) | Interventional | 2020-05-26 | Recruiting | |||
| TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma, a Prospective,Parallel, Randomized, Open Labeled, Multicenter Phase III Clinical Trial[NCT02940925] | Phase 3 | 241 participants (Actual) | Interventional | 2016-10-20 | Completed | ||
| A Multi-institutional, Randomized Controlled, Phase II Clinical Trial on Comparison of Efficacy and Safety of Nedaplatin Plus 5-Fu Combined With and Without Endostar® Continuous Intravenous Infusion in Refractory Nasopharyngeal Carcinoma[NCT02590133] | Phase 2 | 328 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With Intensity-modulated Radiotherapy in High Risk Locregionally Advanced Nasopharyngeal Carcinoma: a Phase 2 Randomized Controlled Trial[NCT02610556] | Phase 2 | 130 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Randomized Phase 3 Trial of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy Versus Concurrent Chemotherapy Alone in High Risk Nasopharyngeal Carcinoma Patients Treated With Intensity-modulated Radiotherapy[NCT02621970] | Phase 3 | 534 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma: a Phase 2 Trial[NCT04870905] | Phase 2 | 100 participants (Anticipated) | Interventional | 2023-03-01 | Not yet recruiting | ||
| Induction Chemotherapy of Docetaxel, Cisplatin and Xeloda in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma[NCT02786641] | Phase 3 | 235 participants (Anticipated) | Interventional | 2016-08-31 | Not yet recruiting | ||
| Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in Induction Chemotherapy Plus Concurrent Chemoradiotherapy for Locoregionally Advanced NPC： a Phase 3, Multicentre, Non-inferiority, Randomised Factorial Trial[NCT03503136] | Phase 3 | 632 participants (Anticipated) | Interventional | 2018-06-30 | Not yet recruiting | ||
| A Randomized Non-inferiority Trial of Radiotherapy Plus Nimotuzumab or Cisplatin in Patients With Favorable Response to Induction Chemotherapy for Low-risk Locoregionally Advanced-Staged Nasopharyngeal Carcinoma[NCT04456322] | Phase 3 | 326 participants (Anticipated) | Interventional | 2020-07-06 | Recruiting | ||
| A Randomized, Open-Label, Phase II Study to Evaluate the Efficacy and Safety of Sintilimab Plus Capecitabine Versus Capecitabine Alone as Adjuvant Therapy for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT05201859] | Phase 2 | 150 participants (Anticipated) | Interventional | 2022-03-29 | Recruiting | ||
| Randomized Phase II Trial of Concurrent Chemoradiotherapy With or Without Nimotuzumab for High Risk Nasopharyngeal Carcinoma After Induction Chemotherapy[NCT04223024] | Phase 2 | 246 participants (Actual) | Interventional | 2019-12-12 | Active, not recruiting | ||
| Changes and Influence Factors of Olfactory Function After Chemo-radiotherapy for Locally Advanced Nasopharyngeal Carcinoma: a Prospective Observational Cohort Study[NCT05146050] | 107 participants (Anticipated) | Observational [Patient Registry] | 2021-12-08 | Recruiting | |||
| A Multicenter and Prospective Clinical Trial of Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma[NCT04522050] | Phase 1 | 65 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| Microbiota, Inflammatory Environment, Clinical and Radiomic Features as Predictors of Normal Tissue Response in Radiotherapy for Prostate and Head-and-neck Cancer[NCT03294122] | 400 participants (Anticipated) | Observational | 2017-02-02 | Recruiting | |||
| Phase 1 Study of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel for Peritoneal Carcinomatosis - PIPAC2 Study[NCT05395910] | Phase 1 | 36 participants (Anticipated) | Interventional | 2022-10-31 | Recruiting | ||
| A Randomized Multicenter Phase II/III Study of Optimized Treatment Strategies for Stage II and III Nasopharyngeal Carcinoma[NCT03908372] | Phase 2/Phase 3 | 120 participants (Anticipated) | Interventional | 2019-06-15 | Recruiting | ||
| A Single-arm Study Evaluating the Relative Dose Intensity of IV CMF Given on Day 1 and Day 8 With Pegfilgrastim Support in Subjects With Stage I-III Breast Cancer[NCT00124111] | Phase 2 | 0 participants | Interventional | Completed | |||
| A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy[NCT00263588] | Phase 2 | 242 participants (Actual) | Interventional | 2005-12-02 | Completed | ||
| Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients[NCT05060471] | Phase 2 | 27 participants (Anticipated) | Interventional | 2021-09-08 | Enrolling by invitation | ||
| A Phase 3, Multicenter, Double-Blind Randomized Study of Mitomycin, 5-Fluorouracil and IMRT Combined With or Without Anti-PD-1 in Patients With Locally Advanced Anal Canal Squamous Carcinoma[NCT05374252] | Phase 3 | 102 participants (Anticipated) | Interventional | 2022-05-07 | Recruiting | ||
| Phase Ⅲ Trial of Induction Chemotherapy（TPF） Followed by Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy (PF) in Patients With High Risk Nasopharyngeal Carcinoma[NCT03306121] | Phase 3 | 322 participants (Anticipated) | Interventional | 2017-11-13 | Active, not recruiting | ||
| BEV-IP: Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis[NCT02399410] | Phase 2 | 60 participants (Actual) | Interventional | 2015-12-31 | Active, not recruiting | ||
| Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors[NCT00416767] | Phase 2 | 20 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Treatment of Liver Metastases With Electrochemotherapy[NCT01264952] | Phase 1/Phase 2 | 16 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II[NCT02352259] | Phase 2 | 23 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma: A Randomized Phase III Trial[NCT04898374] | Phase 3 | 120 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | ||
| A Multicenter Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT00677118] | Phase 3 | 506 participants (Anticipated) | Interventional | 2006-06-30 | Active, not recruiting | ||
| Prospective Comparisons of Survival Outcomes, Safety Profile, and Probability of Returning to Society Between Three Randomized Controlled Trials and Real-world Evidence in Nasopharyngeal Carcinoma.[NCT04108338] | 5,448 participants (Actual) | Observational [Patient Registry] | 2019-06-01 | Completed | |||
| Randomized, Placebo-controlled, Double-blind Phase II Clinical Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Immunotherapy Combined With Concurrent Chemoradiotherapy for High-risk Nasopharyngeal Carcinoma[NCT03925090] | Phase 2 | 150 participants (Anticipated) | Interventional | 2019-12-08 | Active, not recruiting | ||
| Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT: A Single-center, Randomized Controlled Trial[NCT02735317] | Phase 2 | 90 participants (Anticipated) | Interventional | 2016-04-30 | Not yet recruiting | ||
| A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes and Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma[NCT02421640] | Phase 2 | 116 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| A Randomized Trial Comparing Induction Gemcitabine and Cisplatin Plus Intensity-modulated Radiotherapy With Concurrent Cisplatin Plus Intensity-modulated Radiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT02460887] | Phase 3 | 236 participants (Anticipated) | Interventional | 2015-06-30 | Active, not recruiting | ||
| 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation Versus Concurrent Chemoradiation Alone In Patients With Stage N2-3 Nasopharyngeal Carcinoma: A Phase 3 Multicenter Randomised Controlled Trial[NCT02512315] | Phase 3 | 192 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| Phase Ⅲ Trial of Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy (GP Versus PF) in Patients With N2-3 Nasopharyngeal Carcinoma[NCT03321539] | Phase 3 | 216 participants (Anticipated) | Interventional | 2017-10-30 | Active, not recruiting | ||
| A Prospective, Single-arm, Phase II Study of Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin in Locally Advanced Nasopharyngeal Carcinoma.[NCT06059261] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| Clinical Study on the Safety and Efficacy of EBV CAR-T /TCR-T Cells in the Treatment of Recurrent / Refractory EBV Positive Nasopharyngeal Carcinoma[NCT05587543] | Early Phase 1 | 24 participants (Anticipated) | Interventional | 2022-12-28 | Recruiting | ||
| Phase II Study of TPF Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT03020329] | Phase 2 | 37 participants (Anticipated) | Interventional | 2016-11-14 | Recruiting | ||
| Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma: a Multicenter, Randomised, Phase 3 Study.[NCT02460419] | Phase 3 | 104 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Prospective Controlled Randomized Comparative Study About Quality of Life (QoL), Immunomodulation and Safety of Adjuvant Mistletoe Treatment in Patients With Gastric Carcinoma Receiving Chemotherapy After Operation[NCT01401075] | Phase 4 | 32 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Treatment of Malignant Sinonasal Tumours With Intensity-modulated Radiotherapy (IMRT) and Carbon Ion Boost (C12)[NCT01220752] | Phase 2 | 36 participants (Actual) | Interventional | 2011-06-17 | Completed | ||
| Long-term Results of Plasma Epstein-Barr Virus DNA Monitoring In Nasopharyngeal Carcinoma After Curative Treatment[NCT03973723] | 441 participants (Actual) | Observational | 2011-08-01 | Completed | |||
| A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330] | Phase 2 | 60 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Master Protocol for Metastatic Hormone-Resistant Prostatic Carcinoma - Phase II Trials - Protocol 5: Capecitabine[NCT00006023] | Phase 2 | 0 participants | Interventional | 2000-03-31 | Completed | ||
| Phase II Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil Followed by Weekly Docetaxel and Cetuximab in Concurrence With Intensity-modulated Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma (NPC)[NCT01326559] | Phase 2 | 33 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma[NCT00379262] | Phase 3 | 803 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Effect of Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Locoregionally Advanced,Low-risk Nasopharyngeal Carcinoma.[NCT02237924] | Phase 2 | 120 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| Total Neoadjuvant Therapy in Rectal Cancer Treatment[NCT04747951] | Phase 4 | 280 participants (Anticipated) | Interventional | 2020-10-30 | Recruiting | ||
| Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI[NCT01858649] | Phase 2 | 60 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors[NCT01858662] | Phase 2 | 4 participants (Actual) | Interventional | 2014-01-31 | Terminated (stopped due to due to poor recrutment) | ||
| Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC II-IV, With a 5-FU-based Standard Radiochemotherapy Followed by Total Mesorectal Excision.[NCT03034473] | 200 participants (Actual) | Interventional | 2011-08-31 | Active, not recruiting | |||
| Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy[NCT00855946] | 46 participants (Actual) | Observational | 2009-05-31 | Completed | |||
| KCSP Trial of cONsolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After neoadjUvant Concurrent chemoraDiothErapy: A Multicenter, Randomized Controlled Trial (KONCLUDE Trial)[NCT02843191] | Phase 3 | 358 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| A Randomised Study of Sequential Versus Combination Chemotherapy in Patients With Previously Untreated Advanced Colorectal Carcinoma[NCT00312000] | Phase 3 | 820 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Phase II Trial of Fluorouracil (5-FU), Leucovorin (LV), Irinotecan (CPT-11) and Bevacizumab (Anti-VEGF) in Previously Untreated Patients With Advanced Colorectal Cancer[NCT00006786] | Phase 2 | 0 participants | Interventional | 2000-11-30 | Completed | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Randomized Phase Ⅱ Trial of Induction Chemotherapy Using Gemcitabine and Cisplatin in Concurrence With Intensity-modulated Radiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma[NCT01417390] | Phase 2 | 80 participants (Anticipated) | Interventional | 2011-11-30 | Recruiting | ||
| Prospective Non-inferior Clinical Trial Comparing Concurrent Chemoradiotherapy or Radiotherapy Alone in Patients With Intermediate Risk Nasopharyngeal Carcinoma in Intensity-modulated Radiotherapy Era[NCT02633202] | Phase 3 | 338 participants (Anticipated) | Interventional | 2015-11-30 | Recruiting | ||
| Prospective Non-inferior Clinical Trial Comparing Concurrent Chemoradiotherapy or Radiotherapy Alone in Patients With Intermediate Risk Nasopharyngeal Carcinoma in Intensity-modulated Radiotherapy Era[NCT02289807] | 0 participants (Actual) | Interventional | 2015-03-31 | Withdrawn | |||
| Cetuximab Added to Capecitabine, Oxaliplatin and Bevacizumab in Patients With Previously Untreated Advanced Colorectal Carcinoma, a Randomised Phase III Study[NCT00208546] | Phase 3 | 750 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer[NCT00001193] | Phase 2 | 200 participants | Interventional | 1984-11-30 | Completed | ||
| Phase II Randomized Controlled Trial of Concomitant Chemoradiotherapy With Standard Fractionation Compared to Hypofractionated Concomitant Chemoradiotherapy Followed by Brachytherapy, for Clinical Stage III Cervical Cancer Patients[NCT04070976] | 82 participants (Anticipated) | Interventional | 2019-07-01 | Recruiting | |||
| Prospective Study for the Validation of the Genetic Signature 354849 to Predict the Response to Standard Treatment in Patients With Locally Advanced Cervical Cancer[NCT04067882] | 189 participants (Anticipated) | Observational | 2019-09-30 | Recruiting | |||
| CRP on Radiobiological and Clinical Studies on Viral-induced Cancer's Response to Radiotherapy With Comprehensive Morbidity Assessment[NCT00122772] | Phase 3 | 601 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Phase II Trial of Weekly Carboplatin-Paclitaxel Adjuvant Chemotherapy After Intensity Modulated Extended-field Chemoradiation in the Treatment of Locally Advanced Cervical Cancer With Para-aortic Positive Nodes[NCT04016142] | Phase 2 | 21 participants (Actual) | Interventional | 2020-07-15 | Active, not recruiting | ||
| A Phase III Randomized Clinical Trial to Study the Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Uterine Cervix.[NCT03256916] | Phase 3 | 348 participants (Anticipated) | Interventional | 2018-01-16 | Recruiting | ||
| Phase II Trial To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix[NCT04789941] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
| Effect of Neoadjuvant Cisplatin Based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Clinical Outcome and Correlation to Biological Parameters[NCT00603408] | Phase 2 | 5 participants (Actual) | Interventional | 2007-12-31 | Terminated (stopped due to Study was discontinued due to lack of accrual.) | ||
| Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression[NCT02309658] | Phase 2 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Randomized Phase III Clinical Trial of Weekly Versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer[NCT01561586] | Phase 3 | 374 participants (Anticipated) | Interventional | 2012-03-31 | Recruiting | ||
| Study on Adaptive Radiotherapy and Multimodal Information of Cervical Cancer Assisted by Artificial Intelligence[NCT04022018] | 122 participants (Anticipated) | Interventional | 2019-12-18 | Recruiting | |||
| AVF3963s Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer[NCT00600210] | Phase 2 | 0 participants (Actual) | Interventional | 2008-01-31 | Withdrawn (stopped due to low patient accrual) | ||
| A Prospective Phase II Study of Prophylactic TPO Combined With Bone Marrow-Sparing Intensity-Modulated Radiotherapy to Reduce Platelet Inhibition in Patients With Esophageal Cancer Undergoing Concurrent Chemoradiotherapy[NCT05944809] | Phase 2 | 27 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)[NCT05660083] | Phase 2 | 36 participants (Anticipated) | Interventional | 2023-01-12 | Recruiting | ||
| A Clinical Trial to Assess the Relative Efficacy of 5-FU + Leucovorin, 5-FU + Levamisole, and 5-FU + Leucovorin + Levamisole in Patients With Dukes' B and C Carcinoma of the Colon[NCT00425152] | Phase 3 | 2,151 participants (Actual) | Interventional | 1989-07-31 | Completed | ||
| A Prospective Clinical Trial of Improving the Treatment of Thoracic Esophageal Cancer[NCT01137123] | Phase 3 | 301 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Carcinoma of the Nasopharynx[NCT00797290] | 9 participants (Actual) | Observational | 2008-06-30 | Terminated (stopped due to Slow enrollment, Feasibility issues) | |||
| Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy With or Without Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT01872962] | Phase 3 | 480 participants (Actual) | Interventional | 2013-11-30 | Active, not recruiting | ||
| A Randomized Phase III Non-inferiority Study of Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma[NCT01540136] | Phase 3 | 402 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| Effect of Short-duration Preoperative Neoadjuvant Therapy With FOLFOX Based Therapy on Morbidity After Liver Resection for Colorectal Cancer Metastases[NCT00537823] | Phase 2 | 9 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to Poor accrual.) | ||
| Prospective, Randomized Study Aiming to Assess the Benefit of Autohypnosis Learning in the Care of Patients Treated by Adjuvant Chemotherapy for Colorectal or Breast Cancer.[NCT03429296] | 120 participants (Actual) | Interventional | 2018-05-23 | Completed | |||
| A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.[NCT03515798] | Phase 2 | 81 participants (Anticipated) | Interventional | 2018-07-24 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00847912)
Timeframe: date of randomization to last visit before end of study follow up (6/30/2013), assessed up to four years
| Intervention | participants (Number) |
|---|---|
| Arm 1: 5-fluorouracil | 182 |
| Arm 2: Placebo, Vehicle Control | 177 |
Diagnosis of the first Primary Basil Cell Carcinoma (BCC) or primary Squamous Cell Carcinoma (SCC) on the face or ears that was removed surgically. (NCT00847912)
Timeframe: From randomization to last visit prior to end of study date (6/30/2013), assessed up to four years
| Intervention | years (Median) |
|---|---|
| Arm 1: 5-fluorouracil | 3.37 |
| Arm 2: Placebo, Vehicle Control | 3.52 |
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Death on study was defined as death from any cause within 30 days of the last dose of study treatment regimen. (NCT01896531)
Timeframe: Baseline until end of study (up to approximately 7.5 years)
| Intervention | Participants (Count of Participants) |
|---|---|
| Ipatasertib + mFOLFOX6 | 70 |
| Placebo + mFOLFOX6 | 80 |
Duration of objective tumor response in participants with measurable soft tissue disease at baseline was defined as the time from first observation of an objective tumor response until first observation of disease progression, as assessed by the investigator per modified RECIST Version 1.1. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or progression of non-target lesions. (NCT01896531)
Timeframe: Screening, at the end of Cycle 4 (cycle = 14 days) and every fourth cycle thereafter until disease progression or death, whichever occurred first, up to end of study (up to approximately 7.5 years)
| Intervention | months (Median) | ||
|---|---|---|---|
| Randomized | PTEN Loss Tumor | Akt Dx+ | |
| Ipatasertib + mFOLFOX6 | 4.63 | 4.70 | 4.70 |
| Placebo + mFOLFOX6 | 5.85 | 5.98 | 6.80 |
Objective Response Rate was defined as the percentage of participants achieving either a complete response (CR) or a partial response (PR) based on the investigator assessment using RECIST v 1.1. CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm. Partial response (PR): At least a 30% decrease in the sum of diameters of target lesions. (NCT01896531)
Timeframe: Screening, at the end of Cycle 4 (cycle = 14 days) and every fourth cycle thereafter until disease progression or death, whichever occurred first, up to end of study (up to approximately 7.5 years)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Randomized | PTEN Loss Tumors | Akt Dx+ | |
| Ipatasertib + mFOLFOX6 | 52.1 | 50.0 | 52.2 |
| Placebo + mFOLFOX6 | 57.3 | 73.3 | 56.5 |
OS was defined as the time from the date of randomization to the date of death from any cause. Kaplan-Meier estimates were used for evaluation. (NCT01896531)
Timeframe: Baseline up to end of study (up to approximately 7.5 years)
| Intervention | months (Median) | ||
|---|---|---|---|
| Randomized | PTEN Loss Tumors | Akt Dx+ | |
| Ipatasertib + mFOLFOX6 | 11.96 | 14.82 | 11.66 |
| Placebo + mFOLFOX6 | 15.31 | 21.78 | 17.22 |
PFS was defined as the time from randomization to the first occurrence of disease progression (as determined using RECIST Version 1.1 and assessed by the investigator), or death from any cause on study. Progressive disease (PD): At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or progression of non-target lesions. Death on study was defined as death from any cause within 30 days of the last dose of study treatment regimen. Kaplan-Meier estimates were used for evaluation. (NCT01896531)
Timeframe: Screening, at the end of Cycle 4 (cycle = 14 days) and every fourth cycle thereafter until disease progression or death, whichever occurred first, assessed up to approximately 1.75 years
| Intervention | months (Median) | |
|---|---|---|
| All Randomized Participants | Participants With PTEN Loss Tumors | |
| Ipatasertib + mFOLFOX6 | 6.57 | 7.10 |
| Placebo + mFOLFOX6 | 7.52 | 7.39 |
(NCT01896531)
Timeframe: Day 1 at 1 hour and 4 hours post-dose; Day 5, pre-dose and 2 hours post-dose
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| Day 1: 1 hour post-dose | Day 1: 4 hours post-dose | Day 5: pre-dose | Day 5: 2 hours post-dose | |
| Ipatasertib + mFOLFOX6 | 506 | 389 | 90.7 | 557 |
Objective response rate was defined as the percentage of participants with a Complete Response (CR) or Partial Response (PR) as defined by the Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as the disappearance of all target lesions; PR was defined as a 30% decrease in sum of longest diameter of target lesions. (NCT00559845)
Timeframe: Up to 7.5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab | 59.0 |
An adverse event was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. (NCT00559845)
Timeframe: Up to 7.5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab | 100.0 |
Pathological complete response was defined as absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. (NCT00559845)
Timeframe: Up to 7.5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab | 23.2 |
Rate of breast conversing surgery is defined as percentage of participants who achieved breast conversing surgery out of the ITT population without inflammatory breast cancer, as these participants received mastectomy irrespective of their response to neoadjuvant treatment. (NCT00559845)
Timeframe: Up to 7.5 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Breast-conserving | Breast-conserving Plus Axillary Dissection | |
| Bevacizumab | 17.0 | 13.2 |
Disease-free interval was defined as the time from enrollment until recurrence of tumor or death from any cause, and was estimated using the Kaplan-Meier method. The percentage of participants without events at Months 12, 24, 36, 48, and 60 is presented. (NCT00559845)
Timeframe: Months 12, 24, 36, 48, and 60
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| 12 Months | 24 Months | 36 Months | 48 Months | 60 Months | |
| Bevacizumab | 92.2 | 84.3 | 80.4 | 76.5 | 76.5 |
"The duration of CNS objective response, defined as the time from first CNS~Objective response until tumor progression at any site or death due to any cause.~A CNS objective response was defined as either a Complete Response (CR) or Partial Response (PR), as assessed by volumetric analysis of magnetic resonance imaging (MRI), provided there was no progression of systemic disease outside of the CNS, increasing steroid requirements, or worsening of tumor-related neurological signs or symptoms." (NCT00263588)
Timeframe: time from baseline to data cutoff (25 Sept 2007); approximately 2 years
| Intervention | months (Median) |
|---|---|
| Cohort A | 2.43 |
| Cohort B | 1.58 |
Overall survival (OS) defined as the time from initiation of investigational product to death due to any cause. (NCT00263588)
Timeframe: time from baseline to data cutoff (25 Sept 2007); approximately 2 years
| Intervention | months (Median) |
|---|---|
| Cohort A | 10.78 |
| Cohort B | 5.82 |
The CNS disease control rate, defined as the percentage of subjects with CR, PR or stable disease at Week 24 (NCT00263588)
Timeframe: from Start of lapatinib to 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort A | 9 |
| Cohort B | 2 |
Summary of CNS Objective Response (the Complete Response + Partial Response) (NCT00263588)
Timeframe: time from baseline to data cutoff (25 Sept 2007); approximately 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort A | 6 |
| Cohort B | 6 |
Summary of Kaplan-Meier Estimates for Progression Free Survival at Any Site (NCT00263588)
Timeframe: time from baseline to data cutoff (25 Sept 2007); approximately 2 years
| Intervention | months (Median) |
|---|---|
| Cohort A | 2.60 |
| Cohort B | 1.87 |
Physician-reported NSS worksheet is derived from 13 AEs and measured by NCI CTCAE v3.0 grouped into 7 categories: level of consciousness, neurological symptoms, cranial nerves, language, strength, sensation, & ataxia. Improvement of NSS required: Decrease by 1 or more grades from baseline of any tumor-related NSS, with confirmation at least 4 wks later, No development or worsening in any tumor-related NSS during interval, No radiographic evidence of CNS progression (assessed by volumetric MRI) or systemic (non-CNS) progression (assessed by RECIST) during interval, Stable or decreasing steroids during interval as defined by GSK equivalent doses of an alternative corticosteroid or a dose increase for non-tumor related reasons didn't constitute a steroid increase. Improvement in any non-tumor associated NSS didn't constitute improvement in NSS. Neurological exam, using Neurological Examination Worksheet was assessed at baseline & each 4 wks. Categories below are not mutually exclusive. (NCT00263588)
Timeframe: time from baseline to data cutoff (25 Sept 2007); approximately 2 years
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Subjects with NSS improvement | >=20% volumetric reduction of lesion | any volumetric reduction of lesion | volumetric increase or withdrew | |
| Cohorts A and B | 24 | 8 | 14 | 9 |
Summary of Proportion of Subjects with a CNS Objective Response or Improvement in Baseline NSS (NCT00263588)
Timeframe: baseline and weeks 8, 16, 24, 32, 40, 48
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| week 8 | week 16 | week 24 | week 32 | week 40 | week 48 | |
| Cohort A | 23 | 2 | 8 | 17 | 0.0 | 0.0 |
| Cohort B | 14 | 8 | 11 | 0.0 | 0.0 | 0.0 |
Summary of Overall All-cause mortality (Main Study and Extension) (NCT00263588)
Timeframe: time from baseline to data cutoff (25 Sept 2007); approximately 2 years
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Disease under study | Other | |
| Cohort A | 74 | 4 |
| Cohort B | 124 | 4 |
baseline to time of disease progression or death (NCT00263588)
Timeframe: time from baseline to data cutoff (25 Sept 2007); approximately 2 years
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| CNS progression | Non-CNS prgression | CNS and Non-CNS progression | |
| Cohort A | 69 | 1 | 12 |
| Cohort B | 72 | 10 | 36 |
"Summary of CNS Objective Response (Lapatinib Monotherapy - MITT Population)~Response to lapatinib in patients with progressive brain metastases from ErbB2-overexpressing breast cancer.~The primary indicator of drug efficacy was CNS objective response rate. A CNS objective response was defined as either a Complete response (CR) or Partial response (PR), as assessed by volumetric analysis of brain Magnetic resonance imaging (MRI), provided there was no progression of systemic disease outside of the CNS, increasing steroid requirements, or worsening of Neurological signs and symptoms (NSS)~A CNS objective response rate was defined as a 50% volumetric reduction in sum of CNS target lesions, with no new or progressive CNS or non-CNS lesions, no increases in tumor-related steroid requirements and no worsening of neurological signs or symptoms" (NCT00263588)
Timeframe: time from baseline to data cutoff (25 Sept 2007); approximately 2 years
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Complete response (CR) | Partial response (PR) | Stable disease (SD) | Progressive disease (PD) | Unknown | |
| Cohort A | 0 | 6 | 40 | 40 | 8 |
| Cohort B | 0 | 9 | 46 | 70 | 18 |
(NCT01264952)
Timeframe: After operation on day 7
| Intervention | events (Number) |
|---|---|
| Group I | 0 |
| Group II | 0 |
| Group III | 0 |
(NCT01264952)
Timeframe: After operation on tha days 2, 7, 30, monthly
| Intervention | patients with non-severe adverse events (Number) |
|---|---|
| Group I | 3 |
| Group II | 2 |
| Group III | 7 |
"Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI:~Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR" (NCT01264952)
Timeframe: After operation or 1st day after operation, 7th day, 30th day, monthly
| Intervention | metastases (Number) |
|---|---|
| Group I | 10 |
| Group II | 1 |
| Group III | 10 |
Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin | 6.97 |
Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 10.51 |
The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 41.7 |
Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days
| Intervention | participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 56 |
The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 will be utilized for all toxicity reporting. All detailed information regarding serious and other adverse events are listed in the Adverse Event module of these results. (NCT00603408)
Timeframe: 30 days post surgery (week 17-18)
| Intervention | participants (Number) |
|---|---|
| Cisplatin + Radiation + Recommended Surgery | 5 |
(NCT00603408)
Timeframe: 30 days post surgery (week 17-18)
| Intervention | participants (Number) |
|---|---|
| Cisplatin + Radiation + Recommended Surgery | 0 |
OS = Time from registration until death from any cause (NCT00603408)
Timeframe: Until study was terminated (23.5 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Cisplatin + Radiation + Recommended Surgery | 100 |
"Complete response: disappearance of all target lesions, non-target lesions, and normalization of tumor marker level~Partial response: at least a 30% decrease in the sum of the longest diameter (LD) of the target lesions taking as reference the baseline sum LD~Stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD since the treatment started,~Progressive disease: at least a 20% increase in the sum of the LD of the target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, appearance of one more new lesions, or unequivocal progression of existing non-target lesions." (NCT00603408)
Timeframe: At the time of surgery (week 13)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete response | Partial response | Stable disease | Progressive disease | |
| Cisplatin + Radiation + Recommended Surgery | 2 | 3 | 0 | 0 |
Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Local Control Only | Local Control and Distant Metastasis | Distant Metastatsis Only | Secondary Primary - Site Unknown | Surgical Salvage | |
| Recurrence | 6 | 2 | 1 | 2 | 3 |
Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hematologic | Dermatitis | Mucositis/Dysphagia | |
| Acute Toxicity | 12 | 7 | 16 |
(NCT00537823)
Timeframe: 30 days following surgery
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
-Compare total longest diameter from baseline to preoperative CT scan. (NCT00537823)
Timeframe: Completion of neoadjuvant therapy (approximately 8 weeks)
| Intervention | percentage of change of longest diameter (Median) |
|---|---|
| Arm 1 - Wildtype | -23.8 |
| Arm 2 K-Ras 12/13 Codon Mutation | -14.3 |
Number of participants whose tumor size decreased from baseline to completion of preoperative chemotherapy. (NCT00537823)
Timeframe: Upon completion of neoadjuvant chemotherapy (approximately 2 months)
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 4 |
| Arm 2 K-Ras 12/13 Codon Mutation | 2 |
Fraction of patients with any complication grades IV and V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
Fraction of patients with any grade of complication I-V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
(NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Not reported on pathology report | Mild | Aborted surgery | None | |
| Arm 1 - Wildtype | 1 | 1 | 1 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 0 | 1 |
"NASH Scoring~Steatosis **<5% = 0~**5-33%=1~**>33-66%=2~**>66%=3~Lobular inflammation~**No foci=0~**<2 foci per x 200 field=1~**2-4 foci per x 200 field=2~**>4 foci per x 200 field=3~Hepatocellular ballooning **None=0 **Few balloon cells = 1 **Many cells/prominent ballooning=2" (NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Not reported on pathology report | Aborted surgery | Score 0 | |
| Arm 1 - Wildtype | 3 | 1 | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 1 |
Liver only vs distant disease (NCT00537823)
Timeframe: Up to 5 years
| Intervention | participants (Number) | |
|---|---|---|
| Liver only | Distant disease | |
| Arm 1 - Wildtype | 0 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 |
65 reviews available for fluorouracil and Carcinoma
| Article | Year |
|---|---|
Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2021 |
Significant response of pituitary carcinoma to carboplatin, leucovorin and fluorouracil chemotherapy: a pediatric case report and review of the literature.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carc | 2017 |
The paradigm of tumor shrinkage and rapid liver remnant hypertrophy for conversion of initially unresectable colorectal liver metastasis: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Carcinoma; C | 2017 |
Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer.
Topics: Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Deglut | 2017 |
Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian Peop | 2019 |
Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease Progression; Docetaxel | 2013 |
Options for metastatic colorectal cancer beyond the second line of treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2014 |
Concurrent chemoradiotherapy comparison of taxanes and platinum versus 5-fluorouracil and platinum in nasopharyngeal carcinoma treatment.
Topics: Carcinoma; Chemoradiotherapy; Fluorouracil; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplas | 2014 |
Diagnosis and management of DNA mismatch repair-deficient colorectal cancer.
Topics: Adenoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; C | 2015 |
Concurrent chemoradiotherapy was associated with a higher severe late toxicity rate in nasopharyngeal carcinoma patients compared with radiotherapy alone: a meta-analysis based on randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Confidence | 2015 |
Management of sinonasal undifferentiated carcinoma with intracerebral invasion: Clinical experience at a single institution and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma; Chemoradiotherapy | 2016 |
Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part I: Topical Treatments.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Anti-Inflammatory Agents, Non-St | 2016 |
[Current therapeutic options for liver metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Catheter Ablation; Colorect | 2008 |
Malignant neoplasms of the sinonasal tract: report of 71 patients and literature review and analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Child; Child, Preschoo | 2009 |
Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview.
Topics: Adenoma; Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combine | 2009 |
[A case of poorly differentiated adenocarcinoma of the rectum with disseminated carcinomatosis of the bone marrow successfully treated with mFOLFOX-6/bevacizumab].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2010 |
[Molecular subtypes and individualized treatment of breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2010 |
Cetuximab in the treatment of squamous cell carcinoma of the head and neck.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2011 |
Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brea | 2012 |
Definitive treatment of metastatic nasopharyngeal carcinoma: Report of 5 cases with review of literature.
Topics: Adult; Antineoplastic Agents; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Femal | 2012 |
Role of chemotherapy in stage IIb nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant | 2012 |
Trimodality management of sinonasal undifferentiated carcinoma and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradi | 2013 |
Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 18 | 2004 |
Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.
Topics: Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hum | 2006 |
Use of hyperthermic intraperitoneal chemotherapy (HIPEC) in management of peritoneal carcinomatosis from colorectal origin.
Topics: Antineoplastic Agents; Appendiceal Neoplasms; Carcinoma; Colorectal Neoplasms; Combined Modality The | 2005 |
Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Fluoro | 2006 |
Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Biomarkers, Tumor; Carcinoma; Dihydrouracil Dehydrog | 2006 |
[Chemotherapy agents, response rates and mechanisms of resistance in the therapy of the colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2006 |
Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Clinical Trials as Topic; C | 2007 |
The effectiveness of intravenous 5-fluorouracil-containing chemotherapy after curative resection for gastric carcinoma: A systematic review of published randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Female; Fluoro | 2007 |
Chemotherapy of hormonally unresponsive prostatic carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Cispla | 1984 |
Cytotoxic chemotherapy for adrenocortical carcinoma.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adult; Animals; Antineoplastic Combined Chemotherapy Protocols | 1995 |
The role of chemotherapy and adjuvant therapy in the management of colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colonic Neo | 1994 |
Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta | 1994 |
Locally advanced cervical carcinoma: the role of chemoradiation.
Topics: Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Human | 1994 |
Bolus mitomycin C and 5-FU with sequential radiation for poor-prognosis locally advanced cervical cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma; Combined Modality Therapy; | 1996 |
Radiotherapy for carcinoma of the pancreas.
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials a | 1996 |
Adjuvant therapy for colorectal cancer--is there a place for a Northern Ireland study?
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colore | 1994 |
Combined infusional chemotherapy and radiation for esophageal carcinoma: a review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clinica | 1995 |
Treatment of patients with upper gastrointestinal carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Therapy, Com | 1997 |
Sphincter preservation in rectal cancer. Local excision followed by postoperative radiation therapy.
Topics: Abdomen; Anal Canal; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Colostomy; | 1998 |
Induction therapy for rectal carcinoma.
Topics: Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Combined Modality Therapy; Fluorouracil; Huma | 1998 |
[Treatment of peritoneal carcinosis of colorectal origin].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemothe | 1997 |
[Continuous radiosensitizing chemotherapy].
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cisplatin; Clinical Trials as Topic; Combined Modalit | 1999 |
Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma; Fluorouracil; Heart Diseases; Humans; Male; Tongu | 1999 |
Recall phenomenon following epirubicin.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 1999 |
Lacrimal canalicular stenosis associated with systemic 5-fluorouacil therapy.
Topics: Aged; Carcinoma; Colectomy; Colonic Neoplasms; Dacryocystorhinostomy; Female; Fluorouracil; Humans; | 2000 |
[Colon carcinoma. Consensus of therapeutic strategies].
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Che | 2000 |
[New therapeutic options in chemotherapy of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Clinical Tria | 2001 |
[Chemotherapy of colorectal carcinoma].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemo | 2001 |
Alternating chemo-radiotherapy with cisplatin and 5-fluorouracil plus bleomycin by continuous infusion for locally advanced undifferentiated carcinoma nasopharyngeal type.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cispl | 1992 |
Adjuvant treatment of node-positive colon carcinoma with levamisole and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Fluorouracil; Humans; | 1991 |
[Adjuvant therapy in colonic carcinoma].
Topics: Carcinoma; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Levamisole; Neoplasm | 1991 |
Clinical trials of fluorouracil with alpha-interferon in advanced colorectal carcinomas.
Topics: Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; | 1991 |
120-hour 5-fluorouracil (5-FU) continuous infusion (CI) plus BCNU in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Colorectal Neopl | 1991 |
Update in cancer chemotherapy, Part III: Lung cancer, Part 1.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Bleomycin; Carcinoma; C | 1985 |
Management of peritoneal carcinomatosis.
Topics: Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Fluorouracil; Humans; Injections, Intra | 1989 |
Adjuvant chemotherapy for advanced nasopharyngeal carcinoma in childhood.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Child; Combined Modali | 1989 |
Phase I/II study of definitive radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) for advanced or recurrent gynecologic malignancies. Preliminary report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; C | 1989 |
A review of lower genital intraepithelial neoplasia and the use of topical 5-fluorouracil.
Topics: Acquired Immunodeficiency Syndrome; Administration, Topical; Adult; Anal Canal; Anus Neoplasms; Carc | 1985 |
In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma.
Topics: Adenocarcinoma; Animals; Carcinoma; Colonic Neoplasms; Disease Models, Animal; Drug Synergism; Femal | 1988 |
Surgical adjuvant therapy of rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modali | 1988 |
[A case of an exogastric developing-type carcinoma of the stomach and a review of thirty nine cases reported in Japan].
Topics: Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy P | 1988 |
Current progress in the management of cancer. A collective review.
Topics: Adenocarcinoma; Angiography; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Chem | 1969 |
Chemotherapy of ovarian cancer with melphalan.
Topics: Adenocarcinoma; Ascites; Carcinoma; Cyclophosphamide; Female; Fluorouracil; Humans; Injections, Intr | 1968 |
298 trials available for fluorouracil and Carcinoma
| Article | Year |
|---|---|
Study of Efficacy and Toxicity of Capecitabine Maintenance After Response to Docetaxel, Cisplatin, and 5-Fluracil-Based Chemotherapy in Advanced Carcinoma Stomach.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Cisplatin; Docetaxel; Fluor | 2023 |
Effects of increased actinic keratosis count on skin-related quality of life: results from the Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) Trial.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Cell Count; Chemoprevention; Dermatologic Agents; Double | 2019 |
A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Chemotherapy | 2017 |
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2017 |
Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; | 2018 |
Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Disease-Free | 2017 |
Impact of minimum point dose on local control and toxicity in T3-4 nasopharyngeal carcinoma treated with intensity-modulated radiation therapy plus chemotherapy.
Topics: Adult; Aged; Carcinoma; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relati | 2018 |
Quality of life and cost effectiveness in a randomized trial of patients with colorectal cancer and peritoneal metastases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal N | 2018 |
Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinom | 2019 |
A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 2019 |
Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of Ch
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemother | 2013 |
Metronomic chemotherapy in metastatic breast cancer: impact on VEGF.
Topics: Administration, Metronomic; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2012 |
Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous C | 2013 |
Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma.
Topics: Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemot | 2014 |
Randomized study of sinusoidal chronomodulated versus flat intermittent induction chemotherapy with cisplatin and 5-fluorouracil followed by traditional radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; | 2013 |
Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Ci | 2014 |
Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Ci | 2014 |
Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Ci | 2014 |
Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Ci | 2014 |
Metastatic nasopharyngeal carcinoma outcomes in patients on cisplatin with nolatrexed or 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cispl | 2014 |
Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarke | 2014 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Class I Phosphat | 2015 |
Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; | 2015 |
Concurrent Chemoradiotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) in Patients with Nasopharyngeal Carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherap | 2015 |
International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2016 |
[Phase II clinical trial of two different modes of administration of the induction chemotherapy for locally advanced nasopharyngeal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Docetaxel; | 2015 |
A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin | 2016 |
Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Asia, Eastern; Asian People; Carcinoma; Cisplatin | 2016 |
Topical fluorouracil after surgery for ocular surface squamous neoplasia in Kenya: a randomised, double-blind, placebo-controlled trial.
Topics: Administration, Topical; Adult; Antimetabolites, Antineoplastic; Carcinoma; Double-Blind Method; Eye | 2016 |
Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosp | 2016 |
Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvan | 2016 |
Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Dise | 2017 |
Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Fluorouracil; F | 2016 |
Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cyclobutanes; F | 2017 |
Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Diseas | 2008 |
A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2009 |
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcino | 2009 |
Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2009 |
Effects of zinc supplementation on the survival of patients who received concomitant chemotherapy and radiotherapy for advanced nasopharyngeal carcinoma: follow-up of a double-blind randomized study with subgroup analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chi-Square Distribution; Cisplatin; Dose | 2009 |
Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast N | 2009 |
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; | 2010 |
Vinorelbine and fluorouracil plus leucovorin combination (ViFL) in patients with anthracycline and taxane-pretreated metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2010 |
Early supplementation of parenteral nutrition is capable of improving quality of life, chemotherapy-related toxicity and body composition in patients with advanced colorectal carcinoma undergoing palliative treatment: results from a prospective, randomize
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body W | 2010 |
Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Mal | 2009 |
Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 2010 |
Neo-adjuvant chemo-radiation of rectal cancer with volumetric modulated arc therapy: summary of technical and dosimetric features and early clinical experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Carcinoma; Deoxycytidine; Femal | 2010 |
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; | 2010 |
Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2010 |
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma; Fluorouracil; Follow-Up S | 2010 |
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma; Fluorouracil; Follow-Up S | 2010 |
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma; Fluorouracil; Follow-Up S | 2010 |
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma; Fluorouracil; Follow-Up S | 2010 |
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Combined Modality Ther | 2010 |
Capecitabine based postoperative accelerated chemoradiation of pancreatic carcinoma. A dose-escalation study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2010 |
Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 2010 |
Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Carcinoma, Squamous Cell; Com | 2011 |
A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 2011 |
Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta | 2011 |
Phase I study of S-1 plus nedaplatin in patients with advanced/recurrent head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin | 2010 |
Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Ad | 2011 |
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Ad | 2011 |
Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levels.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide | 2011 |
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouracil in locally advanced nasopharyngeal carcinoma.
Topics: Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemother | 2011 |
Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemoradiother | 2012 |
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast | 2012 |
A novel chemo-radiotherapy with low-dose daily cisplatin, 5-fluorouracil and doxorubicin for anaplastic thyroid carcinoma: a preliminary report.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Ad | 2011 |
Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta | 2012 |
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Disease-Free Survival | 2011 |
Apoptosis gene signature of Survivin and its splice variant expression in breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Carcinoma; Cell Line, T | 2011 |
Electrochemotherapy: a new technological approach in treatment of metastases in the liver.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
Electrochemotherapy: a new technological approach in treatment of metastases in the liver.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
Electrochemotherapy: a new technological approach in treatment of metastases in the liver.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
Electrochemotherapy: a new technological approach in treatment of metastases in the liver.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study.
Topics: Adenoviruses, Human; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Chemoradiotherapy; Cho | 2012 |
Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; | 2012 |
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Topics: Administration, Metronomic; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemot | 2012 |
PET/CT for staging and follow-up of pediatric nasopharyngeal carcinoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; | 2012 |
Sequential chemoradiotherapy with gemcitabine and cisplatin for locoregionally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adj | 2013 |
Trimodality management of sinonasal undifferentiated carcinoma and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradi | 2013 |
Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cytokines; Drug Th | 2012 |
Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Breath Tests; Carcinoma; Chemotherapy, Adj | 2013 |
Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluoroura | 2013 |
Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Surv | 2013 |
Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a prospective study.
Topics: Antineoplastic Agents; Carcinoma; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Fluorouracil; | 2013 |
Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Diseas | 2013 |
Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis.
Topics: Antineoplastic Agents; Carcinoma; Female; Fluorouracil; Hot Temperature; Humans; Hyperthermia, Induc | 2002 |
Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluoroura | 2003 |
Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Ci | 2003 |
[Cytoreductive surgery with intraperitoneal chemotherapy in patients with colon cancer and peritoneal carcinomatosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Combined | 2003 |
Synchronous postoperative adjuvant chemoradiation therapy for locally advanced carcinoma of the rectum.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2004 |
Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosp | 2003 |
A phase I/II study of CHARTWEL with concurrent chemotherapy in locally advanced, inoperable carcinoma of the oesophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combi | 2003 |
A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluorouracil; Hu | 2003 |
Definitive chemoradiation in patients with inoperable oesophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 2004 |
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; | 2004 |
A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcin | 2003 |
Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Carcinoma | 2004 |
Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Carcinoma; Cecum | 2004 |
A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 2004 |
Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma; Femal | 2004 |
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Deoxycytidine; Drug Resistance, Neop | 2004 |
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Docetaxel; Female | 2004 |
Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Mo | 2004 |
Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colorectal | 2004 |
A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colo | 2004 |
[Preoperative concurrent radiation therapy and chemotherapy for operable bulky carcinomas of uterine cervix stages IB2, IIA, and IIB with proximal parametrial invasion].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma; Cisplatin; Di | 2004 |
Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 2004 |
Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, Neoplasm; Ant | 2004 |
Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylati | 2004 |
Gene expression profiles of colorectal carcinoma in response to neo-adjuvant chemotherapy.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2004 |
Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Combined Mo | 2004 |
Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cispla | 2005 |
Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy coo
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined | 2005 |
Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; | 2005 |
Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide | 2005 |
Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2005 |
FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Celecoxib; Col | 2005 |
Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
How reliable is MRI for predicting extent of residual breast cancer with different primary medical therapies?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docet | 2005 |
Prediction of mesorectal nodal metastases after chemoradiation for rectal cancer: results of a randomised trial: implication for subsequent local excision.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Fluorouracil; | 2005 |
Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
Topics: Adult; Age of Onset; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Ch | 2006 |
Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modal | 2006 |
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Drug Administr | 2006 |
A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma; Cisplatin; Dos | 2006 |
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2006 |
A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2006 |
Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 2006 |
Telomerase activity, estrogen receptors (alpha, beta), Bcl-2 expression in human breast cancer and treatment response.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Cyclophosphamide; Epirubicin; Estrogen Receptor alpha; Est | 2006 |
Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcino | 2006 |
A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer.
Topics: Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplas | 2006 |
Peritoneal carcinomatosis of colorectal origin.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Chemotherapy, Adjuvant; Co | 2006 |
Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcino | 2006 |
A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ca | 2006 |
A phase II study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin | 2006 |
Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agen | 2007 |
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemothera | 2007 |
Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
Capecitabine therapy of central nervous system metastases from breast cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Central Nervous S | 2007 |
Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease P | 2007 |
Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Diarrhea; Dose-Response Re | 2006 |
A pilot phase II study of capecitabine plus cisplatin in the treatment of recurrent carcinoma of the uterine cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Cisplatin; Deo | 2007 |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2008 |
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinom | 2008 |
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Ne | 2008 |
A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma; Disease-Fre | 2007 |
A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; | 2008 |
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2008 |
Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cohort Studi | 2008 |
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; | 2008 |
[Treatment of advanced ovarian cancer as an interdisciplinary task: surgery, histopathology, radiotherapy, and chemotherapy].
Topics: Adenocarcinoma, Mucinous; Bleomycin; Bone and Bones; Carcinoma; Chlorambucil; Cyclophosphamide; Doxo | 1983 |
Newer techniques in cancer chemotherapy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bleomycin; Bone Marrow Transplantation; Carcinoma; Ce | 1984 |
Chemotherapy of hormonally unresponsive prostatic carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Cispla | 1984 |
Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF).
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Altretamine; Antineoplastic Agents; Carcinoma; Clinical Trial | 1981 |
[Cooperative trials of the Council of Mutual Economic Aid countries on chemoradiotherapy of lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1984 |
Treatment of recurrent and metastatic carcinoma of the cervix: comparison of doxorubicin with a combination of vincristine and 5-fluorouracil.
Topics: Carcinoma; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; H | 1981 |
Triple drug chemotherapy for advanced ovarian carcinoma: comparative study of two regimens.
Topics: Antineoplastic Agents; Bone Marrow Diseases; Carcinoma; Clinical Trials as Topic; Cyclophosphamide; | 1981 |
Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Canada; Carcinoma; Clinical Trials as Topic; Drug Administration | 1980 |
Preliminary report on the efficacy of sequential methotrexate and 5-fluorouracil in advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Drug Administration Schedule; Dr | 1981 |
Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexy-nitrosourea in the treatment of metastatic prostatic cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; F | 1982 |
Gastric carcinoma treated by chemotherapy after resection: a controlled study.
Topics: Adult; Aged; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Gastrecto | 1980 |
High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Drug Resist | 1995 |
A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug | 1994 |
Cytotoxic chemotherapy for adrenocortical carcinoma.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adult; Animals; Antineoplastic Combined Chemotherapy Protocols | 1995 |
Chemotherapeutic treatment of recurrent and/or metastatic nasopharyngeal carcinoma: a retrospective analysis of 40 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamo | 1993 |
A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Resistance; | 1995 |
Phase II study of 5-fluorouracil/leucovorin for pediatric patients with malignant solid tumors.
Topics: Adolescent; Carcinoma; Child; Child, Preschool; Colorectal Neoplasms; Drug Administration Schedule; | 1994 |
Phase II trial of 5-fluorouracil and folinic acid in the treatment of advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Diarrhea; Female; Fluor | 1994 |
A clinical trial of continuous cisplatin-fluorouracil induction chemotherapy and supracricoid partial laryngectomy for glottic carcinoma classified as T2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemother | 1994 |
Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Epir | 1994 |
Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colonic Neoplasms | 1994 |
Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Drug Administ | 1994 |
[Comparison of the therapeutic effect of CMxMF and CAMF regimens in the management of advanced breast cancer patients].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brea | 1993 |
Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta | 1994 |
Combined chemo-radiotherapy with carboplatin, 5-fluorouracil and folinic acid for cancer of the urinary bladder: acute and late side effects.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Combined Modality Ther | 1993 |
Intra-arterial hepatic treatment with carboplatin (CBDCA) and 5-fluorouracil (5-FU) in metastases from colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1993 |
A phase II study of 5-fluorouracil, cisplatin, and 4'-epirubicin in the treatment of advanced solid cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 1993 |
Bolus mitomycin C and 5-FU with sequential radiation for poor-prognosis locally advanced cervical cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma; Combined Modality Therapy; | 1996 |
Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinom | 1996 |
A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Cohort Studies; Colorectal Neopl | 1995 |
Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; | 1996 |
The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Fema | 1996 |
Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma.
Topics: Adult; Aged; Ambulatory Care; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ant | 1995 |
Phase II trial of 5-fluorouracil, leucovorin, interferon-alpha-2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 1996 |
Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Anemia; Antidotes; Antimetabolites, Antineoplast | 1996 |
Simultaneous radiochemotherapy for recurrent and metastatic breast carcinoma: evaluation of two treatment concepts.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 1996 |
Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Female; Fluorouracil; | 1996 |
Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 1996 |
Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1996 |
5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Epirubicin; Female; Fluorour | 1996 |
Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Topics: Adenocarcinoma; Administration, Oral; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplast | 1996 |
A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Colorectal Neopl | 1996 |
[Apropos of two recently published randomized trials of induction chemotherapy in nasopharyngeal and piriform sinus carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Comb | 1996 |
Enhanced induction of apoptosis of human gastric carcinoma cells after preoperative treatment with 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma; Female; Fluorouracil; Huma | 1997 |
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; C | 1997 |
Pilot study of concurrent chemotherapy and radiotherapy for stage IV nasopharyngeal cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Mo | 1997 |
Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 1997 |
Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma type.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Carcinoma; Dose-Response Relationship, Drug; Fem | 1997 |
Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial.
Topics: Carcinoma; Chemotherapy, Adjuvant; Colonic Neoplasms; DNA, Neoplasm; Fluorouracil; Gene Amplificatio | 1997 |
Adjuvant therapy for resectable colorectal carcinoma with 5-fluorouracil portal vein infusion.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorourac | 1997 |
Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial.
Topics: Abdominal Pain; Adult; Aged; Alkaline Phosphatase; Angiography; Antimetabolites, Antineoplastic; Ant | 1997 |
Neoadjuvant chemotherapy with continuous infusion of cisplatin and 5-fluorouracil, with or without leucovorin, for locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Ch | 1996 |
The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
Topics: Administration, Oral; Adult; Aged; Anemia; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Co | 1996 |
Hydroxyurea, 5-fluorouracil infusion, and cisplatin adjunct to radiation therapy in cervical carcinoma: a phase I-II trial of the Gynecologic Oncology Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1997 |
Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 1997 |
Nasopharyngeal carcinoma in childhood and adolescence: concept and preliminary results of the cooperative GPOH study NPC-91. Gesellschaft für Pädiatrische Onkologie und Hämatologie.
Topics: Adenocarcinoma, Clear Cell; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; C | 1997 |
Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protoc | 1998 |
Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosp | 1998 |
Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Cohort Studie | 1998 |
The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta | 1998 |
Induction chemotherapy, surgery, and concomitant chemoradiotherapy for carcinoma of the esophagus: a long-term analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 1998 |
Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma; Cis | 1998 |
[Comparison of adjuvant chemotherapy in breast carcinoma with a combination of cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and AC (doxorubicin, cyclophosphamide). Initial results of a national cooperative study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; | 1998 |
The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; | 1998 |
Pharmacokinetics of recombinant human interferon-alpha 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Drug A | 1998 |
Anticancer effects of preoperative chemotherapy on colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 1998 |
Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma; Cisplatin; Drug Admini | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic cooperative oncology group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Drug Synergism; | 1999 |
Oxaliplatin pharmacokinetics during a four-hour infusion.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Colorectal Neopl | 1999 |
Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Surv | 1999 |
A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplas | 1999 |
Phase I study of 5-fluorouracil administered by protracted venous infusion, leucovorin, and pelvic radiation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Combined Modality | 1999 |
Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosp | 1999 |
Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cispl | 1999 |
Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colonic Neo | 1999 |
Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cycl | 1999 |
Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxyurac | 1999 |
A new combination chemotherapy with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Esophageal Neoplasms; Fluorouracil; | 1999 |
Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineo | 2000 |
Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: A randomized study.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neoplasms; Diseas | 2000 |
Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chi-Square Distribution; Colonic Neoplasms; Female; Fluo | 2000 |
Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Surv | 2000 |
Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Dose-Resp | 2000 |
A phase III study of high-dose intensification without hematopoietic progenitor cells support for patients with high-risk primary breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Car | 2000 |
Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dose-Response Relationship, Drug; E | 2000 |
Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycyti | 2000 |
Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic N | 2000 |
Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin | 2000 |
Induction chemotherapy followed by alternating chemo-radiotherapy in stage IV undifferentiated nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 2000 |
A randomized Phase II trial in patients with carcinoma of an unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Etoposide; Fema | 2001 |
The relationship between improved prognosis in gastric cancer patients in the last 25 years and changing methods of surgical and combined treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcino | 2000 |
Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adj | 2001 |
Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adj | 2001 |
Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adj | 2001 |
Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adj | 2001 |
Comparison of 5-fluorouracil alone, 5-fluorouracil with levamisole, and 5-fluorouracil with hepatic irradiation in the treatment of patients with residual, nonmeasurable, intra-abdominal metastasis after undergoing resection for colorectal carcinoma.
Topics: Abdominal Neoplasms; Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined | 2001 |
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplasti | 2001 |
Adjuvant chemotherapy for gastro-oesophageal cancer with epirubicin, cisplatin and fluorouracil: a single-centre experience.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous | 2001 |
Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 2001 |
Accelerated hyperfractionated radiotherapy with concurrent chemotherapy in locally advanced nasopharyngeal carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Dose | 2001 |
Neoadjuvant chemotherapy plus conventional radiotherapy or accelerated hyperfractionation in stage III and IV nasopharyngeal carcinoma--a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squam | 2001 |
Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cost-Benefit Anal | 2002 |
A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluoroura | 2002 |
A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Child; Cisplatin | 2002 |
The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farbe
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma; Com | 2002 |
The West Midlands gastric carcinoma chemotherapy trial: planning and results.
Topics: Adenocarcinoma; Aged; Carcinoma; Clinical Trials as Topic; Disability Evaluation; Evaluation Studies | 1978 |
The dilemma regarding postoperative chemotherapy in primary carcinoma of the colon.
Topics: Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Colonic N | 1979 |
The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate.
Topics: Carcinoma; Cyclophosphamide; Evaluation Studies as Topic; Fluorouracil; Humans; Male; Neoplasm Recur | 1976 |
Prostatic carcinoma. relationship between primary tumor, histologic grade, and response to chemotherapy.
Topics: Carcinoma; Cyclophosphamide; Fluorouracil; Humans; Male; Prostatic Neoplasms | 1976 |
Immunology and adjuvant chemoimmunotherapy of breast cancer.
Topics: Aged; Animals; Antibodies, Neoplasm; BCG Vaccine; Breast Neoplasms; Carcinoma; Chick Embryo; Cycloph | 1976 |
The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate.
Topics: Carcinoma; Cyclophosphamide; Fluorouracil; Humans; Male; Maryland; Prognosis; Prostatic Neoplasms | 1976 |
[Sequential chemotherapy based on the hypothesis of a circadian rhythm of tumor proliferation].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Circadian R | 1975 |
Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cisp | 1992 |
5-fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma. A phase II trial of the Gynecologic Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Female; Fluorouracil; Humans | 1992 |
Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil.
Topics: Acid Phosphatase; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Doxorubicin; Fluo | 1992 |
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 1991 |
Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; | 1991 |
Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1991 |
A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colorectal Neopla | 1991 |
A randomized study of sequential versus alternating combination chemotherapy in advanced ovarian carcinoma.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cycl | 1990 |
Alpha-2 interferon and 5-fluorouracil in advanced colorectal cancer.
Topics: Adult; Aged; Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule | 1990 |
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1990 |
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1990 |
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1990 |
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1990 |
A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carcinom | 1990 |
Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin | 1990 |
Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma.
Topics: Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Drug Synergism; Drug Therapy, Combination | 1990 |
Randomized neo-adjuvant chemotherapy trial for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamo | 1985 |
[Induction chemotherapy of carcinomas of the oral cavity and oropharynx. Feasibility study, levels and factors of response to treatment. Apropos of 135 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Clinic | 1987 |
Conservation therapy of breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials a | 1989 |
[The results of a modified FAMeth chemotherapy protocol in metastatic stomach carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modali | 1989 |
A Northern California Oncology Group randomized trial of leucovorin plus 5-fluorouracil versus sequential methotrexate, 5-fluorouracil, and leucovorin in patients with advanced colorectal cancer who failed treatment with 5-fluorouracil or 5-fluorodeoxyuri
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Drug Administration Sc | 1987 |
A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials | 1988 |
Chemotherapy of drug-resistant ovarian cancer: a Southwest Oncology Group Study.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clin | 1986 |
[A randomized controlled trial comparing short-term MF chemotherapy with MF plus long-term HCFU chemotherapy as an adjuvant to a curative resection of stomach cancer: Mifurol Study Group for Stomach Cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as | 1988 |
Surgical adjuvant therapy of rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modali | 1988 |
The effects of liver directed radiotherapy and chemotherapy on liver function tests and hematological parameters in patients with surgically resected colon cancer: findings from the Gastrointestinal Tumor Study Group.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Bone Marrow; Carcinoma; Clinical Trials as Topic; | 1987 |
Clinical studies of biochemical modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer by the North Central Cancer Treatment Group and Mayo Clinic.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colonic Neoplasms; Dose-Respon | 1987 |
Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer.
Topics: Blood Platelets; Carcinoma; Clinical Trials as Topic; Cyclophosphamide; Diethylstilbestrol; Estramus | 1986 |
A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1985 |
Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Female; Fluorouracil; Humans | 1986 |
Advanced lung cancer: A clinical trial of radiotherapy plus two drug combination regimens.
Topics: Adenocarcinoma; Amides; Antineoplastic Agents; Carcinoma; Carcinoma, Small Cell; Carcinoma, Squamous | 1973 |
Current therapy approaches of the Division of Cancer Treatment with emphasis on pancreatic carcinoma.
Topics: Adenocarcinoma; Animals; Carcinoma; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials as Topi | 1974 |
[Radiotherapy of malignant neoplasms following synchronisation of cell division rhythm. Experiences following two years of clinical use].
Topics: Animals; Carcinoma; Carcinoma, Squamous Cell; Clinical Trials as Topic; Fluorouracil; Humans; Infusi | 1972 |
Combination therapy with 5-fluorouracil (5-FU; NSC-19893) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) for disseminated gastrointestinal carcinoma.
Topics: Adult; Aged; Anemia, Aplastic; Blood Cell Count; Carcinoma; Clinical Trials as Topic; Colonic Neopla | 1972 |
Radiotherapy plus 5-FU compared to radiotherapy alone for inoperable and unresectable bronchogenic carcinoma.
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Clinical Trials as Top | 1972 |
Carcinoma of the bladder, 5-fluorouracil and the critical role of a placebo. A cooperative group report. I.
Topics: Adolescent; Adult; Aged; Carcinoma; Clinical Trials as Topic; Fluorouracil; Humans; Middle Aged; Neo | 1968 |
Concurrent combination chemotherapy of human solid tumors: experience with a three-drug regimen and review of the literature.
Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Neoplasms; Carcinoma; Child; Child, Preschool; Clinical T | 1969 |
The use of topical 5-fluorouracil in the treatment of skin tumours--preliminary report.
Topics: Aged; Carcinoma; Carcinoma, Basal Cell; Clinical Trials as Topic; Female; Fluorouracil; Humans; Kera | 1969 |
A five year progress report on the effectiveness of intraluminal chemotherapy (5-fluorouracil) adjuvant to surgery for colorectal cancer.
Topics: Carcinoma; Colonic Neoplasms; Female; Fluorouracil; Humans; Injections, Intravenous; Male; Mechloret | 1968 |
707 other studies available for fluorouracil and Carcinoma
| Article | Year |
|---|---|
EGF-functionalized lipid-polymer hybrid nanoparticles of 5-fluorouracil and sulforaphane with enhanced bioavailability and anticancer activity against colon carcinoma.
Topics: Biological Availability; Carcinoma; Cell Survival; Colonic Neoplasms; Drug Carriers; Drug Delivery S | 2022 |
Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil for T3 N0 Glottic Carcinoma Without Vocal Cord Fixation.
Topics: Adult; Aged; Carcinoma; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Laryn | 2022 |
Effects of Mitomycin-C and 5-Fluorouracil on Ocular Adnexal Sebaceous Carcinoma Cells.
Topics: Carcinoma; Cell Survival; Cells, Cultured; Eye Neoplasms; Fluorouracil; Humans; Mitomycin | 2022 |
The natural isoflavone Biochanin-A synergizes 5-fluorouracil anticancer activity in vitro and in vivo in Ehrlich solid-phase carcinoma model.
Topics: Animals; Apoptosis; Carcinoma; Cell Line, Tumor; Drug Synergism; Fluorouracil; Genistein; Humans; Is | 2022 |
Macrophage-targeted anti-CCL2 immunotherapy enhances tumor sensitivity to 5-fluorouracil in a Balb/c-CT26 murine colon carcinoma model measured using diffuse reflectance spectroscopy.
Topics: Animals; Carcinoma; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Macrop | 2022 |
Poorly differentiated carcinoma with neuroendocrine features in two patients with sinonasal tumours: a report of two cases.
Topics: Carcinoma; Carcinoma, Neuroendocrine; Fluorouracil; Humans; Male; Neoplasms, Glandular and Epithelia | 2022 |
Sulforaphane has an additive anticancer effect to FOLFOX in highly metastatic human colon carcinoma cells.
Topics: Aldehyde Dehydrogenase 1 Family; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic | 2022 |
Chloroquine prevents hypoxic accumulation of HIF-1α by inhibiting ATR kinase: implication in chloroquine-mediated chemosensitization of colon carcinoma cells under hypoxia.
Topics: Ataxia Telangiectasia Mutated Proteins; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Chloroquine; Colo | 2023 |
Chloroquine prevents hypoxic accumulation of HIF-1α by inhibiting ATR kinase: implication in chloroquine-mediated chemosensitization of colon carcinoma cells under hypoxia.
Topics: Ataxia Telangiectasia Mutated Proteins; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Chloroquine; Colo | 2023 |
Chloroquine prevents hypoxic accumulation of HIF-1α by inhibiting ATR kinase: implication in chloroquine-mediated chemosensitization of colon carcinoma cells under hypoxia.
Topics: Ataxia Telangiectasia Mutated Proteins; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Chloroquine; Colo | 2023 |
Chloroquine prevents hypoxic accumulation of HIF-1α by inhibiting ATR kinase: implication in chloroquine-mediated chemosensitization of colon carcinoma cells under hypoxia.
Topics: Ataxia Telangiectasia Mutated Proteins; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Chloroquine; Colo | 2023 |
The GSTP1/MAPKs/BIM/SMAC modulatory actions of nitazoxanide: Bioinformatics and experimental evidence in subcutaneous solid Ehrlich carcinoma-inoculated mice.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma; Caspases; Cell Line, Tumor; Computatio | 2023 |
Combination of Copper Metallodendrimers with Conventional Antitumor Drugs to Combat Cancer in In Vitro Models.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Copper; Dendrimers; Doxorubici | 2023 |
Water-soluble copper(II) 5-fluorouracil complexes bearing polypyridyl co-ligands: synthesis, structures and anticancer activity.
Topics: Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Coordination Complexes; Copper; Crystallography, | 2023 |
[A cervical cancer tissue-derived decellularized extracellular matrix scaffold for cervical cancer tissue reconstruction
Topics: Carcinoma; Decellularized Extracellular Matrix; Extracellular Matrix; Female; Fluorouracil; Humans; | 2023 |
The Antitumor Potential of λ-Carrageenan Oligosaccharides on Gastric Carcinoma by Immunomodulation.
Topics: Animals; Carcinoma; Carrageenan; Fluorouracil; Immunity; Immunomodulation; Mice; Stomach Neoplasms; | 2023 |
Propolis-loaded nanostructured lipid carriers halt breast cancer progression through miRNA-223 related pathways: an in-vitro/in-vivo experiment.
Topics: Animals; Ascites; Ascomycota; Breast Neoplasms; Carcinoma; Female; Fluorouracil; Humans; Lipids; Mic | 2023 |
Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone) synergizes with 5-fluorouracil allowing for dose reduction and reduced off-target toxicity in the treatment of colonic and pancreatic cancers.
Topics: Achyrocline; Animals; Carcinoma; Colonic Neoplasms; Colorectal Neoplasms; Drug Tapering; Fluorouraci | 2023 |
Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2020 |
Prognostic Value of TWIST1 and EZH2 Expression in Colon Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Colonic Neoplas | 2021 |
Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5-fluorouracil in vivo.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Carcinoma; Cell Line, Tumor; Cell Proliferation; Col | 2020 |
Conversion therapy in patients with colorectal liver metastases.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineopl | 2021 |
Nasopharyngeal carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Child; Cis | 2021 |
Next generation platinum salt in nasopharygeal carcinoma.
Topics: Carcinoma; Chemoradiotherapy; Cisplatin; Cyclobutanes; Fluorouracil; Humans; Induction Chemotherapy; | 2021 |
Evodiamine Induces Cell Growth Arrest, Apoptosis and Suppresses Tumorigenesis in Human Urothelial Cell Carcinoma Cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinogenesis; Carcinoma; Cell Cycle; Cell Division; | 2017 |
Apoptosis mediated chemosensitization of tumor cells to 5-fluorouracil on supplementation of fish oil in experimental colon carcinoma.
Topics: Animals; Apoptosis; Carcinoma; Cell Proliferation; Colonic Neoplasms; Dextran Sulfate; DNA Damage; D | 2017 |
Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin | 2017 |
Gastrin induces multidrug resistance via the degradation of p27Kip1 in the gastric carcinoma cell line SGC7901.
Topics: Aged; Camptothecin; Carcinoma; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resista | 2017 |
Small molecule inhibitor TW-37 is tolerable and synergistic with chemotherapy in nasopharyngeal carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell | 2017 |
Usefulness of computed tomography density of a tumor in predicting the response of advanced esophageal cancer to preoperative chemotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neo | 2017 |
Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area.
Topics: Adult; Carcinoma; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan | 2018 |
Induction Methotrexate, Cisplatin, and 5-Fluorouracil Versus Cisplatin and 5-Fluorouracil Followed by Radiotherapy in Pediatric Nasopharyngeal Carcinoma: A Retrospective Analysis in a Tertiary Cancer Center.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Child; Cis | 2017 |
[Cancers associated with systemic sclerosis involving anti-RNA polymerase III antibodies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Autoantigens; Carcinoma; Carcinoma, | 2018 |
Fluorescence-Guided Surgery in the Combined Treatment of Peritoneal Carcinomatosis from Colorectal Cancer: Preliminary Results and Considerations.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Coloring Agents; Co | 2018 |
Comparing pathological complete response rate using oral capecitabine versus infusional 5-fluorouracil with preoperative radiotherapy in rectal cancer treatment.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2018 |
Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothe | 2017 |
Chemotherapy regimens containing taxanes or fluorouracil in nasopharyngeal carcinoma: Which better?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Female; Fluorouracil; Humans | 2017 |
ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2017 |
The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism.
Topics: ATP Binding Cassette Transporter, Subfamily B; Carcinoma; Cell Cycle; Cell Movement; Cell Proliferat | 2018 |
TPF induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: Long term results of a Tunisian series.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherap | 2018 |
A Retrospective Study to Compare Five Induction Chemotherapy Regimens Prior to Radiotherapy in the Reduction of Regional Lymph Node Size in Patients with Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Carcinoma; Chemoradiotherapy; China; Cisplatin; Dise | 2018 |
The new 6q27 tumor suppressor DACT2, frequently silenced by CpG methylation, sensitizes nasopharyngeal cancer cells to paclitaxel and 5-FU toxicity via β-catenin/Cdc25c signaling and G2/M arrest.
Topics: Adaptor Proteins, Signal Transducing; beta Catenin; Carcinoma; Carrier Proteins; cdc25 Phosphatases; | 2018 |
Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Rosmarinic acid reduces the resistance of gastric carcinoma cells to 5-fluorouracil by downregulating FOXO4-targeting miR-6785-5p.
Topics: Antimetabolites, Antineoplastic; Antioxidants; Carcinoma; Cell Cycle Proteins; Cell Line, Tumor; Cin | 2019 |
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cap | 2019 |
Undifferentiated Carcinoma of the Pancreas - a Case Report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycy | 2018 |
Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; | 2019 |
Impact of Perioperative Chemotherapy on Prognosis of Patients with Esophageal Carcinoma Undergoing Pulmonary Metastasectomy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; | 2019 |
Nomogram predicted disease free survival for colorectal liver metastasis patients with preoperative chemotherapy followed by hepatic resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine | 2019 |
Hypovolemic shock after pelvic radiotherapy. A rare combination leading to a devastating complication.
Topics: Aged; Anaphylaxis; Anus Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Colon, Si | 2019 |
Survival impact of pulmonary metastasectomy for patients with head and neck cancer.
Topics: Adenoma; Antineoplastic Agents; Carcinoma; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck | 2013 |
Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Carcinoma; Chemoradiotherapy; C | 2013 |
Inhibition of the LKB1-AMPK pathway by the Epstein-Barr virus-encoded LMP1 promotes proliferation and transformation of human nasopharyngeal epithelial cells.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Car | 2013 |
Acute arterial thrombosis following chemotherapy in a patient with a gastric carcinoma.
Topics: Acute Disease; Adult; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Arterial Occlu | 2013 |
Teaching NeuroImages: 5-FU-induced acute leukoencephalopathy.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Carcinoma; Colonic Neoplasms; Fluorouracil; Humans; | 2013 |
Analysis of saliva samples from oncological patients treated with 5-fluorouracil and leucovorin calcium by scanning electron microscopy with energy dispersive system.
Topics: Administration, Intravenous; Adult; Antimetabolites, Antineoplastic; Calcium; Carcinoma; Colonic Neo | 2013 |
Cost effectiveness of neoadjuvant chemotherapy in locally advanced operable head and neck cancer followed by surgery and postoperative radiotherapy: a Markov model-based decision analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cost-B | 2013 |
Multifocal anaplastic pancreatic carcinoma requiring neoadjuvant chemotherapy and total pancreatectomy: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modality Therapy; | 2013 |
Teng-Long-Bu-Zhong-Tang, a Chinese herbal formula, enhances anticancer effects of 5--Fluorouracil in CT26 colon carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma; Caspases; Cell | 2013 |
Unusual ischemic complication of bevacizumab treatment for metastatic colorectal carcinoma.
Topics: Abdominal Pain; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2013 |
Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients.
Topics: Antimetabolites, Antineoplastic; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Ca | 2013 |
FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2013 |
Thymidylate synthase gene polymorphism and survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Flu | 2013 |
Ziyuglycoside II-induced apoptosis in human gastric carcinoma BGC-823 cells by regulating Bax/Bcl-2 expression and activating caspase-3 pathway.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma; Caspase 3; Caspase Inhibito | 2013 |
Comparative cardiac toxicity in two treatment schedules of 5-FU/LV for colorectal carcinoma.
Topics: Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Pressure; Carcino | 2013 |
Mahanine synergistically enhances cytotoxicity of 5-fluorouracil through ROS-mediated activation of PTEN and p53/p73 in colon carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carbazoles; Carcinoma; Cell Line, Tumor; Colonic Neoplasms; DNA-Bi | 2014 |
Evaluation and impact of residual disease in locally advanced cervical cancer after concurrent chemoradiation therapy: results of a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradi | 2013 |
Uracil mustard and 5-fluorouracil combination chemotherapy: a historic record.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Female; Flu | 2013 |
Prospective study of symptom assessment among patients with cervical cancer during concurrent chemoradiotherapy with weekly cisplatin or every-3-week cisplatin and 5-fluorouracil.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Anxiety; Carcinoma; Chemoradiotherapy; Cispl | 2013 |
Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
Topics: Abdominal Abscess; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2014 |
Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin | 2014 |
Prediction of the response to docetaxel-based chemotherapy for locoregionally advanced nasopharyngeal carcinoma: the role of double-phase (99m)Tc-MIBI SPECT/CT.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Docet | 2014 |
A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
[Clinicopathologic characteristics of primary breast leiomyosarcoma: report of a case].
Topics: Actins; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Calcium-Binding Pro | 2013 |
Gemcitabine and Cisplatin followed by chemo-radiation for advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2014 |
Factors affecting outcomes of alternating chemoradiotherapy for nasopharyngeal cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Disease-Free Survival; | 2014 |
HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2014 |
An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; | 2014 |
Non-endemic locoregionally advanced nasopharyngeal carcinoma: long-term outcome after induction plus concurrent chemoradiotherapy in everyday clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2015 |
Synergistic antitumor effect of puerarin combined with 5-fluorouracil on gastric carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Survival; Dis | 2015 |
Integrinβ6-targeted immunoliposomes mediate tumor-specific drug delivery and enhance therapeutic efficacy in colon carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Ca | 2015 |
XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2014 |
Blockage of PTPRJ promotes cell growth and resistance to 5-FU through activation of JAK1/STAT3 in the cervical carcinoma cell line C33A.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Cell Division; Cell Line, Tumor; Cell Movement; Drug Res | 2015 |
Prognostic score for recurrence after Whipple's pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Combined Chemotherapy | 2015 |
Sequential treatment with betulinic acid followed by 5-fluorouracil shows synergistic cytotoxic activity in ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Betulinic Acid; Blotting, Western; Carcin | 2015 |
[18F]-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Value as a Predictor of Adjuvant Chemotherapy Benefits in Patients With Nasopharyngeal Carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Fr | 2015 |
Low percentage of CD24hiCD27⁺CD19⁺ B cells decelerates gastric cancer progression in XELOX-treated patients.
Topics: Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocyte | 2015 |
Ampulla of Vater carcinoma in real-world clinical practice: a case series.
Topics: Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecit | 2015 |
[Study of the relationship among expression of Survivin and MRP and the drug resistance in human nasopharyngeal carcinoma].
Topics: Antineoplastic Agents; Carcinoma; Cisplatin; Drug Resistance, Neoplasm; Fluorouracil; Humans; Immuno | 2015 |
Treatment of T3 laryngeal cancer in the Netherlands: a national survey.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Carboplatin; Ca | 2015 |
PCF Chemotherapy Combined with Surgical Treatment of Late Gastric Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 2014 |
Correlation Between Nuclear Factor E2-Related Factor 2 Expression and Gastric Cancer Progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antioxidants; Carcinoma; Drug Resistance, Neo | 2015 |
Chemotherapy Induced Acute Pericarditis in a Child.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protoco | 2015 |
The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2015 |
The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2015 |
The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2015 |
The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2015 |
The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2015 |
The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2015 |
The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2015 |
The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2015 |
The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2015 |
Pediatric advanced stage nasopharyngeal carcinoma - case report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Fluorouracil; Huma | 2015 |
Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherap | 2016 |
Enhancement of Drug Sensitivity by Knockdown of HIF-1α in Gastric Carcinoma Cells.
Topics: Apoptosis; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; | 2016 |
Olfactory event-related potentials: a new approach for the evaluation of olfaction in nasopharyngeal carcinoma patients treated with chemo-radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Doce | 2016 |
Impact of novel histopathological factors on the outcomes of liver surgery for colorectal cancer metastases.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; C | 2016 |
[Study of introperitoneal hyperthermic perfusion chemotherapy combined with systemic neoadjuvent chemotherapy in treatment of gastric cancer patients with peritoneal carcinomatosis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; | 2016 |
A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Cisplatin; Disease-Free Survival; Drug Therapy, Combi | 2016 |
Knockdown of NFBD1/MDC1 enhances chemosensitivity to cisplatin or 5-fluorouracil in nasopharyngeal carcinoma CNE1 cells.
Topics: Adaptor Proteins, Signal Transducing; Carcinoma; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; D | 2016 |
Epidural analgesia combined with a comprehensive physiotherapy program after Cytoreductive Surgery and HIPEC is associated with enhanced post-operative recovery and reduces intensive care unit stay: A retrospective study of 124 patients.
Topics: Analgesia, Epidural; Analgesia, Patient-Controlled; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2016 |
Chemotherapy With CMF for Triple-Negative Breast Cancer With Carcinoma Erysipelatoides.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluorouracil; H | 2016 |
Advanced-Stage Nasopharyngeal Carcinoma: Restaging System after Neoadjuvant Chemotherapy on the Basis of MR Imaging Determines Survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Chemother | 2017 |
Expression of EIF5A2 associates with poor survival of nasopharyngeal carcinoma patients treated with induction chemotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chem | 2016 |
Induction Chemotherapy Followed by Radiotherapy versus Concurrent Chemoradiotherapy in elderly patients with nasopharyngeal carcinoma: finding from a propensity-matched analysis.
Topics: Aged; Aged, 80 and over; Carcinoma; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Flu | 2016 |
Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: A pooled analysis of two randomised controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deox | 2016 |
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Carcinoma, | 2016 |
Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cis | 2016 |
Usefulness of CTC and DTC-BM Detection for Adjuvant Therapy Effects and Prognosis Prediction in Early Breast Carcinoma: Results of 8-11 Years of Follow-up Evaluation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Marrow; Bone | 2017 |
Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxy | 2017 |
Granulocyte Colony-stimulating Factor Producing Anaplastic Carcinoma of the Pancreas: Case Report and Review of the Literature.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Fe | 2017 |
Positive feedback loop of IL-1β/Akt/RARα/Akt signaling mediates oncogenic property of RARα in gastric carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Cell Cycle; Cell Cycle Proteins; Cell Line, Tum | 2017 |
Target volume delineation for radical radiotherapy of early oesophageal carcinoma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squam | 2017 |
Reduction of carcinomatosis risk using icodextrin as a carrier solution of intraperitoneal oxaliplatin chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cell Movement; | 2017 |
The longest stalk: preserved pituitary function after regression of a giant prolactinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Fluorouracil; Humans; M | 2017 |
Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma; Chemoradiotherapy; Cisplatin; Docetaxel; | 2017 |
Granulocyte-colony stimulating factor producing rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colectomy; Fatal Outcome; | 2008 |
Single-cell transcription site activation predicts chemotherapy response in human colorectal tumors.
Topics: Adenosine Triphosphatases; Algorithms; Antineoplastic Agents; bcl-2 Homologous Antagonist-Killer Pro | 2008 |
Pyogenic granuloma-like lesions caused by capecitabine therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Deoxycytidine; Drug Eruptions; Fingers; Fl | 2008 |
Cytotoxic effects of haplamine and its major metabolites on human cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Line, | 2008 |
Nuclear factor kappa B: a marker of chemotherapy for human stage IV gastric carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Disease-Free Su | 2008 |
Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.
Topics: Adaptor Proteins, Vesicular Transport; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy | 2009 |
[A case of gastric cancer accompanied by disseminated carcinomatosis of bone marrow with DIC recovered by sequential therapy consisting of MTX and 5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Neoplasms; Carcinoembryoni | 2008 |
Adrenal metastasis of breast cancer with involvement of the inferior vena cava.
Topics: Adrenal Gland Neoplasms; Adult; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2008 |
[Intra-arterial chemotherapy and chemoembolization in the combined treatment for locally advanced carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoembolizati | 2008 |
Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Proliferation; Drug Evaluation, Preclinical; Epide | 2008 |
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; A | 2009 |
TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma; Colorectal Neopl | 2009 |
The prognostic impact of occult nodal metastasis in early breast carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axilla; Bone Marrow; | 2009 |
Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth.
Topics: Angiogenesis Inducing Agents; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Cell L | 2009 |
Hyperfractionated accelerated radiotherapy versus conventional fractionation both combined with chemotherapy in patients with locally advanced head and neck carcinomas: a retrospective analysis of a monoinstitutional series.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Dose Fra | 2009 |
Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma; Colorectal Neo | 2009 |
Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; CD40 Ligand; Cell Line, Tumor; C | 2009 |
Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
A retrospective comparison of clinical outcomes and quality of life measures between definitive chemoradiation alone and radical surgery for clinical stage II-III esophageal carcinoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2009 |
Impact of surgical staging in locally advanced cervical cancer and subsequent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Case-Control Studies; Cispla | 2009 |
High-dose definitive concomitant chemoradiotherapy in non-metastatic locally advanced esophageal cancer: toxicity and outcome.
Topics: Aged; Antineoplastic Agents; Carcinoma; Cisplatin; Cohort Studies; Disease-Free Survival; Esophageal | 2010 |
Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2009 |
Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; | 2010 |
Pancreatic cancer therapy with a novel pump for controlled drug release.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Delayed-Action Preparations; | 2010 |
Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Breast Neo | 2010 |
Neoadjuvant chemotherapy in advanced vulvar cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bleomycin; Carcinoma; Cisplatin; Female; Fluo | 2010 |
Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cape | 2010 |
Chemotherapy-associated peripheral sensory neuropathy assessed using in vivo corneal confocal microscopy.
Topics: Aged; Capecitabine; Carcinoma; Colorectal Neoplasms; Cornea; Deoxycytidine; Fluorouracil; Humans; Ma | 2010 |
[Pediatric nasopharyngeal carcinoma: Anatomoclinic aspects, therapeutic results and evolutive particularities].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adju | 2010 |
The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Dideoxynucleotides; Early Growth Respo | 2010 |
Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2010 |
Continuous fall in hemoglobin level is a poor prognostic factor in patients with nasopharyngeal carcinoma treated with radiotherapy.
Topics: Adolescent; Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2010 |
Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemother | 2011 |
Survival of a cohort of patients with intermediate and advanced gall bladder cancer treated with a prospective therapeutic protocol.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Chemotherapy, Adjuvant; Chile; Cho | 2010 |
Enteral feeding during chemoradiotherapy for advanced head-and-neck cancer: a single-institution experience using a reactive approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squa | 2011 |
VEGF -460T → C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Female; Fluo | 2011 |
A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Carcinoma; Cell Migration Assays; Cell Transformation, Neopla | 2010 |
A breast cancer prognostic signature predicts clinical outcomes in multiple tumor types.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Brea | 2010 |
A quantitative evaluation of the determinant proteins for S-1 responsiveness in a biopsy specimen assists in patient selection to neoadjuvant therapy in cases of advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmaco | 2010 |
Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin | 2011 |
Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Colonic Neoplasms; Disea | 2010 |
Patient outcome study of concurrent chemoradiation, external beam radiotherapy, and high-dose rate brachytherapy in locally advanced carcinoma of the cervix.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carci | 2010 |
Abducens ocular neuromyotonia in a patient with nasopharyngeal carcinoma following concurrent chemoradiotherapy.
Topics: Abducens Nerve Diseases; Antineoplastic Agents; Carcinoma; Cisplatin; Diplopia; Drug-Related Side Ef | 2010 |
Aortobifemoral embolism in an 18-year old patient following cisplatin and 5-fluorouracil chemotherapy for nasopharyngeal carcinoma.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aortic Diseases; Arterial O | 2010 |
Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ap | 2011 |
Favorable outcome with bevacizumab after poor outcome with steroids in a patient with temporal lobe and brainstem radiation necrosis.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab | 2011 |
Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Ca | 2012 |
Successful remission of extensive liver metastases in a breast cancer patient with acute liver failure using a combined chemotherapy regimen with mitomycin, folinate, and 5-fluorouracil (Mi/Fo/FU).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Female; Fluorouracil; H | 2010 |
Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcin | 2010 |
Pancreatic metastasis from colon carcinoma treated with radiotherapy with palliative benefit.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Col | 2010 |
A bilateral cicatricial ectropion and bilateral upper lid shortening caused by 5-fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Dihydropyrimidine Dehydrogenase Defic | 2011 |
[mFOLFOX6 for treatment of anal canal cancer with disseminated carcinomatosis of bone marrow--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Marrow Ne | 2010 |
Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biologic | 2011 |
Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas.
Topics: Animals; Carcinoma; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Female; Flow Cyt | 2011 |
Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Ch | 2010 |
Penetration of paclitaxel and 5-fluorouracil in multicellular layers of human colorectal cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Carcinoma; Cell Line, Tumor | 2011 |
Rectal cancer: mucinous carcinoma on magnetic resonance imaging indicates poor response to neoadjuvant chemoradiation.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma | 2012 |
Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Drug E | 2011 |
[Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplat | 2010 |
Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Capeci | 2011 |
Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2011 |
5-Fluorouracil-induced acute dilated cardiomyopathy in a pediatric patient.
Topics: Acute Disease; Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 2011 |
Neoadjuvant radiochemotherapy and surgery for advanced rectal cancer : prognostic significance of tumor regression.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcin | 2011 |
Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clinical Protocols; Dise | 2011 |
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Biomar | 2011 |
The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma.
Topics: Age Factors; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Chemo | 2011 |
Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, M | 2011 |
SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies; Antigens, CD; Antimetabolites, Antineoplastic; | 2011 |
[Successful chemotherapy of carcinomatosis of the bone marrow with disseminated intravascular coagulation from a rectal carcinoma found by eosinophilia].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcino | 2011 |
The amount of neoadjuvant chemotherapy for Barrett's carcinoma does not correlate with long-term survival.
Topics: Aged; Antineoplastic Agents; Barrett Esophagus; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cohort | 2011 |
Intraoperative versus early postoperative intraperitoneal chemotherapy after cytoreduction for colorectal peritoneal carcinomatosis: an experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colonic | 2012 |
SNPs and haplotypes in DPYD and outcome of capecitabine--Letter.
Topics: Carcinoma; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug-Related Sid | 2011 |
SNPs and Haplotypes in DPYD and Outcome of Capecitabine-Letter.
Topics: Carcinoma; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug-Related Sid | 2011 |
[Intraabdominal chemotherapy of prevailing forms of colon cancer].
Topics: Abdominal Cavity; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Fluo | 2011 |
A patient with a metastatic gastroenteropancreatic endocrine carcinoma causing hyperinsulinaemic hypoglycaemia and the carcinoid syndrome.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; Fl | 2011 |
[Primary systemic therapy in breast cancer patients (2007-2010)].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; | 2011 |
Radiotherapy-induced pemphigus vulgaris with autoantibodies targeting a 110 kDa epidermal antigen.
Topics: Acantholysis; Adrenal Cortex Hormones; Antigens; Antineoplastic Agents; Autoantibodies; Carcinoma; C | 2011 |
Concurrent chemoradiotherapy for locoregionally advanced salivary gland malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Female; Fl | 2012 |
5FU continuous infusion in heavily pretreated advanced breast cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Berlin; Breast Neoplasms; Carcinoma; Female; Fluoroura | 2011 |
14-3-3σ regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation.
Topics: 14-3-3 Proteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomar | 2012 |
Treatment results of peritonectomy combined with perioperative chemotherapy for colorectal cancer-patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neo | 2011 |
Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chi-Square Distributi | 2012 |
Radiofrequency ablation combined with systemic chemotherapy in nasopharyngeal carcinoma liver metastases improves response to treatment and survival outcomes.
Topics: Carcinoma; Catheter Ablation; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Fluo | 2012 |
Comparison of concurrent chemoradiotherapy versus induction chemotherapy followed by radiation in patients with nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemother | 2012 |
Efficacy of the CMFVP regimen in patients with metastatic breast cancer previously treated with anthracycline and taxane.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemo | 2012 |
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2012 |
[Postradiotherapy complications and their correction ways at patients with nasopharyngeal carcinoma].
Topics: Carcinoma; Cisplatin; Combined Modality Therapy; Epithelium; Fluorouracil; Humans; Nasopharyngeal Ca | 2012 |
Effectiveness and safe use of modified FOLFOX-6 for metastatic gastric cancer with signet ring cell components complicated by disseminated intravascular coagulation and diffuse bone marrow carcinomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcinoma; Carcinoma, Signet | 2012 |
Effects of Agaricus blazei Murill extract on sensitivity to chemotherapeutic agents in HeLa cells and its resistant sublines.
Topics: Agaricus; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological | 2008 |
Nonspecific but significant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Signet Ring Cell; Colonic Neop | 2012 |
Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Capecitabine; Carcinoma; | 2012 |
Experience with combination of docetaxel, cisplatin plus 5-fluorouracil chemotherapy, and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug | 2013 |
Efficient inhibition of colorectal peritoneal carcinomatosis by drug loaded micelles in thermosensitive hydrogel composites.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Drug Carriers; | 2012 |
Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colo | 2012 |
Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer.
Topics: Angiogenesis Inducing Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cap | 2012 |
Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Ca | 2012 |
Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Capecitabine; Carcinoma | 2012 |
Onset of segmental colitis associated with diverticulosis after treatment with bevacizumab for metastatic colorectal carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carc | 2012 |
Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Deoxycytidine; Dise | 2012 |
[A case of advanced primary colorectal carcinoma accompanied by liver metastasis in which ileus developed due to marked fibrosis with cicatricial formation in primary colorectal cancer treated by chemotherapy including bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carc | 2012 |
Lung metastases of epithelial-myoepithelial carcinoma of the parotid gland successfully treated with chemotherapy: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Docetaxel; Fluorouracil | 2013 |
Multidisciplinary therapy consisting of minimally invasive resection, irradiation, and intra-arterial infusion of 5-fluorouracil for maxillary sinus carcinomas.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Female; Fluorouracil; Follow-Up Studies; Humans; Infusio | 2013 |
Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Cell Cy | 2012 |
Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Car | 2012 |
New strategy in hepatic metastatic colorectal cancer: tomotherapy and capecitabine followed by hepatic surgical resection.
Topics: Antineoplastic Agents; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Fluorou | 2012 |
A mixture of amino acids and other small molecules present in the serum suppresses the growth of murine and human tumors in vivo.
Topics: Amino Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Caspase | 2013 |
Early growth response protein-1 promoter-mediated synergistic antitumor effect of hTERTC27 gene therapy and 5-Flurorouracil on nasopharyngeal carcinoma.
Topics: Animals; Carcinoma; Cell Growth Processes; Cell Line, Tumor; Combined Modality Therapy; Early Growth | 2012 |
Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma; Chemoradiotherapy | 2012 |
Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets.
Topics: Adenocarcinoma; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Fluoroura | 2012 |
Metastatic human papillomavirus-positive nasopharyngeal carcinoma with an unusual pattern of aggressive hematogenous spread.
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biomarkers, Tumor; Carb | 2012 |
Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2012 |
Occurrence of Sjögren syndrome in a long-term survivor patient with metastatic colon carcinoma treated with GOLFIG regimen.
Topics: Adjuvants, Immunologic; Administration, Metronomic; Aged; Antineoplastic Combined Chemotherapy Proto | 2012 |
Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineo | 2012 |
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2013 |
Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
5-Fluorouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells.
Topics: Apoptosis; Calcium; Calcium Signaling; Calmodulin; Carcinoma; Caspases; Cell Line, Tumor; Colonic Ne | 2013 |
Chemosensitivity in ovarian metastases from gastric cancer: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Female; Fluorouracil | 2013 |
Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptos | 2013 |
Importance of methanogenic flora in intestinal toxicity during 5-fluorouracil therapy for colon cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Colon; Colorectal Neoplasms; Female; Fluorouracil; Human | 2013 |
5-FU-induced cardiac toxicity--an underestimated problem in radiooncology?
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Cardiotoxins; Chemoradiotherapy; Electrocardiograp | 2012 |
Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; | 2013 |
Comparison of treatment compliance and nutritional outcomes among patients with nasopharyngeal carcinoma with and without percutaneous endoscopic gastrostomy during chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Ci | 2012 |
Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy?
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Non-surgical treatment for afferent loop syndrome in recurrent gastric cancer complicated by peritoneal carcinomatosis: percutaneous transhepatic duodenal drainage followed by 24-hour infusion of high-dose fluorouracil and leucovorin.
Topics: Adenocarcinoma; Afferent Loop Syndrome; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2002 |
Selective induction of colon cancer cell apoptosis by 5-fluorouracil in humans.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Cell Division; Colon | 2002 |
Treatment of maxillary sinus carcinoma: clinical results using the Kitasato modality.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Protocols; Carcinoma; Combined | 2002 |
Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Colorectal Neoplasms | 2002 |
Cytotoxicity of combinations of IFN-beta and chemotherapeutic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Ce | 2002 |
Prognostic impact of reoxygenation in advanced cancer of the head and neck during the initial course of chemoradiation or radiotherapy alone.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Cell Hypoxia; Female; Fluorouracil; Head | 2003 |
Quantification of human Alu sequences by real-time PCR--an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants.
Topics: Alu Elements; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Colonic Neoplasms; DNA, N | 2002 |
Expression of thymidylate synthase and thymidine phosphorylase in human breast carcinoma: implication for method to detect expression of these molecules in clinic.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Female | 2003 |
Expression of copper-transporting P-type adenosine triphosphatase in human esophageal carcinoma.
Topics: Adenosine Triphosphatases; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cation T | 2003 |
Epidural metastasis in nasopharyngeal carcinoma.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Cervical Vertebrae; Cispla | 2003 |
[Complete remission of esophageal undifferentiated carcinoma with nedaplatin and 5-FU chemotherapy and endoesophageal brachytherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma; Combined Modality Th | 2003 |
Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosp | 2003 |
5-Fluorouracil efficiently enhanced apoptosis induced by adenovirus-mediated transfer of caspase-8 in DLD-1 colon cancer cells.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Caspase 8; Caspase 9; Caspases; | 2003 |
Linear accelerator-based stereotactic radiosurgery for limited, locally persistent, and recurrent nasopharyngeal carcinoma: efficacy and complications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemother | 2003 |
Outpatient weekly 24-hour infusional adjuvant chemotherapy of cisplatin, 5-fluorouracil, and leucovorin for high-risk nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 2003 |
The significance of cardiac doses received during chemoradiation of oesophageal and gastro-oesophageal junctional cancers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2003 |
Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Bl | 2003 |
Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line.
Topics: Active Transport, Cell Nucleus; Antimetabolites, Antineoplastic; Apoptosis; Binding Sites; Carcinoma | 2003 |
Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy.
Topics: Alprostadil; Animals; Antimetabolites, Antineoplastic; Blood Pressure; Carcinoma; Cell Division; Dru | 2003 |
Observations on the use of 5-fluorouracil in metastatic carcinoma of the breast.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Carcinoma; Fluorouracil; Humans; Uracil | 1961 |
Use of 5-fluorouracil in treatment of bladder carcinomas.
Topics: Antineoplastic Agents; Carcinoma; Fluorouracil; Uracil; Urinary Bladder Neoplasms | 1960 |
Combination therapy with 5-fluorouracil and cobalt-60 for inoperable carcinoma of the lungs.
Topics: Antineoplastic Agents; Carcinoma; Cobalt; Cobalt Radioisotopes; Combined Modality Therapy; Fluoroura | 1962 |
5-Fluorouracil in the treatment of inoperable carcinoma of the colon and rectum.
Topics: Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Fluorouracil; Humans; Rectal Neoplasms; Rectum; | 1962 |
Continuous intraarterial chemotherapy in advanced bladder cancer. A preliminary report.
Topics: Carcinoma; Carcinoma, Papillary; Carcinoma, Transitional Cell; Fluorouracil; Humans; Neoplasms; Urin | 1963 |
Antitumor action of several new piperazine derivatives compared to certain standard anticancer agents.
Topics: Animals; Antineoplastic Agents; Carcinoma; Carcinoma 256, Walker; Fluorouracil; Humans; Mechloretham | 1963 |
Antimitotic action of 5-(2'-bromo-acetamido)-uracil on the Ehrlich ascites tumor.
Topics: Animals; Antimitotic Agents; Antineoplastic Agents; Carcinoma; Carcinoma, Ehrlich Tumor; Fluorouraci | 1962 |
The response of squamous cell carcinoma to intra-arterial infusion with 5-fluorouracil.
Topics: Carcinoma; Carcinoma, Squamous Cell; Fluorouracil; Humans; Infusions, Intra-Arterial | 1962 |
Studies on resistance against 5-fluorouracil. III. Selective value of resistant, uridine kinase-deficient tumor cells.
Topics: Animals; Carcinoma; Carcinoma, Ehrlich Tumor; Fluorouracil; Humans; Phosphotransferases; Uridine Kin | 1962 |
Carcinoma of the stomach: treatment with 5-fluorouracil.
Topics: Carcinoma; Fluorouracil; Humans; Stomach Neoplasms | 1963 |
Controlled-dose therapy as an adjunct to surgery.
Topics: Carcinoma; Carcinoma 256, Walker; Floxuridine; Fluorouracil; Humans; Protein Deficiency | 1963 |
The use of combination 5-fluorouracil and supervoltage irradiation therapy in advanced carcinoma of the urinary bladder--a preliminary report.
Topics: Carcinoma; Cell- and Tissue-Based Therapy; Fluorouracil; Humans; Multiple Myeloma; Plasma Cells; Ura | 1962 |
INHIBITION OF EHRLICH ASCITES TUMOR WITH 5-FLUOROURACIL AND OTHER AGENTS.
Topics: Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Ehrlich Tumor; Floxuridine; Fluorouracil; Hydr | 1963 |
IN VITRO TEST SYSTEMS FOR CANCER CHEMOTHERAPY. II. CORRELATION OF IN VITRO INHIBITION OF DEHYDROGENASE AND GROWTH WITH IN VIVO INHIBITION OF EHRLICH ASCITES TUMOR.
Topics: Animals; Antineoplastic Agents; Arsenicals; Carbamates; Carcinoma; Carcinoma, Ehrlich Tumor; Colchic | 1963 |
PRELIMINARY OBSERVATIONS ON CARCINOMA OF THE CERVIX TREATED WITH 5-FLUOROURACIL.
Topics: Carcinoma; Female; Fluorouracil; Humans; Injections, Intravenous; Mortality; Neoplasms; Stomatitis; | 1964 |
INFUSION OF 5-FLUOROURACIL IN CYLINDROMA TREATMENT.
Topics: Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Basal Cell; Fluorouracil; Humans; Injections, Intra | 1964 |
A REPORT OF THE SYSTEMIC USE OF 5-FLUOROURACIL IN THE TREATMENT OF CHINESE CANCER PATIENTS.
Topics: Adenocarcinoma; Aged; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; China; Fallopian Tube N | 1964 |
ALKYLATING AGENTS, ANTI-METABOLITES, ALKALOIDS AND X-RAYS IN THE TREATMENT OF INOPERABLE BRONCHOGENIC CARCINOMA.
Topics: Alkaloids; Alkylating Agents; Antimetabolites; Antineoplastic Agents; Carcinoma; Carcinoma, Bronchog | 1964 |
CLINICAL STUDIES OF COMBINED CHEMOTHERAPY AND IRRADIATION IN INOPERABLE BRONCHOGENIC CARCINOMA.
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide; Fluo | 1964 |
HORMONAL THERAPY OF METASTATIC FEMALE BREAST CARCINOMA. IV. 17-BETA-AMINO-5-ALPHA-ANDROSTAN-11-BETA-OL.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Female; Fluorouracil; Humans; Neoplasm Metastasi | 1964 |
TREATMENT OF BLADDER TUMORS BY DIRECT INSTILLATION OF 5-FLUOROURACIL. EXPERIMENTAL OBSERVATIONS IN DOGS.
Topics: Amines; Animals; Carcinogens; Carcinoma; Carcinoma, Transitional Cell; Dogs; Fluorouracil; Gastroent | 1964 |
ACUTE CEREBELLAR SYNDROME SECONDARY TO 5-FLUOROURACIL THERAPY.
Topics: Abdominal Neoplasms; Adenocarcinoma; Bone Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, | 1964 |
EFFECTS OF URACIL MUSTARD ON IN VIVO INCORPORATION OF PRECURSORS INTO NUCLEIC ACIDS OF THE WALKER TUMOR.
Topics: Animals; Carcinoma; Carcinoma 256, Walker; DNA; DNA, Neoplasm; Fluorouracil; Kinetics; Metabolism; N | 1964 |
PERFUSION TREATMENT OF CANCER.
Topics: Carcinoma; Carcinoma, Squamous Cell; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Fluo | 1965 |
PELVIC PERFUSION AND CARCINOMA OF THE RECTUM.
Topics: Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Equipment and Supplies; Fluorouracil; Humans; M | 1965 |
EFFECTIVENESS AND TOXICITY OF PROLONGED INFUSIONS OF 5-FLUOROURACIL IN THE TREATMENT OF CANCER.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma; Carcinoma, Sq | 1965 |
TREATMENT OF BLADDER TUMORS BY INSTILLATION OF THIO-TEPA, ACTINOMYCIN D, OR 5-FLUOROURACIL.
Topics: Carcinoma; Carcinoma, Papillary; Dactinomycin; Drug Therapy; Fluorouracil; Humans; Neoplasms; Thiote | 1965 |
FLUORINATED PYRIMIDINES. XXII. EFFECTS OF VARIOUS COMPOUNDS ON THE INCORPORATION OF (14C)FORMATE INTO DNA THYMINE IN SUSPENSIONS OF EHRLICH ASCITES CELLS.
Topics: Animals; Antineoplastic Agents; Ascites; Carbon Isotopes; Carcinoma; Carcinoma, Ehrlich Tumor; DNA; | 1964 |
SQUAMOUS CELL CARCINOMA OF ORAL CAVITY; INTRA-ARTERIAL INFUSION WITH FLUOROURACIL AND IDOXURIDINE.
Topics: Carcinoma; Carcinoma, Squamous Cell; Drug Therapy; Fluorouracil; Humans; Idoxuridine; Infusions, Int | 1965 |
Clinical studies with 5-fluorouracil in 47 patients.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Carcinoma; Carcinoma, Squamous Cell; Fluorourac | 1962 |
Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopl | 2003 |
[A gastroenterology unit experience with adjuvant chemotherapy for non-metastatic colon cancer: results from 24 cases].
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluor | 2003 |
Anal canal cancer treatment: practical limitations of routine prescription of concurrent chemotherapy and radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2003 |
Modified pharmacokinetic modulating chemotherapy using 5-fluorouracil, UFT, and taxotere (docetaxel) for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Docetaxel; Fluorouracil; Humans; Infusion | 2003 |
Response of neoplastic meningitis from solid tumors to oral capecitabine.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcin | 2003 |
Enhanced radiosensitization and chemosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8.
Topics: Animals; Annexin A5; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma; Cell | 2004 |
Effect of carcinomatosis and intraperitoneal 5-fluorouracil on peritoneal blood flow modulated by vasopressin in the rat as measured with the 133Xe-clearance technique.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Fluorouracil; Hemostatics; Infusions, Intraveno | 2004 |
Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
Topics: Adjuvants, Immunologic; Aged; Antimetabolites, Antineoplastic; Carcinoma; Cell Adhesion Molecules; C | 2004 |
Influence of high-dose leucovorin and 5-fluorouracil chemotherapy regimen on P wave duration and dispersion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Carcinoma; Colorectal Neoplas | 2004 |
Reactivation of hepatitis C virus after chemotherapy for colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colonic Neoplasms; Fl | 2004 |
Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2004 |
Concurrent chemoradiotherapy in locoregionally recurrent nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 2004 |
Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?--a prospective clinical study.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X | 2004 |
Secretory breast carcinoma--case report and review of the medical literature.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma; Com | 2004 |
Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Sq | 2004 |
hTERT antagonizes p53-induced apoptosis independently of telomerase activity.
Topics: Apoptosis; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; DNA-Bind | 2005 |
Cardiotoxicity and neurotoxicity of high-dose continuous fluorouracil as a result of degradation compounds in the drug vials.
Topics: Acetaldehyde; Aged; Antimetabolites, Antineoplastic; Brain Diseases; Carcinoma; Chemistry, Pharmaceu | 2004 |
Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2005 |
Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoma; | 2005 |
[A comparison of two modalities of complex chemoradiotherapy for locally advanced nasopharyngeal carcinoma].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant | 2004 |
Effects of p21cip1/waf1 overexpression on growth, apoptosis and differentiation in human colon carcinoma cells.
Topics: Agar; Alkaline Phosphatase; Apoptosis; Blotting, Western; Butyrates; Carcinoma; Cell Cycle Proteins; | 2005 |
Slow evolution of liver metastasis from colon cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Colectomy; Colorectal Neoplasms; Disease-Free Survival; | 2005 |
Inguinal canal as an anatomic sanctuary site of relapse in peritoneal carcinomatosis previously treated with intraperitoneal chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplas | 2005 |
Treatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Dose Fractionatio | 2005 |
[Therapeutic effect of medical therapy upon undifferentiated nasopharyngeal carcinoma: analysis of 149 cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Combin | 2001 |
5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2005 |
Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 2006 |
Nasopharyngeal carcinoma in the pediatric age group: the northern Israel (Rambam) medical center experience, 1989-2004.
Topics: Adolescent; Age Distribution; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, | 2005 |
Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brain; Breast Neoplasms; Capecitabine; Carcinoma; Deox | 2005 |
Can plasma Epstein-Barr virus DNA levels be used to monitor nasopharyngeal carcinoma progression?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma; Case-Control Studies; Cisplat | 2005 |
[Irinotecan in combination with 5-fluorouracil and leucovorin in the treatment of metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neo | 2005 |
Tumor quantification of several fluoropyrimidines resistance gene expression with a unique quantitative RT-PCR method. Implications for pretherapeutic determination of tumor resistance phenotype.
Topics: Antimetabolites, Antineoplastic; Biopsy; Carcinoma; Colorectal Neoplasms; DNA Primers; DNA, Compleme | 2006 |
[Topical and systemic chemotherapy with 5-fluouracil in facial carcinoma secondary to xeroderma pigmentosum].
Topics: Administration, Cutaneous; Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents | 2005 |
Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bone M | 2006 |
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression levels in tumor and normal tissue specimens of T3 human colorectal carcinoma.
Topics: 5'-Nucleotidase; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; CD3 Complex; Colorectal | 2006 |
Docetaxel administered during pregnancy for inflammatory breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide | 2006 |
In response to: 'On prejudice and facts and choices', an editorial by Kohne and Folprecht.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Choice Behavior; Clinical T | 2006 |
[A case of gastric endocrine cell carcinoma with liver metastasis showing rapid growth during pregnancy and marked reduction by systemic chemotherapy after delivery].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Delivery, Obstetric; Dr | 2006 |
Epithelial-myoepithelial carcinoma of the submandibular gland with symptomatic lung metastases treated with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Cyc | 2006 |
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Proliferation; Colonic Neopla | 2005 |
[Treatment of malignant ovarian tumours in Georgia in 1990-2000].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Cyclophosphami | 2006 |
Comparison of local recurrence and distant metastases between breast cancer patients after postmastectomy radiotherapy with and without immediate TRAM flap reconstruction.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2006 |
Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
alpha-Fetoprotein shields hepatocellular carcinoma cells from apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand.
Topics: alpha-Fetoproteins; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; C | 2007 |
Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Caco-2 Cells; Capecitabine; Carcino | 2006 |
Success of neoadjuvant chemotherapy in conversion of mastectomy to breast conservation surgery.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 2006 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormon | 2006 |
Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cispl | 2006 |
[A case of successfully treated unresectable multiple liver metastases from colon cancer by hepatic arterial infusion chemotherapy and systemic chemotherapy].
Topics: Aged; Camptothecin; Carcinoma; Colectomy; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Art | 2006 |
Overexpression of the orotate phosphoribosyl-transferase gene enhances the effect of 5-fluorouracil on gastric cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma; Cell Line, Tumor; DNA, Compl | 2006 |
[Anesthetic management for scheduled peritonectomy and hyperthermic intraperitoneal chemotherapy in 20 patients].
Topics: Adult; Aged; Analgesia, Epidural; Anesthesia, General; Anesthesia, Inhalation; Anesthesia, Intraveno | 2006 |
Outcomes of hepatic artery infusion therapy for hepatic metastases from colorectal carcinoma after radiological placement of infusion catheters.
Topics: Aged; Angiography; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Car | 2007 |
[Complete regression after neoadjuvant chemotherapy in locally advanced gastric cancer causing peritonitis carcinomatosa--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma; Chemotherapy, Adjuvant; Cisplati | 2006 |
Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Apoptosis; Carcin | 2007 |
Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma; Chemothe | 2007 |
XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cisplatin; | 2007 |
[Capecitabine-induced hyperpigmentation].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Female; F | 2007 |
[Long-term efficacy of induction chemotherapy plus concurrent radiochemotherapy on advanced nasopharyngeal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Dis | 2007 |
DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neoplasms; Di | 2007 |
Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in patients with carcinoma of unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluoroura | 2007 |
Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients.
Topics: Antimetabolites, Antineoplastic; Becaplermin; Capecitabine; Carcinoma; Combined Modality Therapy; De | 2008 |
Therapy of colon carcinoma: an oncology perspective. Interview with Piotr M. Czaykowski by Paul C. Adams.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
The characteristics of Hep-2 cell with multiple drug resistance induced by Taxol.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2007 |
Inhibition of human gastric carcinoma cell growth by treatment of N(3)-o-toluyl-fluorouracil as a precursor of 5-fluorouracil.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Cell P | 2007 |
Long-term survival of resectable subset after induction chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Car | 2008 |
Induction chemotherapy followed by alternating chemo-radiotherapy in non-endemic undifferentiated carcinoma of the nasopharynx: optimal compliance and promising 4-year results.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squam | 2008 |
Coordinated chemoradiation therapy with genital preservation for the treatment of primary invasive carcinoma of the male urethra.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Cohort Studies; Combined Modality | 2008 |
Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Cell Proliferation; Dihydrouracil Dehy | 2008 |
Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2007 |
Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2008 |
Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2008 |
Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2008 |
Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2008 |
Integrated gene expression profile predicts prognosis of breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, | 2009 |
Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 2008 |
Continuous intra-arterial chemotherapy with 5-fluorouracil and cisplatin for locally advanced anaplastic carcinoma of the pancreas.
Topics: Carcinoma; Cisplatin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Middle Aged; Pancreat | 2008 |
Low-cost outpatient chemotherapy regimen of cisplatin, 5-fluorouracil and leucovorin for advanced head and neck and esophageal carcinomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2008 |
Downregulation of BMI-1 enhances 5-fluorouracil-induced apoptosis in nasopharyngeal carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Carcinoma; Cell Line, Tumor; | 2008 |
Preoperative intensity-modulated radiotherapy and chemotherapy for locally advanced vulvar carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2008 |
Cancer of the bladder. Combined 5-fluorouracil and cobalt-60 teletherapy.
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Cobalt; Cobalt R | 1964 |
[Attack treatment of broncho-pleuro-pulmonary cancer by polychemotherapy under the protection of phytohemagglutinin].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Betametha | 1967 |
5-fluorouracil modulation of dihydrofolate reductase RNA levels in methotrexate-resistant KB cells.
Topics: Carcinoma; Cell Division; Cell Line; Clone Cells; Fluorouracil; Gene Amplification; Humans; Kinetics | 1983 |
Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
Topics: Adult; Aged; Aspartic Acid; Carcinoma; Colonic Neoplasms; Drug Administration Schedule; Drug Eruptio | 1983 |
Combination chemotherapy for metastatic carcinoma of the ampulla of Vater--report of three cases.
Topics: Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Common Bile Duct | 1984 |
Analysis of the results of our combined therapy for maxillary cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell | 1980 |
Potentiation of the antitumor action of 5-fluorouracil with 5-ethyl-2'-deoxyuridine in human colorectal tumor xenografts.
Topics: Adenocarcinoma, Mucinous; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Coloni | 1984 |
[Experiences with Volm's short-term tumor test in the primary treatment of ovarian carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Division; Cells, Cultured; Cisplatin | 1984 |
Late results of postoperative long-term cancer chemotherapy for the gastric cancer patients subjected to curative resection.
Topics: Antibiotics, Antineoplastic; Carcinoma; Dose-Response Relationship, Drug; Drug Administration Schedu | 1983 |
[Chemotherapy of epithelial ovarian carcinoma].
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chlorambucil; Cisplatin; Cyc | 1983 |
Impact of adjuvant chemotherapy on cosmesis and complications in stages I and II carcinoma of the breast treated by biopsy and radiation therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Diseases; Breast Neoplasms; Ca | 1984 |
Combination chemoimmunotherapy for advanced gastric carcinoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Ca | 1984 |
[5-Fluorouracil treatment combined with ascorbic acid in patients with disseminated stomach cancer].
Topics: Adenocarcinoma; Adult; Aged; Ascorbic Acid; Carcinoma; Combined Modality Therapy; Female; Fluorourac | 1984 |
[Chemotherapeutic responses of a primary tumor and its pulmonary metastases in murine tumor systems in relation to its proliferative properties].
Topics: Animals; Carcinoma; Fluorouracil; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Ne | 1984 |
Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil.
Topics: Animals; Carcinoma; Cell Line; Deoxyuracil Nucleotides; Fluorodeoxyuridylate; Fluorouracil; Humans; | 1984 |
Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil.
Topics: Actuarial Analysis; Adenocarcinoma; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protoco | 1983 |
[Ovarian carcinoma: surgery and polychemotherapy with cisplatin. Considerations on a clinical case].
Topics: Carcinoma; Cisplatin; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Me | 1983 |
Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil.
Topics: Animals; Carcinoma; Chromatography, Gel; Fibroblasts; Fluorouracil; Folic Acid; gamma-Glutamyl Hydro | 1983 |
[Results of combined treatment of cancer of the stomach taking into consideration tumor sensitivity to 5-fluorouracil].
Topics: Adenocarcinoma; Adult; Carcinoma; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies | 1984 |
[Surgical method and combination chemotherapy in treating stage-III and IV ovarian cancer].
Topics: Altretamine; Antineoplastic Agents; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Evaluati | 1980 |
Chemoprevention of development of colonic adenomatosis and carcinomatosis with 5-fluorouracil and ftorafur on animal model.
Topics: Adenoma; Animals; Carcinoma; Colon; Colonic Neoplasms; Female; Fluorouracil; Methylnitrosourea; Neop | 1980 |
Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Carcinoma; Cisplatin; Cyclophosphamide; Doxorubicin | 1981 |
Management of inflammatory carcinoma of breast with combined modality approach - an update.
Topics: Adult; Aged; Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Carcinoma; Cobalt Radioisotopes; | 1981 |
Antitumor activity of methyl (5-fluoro-1H-2-oxo-4-pyrimidinyl beta-D-glucopyranosid)uronate against various experimental tumors.
Topics: Animals; Antineoplastic Agents; Carcinoma; Carcinoma 256, Walker; Female; Fluorouracil; Lung Neoplas | 1981 |
[Conservative treatment of primary and recurrent malignant stomach neoplasms].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male | 1981 |
Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Blood Cell Count; Carcinoma; Drug Admin | 1983 |
Radiation therapy and chemotherapy in the treatment of primary anal canal carcinoma.
Topics: Anus Neoplasms; Carcinoma; Female; Fluorouracil; Humans; Male; Mitomycins | 1983 |
Early combined hormonal and chemotherapy for metastatic prostatic carcinoma.
Topics: Aged; Bone Neoplasms; Carcinoma; Castration; Cyclophosphamide; Diethylstilbestrol; Fluorouracil; Hum | 1983 |
[Advanced epithelial cancers of the ovary: results of 4 chemotherapy protocols (110 cases)].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Cisplatin; Cyclophosphamide; Drug Therapy, Combinatio | 1982 |
Adjuvant chemotherapy (CMF) for breast carcinoma: hematological side effects.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Carcinoma; Cyclophosp | 1982 |
Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil.
Topics: Animals; Carcinoma; Cell Line; Deoxyribonucleosides; Deoxyribose; Deoxyuridine; Drug Synergism; Fluo | 1981 |
Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU.
Topics: Adult; Aged; Aspartic Acid; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Drug Evaluation; Drug Th | 1982 |
Initial chemoimmunotherapy in inflammatory carcinoma of the breast.
Topics: Aged; Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Carcinoma; Doxorubicin; Drug Evaluation; | 1982 |
Estrogen receptor status in inflammatory breast carcinoma.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cyclophosphamide; Doxorubicin; Drug Therapy, Com | 1982 |
Combination chemotherapy in advanced carcinoma of the cervix.
Topics: Alopecia; Antineoplastic Agents; Carcinoma; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Hum | 1982 |
[Antineoplastic activity of lambdamycin in different murine test models compared with cyclophosphamide, 6-mercaptopurine and 5-fluorouracil (author's transl)].
Topics: Animals; Benzopyrans; Carcinoma; Cyclophosphamide; Fluorouracil; Glycosides; Leukemia, Experimental; | 1981 |
Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines.
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma; Cell Line; Colonic Neoplasms; Drug Administration Sched | 1980 |
Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tum | 1994 |
The style of early clinical research reporting: what are we saying and how do we say it?
Topics: Abstracting and Indexing; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Car | 1993 |
Chemotherapy of recurrent/advanced cervical cancer: results of the Yale University PBM-PFU protocol.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Female | 1994 |
Reticulate pigmentation due to 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Erythema; Fluorouracil; Humans | 1995 |
Ethmoid sinus leiomyosarcoma after cyclophosphamide treatment.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Ch | 1995 |
5-Ethoxy-2'-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Cell Division; Colonic Neoplasms; Deoxyuridine; | 1995 |
Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions.
Topics: Carcinoma; Catheterization, Peripheral; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Stability | 1995 |
[The use of endolymphatic chemotherapy in patients with metastatic stomach cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1994 |
[A case of meningeal carcinomatosis which occurred after treatment for recurrence of the cervical carcinoma].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combine | 1995 |
SMS 201.995 (Sandostatin) enhances in-vitro effects of 5-fluorouracil in colorectal cancer.
Topics: Adenocarcinoma; Carcinoma; Colonic Neoplasms; Colorimetry; Drug Synergism; Fluorouracil; Humans; Oct | 1995 |
Chemotherapy induced refractory anaemia with ring sideroblasts in carcinoma breast.
Topics: Aged; Anemia, Refractory; Anemia, Sideroblastic; Antineoplastic Combined Chemotherapy Protocols; Bon | 1994 |
Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined M | 1995 |
Synchronization of cells in the S phase of the cell cycle by 3'-azido-3'-deoxythymidine: implications for cell cytotoxicity.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Cell Survival; Colonic Neoplasms; | 1995 |
Long-term follow-up of patients with epithelial carcinoma of the ovary.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; Cytarabine; | 1994 |
Concomitant chemoradiation prior to surgery in the treatment of advanced cervical carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 1994 |
[The evolution of the liver metastases from colorectal carcinoma treated with hepatic intra-arterial chemotherapy. The echographic and CT aspects].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Floxuridine; Fluoro | 1994 |
[The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1994 |
Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin.
Topics: Aclarubicin; Animals; Carbazilquinone; Carcinoma; Cell Nucleus; CHO Cells; Cisplatin; Cricetinae; Cy | 1994 |
Patterns of early treatment failure in non-metastatic nasopharyngeal carcinoma: a study based on CT scanning.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma; C | 1994 |
Myocardial ischemia after 5-fluorouracil chemotherapy.
Topics: Adult; Carcinoma; Fluorouracil; Humans; Male; Myocardial Ischemia; Tonsillar Neoplasms | 1993 |
Increased chemocytotoxicity to colon cancer cells by shock wave-induced cavitation.
Topics: Air; Carcinoma; Cell Cycle; Cell Survival; Colonic Neoplasms; Combined Modality Therapy; Deoxyuridin | 1994 |
Concomitant chemoradiotherapy for advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cobal | 1994 |
[Adjuvant chemotherapy in ovarian carcinoma. Preliminary results].
Topics: Adnexa Uteri; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bulgaria; Carcinoma; Chem | 1993 |
Radiation therapy in the conservative treatment of carcinoma of the anal canal.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Carcinom | 1994 |
Inhibition of dihydropyrimidine dehydrogenase by alpha-interferon: experimental data on human tumor cell lines.
Topics: Carcinoma; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Drug Screening Assa | 1994 |
Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats.
Topics: Animals; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Cytotoxicity, Immunologic; Fluo | 1994 |
Central pontine myelinolysis: report of two occurrences after cisplatin-containing chemotherapy for nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluorouracil; H | 1993 |
Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Doxoru | 1994 |
Surgical stage IV endometrial carcinoma: a study of 47 cases.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclo | 1994 |
Locoregionally advanced paranasal sinus carcinoma. Favorable survival with multimodality therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Ci | 1993 |
A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colonic Neoplasms | 1993 |
A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1993 |
Combined chemotherapy and radiation for bulky stages I-II cervical cancer: comparison of concurrent and sequential regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, A | 1993 |
Primary chemotherapy and radiosurgical breast-conserving treatment for patients with locally advanced operable breast cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Intraductal, | 1993 |
A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colonic Neoplasms | 1993 |
[Quandrantectomy in the conservative treatment of breast carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined Modality Thera | 1993 |
5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Topics: Animals; Carcinoma; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Synergism; Enzyme | 1995 |
5-Fluorouracil metabolism and cytotoxicity after pre-treatment with methotrexate or thymidine in human hypopharynx and colon carcinoma xenografts: a 19F-nuclear magnetic resonance spectroscopy study in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Colonic Neoplasms; Fluorine Radioisotopes; Fluo | 1996 |
Pre-operative interleukin-2 immunotherapy induces eosinophilic infiltration in colorectal neoplastic stroma.
Topics: Adult; Antineoplastic Agents; Carcinoma; Chemotaxis, Leukocyte; Chemotherapy, Adjuvant; Colorectal N | 1995 |
Bioavailability of subcutaneous 5-fluorouracil: a case report.
Topics: Antidotes; Antimetabolites, Antineoplastic; Biological Availability; Carcinoma; Colorectal Neoplasms | 1996 |
Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.
Topics: Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Ce | 1996 |
Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1996 |
Curative reoperations for locally recurrent rectal cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Ma | 1996 |
[A combination chemotherapy with CDDP and 5-FU effective for pulmonary metastases in a case of parotid gland carcinoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 1996 |
Nasopharyngeal carcinoma with metastatic disease to mediastinal and hilar lymph nodes: an indication for more aggressive treatment.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemothe | 1996 |
A prospective evaluation of the treatment of primary or metastatic liver carcinoma with hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1996 |
How should cancer presenting as a malignant pleural effusion be managed?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carcinoma; Cisplatin; Epi | 1996 |
Ileostomy dysfunction with adjuvant chemoradiation for rectal carcinoma requiring in-hospital management: a cause for concern.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Dehydration; Fluorouracil; Hospi | 1996 |
Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia.
Topics: Animals; Antimetabolites, Antineoplastic; Base Sequence; Carcinoma; Cell Survival; Cloning, Molecula | 1996 |
Pharmacological effects of 5-fluorouracil microspheres on peritoneal carcinomatosis in animals.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Drug Screening Assays, Antitumor; Fluorouracil; | 1996 |
Preliminary report of outpatient weekly adjuvant chemotherapy for high-risk nasopharyngeal carcinoma.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1996 |
[The acute toxicity of the simultaneous radiochemotherapy of rectal carcinoma].
Topics: Acute Disease; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Female; Fluoroura | 1997 |
Combined concomitant boost radiotherapy and chemotherapy in stage III-IV head and neck carcinomas: a comparison of toxicity and treatment results with those observed after radiotherapy alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Fem | 1997 |
Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study.
Topics: Adult; Aged; Antidotes; Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Fluorouracil; Follow | 1997 |
18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil.
Topics: Aged; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neoplasms; Drug Interactions | 1998 |
Reconstruction with free jejunal autograft after circumferential pharyngolaryngectomy: eighty-three cases.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma; Cisplatin; Combined Modality Therapy; Fem | 1998 |
[Continuous intravenous infusional 5-FU compared with bolus administration in metastatic colorectal carcinoma].
Topics: Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, I | 1998 |
Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Cisplatin; Doxorubicin; Drug Scre | 1998 |
[Perspectives in the treatment of peritoneal carcinosis].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1997 |
Alcohol consumption enhances liver metastasis in colorectal carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Analysis of Variance; Antineoplastic Agents; Blood | 1998 |
Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1998 |
Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 1998 |
[Thymic anaplastic carcinoma successfully controlled by combination chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; Doxor | 1998 |
Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: in vitro and in vivo study.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Colonic Neoplasms; Drug Synergism; Floxuridine; | 1999 |
[An addendum to the article by C. Rödel, W. Hohenberger, R. Sauer. Adjuvant and neoadjuvant radiochemotherapy of rectal carcinoma. Strahlenther Onkol 1998; 174: 497-504 (Nr. 10)].
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Fluorouracil; Humans; Radiothera | 1999 |
A comparison of conventional and conformal radiotherapy of the oesophagus: work in progress.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Esophageal Neoplasms; Feasibility Studies; Fluorouracil; | 1998 |
Treatment of colorectal carcinoma in adolescents and young adults with surgery, 5-fluorouracil/leucovorin/interferon-alpha 2a and radiation therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant | 1999 |
Complete regression of recurrent esophageal carcinoma with reduced expression of glutathione S-transferase-pi by treatment with continuous infusion of 5-fluorouracil and low-dose cisplatin infusion.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1999 |
Metaplastic breast cancer: prognosis and response to systemic therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 1999 |
Telomerase enzyme activity and RNA expression in adriamycin-resistant human breast carcinoma MCF-7 cells.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Carcinoma; Cell Count; Cell | 1999 |
The integrated treatment of peritoneal carcinomatosis. A preliminary experience.
Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Carcinoma; Chemotherapy, Adjuvant; Chemotherapy, Cance | 1999 |
Continuous infusion 5-fluorouracil as salvage chemotherapy in patients with advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Catheterization, Central Venous; Cohort Studies; Colonic | 1999 |
Improved outcome following preoperative radiochemotherapy: 40.5 Gy accelerated hyperfractionation and 5-fluorouracil suppositories for patients with carcinoma of the lower rectum.
Topics: Administration, Rectal; Aged; Antimetabolites, Antineoplastic; Carcinoma; Case-Control Studies; Comb | 1999 |
Neoadjuvant chemotherapy and radiation therapy compared with radiation therapy alone in advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Car | 1999 |
Malignant acanthosis nigricans: potential role of chemotherapy.
Topics: Acanthosis Nigricans; Aged; Anal Canal; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic | 1999 |
p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colonic Neo | 2000 |
Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin | 2000 |
The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2000 |
Theoretical considerations and in vitro concentration response studies with two human colorectal carcinoma cell lines. The rational experimental base for clinical studies in regional chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2000 |
[A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2000 |
Oxaliplatin, 5-fluorouracil, and folinic acid (Folfox) in patients with metastatic renal cell carcinoma: results of a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Female; Fluorouracil; Humans; Immun | 2000 |
Improved outcome secondary to concurrent chemoradiotherapy for advanced carcinoma of the nasopharynx: preliminary corroboration of the intergroup experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Dis | 2000 |
The effect of nodal status on determinants of initial treatment response and patterns of relapse-free survival in nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma; Cisplatin; Disease- | 2000 |
Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma; Chemotherapy, A | 2000 |
Nasopharyngeal carcinoma in childhood and adolescence: a single-institution experience with combined therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Child; Cisplatin; | 2000 |
Bcl-w is an important determinant of damage-induced apoptosis in epithelia of small and large intestine.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma; Epithelial Cells; Fluorouracil; Gamma | 2000 |
Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Cancer, Region | 2000 |
Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.
Topics: Adenocarcinoma; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Carcinoma; Cell Cycle; Dose | 2000 |
Chemoradiotherapy for advanced lymphoepithelioma-like carcinoma of the lung.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Cisplatin; Female; Fluorou | 2000 |
Antitumor activity of 2-amino-4,4alpha-dihydro-4alpha, 7-dimethyl-3H-phenoxazine-3-one against Meth A tumor transplanted into BALB/c mice.
Topics: Animals; Antineoplastic Agents; Body Weight; Carcinoma; Female; Fluorouracil; Leukocyte Count; Mice; | 2000 |
UCN-01 (7-hydroxystaurosporine) enhances 5-fluorouracil cytotoxicity through down-regulation of thymidylate synthetase messenger RNA.
Topics: Alkaloids; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemother | 2000 |
Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 2000 |
Surgical and combined treatment of gastric cancer--own experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma; Chemotherapy, A | 2000 |
In vitro evaluation of GL331's cancer cell killing and apoptosis-inducing activity in combination with other chemotherapeutic agents.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Doxorubic | 2000 |
Adjuvant post-operative chemotherapy in bitches with mammary cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinosarcoma; Chemotherapy, Ad | 2001 |
Standard chemotherapy for gastric carcinoma: is it a myth?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Epirubicin; Fluor | 2001 |
Pigmented intraosseous odontogenic carcinoma of the maxilla: a pediatric case report and differential diagnosis.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Ch | 2001 |
5-fluorouracil-induced balanitis in a patient with oesophageal carcinoma.
Topics: Antimetabolites, Antineoplastic; Balanitis; Carcinoma; Esophageal Neoplasms; Fluorouracil; Humans; M | 2001 |
Endoscopic Nd:YAG laser therapy combined with local chemotherapy of superficial carcinomas of the oesophagus and gastric cardia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cardia; Combined Modality Th | 2001 |
In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase.
Topics: Antimetabolites, Antineoplastic; Cancer Vaccines; Carcinoma; Cell Line; Colonic Neoplasms; Drug Resi | 2001 |
Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcin | 2001 |
Prognostic value of thymidine phosphorylase expression in breast carcinoma.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2002 |
Evaluation of cytokeratin-19 mRNA as a tumor marker in the peripheral blood of nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Cisplatin | 2002 |
Selective approaches to gastric cancer patients with liver metastases: role of liver-directed chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Doxorubicin; Fluorouracil; Humans; Infusi | 2001 |
[Personal experience with intra-arterial locoregional chemotherapy of liver metastases from colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Doxorubicin; Female | 2001 |
Markers of drug resistance in relapsing colon cancer.
Topics: Aneuploidy; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Agents; ATP Binding Cassette | 2002 |
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc | 2001 |
Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carcinoma; Cisplatin; Dru | 2002 |
Echogenicity of liver metastases from colorectal carcinoma is an independent prognostic factor in patients treated with regional chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Female; Flox | 2002 |
Prognostic factors for patients with metastatic colorectal cancer receiving protracted venous infusion of 5-FU.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Humans | 2002 |
A breakthrough in cryosurgery.
Topics: Antimetabolites, Antineoplastic; Bronchial Fistula; Carcinoma; Cryosurgery; Fistula; Fluorouracil; H | 2002 |
Long-term survival of nasopharyngeal carcinoma patients treated with adjuvant chemotherapy subsequent to conventional radical radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; | 2002 |
Letter: Treatment of small-cell carcinoma of bronchus.
Topics: Adult; Aged; Bronchial Neoplasms; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Female; Fl | 1975 |
[Chemoradiation therapy of inoperable lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Dactinomycin; Fl | 1975 |
[Recent personal results in advanced bronchial cancer. Palliative immuno-chemotherapy. 63 cases].
Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamou | 1976 |
Antibody-drug synergism: An assessment of specific passive immunotherapy in bronchial carcinoma.
Topics: Animals; Antibodies, Neoplasm; Antineoplastic Agents; Bleomycin; Bronchial Neoplasms; Carcinoma; Cyc | 1977 |
Biochemical aspects of chemotherapy of mouse colon carcinoma: fluoropyrimidines and pyrazofurin.
Topics: Amidophosphoribosyltransferase; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcino | 1977 |
[Determination of individual sensitivity of gastric cancer to 5-fluorouracil by tumor tissue respiratory and glycolytic indices].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Carcinoma; Fluorouracil; Glycol | 1975 |
Primary carcinoma of the liver.
Topics: Adenoma, Bile Duct; Adolescent; Adult; Aged; Carcinoma; Carcinoma, Hepatocellular; Child; Child, Pre | 1976 |
[Experiences with drug therapy of advanced metastatic carcinoma of the breast (author's transl)].
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Car | 1976 |
Trial of anticancer pellet in malignant brain tumours; 5 FU and urokinase embedded in silastic.
Topics: Animals; Brain Neoplasms; Carcinoma; Drug Implants; Endopeptidases; Fluorouracil; Glioma; Humans; Ne | 1979 |
Chemotherapeutic agents and estradiol receptor binding capacity.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Dianhydrogalactitol; Estradiol; Female; | 1979 |
Histological evaluation of the effect of 5-FU emulsion on lymph node metastasis of stomach cancer.
Topics: Adenocarcinoma; Administration, Oral; Carcinoma; Emulsions; Fluorouracil; Humans; Lymph Nodes; Lymph | 1978 |
Initial levels of CEA and their rate of change in pancreatic carcinoma following surgery chemotherapy and radiation therapy.
Topics: Alkaline Phosphatase; Carcinoembryonic Antigen; Carcinoma; Cholestasis; Fluorouracil; Humans; Neopla | 1978 |
Combined surgery, radiotherapy and regional chemotherapy in carcinoma of the maxillary sinus.
Topics: Bromodeoxyuridine; Carcinoma; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Fluorouracil; | 1978 |
Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
Topics: Animals; Carcinoma; Cell Line; Drug Resistance; Drug Therapy, Combination; Female; Fluorouracil; Leu | 1976 |
[Continuous local application of cytostatics for bronchial carcinoma and mediastinal lymph node metastasisization (author's transl)].
Topics: Adenocarcinoma; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regi | 1976 |
Management of hepatic metastases.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Agents; Carcinoma; Chemotherapy, Cancer, Regional P | 1977 |
Grand Rounds: Adjuvant therapy of breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Fem | 1977 |
Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer (Dukes' class C): prolongation of disease-free interval and survival.
Topics: BCG Vaccine; Carcinoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasm | 1977 |
[Late results of lung cancer therapy (according to material from the Kazakh Scientific Research Institute of Oncology and Radiology)].
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Follow-Up Studi | 1976 |
The therapeutic response of three human tumor lines maintained in immune-suppressed mice.
Topics: Animals; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma; Cell Line; Chromosomes; Colonic Neop | 1975 |
Metastatic adrenal cortical carcinoma. Documented cure with combined chemotherapy.
Topics: Adolescent; Adrenal Gland Neoplasms; Carcinoma; Drug Therapy, Combination; Female; Fluorouracil; Hum | 1975 |
[Radiotherapy combined with halogenated pyrimidines--fundamental and clinical studies (author's transl)].
Topics: Animals; Carcinoma; Carcinoma, Ehrlich Tumor; Female; Fluorouracil; Halogens; Head and Neck Neoplasm | 1975 |
Immunostimulation with intraperitoneally administered bacille Calmette Guérin for advanced malignant tumors of the gastrointestinal tract.
Topics: Adult; Aged; BCG Vaccine; Bile Duct Neoplasms; Carcinoma; Colonic Neoplasms; Cyclophosphamide; Femal | 1976 |
Clinical evaluation of ftorafur (pyrimidine-deoxyribose n1-2'-furanidyl-5-fluorouracil).
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Drug Evaluation; Female; Fluorouracil; Gastrointestinal Dise | 1976 |
[The percutaneous-endocavitary irradiation of esophageal carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma; Cisplatin; Combined Modali | 1992 |
[Preoperative administration of 5-FU emulsion for lymph nodes metastasis of pancreatic carcinoma].
Topics: Administration, Oral; Carcinoma; Emulsions; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; | 1992 |
[Evaluating the effectiveness of chemotherapy in patients with head-neck tumors using positron emission tomography (PET scan)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Carcinoma; Carcinoma, Squamous Cell; | 1992 |
Intra-abdominal panniculitis can mimic recurrent stomach carcinoma.
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Diagnosis, Diff | 1992 |
High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; | 1992 |
Achieving local control for inflammatory carcinoma of the breast.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cobalt Radioisotopes; C | 1992 |
[Platelet aggregation during adjuvant chemotherapy with CMF].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1991 |
[Possibilities of the cytological method in the determination of therapeutic pathomorphosis of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carcinoma; Carcinoma, Intr | 1991 |
Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 1991 |
Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer.
Topics: Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethas | 1991 |
Gastrointestinal toxicity of 5-FU and 5-FUDR: radiographic findings.
Topics: Aged; Carcinoma; Duodenitis; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Ileitis; Inf | 1991 |
[The adjuvant chemotherapy of patients with colorectal carcinoma (preliminary report)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adju | 1991 |
Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Enzyme Activation; Flu | 1991 |
[Chemotherapeutic pathomorphosis of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carcinoma; Carcinoma, Intr | 1990 |
[Results of treatment following breast-saving therapy: analysis of intramammary recurrence].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, | 1990 |
Drug response of head and neck tumors in native-state histoculture.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cell Division; | 1991 |
5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcino | 1991 |
What were the received dose intensities in the three arms?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Doxor | 1991 |
What is the value of methotrexate in the treatment of advanced colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Fluorouracil; Human | 1991 |
5-Fluorouracil and recombinant alpha interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Fluorouracil; Human | 1990 |
Anti-proliferative effects of tumor necrosis factor, gamma interferon and 5-fluorouracil on human colorectal carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Division; Cell Line; Colorectal Neop | 1990 |
Growth-inhibitory effect of combination chemotherapy for human pancreatic cancer cell lines.
Topics: Aclarubicin; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 1990 |
[Hemosorption and polychemotherapy with hyperglycemia in the treatment of ovarian cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Carcinoma; Combined Modality T | 1990 |
Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, | 1990 |
Therapeutic strategies in inflammatory breast carcinoma based on prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined Modality Thera | 1990 |
[Possible value of variations in the serum alkaline DNAse activity in the prognosis of cancers of the upper respiratory-digestive tract treated by chemotherapy].
Topics: Adult; Aged; Carcinoma; Cisplatin; Deoxyribonucleases; Female; Fluorouracil; Head and Neck Neoplasms | 1990 |
[A phase II study of 5-fluorouracil/cisplatin in recurrent cervical cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Evaluation; Female; Fluor | 1990 |
Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined M | 1990 |
Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
Topics: Animals; Carcinoma; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule | 1990 |
[Study of procreation capacity of men after treatment of their malignant tumors (melanoblastoma, thyroid carcinoma) with ionizing radiation and cytostatic agents].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cobalt Radioisotopes; Cyclophospha | 1990 |
Bilateral total corneal epithelial erosion as a side effect of cytotoxic therapy.
Topics: Aged; Carcinoma; Cornea; Fluorouracil; Humans; Male; Stomach Neoplasms; Visual Acuity | 1990 |
Does adjuvant therapy work in colon cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Combined Modality Ther | 1990 |
Tissue distribution of [18F]-5-fluorouracil in mice: effects of route of administration, strain, tumour and dose.
Topics: Animals; Carcinoma; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Fluorine Radioisoto | 1990 |
[The role of radiotherapy in the multimodal treatment of locally advanced breast carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined M | 1990 |
Carcinoma of the nasopharynx. An analysis of 91 cases and a comparison of differing treatment approaches.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomyc | 1986 |
Experimental studies on interactions of radiation and cancer chemotherapeutic drugs in normal tissues and a solid tumour.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carcinoma; Cisplatin; Combined Modality Therapy; Cyclopho | 1986 |
Multimodality treatment in anaplastic giant cell thyroid carcinoma.
Topics: Bleomycin; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Fluorouracil; Humans | 1987 |
Excellent response to cis-platinum-based chemotherapy in patients with recurrent or previously untreated advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carci | 1988 |
[Chemotherapy and partial surgery in epithelioma of the pharyngo-larynx].
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; | 1988 |
Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, A | 1989 |
Multimodal treatment for inflammatory breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined M | 1989 |
Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neop | 1989 |
Phase II evaluation of peroral carmofur, cyclophosphamide, and hexamethylmelamine as a second-line therapy in advanced epithelial ovarian carcinoma.
Topics: Administration, Oral; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carc | 1989 |
Adjuvant effects of calmodulin antagonists on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur) and a mixture of ftorafur and uracil (UFT) in nude mice bearing human ovarian carcinomas.
Topics: Animals; Calmodulin; Carcinoma; Drug Combinations; Drug Synergism; Female; Fluorouracil; Mice; Mice, | 1989 |
Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Fluorouracil; Humans; Infusi | 1989 |
Primary treatment of carcinoma of the anus by combined radiotherapy and chemotherapy.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma; Combined Modality Therapy; Female; Fluorouracil; Follow-Up S | 1989 |
[Anal neoplasms. Treatment with radiotherapy and exclusive chemotherapy].
Topics: Aged; Anus Neoplasms; Carcinoma; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Midd | 1989 |
Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes.
Topics: Animals; Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Drug Resistance; Female; Floxuridine; | 1989 |
Therapy of advanced gastric carcinoma. The Georgetown-Lombardi Cancer Center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Fluo | 1989 |
[Preoperative intensive chemotherapy of operable breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, | 1989 |
Clinical trials referral resource. Adjuvant treatment of colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; | 1989 |
Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Fluorouracil; Human | 1989 |
Effects of 5-fluorouracil on cytotoxicity and RNA metabolism in human colonic carcinoma cells.
Topics: Carcinoma; Cell Line; Cell Survival; Colonic Neoplasms; DNA Probes; Dose-Response Relationship, Drug | 1989 |
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcino | 1989 |
[The effect of chemotherapy on survival time in advanced breast carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carmustine; Combined Mo | 1989 |
The effect of sequential methotrexate and 5-fluorouracil in patients with recurrent head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Administration Schedule | 1989 |
Advanced gastric cancer: a new combined surgical and oncological approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 1989 |
Inflammatory carcinoma of the breast: treatment results on 107 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 1989 |
Metastatic sweat gland carcinoma: response to 5-fluorouracil infusion.
Topics: Aged; Carcinoma; Fluorouracil; Humans; Infusions, Parenteral; Male; Neoplasm Metastasis; Sweat Gland | 1989 |
A clinical study of 407 cases of nasopharyngeal carcinoma in Hong Kong.
Topics: Adult; Aged; Brachytherapy; Carcinoma; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; H | 1989 |
Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Dose- | 1989 |
[Clinical and histologic effects of preoperative combination chemotherapy of breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Intra | 1988 |
Phase II trial of continuous-infusion iproplatin (CHIP) and 5-fluorouracil (5-FU) in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Color | 1989 |
Neoadjuvant or definitive alternating chemotherapy and radiotherapy for infiltrating bladder cancer.
Topics: Adjuvants, Pharmaceutic; Aged; Carcinoma; Cisplatin; Combined Modality Therapy; Drug Administration | 1989 |
Hepatic artery infusion chemotherapy for colorectal metastases: a personal experience.
Topics: Adult; Aged; Carcinoma; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans | 1985 |
Combined therapy of polyamine antimetabolites and antitumor drugs for human gastric cancer xenotransplanted into nude mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcino | 1986 |
Toxicity and antitumor effect of 5-fluorouracil and its rescue by uridine.
Topics: Animals; Body Temperature Regulation; Carcinoma; Colonic Neoplasms; Dose-Response Relationship, Drug | 1986 |
Inhibition of thymidylate synthase after administration of doxifluridine in a transplantable colon carcinoma in the rat.
Topics: Animals; Carcinoma; Colonic Neoplasms; Female; Floxuridine; Fluorodeoxyuridylate; Fluorouracil; Male | 1988 |
Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines.
Topics: Carcinoma; Cell Survival; Colorectal Neoplasms; Drug Synergism; Floxuridine; Fluorouracil; Humans; L | 1988 |
Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1985 |
[A clinical study of radiotherapy with HCFU for advanced and recurrent breast cancers. Radiation and HCFU Study Group for breast cancer].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Eval | 1985 |
Reversible leukoencephalopathy caused by 5-fluorouracil derivatives, presenting as akinetic mutism.
Topics: Anal Gland Neoplasms; Animals; Breast Neoplasms; Carcinoma; Female; Fluorouracil; Humans; Leukoencep | 1986 |
Hexamethylmelamine, methotrexate, 5-fluorouracil as second line chemotherapy after platinum for epithelial ovarian malignancies.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modali | 1986 |
[Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; | 1986 |
Prognostic factors in metastatic carcinoma of unknown primary.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 1986 |
[Determination of the individual sensitivity of human stomach cancer cells to fluoropyrimidines by the cytomorphological criteria of heterotransplants in diffusion chambers].
Topics: Adenocarcinoma; Animals; Carcinoma; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Fe | 1986 |
Mitomycin C associated hemolytic uremic syndrome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Doxorubicin; Fluorouracil; Hemolyti | 1987 |
[Chemotherapy of epithelial ovarian cancer: CHexUP versus thio-tepa].
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; | 1987 |
Adjuvant chemotherapy for invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Transitional Cell; Cispl | 1987 |
Management of inflammatory carcinoma of the breast with combined modality therapy including intraarterial infusion chemotherapy as an induction therapy. Long-term follow-up results of 28 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined M | 1988 |
Alternated pre-cystectomy chemo-radiotherapeutic treatment in patients with locally advanced bladder cancer: a preliminary report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Flu | 1988 |
The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 1988 |
[Inflammatory breast carcinoma--possibilities and results of surgical treatment and adjuvant chemotherapy, especially when done preoperatively].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Doxor | 1988 |
Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apudoma; Carcinoma; Dacarbazine; Female; Fluo | 1988 |
[Topical chemotherapy in the surgical treatment of recurrent skin carcinoma].
Topics: Administration, Topical; Aged; Carcinoma; Combined Modality Therapy; Female; Fluorouracil; Humans; N | 1988 |
Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Breast Neoplasms; Carcin | 1988 |
5-Fluorouracil, doxorubicin, and cisplatin regimen in adrenal cortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxo | 1988 |
Advanced colorectal carcinoma--5 year survival of 76 cases treated at the Department of Therapeutic Radiology, Singapore General Hospital.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma; Colonic Neoplasms; Co | 1987 |
Principia of cancer therapy. XIX. Effects of per rectum carmofur on radiotherapeutic efficacy of rectal carcinomas.
Topics: Carcinoembryonic Antigen; Carcinoma; Fluorouracil; Humans; Metabolic Clearance Rate; Rectal Neoplasm | 1987 |
Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.
Topics: Carcinoma; Cell Line; Cisplatin; Drug Synergism; Female; Fluorodeoxyuridylate; Fluorouracil; Folic A | 1986 |
Acute myelocytic leukemia following radiation and chemotherapy for esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therap | 1987 |
Comparison of unique leucovorin and 5-fluorouracil "escalating" and "maximum" dosage strategies.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dose-Response Relation | 1987 |
A phase II trial of 5-fluorouracil and high-dose leucovorin in gastric carcinoma and a phase I trial of intraperitoneal 5-fluorouracil and leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dose-Response Relationship, | 1987 |
Local management in primary breast cancer. Our experience of 331 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 1987 |
Phase II trial of combined 5-fluorouracil plus doxorubicin plus cisplatin (FAP regimen) in advanced gastric carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Drug Administrati | 1987 |
Pancreatic giant cell carcinoma of the osteoclastic type: response to 5-fluorouracil and radiation.
Topics: Aged; Carcinoma; Combined Modality Therapy; Fluorouracil; Humans; Male; Pancreatic Neoplasms | 1986 |
Technical aspects of intraperitoneal chemotherapy in abdominal carcinomatosis.
Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherap | 1986 |
[Antimetastatic properties of aloe juice].
Topics: Aloe; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cyc | 1986 |
Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antipyrine; Biotransformation; Breast N | 1987 |
Management of inflammatory carcinoma of the breast. A combined modality approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined M | 1985 |
Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay.
Topics: Adenocarcinoma; Altretamine; Anti-Mullerian Hormone; Ascitic Fluid; Carcinoma; Chromatography, Affin | 1985 |
Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluoroura | 1986 |
Two years of high-dose cyclophosphamide and 5-fluorouracil followed by surgery after 3 months for acute inflammatory breast carcinomas. A phase II study of 25 cases with a median follow-up of 35 months.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcin | 1986 |
[Ribamidil as a modulator of the toxic effect of 5-fluorouracil].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cells, Cultured; DNA, Neoplasm; | 1985 |
Cisplatin bolus and 5-FU infusion chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1985 |
[Neoplasms of the vulva].
Topics: Aged; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cobalt Radioisotopes; Erythroplasi | 1985 |
Early diagnosis and management of premalignant lesions and early invasive cancers of the vulva.
Topics: Adult; Aged; Carcinoma; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metas | 1971 |
[Esophageal tumors--therapeutic problems].
Topics: Adenocarcinoma; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cobalt Isotopes; Esophageal Neoplasm | 1972 |
Improved palliation of pancreatic carcinoma.
Topics: Adult; Aged; Carcinoma; Chromium Isotopes; Cobalt Isotopes; Diagnostic Techniques, Surgical; Female; | 1973 |
Carcinoma of pancreas--palliative radiotherapy.
Topics: Carcinoma; Cobalt Isotopes; Fluorouracil; Humans; Liver Neoplasms; Neoplasm Metastasis; Palliative C | 1973 |
[Intra-arterial chemotherapy of head and neck tumors: statistical study of 129 cases treated at the Institut Gustave Roussy].
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Facial Neoplasms | 1973 |
Clinical staging of carcinoma of the uterine tube.
Topics: Adult; Aged; Barium; Carcinoma; Fallopian Tube Neoplasms; Female; Fluorouracil; Humans; Middle Aged; | 1967 |
The second look operation for carcinoma of the colon after administration of 5-fluorouracil.
Topics: Carcinoma; Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; | 1968 |
Operation, external irradiation, radioactive isotopes, and chemotherapy in treatment of metastatic ovarian malignancies.
Topics: Ascites; Carcinoma; Chlorambucil; Cyclophosphamide; Dactinomycin; Female; Fluorouracil; Follow-Up St | 1968 |
[Loco-regional and sequential chemotherapy of advanced cancer].
Topics: Adult; Carcinoma; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Dysgerminoma; | 1968 |
Comparison of the effects of several inhibitors of the synthesis of nucleic acids upon the viability and progression through the cell cycle of cultured H. Ep. no. 2 cells.
Topics: Antimetabolites; Azaguanine; Carcinoma; Cell Division; Cell Line; Cell Survival; Cytarabine; DNA Rep | 1972 |
Treatment of intracranial gliomas and metastatic carcinomas by local application of cytostatic agents.
Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carcinoma; Female; Fluorouracil; Glioblastoma; | 1968 |
[Pathologic anatomy of rectal cancer treated by intra-arterial administration of 5-fluoruracil].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Female; | 1970 |
Growth inhibiting effects of cytotoxic agents on human tumor and tumor-bearing normal tissue in vitro.
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Intra | 1971 |
[Radiotherapy following synchronisation of the cell-division rhythm].
Topics: Animals; Carcinoma; Carcinoma, Squamous Cell; Cell Division; DNA; Fluorouracil; Humans; Mice; Neopla | 1972 |
Genetic studies of respiratory syncytial virus temperature-sensitive mutants.
Topics: Alkanesulfonates; Carcinoma; Cell Line; Crosses, Genetic; Fluorine; Fluorouracil; Genetic Complement | 1973 |
[Indications and medical therapy of hypoglycemic beta-insular].
Topics: Adenoma, Islet Cell; Adrenal Cortex Hormones; Antineoplastic Agents; Carcinoma; Diazoxide; Diuretics | 1973 |
Conditional lethal mutants of vesicular stomatitis virus. I. Phenotypic characterization of single and double mutants exhibiting host restriction and temperature sensitivity.
Topics: Animals; Carcinoma; Cell Line; Cell-Free System; Chick Embryo; Culture Techniques; Dactinomycin; DNA | 1974 |
Heparin anticoagulation as adjuvant to chemotherapy in carcinoma of the lung.
Topics: Aged; Antineoplastic Agents; Blood Coagulation; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Small | 1974 |
[Determination of the individual sensitivity of gastric cancerous tumors to 5-fluorouracil according to respiratory and glycolytic indices].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Carcinoma; Drug Evaluation, Pre | 1974 |
[Hormone therapy and chemotherapy of metastasizing breast cancer. Experiences of the Basle Oncology Center, 1969-72].
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Castration; Cyclophosphamide; Drug Therapy, Comb | 1974 |
[Application of morphological and histochemical methods for evaluation of cytostatic effects on organ cultures of malignant tumors].
Topics: Animals; Antineoplastic Agents; Carcinoma; Culture Techniques; Female; Fluorouracil; Histocytochemis | 1974 |
[Effects of 5-fluorouracil (5-FU) ointment on intraepithelial carcinoma of the cervix].
Topics: Administration, Topical; Adult; Carcinoma; Female; Fluorouracil; Humans; Middle Aged; Ointments; Ute | 1974 |
In vitro estimate of sensitivity of individual human tumors to antitumor agents.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Arsenicals; Benzoates; Breast Neoplasms; Carbon Radi | 1974 |
Antigenicity of C 3 H mammary carcinoma in isogenetic hosts: preliminary studies.
Topics: Animals; Antigens, Neoplasm; Carcinoma; Fluorouracil; Immunologic Techniques; Mammary Neoplasms, Exp | 1973 |
The gallbladder as a conduit between the liver and intestine.
Topics: Adenocarcinoma; Adolescent; Adult; Bile Ducts; Carcinoma; Cholangiography; Common Bile Duct; Drainag | 1973 |
The continuous arterial infusion of 5-fluorouracil as a therapeutic adjunct in the treatment of advanced carcinoma of the bladder and prostate. A preliminary report.
Topics: Aged; Carcinoma; Cobalt Isotopes; Dose-Response Relationship, Drug; Dose-Response Relationship, Radi | 1973 |
[Principles, technic and clinical performance of synchronized radiotherapy].
Topics: Adenocarcinoma; Adult; Aged; Androstanols; Bone Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, S | 1972 |
[The state of parietal carbohydrate hydrolysis following a single administration of antitumor drugs to intact and tumorous animals].
Topics: Animals; Carcinoma; Cyclophosphamide; Digestion; Female; Fluorouracil; Furans; Hydrolysis; Intestine | 1972 |
The value of megavolt therapy in carcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Cardia; Cell Division; Cobalt Isotopes; Female; Fluorouracil | 1972 |
Chemotherapy for carcinoma of the pancreas.
Topics: Adult; Aged; Autopsy; Biopsy; Carcinoma; Female; Fluorouracil; Humans; Laparotomy; Male; Middle Aged | 1973 |
Combined chemotherapy and radiation therapy in spindle and giant cell carcinoma of the thyroid gland. Report of a case.
Topics: Aged; Carcinoma; Cobalt Isotopes; Cyclophosphamide; Female; Fluorouracil; Humans; Neoplasm Metastasi | 1973 |
Disseminated breast carcinoma. Treatment with combination chemotherapy.
Topics: Adenocarcinoma; Adult; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Fem | 1973 |
Synchronization of human tissues and its consequences for cancer therapy in ENT. Cell kinetic and clinical studies.
Topics: Aged; Animals; Carcinoma; Carcinoma, Squamous Cell; Cell Division; DNA Replication; DNA, Neoplasm; E | 1974 |
[Progress in chemotherapy of solid tumors and malignant lymphomas (continued)].
Topics: Adult; Antineoplastic Agents; Carcinoma; Choriocarcinoma; Female; Fluorouracil; Gonadal Steroid Horm | 1967 |
Regional chemotherapy of cancer of the head and neck.
Topics: Antineoplastic Agents; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Head; Head | 1966 |
[Our experiences with polychemotherapy of malignant endothoracic tumors (103 cases)].
Topics: Adenocarcinoma; Adult; Androgens; Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma; C | 1968 |
[3 years of polychemotherapy of pleuro-pulmonary cancer. Apropos of 95 cases].
Topics: Androgens; Antibiotics, Antineoplastic; Antineoplastic Agents; Ascorbic Acid; Azirines; Bronchial Ne | 1968 |
[Trial treatment of bronchial cancer by polychemotherapy].
Topics: Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Colchicin | 1968 |
[Effects of 5-FU (5-fluorouracil) in 4.3MeV Linac x-ray treatment of advanced cancer].
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fl | 1968 |
Cytotoxic agents in the treatment of malignant disease.
Topics: Antimetabolites; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Chlorambucil; Choriocarcinoma; | 1968 |
[Management of bladder carcinoma].
Topics: Carcinoma; Cobalt Isotopes; Fluorouracil; Gold Isotopes; Humans; Radioisotope Teletherapy; Radiother | 1969 |
[Use of vitamin B-15 in experimental tumor chemotherapy].
Topics: Animals; Antineoplastic Agents; Carbon Tetrachloride Poisoning; Carcinoma; Chemical and Drug Induced | 1970 |
Rh-incompatible platelet transfusions--risks and consequences of sensitizing immunosuppressed patients.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Antibodies; Antibody Formation; Blood Group Incompatibili | 1971 |
Chemotherapy in the management of metastatic cancer of unknown primary site.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Chlorambucil; Cyclopho | 1972 |
Topical chemotherapy of advanced cutaneous malignancy with 5-Fluorouracil creme.
Topics: Aged; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Carcinoma, Squamous Cell; Esthetics | 1971 |
[Gallbladder cancer].
Topics: Adenocarcinoma; Adenoma; Carcinoma; Cholelithiasis; Fluorouracil; Gallbladder Neoplasms; Humans; Mel | 1971 |
Arginine requirement for late mRNA transcription of vaccinia virus in KB cells.
Topics: Arginine; Carbon Isotopes; Carcinoma; Cell Line; Centrifugation, Density Gradient; DNA Replication; | 1971 |
Association of cancer of the breast and acute myelocytic leukemia.
Topics: Adenocarcinoma; Adult; Aged; Anti-Bacterial Agents; Breast Neoplasms; Carcinoma; Female; Fluorouraci | 1967 |
Cryohypophysectomy: indications, technic, and results.
Topics: Acromegaly; Adenoma, Chromophobe; Adult; Breast Neoplasms; Carcinoma; Castration; Cryosurgery; Cushi | 1967 |
Clinical trials of a new antitumor polypeptide: neocarzinostatin (NCS).
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Cyclophosphamide; Female; Fluorouracil; Humans; | 1969 |
[Treatment of carcinoma and precancerosis using 5-fluorouracil].
Topics: Aged; Carcinoma; Carcinoma, Basal Cell; Female; Fluorouracil; Humans; Keratosis; Occlusive Dressings | 1970 |
[Epitheliomatosis on therapeutic chronic arsenicism].
Topics: Aged; Arsenic; Carcinoma; Female; Fluorouracil; Humans; Skin Neoplasms | 1970 |
Survival of patients treated with systemic fluorouracil for hepatic metastases.
Topics: Adult; Age Factors; Aged; Carcinoma; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hum | 1970 |
[Attempts at intra-arterial infusion therapy in advanced breast cancer].
Topics: Adult; Breast Neoplasms; Carcinoma; Female; Fluorouracil; Humans; Injections, Intra-Arterial; Middle | 1970 |
An evaluation of combination chemotherapy with procarbazine (NSC-77213) and 5-fluorouracil (NSC-19893) in advanced carcinoma of the lung.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Benzoates; Blood Cell Count; Carcinoma; Carcinoma, Bro | 1970 |
[Experimental results of the use of polychemotherapy in malignant tumors].
Topics: Amides; Amputation, Surgical; Animals; Antineoplastic Agents; Benzoates; Carcinoma; Cyclophosphamide | 1970 |
[Modalities and results of anticancer polychemotherapy in 73 cases of advanced broncho-pleuro-pulmonary cancer].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bronchial Neoplasms | 1968 |
[Polychemotherapy of bronchopulmonary cancer].
Topics: Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Cyclophos | 1968 |
Hepatic artery and celiac axis infusion for the treatment of upper abdominal malignant lesions.
Topics: Abdominal Neoplasms; Carcinoma; Celiac Artery; Fluorouracil; Gastrointestinal Neoplasms; Head and Ne | 1968 |
[218 cases of prolonged polychemotherapy in advanced cancer (especially bronchopulmonary). Modalities and results].
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bronchial Neop | 1968 |
Effect of chemotherapy on uptake of alkali metals by experimental tumors.
Topics: Animals; Azaserine; Carcinoma; Cesium; Cyclophosphamide; Fluorouracil; In Vitro Techniques; Mammary | 1968 |
[Perioperative antiblastic drug therapy with triethyleniminobenzoquinone and 5-fluorouracil in uterine neoplasms].
Topics: Antineoplastic Agents; Carcinoma; Female; Fluorouracil; Humans; Hysterectomy; Neoplasm Metastasis; N | 1968 |
[Chemotherapy of advanced gastric carcinoma with 5-fluorouracil].
Topics: Carcinoma; Fluorouracil; Humans; Stomach Neoplasms | 1968 |
Metastatic tumor to the breast simulating bilateral primary inflammatory carcinoma.
Topics: Breast Neoplasms; Carcinoma; Diagnosis, Differential; Female; Fluorouracil; Humans; In Vitro Techniq | 1966 |